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Abstract
Despite the involvement o f multiple genetic variants of HIV in the causation of disease 
worldwide, most research has focussed on subtype B, the prevalent subtype in the 
western world. As a consequence, it is currently not clear whether genetically distinct 
HIV strains have different biological properties that cause differences in in vivo 
transmission, disease progression, replication capacity or sensitivity to antiretroviral 
drugs. In order to increase the ease o f classification of viral diversity and thus aid 
studies into its importance, a novel genotyping tool for classifying HIV-1 subtype based 
on pol sequence, produced routinely during drug resistance monitoring, has been 
developed in this thesis. A dataset o f 187 full-length HIV-1 sequences was used to 
generate Gag, Pol, Protease-Reverse Transcriptase (PR-RT) and Env protein sequence 
alignments. Phylogenetic analyses enabled generation of subtype specific alignments 
and, whilst sequence variation in the PR-RT dataset was low, this variation was 
adequate for PR-RT subtype assignment. The subtyping tool, named STAR, utilises 
position specific scoring matrices (PSSMs) derived from these subtype specific multiple 
sequence alignments and results in highly accurate reclassification of the subtype 
alignment sequences, with 98.6% of sequences being accurately assigned a subtype.
Subsequent to the development o f STAR the importance of HIV genetic variation 
classified as subtype, was addressed. A comparison of the relative growth capacity o f 
HIV-1 primary isolates o f subtypes A, B, C, D, F, group O and HIV-2 was performed in 
two T-cell environments. A novel reporter cell line was developed specifically to 
facilitate this work. Clear and consistent differences in in vitro growth phenotype in 
terms o f rate and cytopathogenicity were detected, indicative of intrinsic differences 
between the HIV-1 types and subtypes. This work was extended by the utilisation of 
microarray technology which offers the possibility to analyse, at any given time point, 
the transcriptome o f a virus-infected cell. A comparison of the transcriptional responses 
within T-cells to infection with HIV-1 subtype B, Group O and HIV-2 enabled 
identification of both core and diverging transcriptional response programs. Whilst the 
core response program provides insight into the most essential interactions between 
virus and host during HIV infection o f T-cells, analysis of the diverging responses 
provide evidence that genetically divergent strains of HIV may interact differently with 
the host. It is proposed that these differences may have the potential to influence 
disease outcome.
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Chapter 1.0 Introduction
1.1 History
In June 1981, the Centres for Disease Control (CDC) published a report about the 
occurrence, without identifiable cause, o f a rare lung infection Pneumocystis carinii 
pneumonia (PCP) in five men in Los Angeles (MMWR weekly, 1981). A few days 
later, following these reports o f PCP and other rare life-threatening opportunistic 
infections, the CDC formed a Task Force on Kaposi's Sarcoma and Opportunistic 
Infections (KSOI). At this time a number o f theories were developed about the possible 
cause of these opportunistic infections and cancers. Early theories included infection 
with cytomegalovirus and the use o f amyl nitrite or butyl nitrate "poppers" and 
"immune overload" (Gottlieb et al., 1981, Goedert et al., 1982). Five months later in 
December 1981, however, when the first cases of PCP were reported in injecting drug 
users it was clear that this disease not only affected gay men, but other population 
groups (Masur et al., 1981). At the same time the first case o f such an illness was 
documented in the UK (du Bois et al., 1981).
By 1982 the disease still did not have a name, with different groups referring to it in 
different ways. The CDC referred to it by reference to the diseases that were occurring, 
although on some occasions they referred to it as KSOI, the name already given to the 
CDC task force. Journals chose a different nomenclature, with the Lancet calling it the 
'gay compromise syndrome', whilst at least one newspaper referred to it as GRID (gay- 
related immune deficiency) (Brennan and Durack, 1981, Altman, 1982) and another 
newspaper described it as 'gay cancer' and 'community-acquired immune dysfunction' 
(The Washington Blade, 1982).
In June 1982, a breakthrough was made in the reporting of a group of cases amongst 
gay men in Southern California, suggesting that this disease might be caused by an 
infectious agent that was sexually transmitted (MMWR weekly, 1982-a). By the 
beginning o f July a total o f 452 cases, from 23 American states, had been reported to 
the CDC (CDC, 1982). By August the disease was being referred to by its new name of 
Acquired Immunodeficiency Syndrome, or AIDS (Marx, 1982).
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In December 1982, a 20-month old child who had received multiple transfusions of 
blood and blood products died from infections related to AIDS providing further 
evidence that AIDS was caused by an infectious agent. At the same time the CDC 
reported the first cases o f possible mother to child transmission o f AIDS (MMWR 
Weekly, 1982-b). A report was also published which stated that a disease previously 
known as "slim”, was actually an African form of AIDS (Kamradt et al., 1985). With 
the dawn o f 1983, it became evident that AIDS could also be transmitted heterosexually 
from men to women.
It was in May 1983 that researchers at the Institut Pasteur in France reported that they 
had isolated a new virus, which they believed was the cause of AIDS (Barre-Sinoussi et 
a l, 1983). They had detected reverse transcriptase (RT) activity in the culture 
supernatant o f a lymph node biopsy from a patient with lymphadenopathy, a condition 
already associated with individuals at risk for AIDS. The presence o f RT activity was 
indicative o f the presence o f a retrovirus, at the time only two o f which were known: 
Human T-cell Leukaemia virus I (HTLV-I, Gallo et a l, 1981) and II (Kalyanaraman et 
a l, 1982). Proteins from the infected cell extracts, however, could not be precipitated 
with antibodies to either virus (Barre-Sinoussi et al., 1983), suggesting it was distinct 
from both. It was named Lymphadenopathy Associated Virus (LAV). In 1984, similar 
reports of virus isolation from AIDS patients were made (Popovic et a l, 1984). In this 
case the vims was named HTLV-III, because o f apparent similarities in the host cell 
preference of this new vims to HTLV-I and -II. Further studies demonstrated the 
presence of LAV-like viruses in the PBMCs of homosexual men with AIDS, and 
furthermore the presence o f high antibody titres against the vims in the otherwise 
healthy male homosexual control group (Levy et a l, 1984). These vimses were named 
AIDS-related vimses (ARVs). The subsequent cloning and sequencing of LAV (Alizon 
et a l, 1984), HTLV-III (Ratner et al., 1985) and ARV (Luciw et a l, 1984), however, 
revealed that HTLV-III and ARV were 99% and 95% similar to LAV, respectively. 
This implied that the vimses isolated in separate laboratories were actually the same 
(Montagnier et a l, 2002). Numerous studies where HTLV-III/LAV/ARV was isolated 
from people either at risk or suffering from AIDS provided further evidence that this 
vims was causing the disease (Gallo et al., 1984, Casareale et al., 1984, Safai et al., 
1984, Cheingsong-Popov et al., 1984, Samgadharan et al., 1984, Goedert and Gallo,
1985).
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In the meantime, in Europe, two separate AIDS epidemics were occurring. In France 
and Belgium AIDS was occurring mainly in people from Central Africa or those with 
links to the area, whilst in the UK, West Germany and Denmark the majority o f people 
with AIDS were homosexual (Weller et al., 1984). In the UK people in risk groups 
considered particularly susceptible to AIDS were asked not to donate blood (Gunson,
1986). The first meeting to assess the global AIDS situation took place, which initiated 
global surveillance by the World Health Organisation (WHO). It was reported that 
AIDS was present in the U.S.A., Canada, fifteen European countries, Haiti, and Zaire as 
well as in seven Latin American countries. There were also cases reported from 
Australia and two suspected cases in Japan (WHO, 1983). By the end of 1984, there 
had been 7699 AIDS cases and 3665 AIDS deaths in the USA, and 762 cases had been 
reported in Europe (AIDS Activity, CDC, 1984, MMWR Weekly, 1985). In the UK 
there had been 108 cases and 46 deaths (Department o f Health & Social Security, 1985). 
In 1985, CDC classified routes of transmission as ‘intimate sexual contact; sharing 
contaminated needles; transfusion o f whole blood, blood cellular components, plasma 
or clotting factor concentrates that have not been heat treated; and from an infected 
mother to her child before, at, or shortly after birth’ (MMWR, 1985).
At the same time, controversy regarding the nomenclature of HTLV-III/LAV/ARV 
came to a head (Marx, 1985). Gallo and colleagues maintained that the virus should be 
named HTLV-III, because of its predilection for infecting T-cells o f the helper class. 
He also changed the HTLV acronym from meaning Human T-cell Leukaemia virus to 
Human T-cell Lymphotropic virus to reflect both this, and the fact that HTLV-III was 
not associated with T-cell proliferation and leukaemias, but rather T-cell death. 
Montagnicr, Levy and others, however, felt that these distinguishing features meant that 
HTLV-III/LAV/ARV required a new name. Sequencing had shown that, whilst having 
all the sequence features of a retrovirus, HTLV-III/LAV/ARV also possessed additional 
open reading frames, more in common with a subgroup of the retroviruses known as the 
lentiviruses (Wain-Hobson, Alizon and Montagnicr, 1985, Sonigo et al., 1985), 
furthering their cause. Accordingly, a meeting of the International Committee of the 
Taxonomy of Viruses was convened by Harold Varmus and, amongst others, the main 
protagonists (Montagnicr, Gallo and Levy) came together. A decision was made that the 
virus should be named Human Immunodeficiency Virus (HIV), later modified to HIV-1 
with the discovery o f a variant of this virus in West Africa, termed HIV-2 (Clavel et al.,
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1986-a,b). At the time, however, Various was quoted as saying “..these deliberations 
can be irrelevant to the way people behave, nothing we do is binding. If someone wants 
to ignore it, he can.” Despite this, HIV has passed into common parlance as the virus 
that causes AIDS.
By the end of the next year, 85 countries had reported 38,401 cases of AIDS to the 
WHO (Bureau of Hygiene & Tropical Diseases, 1986). Eighteen years later, an 
estimated 39.4 million people are living with HIV, with 4.9 million new infections and
3.1 million deaths due to AIDS in the past year alone. Some 65% of these infections 
affect people in sub-Saharan Africa (Figure 1.0).
Figure 1.0 A dults and children estim ated  to  be living with HIV a s  o f the end of 2004.
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1.2 HIV Structure
HIV-1 and -2  are the only members of the Lentivirus genus known to affect humans, 
within the family Retroviridae. Whilst retroviruses are characterised by the presence of 
certain features, including a genome composed of ribonucleic acid (RNA); a common 
structure encoded by three polyprotein genes: group specific antigen (gag), polymerase 
(pot) and envelope (env); a life cycle in which the viral genome is reverse transcribed 
and inserted into the genetic material of the host; and the ability to alter their genomes 
rapidly by mutation in response to environmental conditions, lentiviruses have 
additional complex combinations of genes and as the name implies are 'slow' viruses 
with the potential for long periods of latent infection, prior to causing disease. Figure
1.1 shows the structure of a mature HIV-1 virion and the organisation of its genome.
Figure 1.1 HIV-1 gen om e organisation and viral structure.
(A) Several coding regions overlap and others are discontinuous. Splicing variations generate 
the full complement of transcripts required for viral replication. (B) The HIV-1 virion particle.
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Pol Reverse transcriptase 
Integrase and Vpr
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A- Reproduced from http://w w w .hsph.hai^ ard.edu/hai/research/discoveries.htm l 
B- M odified from Nature M edicine, 2003 (NPG)
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As depicted in Figure 1.1, the virus is composed o f six structural proteins that surround 
and protect two strands o f positive sense genomic RNA and which mediate interactions 
with host cells. In addition there are three enzymes and six accessory proteins, which 
function in a variety o f processes during viral replication. The size, function and 
localization of each of these proteins are detailed in Table 1.0.
Table 1.0 Viral protein components of the HIV virion.
NAME SIZE FUNCTION LOCALISATION
Gag
MA (matrix)
CA (capsid) 
NC
(nucleocapsid)
p6
p l7
p24
P7
p6
membrane anchoring; Env interaction; nuclear 
transport o f  viral core 
core structure 
binds RNA
binds Vpr
virion
virion
virion
virion
Pol
PR (Protease) 
RT (Reverse 
transcriptase) 
RNaseH 
IN (Integrase)
plS
pSI
p l5  
p31
Gag/Pol cleavage and maturation 
reverse transcription
RNase H activity 
DNA provirus integration
virion
virion
virion
virion
Env gp 120/ gp4l
external viral glycoproteins bind to CD4 and 
secondary receptors
plasma membrane, 
virion envelope
Tat pi 6/ p l4
viral trancriptional transactivator primarily in 
nucleolus/nucleus
Rev p 19 RNA transport, stability and utilization factor
primarily in 
nucleolus/ nucleus 
shuttling between 
nucleolus and 
cytoplasm
Vif p23 promotes virion maturation and infectivity - circumvents action o f host anti-viral factors
cytoplasm
(cytosol, membranes)
Vpr p 10— 15
promotes nuclear localisation o f pre-integration 
complex, inhibits cell division, arrests infected 
cells at G2/M
virion,
nucleus (nuclear 
membrane?)
Vpu p 16
promotes extracellular release o f  viral particles; 
degrades CD4 in the ER; only in HIV-1 and 
SIVcpz
integral membrane 
protein
Nef P25P27
CD4 and class I downregulation 
(myristylated protein)
plasma membrane, 
cytoplasm (virion?)
Vpx pi 2 16 Vpr homolog in HIV-2
only in virion 
(nucleus?)
R eproduced from  HIV Sequence C om pendium , 2003.
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13 HIV Replication
The retroviral life cycle is typified by a number of processes. Following entry to a cell 
these include: reverse transcription of the viral ssRNA genome to dsDNA; incorporation 
of viral DNA into the chromosomes of the host cell where it is known as a provirus; and 
transcription of this integrated genome by the host’s RNA polymerase enzymes to 
create new viral ssRNA. This RNA can then function as mRNA to make viral proteins 
or be packaged as genome into new viral particles. An overview of the HIV replication 
is illustrated is Figure 1.2.
FUSION AND 
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JRANSLATION /
:x p r e s s io n
* Un-spliccd
.RNA
REVERSE
TRANSCRIPTION]CD4 DEGRADATION
RIBOSOMAL
TRANSLATION
GENOME
RECOGNITIONASSEMBLY
Figure 1.2 Overview of the HIV replication cycle.
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1.3.1 Host cells, binding and fusion
The main cell surface molecule to which HIV binds with high affinity is CD4 
(Dalgleish et al., 1984, Klatzmann et al., 1984). This cell-surface glycoprotein is 
present at low concentration on monocytes, macrophages and antigen presenting 
dendritic cells. It is present in abundance, however, on the surface of immature T 
lymphocytes and mature circulating T-helper cells (Sattentau and Weiss, 1988), making 
these cells a prime target for infection. In addition to CD4, HIV-1 requires a co- 
receptor for cell entry, the type o f which defines two ‘groups’ o f HIV: macrophage 
tropic strains, which use the P-chemokine receptor CCR5 (Dragic et al., 1996, Alkhatib 
et al., 1996); and T-cell tropic strains, which use the a-chemokine receptor CXCR4 
(Feng et al., 1996). Although CCR5 and CXCR4 are the major coreceptors used in 
vivo, there are at least 12 other members o f the chemokine receptor family and related 
’’orphan" receptors, that can support infection o f cell lines in vitro (Willey et al., 2003). 
HIV-2 isolates can use a wider range o f these alternative coreceptors than HIV-1, often 
as efficiently as they use CCR5 and/or CXCR4 (Clapham and McKnight, 2002, Reeves 
and Dorns, 2002).
Mechanistically, the interaction between host and virus membranes is initiated by the 
gpl20 subunit of the viral envelope binding to the cellular CD4 molecule; this receptor 
binding induces conformational changes in the viral envelope protein that include 
exposure o f a previously hidden, highly conserved domain that binds to the coreceptor. 
Coreceptor binding then induces conformational changes in the gp41 envelope subunit 
that results in the insertion of a fusion peptide into the target cell membrane and the 
binding o f two gp41 helical regions. This mechanically draws the viral and cell 
membranes together, permitting membrane fusion (Dorns and Trono, 2000).
Cell tropism, as defined by coreceptor usage, plays a role in both virus transmission and 
disease progression (Huang et al., 1996). The majority o f transmitted viruses are R5- 
tropic, a fact that is demonstrated in vivo by the substantial protection from infection 
that individuals homozygous for a 32-base pair (bp) deletion in CCR5 possess (Dean et 
al., 1996, Liu et al., 1996, Samson et al., 1996). CXCR4-using variants emerge late in 
disease in up to 50% of AIDS patients (Tersmette et al., 1988). This change in 
coreceptor use correlates with disease progression in infected individuals (Connor et al., 
1997), but it is not a prerequisite, as not all infected individuals demonstrate a
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coreceptor switch (de Roda Husman et al., 1999). Furthermore, in patients infected with 
a particular genetic subtype o f HIV-1 (C) viral switching to X4-usage is rarely detected. 
Although primary X4 strains can infect macrophages via CXCR4 (Simmons et al., 
1998, Valentin et al., 2000), these variants primarily target new populations of T cells 
that express CXCR4 but not CCR5, such as naive T-cells (Blaak et al., 2000). Whilst 
the mechanisms of receptor binding, conformational changes, fusion and the subsequent 
process o f reverse transcription are now fairly well defined, very little is known about 
the concurrent uncoating process.
1.3.2 Uncoat mg and reverse transcription
The fusion o f viral and cellular membranes delivers the viral core into the cytoplasm, 
where the viral RNA is reverse transcribed by the virion-packaged reverse transcriptase 
(RT), generating a linear double-stranded DNA molecule. Although there is evidence 
for limited DNA synthesis in virions prior to infection (Lori et al., 1992, Trono et al.,
1992), reverse transcription usually occurs after the release o f the viral core into the 
cytoplasm of the target cell. The trigger for the initiation of reverse transcription is not 
clearly understood, but exposure o f the incoming viral ribonucleoprotein complex to a 
significant concentration o f deoxyribonucleotides in the cytoplasm is thought to play an 
important role (reviewed in Goff, 2001).
Specifically, following its release into the cytoplasm, the viral core undergoes a partial 
and progressive disassembly (uncoating). This results in the generation of subviral 
particles termed reverse-transcription complexes (RTCs) and pre-integration complexes 
(PICs). Some viral and cellular proteins appear to influence the uncoating and/or the 
reverse-transcription o f retroviruses, including HIV-1 Nef, Vif and the cellular protein 
cyclophilin A (CypA), and in some cases their mode o f action is not entirely clear 
(reviewed in Nisole and Ali Saib, 2004). In the case of Vif, this protein has been shown 
to counteract the antiviral activity o f CEM15/APOBEC3G by preventing its 
incorporation into progeny virions (Lecossicr et al., 2003, Mangeat et al., 2003, Marin 
et al.. 2003, Sheehy et at., 2003). This cellular protein inhibits HIV replication at the 
step of reverse-transcription, so this finding is consistent with the prior observation that 
viruses lacking Vif are unable to complete viral DNA synthesis (von Schwedler et al.,
1993). In a similar interaction, CypA is believed to protect the viral capsid from the
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hum an restric tion factor R e fl, leading to  an increase in HIV-1 infectiv ity  (T ow ers et al, 
2003).
R everse transcrip tion proceeds w ith in  RTCs. This process is catalysed by the viral 
reverse transcrip tase and involves the synthesis o f  several DN A interm ediates. Through 
reposition ing  o f  these on the RNA genom e tem plate, self-prim ing enables the synthesis 
o f  doub le stranded DNA. A schem atic represen tation  o f  this process is show n in Figure 
1.3. D ue to the d iscontinuous nature o f  th is process, recom bination betw een different 
viral genom es, w ithin the sam e cell, m ay take place (Tang, Kuhen and W ong-Staal, 
1999).
Figure 1.3 Schem atic of reverse transcription of the HIV genom e.
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As shown in Figure 1.3, the first event in reverse transcription o f the HIV genome is 
synthesis o f strong-stop DNA, mediated by the viral reverse transcriptase (RT). This 
sequence corresponds to the extreme 5’ end of the viral RNA genome template and is 
generated by binding o f the 3’ terminal 18-19 nucleotides o f a host-derived transfer 
RNA (tRNA) lysine to a complementary sequence in the viral RNA, the primer binding 
site (PBS) (1). Strong-stop DNA is synthesised (2), the integral RNAse H activity of 
the RT enzyme subsequently degrading the viral RNA in the RNA-DNA heteroduplex 
(3). This reveals complementary R regions (within the LTR) at both 5’ and 3’ ends of 
the genome, which enables the hybridisation of strong-stop DNA to the 3’ end of the 
RNA template genome, referred to as first strand transfer (4). The strong-stop DNA 
now acts as a primer for minus strand DNA synthesis, which forms the complete 3’ 
LTR (5). RNAse H activity o f RT again degrades the RNA template in the 
heteroduplex formed. The polypurine tract (in the viral RNA template PPT), however, 
is more resistant to degradation, resulting in formation o f a small DNA/RNA 
heteroduplex region in the otherwise minus strand DNA copy of the viral genome (6). 
This region acts as a primer for positive strand strong-stop DNA synthesis, which in this 
instance corresponds to the extreme 3’ end o f the minus strand viral DNA template, 
including the tRNA complex at the PBS (7). Degradation of the tRNA exposes the 
ssDNA of the PBS which is complementary to the PBS at the 3’ end of the minus strand 
strong-stop DNA, enabling second strand transfer (8). Minus strand DNA is extended 
to the ends of the plus strand DNA, completing its synthesis. Extension of plus strand 
strong-stop DNA actually displaces approximately 100 nucleotides, creating a region of 
triple-stranded DNA termed the central flap (not shown). Within the cytoplasm, the 
reverse transcribed genome associates with several host proteins, forming the pre- 
integration complex (PIC). Once within the nucleus, cellular enzymes repair DNA and 
nicks to generate a continuous, linear, double stranded viral DNA, complete with two 
LTRs, ready for integration. For a review o f this process sec Tang, Kuhen and Wong- 
Staal, 1999.
1.3.3 Import into the nucleus
As indicated in Figure 1.2, the HIV life cycle requires the integration of the viral DNA 
into the host cell genome to form a provirus. To achieve this, PICs, must enter the 
nucleus (for review see Sherman and Greene, 2002). For most retroviruses PICs are 
only able to enter the nucleus when the cell is undergoing mitosis, hence nuclear entry
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is dictated by the cell cycle and replication is not possible within non-dividing cells. 
Lentiviruses such as HIV, however, can productively infect non-dividing cells such as 
macrophages or quiescent T lymphocytes, indicating that PICs are able to actively cross 
the nuclear membrane (Weinberg et a l, 1991, Bukrinsky et al., 1992). Since HIV PICs, 
composed of the double-stranded linear DNA associated with the viral proteins MA, 
RT, IN and Vpr have an estimated diameter o f 56 nm (Miller, Famet and Bushman,
1997) and the central channel o f the nuclear pore has a maximum diameter of 25 nm, 
HIV has developed a strategy to enable passage through these structures. The actual 
mechanism, however, remains elusive.
It has been proposed that HIV uses the host cell cytosolic nuclear transport machinery 
to transfer its DNA into the nucleus, via nuclear pores, based on the presence of nuclear 
localisation signals in components o f the PIC including the IN and MA proteins 
(Bukrinsky et al., 1992). Involvement o f Vpr (another protein component o f PICs) in 
nuclear import, however, is one of the most controversial. It has been found to interact 
directly with components of the nuclear pore complex, which is believed to enhance 
nuclear import efficiency (Popov et al., 1998 a,b). In addition, Vpr expression has been 
shown to induce transient bulges in the nuclear envelope, which can rupture, creating a 
channel between the nucleus and the cytoplasm through which PICs may pass (de 
Noronha et al., 2001). The precise role o f these nuclear envelope disruptions, however, 
remains uncertain as Vpr-deficient viruses can infect non-dividing cells efficiently 
(Bouyac-Bertoia et a l, 2001, Reil et a l, 1998). In contrast, the Vpx protein encoded by 
HIV-2 and SIV has been shown to be both necessary and sufficient for the nuclear 
import of PICs (Fletcher et a l, 1996). Finally, a non-protein component of the PIC that 
has been described to be important for nuclear entry is the central flap, created during 
reverse transcription of the viral RNA genome. It has been proposed to act as a cis- 
acting determinant in nuclear import as its elimination has been shown to result in 
accumulation o f linear viral genomic DNA in the cytosol (Zennou et a l, 2000).
1.3.4 Integration into the host genome
Once within the host cell nucleus, integration of viral DNA into the host cell genome 
proceeds. Figure 1.4 shows a schematic of the integration process.
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Figure 1.4 S ch em atic  o f viral integration.
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T he p rocess o f  in tegration  is in itiated  and cata lysed  by  the association o f  the viral 
protein IN w ith each end o f  the linear doub le  stranded  viral D N A  genom e. H ere, it 
rem oves tw o nucleo tides from  the 3 ’ term inus o f  each strand, and catalyses a 
nucleophilic attack o f  the recessed  3 ’ hydroxyl (O H ) groups on phosphodiester bonds in 
each  o f  the target ce llu lar D N A  strands. Each strand o f  the viral D N A  is then jo in ed  to 
the ce llu lar DN A , leav ing  a 4-6  bp m ism atch  at each  end. C ellu lar gap repair enzym es 
rep a ir these, leaving a 4 -6  bp duplication  at both  the 5 ’ and the 3 ’ ju nction  betw een host 
ce llu la r D N A  and viral D N A  (H indm arsh  and Leis, 1999). T he in tegration p rocess is 
be lieved  to be sem i-random , in that there are certain  ‘h o t-sp o ts’ w here in tegration 
occurs w ith g reater frequency, w hich typ ically  correspond to transcrip tionally  m ore 
ac tive sites w ith in  host ch rom osom es (S ch roder et a l, 2002).
1.3.5 Transcription o f  viral genome
HIV transcrip tion  is m ediated  by a single p rom oter in the 5' LTR. Expression from the 
5' LTR  generates a 9.3 k ilobase (kb) p rim ary  transcrip t w hich is approxim ately  600 
bases  sho rter than the p rovirus at the 5 ’ end , and w hich encodes all nine HIV  genes.
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This primary transcript can be spliced into one o f more than 30 mRNA species 
(Schwartz et al., 1990) or packaged without further modification into virion particles (to 
serve as the viral RNA genome). The U3 region (for unique 3' sequence) is 
approximately 450-bp in length and, as shown (Figure 1.3), is located at the 5' end of 
each LTR. The U3 region contains most o f the cis-acting DNA elements, which are the 
binding sites for cellular transcription factors (reviewed in Pereira et al., 2000). The 
central region of each LTR contains the 100 bp R (repeated sequence) region. 
Transcription begins at the first base o f the 5’ R region and polyadenylation occurs 
immediately after the last base o f the 3 ’ R region. The U5 region (for unique 5' 
sequence) is 180-bp in length and contains the Tat binding site and packaging sequences 
o f HIV.
The process o f transcription o f the viral genome is initiated by the binding of the host 
RNA polymerse II enzyme (RNA pol II), together with several regulatory factors 
(TFIIA, TFIIB, TFIID, TF1IE, TFIIF and TFIIH), to the TATA box present in the basal 
promoter region o f the 5’ LTR U3. The helicase action o f TFIIH results in separation o f 
an 11 bp stretch o f the DNA and phoshorylation o f the C-terminal domain (CTD) of the 
RNA pol II enzyme, initiating elongation o f the transcript. The phosphorylation of the 
RNA pol II enzyme is regulated by both negative transcription elongation factors (N- 
TEFs) and positive transcription elongation factors (P-TEFs), the main positive 
elongation factor involved being P-TEFb, which is composed of two subunits: cyclin T1 
and cyclin dependent kinase 9 (cdk9). Specifically, this phosphorylates the CTD of 
RNA pol II, complexed to the HIV promoter, causing the dissociation of two N-TEFs, 
DSIF and NELF (Garber and Jones, 1999). In addition to these host factors, however, 
in order for full-length transcription o f the viral genome to occur, the viral protein Tat is 
required. This protein binds to a short stem-loop structure present in the R-region of 
each viral transcript, named the trans-activation response element (TAR). This binding 
facilitates Tat interaction with the cyclin T1 component of PTEF-b, in effect recruiting 
it into the transcriptional complex and enabling it to phosphorylatc the CTD of RNA pol 
II, resulting in the enhanced transcript elongation required (Daclemans, De Clercq and 
Vandammc, 2001). In addition, it should be noted that early expression of viral genes 
from unintegrated viral cDNA has also been described (Butera et al., 1991, Stevenson et 
al., 1990, Teo et al., 1997, Cara et al., 1996, Wu and Marsh, 2003). Although the role of
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this early expression is not clear, it is enhanced in the presence o f Vpr (Poon and Chen, 
2003).
1.3.6 Nuclear export o f  viral RNA
The primary HIV-1 transcript contains multiple splice donors (5' splice sites) and splice 
acceptors (3* splice sites), which can be processed to yield more than 30 alternative 
mRNAs (Schwartz et al., 1990). HIV-1 mRNAs fall into three size classes: an 
unspliced 9-kb primary transcript which can be expressed to generate the Gag and Gag- 
Pol precursor proteins or be packaged into virions to serve as genomic RNA; 
incompletely spliced RNA which can potentially express Env, Vif, Vpu, Vpr and the 
single-exon form of Tat (~ 4 kb); and fully spliced RNA, which have the potential to 
express Rev, Nef, and the two-exon form o f Tat (~2 kb) (Malim and Cullen, 1993).
Normally cellular RNAs must be completely spliced before they can exit the nucleus in 
order to prevent the translation o f intronic sequences contained in partially spliced 
mRNAs. In the case of HIV, therefore, fully spliced viral mRNAs exit the nucleus by 
using the export pathway followed by the majority o f cellular mRNAs, resulting in the 
immediate expression o f Nef, Tat, and Rev. In contrast, the two RNA species that 
contain intronic sequence (unspliced and singly spliced viral RNAs) require assistance 
in order to bypass the normal "check point" o f RNA splicing and be exported from the 
nucleus. This is achieved by the action o f the regulator o f expression o f virion (Rev) 
protein, which binds to viral RNAs that retain intron sequences. This interaction is 
mediated by a 351 nt region of extensive secondary structure, within the Env coding 
region, called the Rev response element (RRE) (Mann et al., 1994). Rev contains both 
nuclear export and import signals, so it may shuttle both in and out of the nucleus, 
depositing intron containing viral RNAs in the cytosol (Meyer and Malim, 1994). As 
threshold levels of Rev are necessary for exporting intron-containing HIV mRNAs, this 
explains why these encode the viral late gene products.
1.3.7 Translation o f  viral RNA
HIV-1 mRNA, once within the cytosol, is translated into protein by the host cell 
translation machinery. Structural proteins encoded by the Gag gene are translated from 
an unspliced, genomic viral RNA as a 55 kDa fusion protein including MA, CA, NC 
and p6. In approximately one in every twenty Gag translation events, however, the
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cellular translation machinery undergoes a -1 frameshift in the p6 coding region. In this 
event, translation does not stop at the Gag stop codon, but continues on into the adjacent 
Pol sequence to generate a 160 kDa polyprotein fusion o f Gag and Pol, including PR, 
RT and IN. It is the activity o f PR that releases the individual enzymatic protein 
components within this polyprotein (Cimarelli and Darlix, 2002). A single spliced viral 
RNA encoding the envelope proteins gp41 and gpl20 is targeted to the endoplasmic 
reticulum (ER), where a gpl60 precursor is synthesised alongside other integral 
membrane proteins synthesised by the host. Here, gpl60 is glycosylated and associates 
into trimers before being cleaved to form gpl20 and gp41 within the golgi apparatus. 
This mature envelope protein is then trafficked to the cell membrane, for viral assembly 
and budding.
1.3.8 Virion assembly and budding
There are still many processes not fully understood in terms o f the location in the host 
cell at which retrovirus assembly takes place, and the mechanism by which Gag 
proteins target the subcellular site o f assembly. It is widely held, however, that the first 
stage in virion assembly is the targeting o f the Gag precursor to the host cell membrane. 
This is mediated by the M-domain, at the N-terminus o f this polyprotein, which inserts 
into the plasma membrane and enables electrostatic interaction between the polar 
phopholipid head groups within the membrane and a number o f basic amino acid 
residues within the M-domain. Each virion requires the incorporation o f approximately 
1200 Gag molecules, association between which are mediated by interaction domains 
within NC, MA and CA proteins. The NC protein, within Gag, also includes two Cys- 
His boxes that bind to the virion packaging signal sequence, present in viral genomic 
RNA. This ensures the inclusion o f viral genome within particles, as they form at the 
cell surface (Kaplan, 2002).
The gradual accumulation o f Gag molecules at the cell membrane results in the 
formation o f ‘blebs’, which increase in size and curvature until the membrane can fuse 
behind the viral particle, releasing an immature virion (Gottlinger, 2001). Several host 
proteins have been implicated in this budding process, including tumour susceptibility 
protein-101 (TsglOl), ALG-2-interacting protein 1 or ALG-2-interacting protein X 
(AIPl/Alix) and vacuolar sorting protein-4 (Vps4). In the absence o f TsglOl and Vps4, 
aberrant viral budding occurs: viral particles remain tethered to the cell membrane by
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stalk-like projections (Garrus et al., 2001). Finally, viral particles are only fully 
infectious once they have matured. This process involves cleavage of Gag into its 
constituent parts by PR, as described (section 1.3.7): MA lines the inside o f the viral 
envelope, CA monomers condense to form a cylindrical core, which surrounds the NC- 
coated viral genomic RNA (Briggs et al., 2003, Figure 1.1/ l .2).
It has been recognized, however, that in certain cell types such as macrophages 
assembly and budding o f HIV virions can take place at an intracellular compartment. 
Several groups have recently demonstrated that this compartment is the late endosome 
or multivesicular body (MVB), and it now appears that while the plasma membrane 
likely represents the predominant site o f assembly for these viruses, Gag can also target 
and assemble in an endosomal compartment in a variety o f cell types (reviewed in Freed 
and Ross, 2004).
In addition, as it buds through the host membrane the HIV virion acquires several host 
molecules, both within its viral envelope and the particle itself (reviewed in Ott, 2002). 
There is evidence, however, that this process is not random (Nguyen and Hildreth,
2000). Rather, it is suggested that the virions preferentially assemble and bud through 
microdomains within the cell membrane termed ‘lipid rafts’. Specifically, it has been 
suggested that the Env glycoproteins traffic with cholesterol and sphingolipids from the 
golgi apparatus to these rafts (Campbell, Crowe and Mak, 2001). There is evidence that 
Gag too is targeted to these raft domains, after binding to the membrane (Ono and 
Freed, 2001). This, in combination with a similarity between the molecular components 
o f lipid rafts and the HIV viral envelope, is suggestive that viral budding and perhaps 
assembly, occurs at membrane raft domains.
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1.4 HIV and AIDS
As described  in section 1.1, HIV has been characterised  as the causative agent o f  A ID S, 
w hich as a d isease m ay be d ivided into both acute and chronic phases. The acute phase, 
in m ost individuals, is associa ted  w ith a b rie f period o f  flu-like illness (C ooper et al., 
1985) and is characterised  by a high level o f  viraem ia, the rapid evolution o f  a cytotoxic 
T -cell (C T L ) response, the synthesis o f  an tibodies d irected  against the virus and virally 
infected  cells, and a rapid decline in C D 4+ T -cells. D espite pow erful cell-m ediated and 
hum oral responses to HIV infection, how ever, sterilising im m unity is not achieved and 
a chronic infection is established. O ver the course o f  several years, continuous HIV 
replication results in C D 4+ T-cell attrition , increasing viral load and the occurrence o f  
A ID S-defining infections and cancers, d irectly  due to im m une deficiency (F igure 1.5). 
In the m ajority o f  individuals, this chronic phase lasts for approxim ately  eight to ten 
years. T here is, how ever, som e variation in this in that a sm aller percentage 
(approxim ately  10%) o f  ind iv iduals progress rapidly and develop AID S w ithin tw o or 
three years (rapid progressors). C onversely , an even sm aller percentage o f  HIV infected 
individuals are term ed long-term  non-progressors (LT N P) (Sheppard et al., 1993).
Figure 1.5 G eneralised im m unological profile of a HIV-1 infected individual with 
progressive infection.
CTL response
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By definition, LTNP remain asymptomatic, with normal CD4 cell counts and low or 
undetectable viral load, in the absence o f any antiretroviral therapy. The cause of the 
lack o f progression in these persons is unclear, but it seems to result from the interaction 
between multiple factors linked to the virus and the host (Anastassopoulou and 
Kostrikis, 2003). HIV-2 infection is distinct from HIV-1, however, in that the majority 
o f HIV-2 infected individuals display disease progression similar to that o f HIV-1 
LTNP (Kanki, 1999). The recognition o f what factors are the main determinants for 
protection against disease progression in HIV-1 LTNP and HIV-2 infection are o f great 
interest, since it may allow new treatment strategies to be designed (Rodes et al., 2004).
1.4.1 Transmission and targets fo r  HIV infection
The main routes o f HIV-1 transmission are listed in Table 1.1. World-wide, the vast 
majority o f new infections are acquired through heterosexual contact, although in 
different geographical locations the relative contribution o f different transmission routes 
may differ (Hansasuta and Rowland-Jones, 2001).
Despite there being a wealth o f information regarding routes o f HIV infection, however, 
very little is known about the actual molecular processes involved in sexual 
transmission. In the case o f male to female transmission, as semen has been shown to 
contain both free infectious HIV-1 virions and HIV-1-infected cells, transmission could 
potentially occur via cell-free or cell-associated virus (Zhang et al., 1998). Current data 
suggest that there are at least two routes to penetrate the vaginal epithelium and reach 
lymphoid tissues: trans-epithelial migration of infected Langerhans cells or virus 
penetration into the lamina propria through loss o f epithelial integrity resulting in direct 
infection of lymphocytes, dendritic cells and macrophages. The matter of which cells 
are first to be infected, however, is a matter o f some controversy and whilst the lack of 
an in vivo model has hampered this field o f study, certain in vitro studies have been 
useful.
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Table 1.1 Routes and likelihood of HIV-1 transmission.
STUDY
POPULATION TRANSMISSION ROUTE
TRANSMISSION
PROBABILITY
Heterosexual US (male to female) 0 .0008-0.001
US (from male to female, and from female to 
male)
0 .001
Europe (from male to female, and from 
female to male)
0.0005-0.001
Thailand (from male to female) 0.002
Thailand (from female sex workers to men) 0.03-0.06
Kenya 0.1
Homosexual US (receptive anal sex with ejaculation) 0.005-0.03
Perinatal transmission Thailand
- Without AZT 18.9%
- With AZT 
Cote d'Ivoire
9.4%
- Without AZT 24.9%
- With AZT 
USA
With Caesarean section and anti­
retrovirals:
15.7%
- All three trimesters 2%
- One or two trimesters 
Without Caesarean section but with anti­
retrovirals:
8.2%
- All three trimesters 7.3%
- One or two trimesters 16.4%
Without caesarean or antiretrovirals 19.0%
Newborn Breastfeeding:
- 6 weeks 3.9%
- 14 weeks 10.2%
- 6 months 11.3%
- 12 months 14.1%
- 24 months 16.2%
Healthcare workers Percutaneous (Thailand) < 0.5%
Percutaneous (Holland) 
Percutaneous (Tanzania)
0.3%
Healthcare workers 0.27%
Surgeons 0.7%
Blood recipients Blood transfusion -  screened blood
- Developed countries 0.003-0.0007%
- Developing countries 5-10%
Intravenous drug users Blood contamination No reports
Artificial insemination 
with contaminated 
sperm
Case report
R eproduced  from H ansasuta and R ow land-Jones, 2 0 0 1.
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An organ culture o f human cervical tissue identified the earliest infected cells to be 
CD4+ T-cells residing in the lamina propria o f the mucosa (Gupta et a l, 2002). Whilst 
rare in the periphery, these predominantly CCR5+/CXCR4-/CD4+ memory T-cells are 
abundant in mucosal tissues, representing a large proportion o f the total T-cell pool, 
potentially providing an important site for viral replication during acute infection. In 
terms o f Langerhans cells (LCs), these reside in the cervicovaginal epithelium and their 
normal trafficking pattern to T cell zones o f lymph nodes suggests a significant role in 
HIV transmission (Romani et al., 2001). HIV may come into direct contact with these 
cells either through exposure o f cellular processes to virions in the vaginal lumen or 
through trauma, which may increase the number o f LCs exposed to virus. It is unclear 
whether exposure to HIV virions alone is sufficient to induce LC migration but skin- 
derived LCs are susceptible to HIV infection (Kawamura et a l, 2000, Tchou et al.,
2001) and infected LCs are readily detectable in the oral (Chou et al., 2000) and vaginal 
mucosa (Bhoopat et a l, 2001) of HIV positive individuals. HIV-infected mucosal LCs 
may therefore mediate transmission o f HIV across the intact genital epithelium. In 
addition to epithelial LCs, CD la -, CD4+ sub-epithelial dendritic cells (DCs) have a 
similar capacity for uptake and transport o f virus to draining lymph nodes. These cells 
express C-type lectin receptors including DC-specific intercellular adhesion molecule 
(ICAM)-grabbing non-integrin (DC-SIGN) (Geijtenbeek et a l, 2000), which binds HIV 
via interaction with high mannose residues expressed on viral gpI20. Virus is 
internalised by the DC and retained in an infectious form for up to 5 days (Pohlmann, 
Baribaud and Dorns, 2001), time enough for the dissemination o f infectious virions to 
the T-cell-rich environment of the lymph nodes without direct DC infection. Infected 
DCs residing in lymphoid tissue are thus thought to represent an important viral 
reservoir, throughout the course o f disease. Finally, although the prevalence o f HIV-I- 
infected macrophages in mucosal surfaces is low (0.06% of lamina propria mononuclear 
cells), the extraordinary size of mucosal surfaces (in particular GALT) imparts to 
intestinal macrophages a prominent role as a HIV-1 reservoir (Smith et a l, 2003). 
Furthermore, monocytes/macrophages may act as a Trojan horse to transmit HIV-1 to 
the central nervous system (Verani, Gras and Pancino, 2005).
1.4.2 Immune response to HIV infection and immune deficiency
As indicated in Figure 1.5, antibodies can be detected in the blood at high titre during 
the acute phase of infection. The evolution of a CD8+ T cell-mediated immune
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response at this time correlates with the reduction in viraemia shown; antibodies 
generated at this stage often directed against the HIV-1 structural proteins (Pantaleo and 
Fauci, 1996). In this acute phase, in addition to viral cytopathic effects, CD8-mediated 
killing is thought to contribute to CD4+ depletion. It is when the acute phase viraemia 
is brought under control that CD4+ count can rebound and chronicity is established. 
During this phase, chronic activation o f the immune system can strain homeostasis of 
naive and resting memory T cell pools indirectly in a number o f ways and, when 
coupled to the impact of ongoing, low-level destructive events mediated by virus, this 
strain leads to the progressive depletion o f CD4+ T cell pools. Cumulative HIV- 
induced damage to the thymus and bone marrow, together with age-related reduction in 
thymic output, also limits the capacity o f the body to replenish the naive T-cell pool 
during chronic infection, contributing to the gradual CD4+ and CD8+ T-cell decline. 
Maintenance o f a strong cell-mediated response to HIV-1 infection has been associated 
with non-progressive infection (Copeland and Heeney, 1996), but viral escape from 
immune control is a defining feature o f HIV infection. The ability o f HIV to rapidly 
mutate and evolve under immune pressure ultimately renders both CTL and antibody 
responses sub-optimal, and viral replication cannot be contained indefinitely. It is also 
the case that HIV has evolved specific and directed mechanisms to interfere with host 
immune responses, including down regulation of MHC class I on infected cells by the 
accessory protein Nef.
It is, however, not only loss of T-cells that results in the development of immune 
deficiency. Polyclonal B-cell activation and production o f autoantibodies contributes to 
a widespread immune dysfunction, alongside a reduction in natural killer (NK) cell and 
cytotoxic T-cell activity. T-helper cells also become less responsive to antigens, 
possibly due to: gpl20 and Tat-induced anergy (Copeland and Heeney, 1996); defects 
in the function of antigen presenting cells (APCs) (Donaghy et al., 2003); and 
perturbations in the cytokine signalling network (Shearer and Clerici, 1998). It seems 
that destruction of the immune system is generally not part of HIV’s ‘strategy’, but 
rather AIDS is a consequence of incomplete adaptation of this virus to a relatively new 
host. For a concise review of T-cell dynamics in HIV-1 infection sec Douck, Picker and 
Koup, 2003.
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1.4.3 Features o f  HIV disease and therapy
As described in section 1.1, HIV infection was first recognised due to a specific 
complex o f illnesses in otherwise healthy individuals, characteristic o f immune 
deficiency. Today, the complex o f illnesses that are associated with and indeed define 
AIDS, is very well characterised. The WHO disease staging system is shown in Table 
1.2. Early in the epidemic, however, treatment of AIDS was in fact treatment o f these 
opportunistic infections resulting from immune deficiency. It was not until 1989 and 
development o f the first directed anti-HIV drug that treatment of the viral cause of 
immune deficiency began. ACTG019 was a trial o f the drug zidovudine, or AZT, 
which showed that AZT could slow progression to AIDS in HIV positive individuals in 
the absence of symptoms. In the same year the second drug for the treatment o f AIDS, 
dideoxyinosine (ddl), was made available to people with AIDS, even though only 
preliminary tests had been completed. Today, there are currently 20 approved 
antiretroviral drugs in the UK and many more in the expanded access programmes and 
trials. In terms of classification these anti-virals can be split into four main groups: 
nucleoside reverse transcriptase inhibitors (NRTIs); non-nucleoside reverse 
transcriptase inhibitors (NNRTIs); protease inhibitors (Pis); and fusion or entry 
inhibitors. These are detailed comprehensively in Stolk and Liiers, 2004, and at 
http://www.avcrt.org/introtrt.htm. In current times the use of three or more drugs in 
combination, termed highly active antiretroviral therapy (HAART), has greatly 
improved the prognosis o f HIV positive individuals by effective suppression of viral 
replication for long periods of time.
The hypermutability of the HIV genome due to the lack of proofreading ability o f the 
viral reverse transcriptase (see section 1.5.2.1), however, means that drug resistant 
viruses rapidly evolve under drug selection pressure. Experience has shown that by 
reducing viral load to below the limit o f detection on initiation of HAART, this risk of 
developing drug resistance can be greatly reduced. In the longer term this may reduce 
the deterioration in immune function and risk of clinical disease progression.
40
Table 1.2 WHO disease staging system for HIV Infection and Disease in Adults and 
Adolescents.
CLINICAL STAGE I:
Asymptomatic
Generalized lymphadenopathy
Performance scale l : asymptomatic, normal activity
CLINICAL STAGE II:
Weight loss, < 10% of body weight
Minor mucocutaneous manifestations (seborrheic dermatitis, prurigo, fungal nail infections, recurrent 
oral ulcerations, angular cheilitis)
Herpes zoster within the last five years
Recurrent upper respiratory tract infections (i.e. bacterial sinusitis)
Performance scale 2: symptomatic, normal activity_____________________________________________
CLINICAL STAGE III:
Weight loss, > 10% o f body weight 
Unexplained chronic diarrhoea > 1 month
Unexplained prolonged fever (intermittent or constant), > 1 month 
Oral candidiasis (thrush)
Oral hairy leucoplakia 
Pulmonary tuberculosis
Severe bacterial infections (i.e. pneumonia, pyomyositis)
Performance scale 3: bedridden < 50% o f the day during last month______________________________
CLINICAL STAGE IV:
HIV wasting syndrome 
Pneumocystis carinii pneumonia 
Toxoplasmosis o f the brain 
Cryptosporidiosis w ith diarrhoea > 1 month 
Cryptococcosis, extrapulmonary
Cytomegalovirus disease o f an organ other than liver, spleen or lymph node (e.g. retinitis)
Herpes simplex virus infection, mucocutaneous (>1 month) or visceral
Progressive multifocal leucoencephalopathy
Any disseminated endemic mycosis
Candidiasis o f esophagus, trachea, bronchi
Atypical mycobacteriosis, disseminated or lungs
Non-typhoid Salmonella septicemia
Extrapulmonary tuberculosis
Lymphoma
Kaposi’s sarcoma
HIV encephalopathy
Performance scale 4: bedridden > 50% o f the day during last month 
Source: h ttp ^ /w w w .avcrt.oru/hivstages.htm
C o m p ared  to  m o n o th erap y , th ere fo re , the use o f  H A A R T  is p referab le , but u ltim ate ly  
p a tien ts  on  H A A R T  do  fail therapy  in tim e. E stim a tes  are that 1/10 A ID S  p atien ts  in 
the U K  have failed  H A A R T  and req u ire  ‘sa lv ag e  th e ra p y ’, and  1/50 A ID S patien ts  
h a rb o u r v irus that is resistan t to  all d ru g s cu rren tly  av a ilab le  (K enyon , 2001). G iven  an 
in c reased  u n d ers tan d in g  o f  th is co st/b en e fit re la tio n sh ip  for p a tien ts  on H A A R T , there
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has recently been a move towards more conservative therapy, due to concerns about 
relative patient benefit versus toxicities and the difficulties of adhering to a complicated 
regimen, in the long term (Mocroft and Lundgren, 2004).
1.5 HIV Genetic Diversity and Nomenclature
One of the greatest influences in our understanding of the origin of HIV was the 
discovery that closely related viruses were present in a wide variety of African primates. 
HIV and these viruses, the simian immunodeficiency viruses (SIVs), together comprise 
the primate lentiviruses. With the exception of laboratory-associated infections of 
Asian macaques, however, studies o f the natural history of SIVs in wild primate 
populations suggest that these close relatives of HIV do not cause disease in their hosts. 
The implications o f this are crucial in our understanding of HIV evolution and 
pathogenesis.
1.5.1 HIV nomenclature
Following publication o f the first complete HIV-1 genome sequence in 1985 (Ratner et 
al., 1985), extensive sequencing revealed a wide range of genetic variants o f this virus 
infecting people worldwide. First attempts to classify HIV-1 sequences were made in 
1988, the approach being to separate viruses into European/North American and African 
strains, based on the divergence of these sequence groups in phylogenetic trees (Li et al. 
1988; Smith et al. 1988). As additional sequences from other geographic regions were 
generated, however, it became apparent that this method of classification was too 
simple. Instead, phylogenetic analysis o f env gene sequences revealed multiple 
phylogenetic clusters (referred to as ‘clades’ or ‘subtypes’). Today, HIV-1 has formally 
been split into three lineages; M (major), O (outlier) and N (non-M/O) (Simon et al.,
1998). These are inferred to correspond to separate zoonotic transmission events of 
simian immunodeficiency virus (SIV-cpz) from the chimpanzee to humans (Figure 1.6). 
Group M accounts for the majority o f HIV-1 infections worldwide and has been 
classified into 9 major subtypes termed A-D, F-H, J and K.
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Figure 1.6 Tree sh ow in g the evolutionary history o f the primate lentiviruses.
B ecause both the HIV-1 and HIV-2 lineages (red branches) fall within the simian 
immunodeficiency viruses (SIVs) that are isolated from other primates, they represent 
independent cross-species transmission events. The tree and other evidence also indicate that 
HIV-1 groups M, N and O represent separate transfers from chim panzees (SIVcpz), because  
there is a mixing of the HIV-1 and SIV lineages. Similarly, HIV-2 seem s to have been 
transferred from sooty mangabey monkeys (SIVsm) on more than one occasion. Reproduced 
from Rambaut e t  al.. 2001.
The term  ‘sub-sub type’ is used to classify  d istinctive lineages that are closely related to 
a particu lar subtype, but betw een w hich there is insufficient genetic difference to ju stify  
partitioning into a further subtype division. T hese include A l and A2, and FI and F2 
w ithin the subtype A and F groupings (R obertson et al., 2000). W hilst HIV subtypes do 
associate w ith certain geographical locations, g iven the ease o f  intercontinental travel, 
som e locations such as large cities are the foci for m ultip le circulating subtypes o f  H IV - 
1. T he presence o f  the overall high num ber o f  HIV-1 subtypes co-circulating in the 
D em ocratic Republic o f  C ongo is suggestive that this region is the epicentre o f  HIV-1 
group M (V idal et al., 2000b).
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HIV-2 is distinct from HIV-1 as, whilst HIV-1 is closely related to SIVs from 
chimpanzees, HIV-2 is closely related to SIV isolated from sooty mangabeys (Figure 
1.6). Like HIV-1, however, HIV-2 has also been classified into sub-groups based on 
genetic variation, in this case referred to as groups A-G. No sooty mangabey virus with 
a sequence falling within the HIV-2 groups A, B, C, F or G has been found, but within 
groups D and E, sooty mangabey viruses have been sequenced which are very similar to 
HIV-2 virus sequences. It thus appears that each group of HIV-2 represents at least one 
separate sooty mangabey to human transmission event (Gao et al., 1992).
Following the description of HIV-1 subtypes it was recognised that intersubtype 
recombinants could develop, for example subtype E (env gene) recombined with 
subtype A (gag gene). Such viruses with a recombinant lineage, which are fully 
transmissible, pathogenic and appear to play an important role in the HIV pandemic, are 
formally classified as circulating recombinant forms (CRFs) (Comelissen et al., 2000). 
All members of a specific CRF group share an identical mosaic structure as they appear 
to be descended from the same initial recombination event(s). To date 16 CRFs have 
been formally recognised, the specific recombination characteristics for each CRF 
shown in the published reference sequences (Table 1.3).
Table 1.3 Summary of circulating recombinant forms.
NAME REFERENCESTRAIN SUBTYPES REFERENCE
CRFOI AE CM240 A, E Carr et al.. 1996
CRF02 AG IbNG A. G Howard and Rasheed 1996
CRF03 AB Kail 53 A. B Liitsola et a t .  1998; Lukashov et al.. 1999
C’RF04_cpx 94CY032 A. G. H. K, U Nasioulas et a t .  1999; Paraskevis et al., 2001
CRF05 DF VI13 10 D. F Laukkanen et a t .  2000
CRF06_cpx BFP90 A. G. J. K Oelrichs et at .  1998; Montavon et a t .  2002a; 
Vidal et at .  2000a
C RF07 BC CN54 B'. C Rodenburg et at .  2001
CRF08 BC GX-6F B \ C Piyasirisilp et at .  2000, Rodenburg et at .  2001.
CRF09 cpx 96GH29M not yet p u b lish ed McCutchan et at .  2000
CRFIO CD TZBF061 C, D Koulinska et at .  2001
CRFl l cpx GRI7 A. CRFOI AE. G. J Paraskevis et at .  2000, Montavon et at .  2002b
CRFI2 BF ARMA159 B. F Carr et a t .  2001, Thomson et at .  2002
CRF 13 cpx 96CM-1849 A, CRFOI AE. G. J. U Wilbe et at .  2002
C RF 14 BG X397 B. G Delgado et at .  2002
CRF15 OIB 9 9 T H .M U 2 0 7 9 CRFOI AE. B l ovanabutra et at .  2003
CRF 16 A2D KISII5009 A2, D (iao et at .  2001
Source: http://w w w .hiv .lanl.gO v/content/h iv-db/H elpD ocs/subtypes-m ore.h tm l#H IV -2
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1.5.2 HIV evolution
It is generally accepted that the diversity within a viral population is a reflection o f that 
virus’ natural history. In the case of HIV, with an evolution rate of nearly 2.4 x 10‘3 
substitutions per base pair per year (Korber et al., 2000), this virus has the capacity to 
undergo genomic diversification at a rate 5-6 orders of magnitude faster than 
mammalian genes (Kumar and Subramanian, 2002). This feature makes HIV one of the 
fastest evolving organisms known to date, and makes the process o f understanding its 
natural history through the anaylsis o f gene sequences a unique challenge. The 
combination of extreme viral genetic plasticity with a complex combination of 
conflicting evolutionary forces is expressed via viral molecular adaptation and random 
genetic drift. The natural history o f HIV, as told in its genes, is hence inextricably tied 
to features o f both host and virus biology.
1.5.2.1 Mechanisms o f  generating viral variation
The relative contributions o f selection versus stochastic processes in driving viral 
diversification largely remain unresolved. The mechanistic processes that result in 
sequence variation, regardless o f the driving force, however, are well established.
Mutation and replication rate
As described in section 1.3, the replication o f H IV-1 involves the reverse transcription 
o f the viral genome into a DNA copy that integrates into the host cell genome. The 
viral reverse transcriptase, however, lacks proofreading capabilities due to a lack o f 3’- 
5’ exonuclease activity. For HIV-1, therefore, misincorporation, deletion, insertion or 
duplication o f nucleotides occurs during the process of reverse transcription at a 
frequency of KT4 to 10‘5. Together with an in vivo virus production rate of over 109 
virions per day, the persistence of viral infection and the vast number of people infected, 
this error frequency gives HIV-1 the potential for enormous expansion of viral diversity. 
Within the viral genome it is also the case that there is a profound bias toward G to A 
mutations, known as hypermutation (Vartanian et al., 1991). The reason for this has 
been elucidated in the last few years with the characterisation of the host anti-viral 
protein APOBEC3G (Sheehy et al., 2002), which is a member of a protein family that 
edits DNA/RNA by deaminating cytosine to yield uracil (Harris et al., 2003, Lecossicr 
et al., 2003, Mangeat et al., 2003, Zhang et al., 2003). In the absence of the HIV 
accessory protein Vif, ABOBEC3G is packaged into virus particles and carried forward
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into the next infection, where minus strand reverse transcribed DNA is affected by its 
action resulting in complete disruption of coding capacity and degradation. The viral 
protein V if counteracts the action o f APOBEC3G by binding it, inducing its 
ubiquitination and subsequent proteosomal degradation -  precluding its incorporation 
into new viral particles and hence its anti-viral affects (Mariani et al., 2003, Marin et al., 
2003, Sheehy et al., 2003, Stopak et a l, 2003, Yu et al., 2003). The existence of such 
anti-viral proteins, now known to be a powerful mechanism in vertebrate innate 
immunity (Harris and Liddament, 2004), has thus been imprinted on the HIV genome.
Recombination
An additional mechanism by which HIV sequence diversity may be generated is 
recombination. This process requires the co- or super-infection o f a single host cell by 
more than one viral particle, during which one copy o f each parental genome is 
encapsidated into a heterozygous virion. When infection by this virus occurs, a 
recombinant genome is generated as a result o f RT switching between alternative 
genomic templates (Goodrich and Duesberg. 1990). The viral RT is highly 
recombination prone, with an estimated 3 recombination events occurring per genome 
per round o f replication (Jetzt et al., 2000). As a result, at least 10% of the HIV-1 
strains circulating to date result from recombination among distinct viral subtypes 
(McCutchan, 2000), and recombination has now been detected at all phylogenetic 
levels: among primate lentiviruses, among HIV-1 groups, among subtypes and within 
subtypes (Rambaut et al., 2001).
1.5.2.2 Driving forces behind HIV sequence variation
As outlined in section 1.5.1, sequence variation within HIV has been quantified to a 
certain extent by the segregation of available sequence data into groups, subtypes and 
sub-subtypes. When considering this classification in the context of the driving forces 
behind sequence variation, however, one must remember that it is entirely artificial - 
based on sequence divergence alone. In asking why the subtypes have arisen, therefore, 
because this classification is not based upon phenotypic divergence the main 
explanation given is that it is likely that the different HIV-1 subtypes as we know them 
have arisen due to ‘founder effects’ in distinct populations (Rambaut et a l, 2001). In 
the case of subtype B in gay men in the US for example, introduction o f this genetic 
variant some time in the late 1970s/early 1980s was associated with high rates of
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partner exchange and risky behaviour: the ideal epidemiological conditions for 
transmission. This means that subtype B rapidly expanded and as a consequence has 
long been associated with this risk group and geographical location (amongst others). 
As there is no evidence to suggest that subtype B is more readily transmissible by 
unprotected anal sex than any other viral subtype, the probability that founder effect has 
resulted in the prevalence of HIV subtype B in this situation seems high. It is generally 
accepted that it is unlikely that fitness differences between subtypes determine subtype 
structure and distribution.
In reality it is also likely that there are HIV variants in existence that would fill the 
‘sequence gaps’ between the subtypes as we know them, but incomplete sampling for 
now leaves us with this HIV classification. The fact remains, however, that whilst it is 
unlikely that biological differences between HIV genetic variants initiated their 
introduction and consequent spread in different host populations, the historical presence 
o f different viral subtypes in genetically very different host populations may have 
modelled, and may in the future continue to model, their genetic and thus potentially 
also their biological properties. The question as to whether host adaptation within 
different populations results in selection o f viruses with different biological 
characteristics is a contentious one.
When considering the generation o f HIV sequence diversity, therefore, one must first 
consider the variety of selection pressures involved. In the case of HIV these include 
selection within the host during the course o f infection, exerted largely by immune 
pressure, host anti-viral factors and antiretroviral therapy (resulting in intra-host 
evolution), and selection between hosts (resulting in inter-host evolution). The latter is 
exerted by both behavioural and genetic diversity within the host population and is 
strongly effected by selection during transmission. It is because of these differences 
between the driving forces for inter- and intra-host evolution that the former is not 
merely a reflection of the latter, on a population scale.
Intra-host evolution
As mentioned, soon after infection HIV is subjected to strong, non-random selection 
pressures within the host. In such adverse environmental conditions, adaptation takes 
place rapidly and Darwinian evolution is played out in HIV populations within infected
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individuals (Darwin, 1859). Viruses successively fix mutations that enable evasion of 
immune responses (env gene, Richman et a l, 2003) and drug selection {pol gene, Pillay 
et a l, 2000). Despite potentially decreased fitness these latter mutations often remain in 
the absence of therapy, most of them becoming fixed in the viral population due to the 
adaptive benefit they confer. Furthermore, additional changes occur which can 
compensate for this loss of replicative fitness in drug-resistant mutants (Quinones- 
Mateu, 2002). It is widely accepted, however, that despite the strong influence of 
positive selection in intra-host evolution, allele fixation in HIV populations is often also 
a stochastic process driven by genetic drift, where survival o f lineages on the basis of 
pure chance rather than fitness does take place (Leigh-Brown and Richman, 1997). In 
this situation the effective viral population size (virus that can contribute to the next 
generation) is important, as in large populations the abundance o f viral variants is 
subject to fitness competition, while in a small population the fate o f mutants is more 
sensitive to the influence o f random events, independent o f their fitness. It is not 
agreed, however, whether intra-host effective population size o f HIV-1 is large or small 
and thus what the relative influences of positive and stochastic processes of selection 
are. Considering the ‘lifetime’ o f an average HIV infection, it seems most likely that 
both are important in governing the evolution o f HIV within an individual over time, 
with positive selection dominating under the heavy barrage of the intra-host 
environment, whereas the drop in effective population size resulting from 
seroconversion, drug therapy, or immune reconstitution may increase the role of 
stochastic forces.
Inter-host evolution
Given that HIV-1 intra-host evolution is shaped by the gain and loss o f advantageous 
and disadvantageous mutations respectively, the inter-host evolution o f HIV shows little 
evidence of being driven by positive selection. It has been shown that host-to-host 
transmission of HIV-1 is accompanied by a loss of genetic diversity, through a 
bottleneck effect (reviewed in Rambaut et a l, 2001). In this case, only a small subset of 
the donor’s viral population is successfully passed on to the recipient, yielding a very 
homogenous population during primary infection (Delwart et a l, 2002), which may not 
represent either the majority or the most fit viral sub-population from the donor. This 
bottleneck, however, does depend on population size and transmission route (Dickover 
et a l, 2001). The impact of stochastic processes on inter-host viral evolution is further
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enhanced by host behavioural factors. In addition to the bottleneck o f the transmission 
event itself, the vast differences between rates o f partner exchange on an individual 
basis further enhance the process of genetic drift. That is, viral strains with 
advantageous mutations may be transmitted successfully to a new host, but that host 
may be one with a very low rate o f partner exchange. Consequently, this move in the 
direction o f positive selection is halted. Conversely, a particularly unfit virus may find 
itself in the situation of infecting a person with a high probability o f activity resulting in 
transmission. Hence, the processes at work in relation to transmission of HIV by no 
means guarantee the propagation o f the most fit virus, and an overall increase viral 
fitness at the population level.
During the process of infection, as described, there is a great pressure exerted by the 
host resulting in positive selection o f advantageous mutations and out-growth o f viruses 
best adapted to that host. The main point o f controversy when considering this process 
o f positive selection is, within a specific host population o f similar genetic composition 
i.e. ethnic origin, is it likely that the viruses within these populations will experience 
intra-host positive selection in the ‘same direction’. It has been argued that 
advantageous mutations, such as those conferring escape from the activity of cytotoxic 
T-lymphocytes (CTL), might not appear until relatively late in infection (Goulder et al., 
1997). If these positively selected escape mutants do not appear until after most 
individuals have transmitted their virus, natural selection o f this advantageous mutant 
will not occur at the population level. Furthermore, it has been shown that in some 
cases when transmission of CTL escape mutants does occur, if the virus is transmitted 
to an individual with a non-matched human-leukocyte antigen (HLA) background, then 
the CTL escape mutations are in fact deleterious and are removed by purifying selection 
(Leslie et a l, 2004).
There is, however, some evidence that the influence o f host genetics in different 
populations has indeed moulded the genomes o f the dominant viral subtype in 
circulation, and that to a certain extent positive selection o f HIV does occur inter-host, 
at the population level and can influence the biological properties of different HIV 
subtypes. Specifically, a recent study investigated the likely selective pressures that 
have affected HIV-1 group M env sequences and their diversification from the original 
group M founder virus (Travers et al., 2005). Each individual subtype was compared
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to all other group M subtypes in an attempt to identify amino acid sites whose 
evolutionary history appeared to be unique in terms o f selective constraints for that 
subtype. The authors showed that there was considerable heterogeneity o f evolutionary 
mechanisms among the different subtypes and identified groups o f sites that were 
subject to different selective constraints in the lineages leading to each subtype. One 
category o f amino acids were identified that had undergone positive selection for 
subtypes C, FI and G, but had undergone purifying (negative) selection in all other 
subtypes. Amino acid sites within subtypes A and K. formed the second category 
identified, which had undergone purifying selection in these lineages, but had 
undergone positive selection in all others. Whilst the functional consequences of these 
differences have not been shown, it was hypothesised that the heterogeneous selection 
pressures exerted by different host populations within which the HIV-1 subtype lineages 
diverged, may account for the various levels o f fitness that have been observed in the 
group M subtypes. For example, amino acid residues involved in CD4 binding, sites 
involved in CCR5 to CXCR4 coreceptor switch, sites within the flexible linker o f gp41 
(important for tethering gp41 to the transmembrane segment, coreceptor binding and 
host cell entry) and sites corresponding to known neutralising antibody epitopes, had all 
undergone differential selection processes. Whilst a small study, this work is novel in 
that it considers for the first time that the evolution o f the HIV group M subtypes, under 
different selection pressures in different host populations, may have resulted in subtype- 
specific genetic differences and thus potentially subtype-specific biological differences.
1.5.3 The Importance o f  Genetic variation: o f  the Host and the Virus 
Host
The importance of host genetic variation in determining the outcome of HIV infection 
has been studied for some time and, whilst well established, the full extent o f this has 
yet to come to light. The majority o f information relates to human genetic factors that 
may affect the probability of acquisition o f infection, rather than those that may affect 
the probability o f propagation of infection. It is difficult, however, to distinguish the 
affects o f the infecting donor and infected recipient in terms of transmission, although 
in some cases the relative contributions are clear. Table 1.4 shows a number of 
associations between human gene polymorphisms and susceptibility to HIV-1 infection, 
and subsequent disease progession, which have been characterised.
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Table 1.4 Associations between human gene polymorphisms and susceptibility to HIV* 
1 infection.
Gene, Marker or Variant Transmission mode Ethnicity o f subjects (location) Subtype
Effect on 
risk
CCR5
A32 (HHG*2) *2 
Homo/heterozygous
Promoter HUE (P I/F I)* 3 
Homozygous
MSM, IDU, Het, Tx, White (multiple) B 
MTC*1 White (multiple) B
MSM, IDU, Het White, African American (US) B 
MTC White (Argentina) B
Decrease
None
Increase
Increase
HLA
Concordance at HLA 1 loci or MTC African (Kenya) A Increase
HLAB Het White (UK) B Increase
MTC African American (US) B Increase
Het Zambian C Increase
MTC African (Kenya) A Decrease
A2/6802 and A0206/6802*4 MSM White (US) B Decrease
CHEMOKINE GENES 
CCL3L1 -  segmental Multiple Multiple Multiple Decrease
duplication o f gene (more 
copies relative to same 
members o f ethnic group)
rr  ........----------------------- —
user; Het, heterosexual; Tx, transfusion or blood product; MTC, mother to child.
*2 The A32 (HHG*2) variant is a 32 bp deletion in the region coding for a transmembrane domain o f the 
CCR5 coreceptor. Homozygosity affords almost complete protection, and heterozygosity slight 
protection.
*3 This CCR5 haplotype enhances risk of infection (for CCR5 haplotype nomenclature see Gonzales et 
al.. 1999).
*4 Designations are for HLA supertype (see MacDonald et al.. 2001)
Modified from Kaslow, Dorak and Tang, 2005.
Chemokine receptors and their ligands play an important role in modulating 
susceptibility to HIV-1 infection. The importance of the CCR5 receptor is outlined in 
Table l.4, and in addition to this other receptors and their ligands have been implicated. 
For example, coding polymorphisms in the CCR2 gene have been associated with a 
favourable prognosis during infection, as have changes in the CCL5 gene that encodes 
RANTES (the ligand for CCR5). Changes in the latter in different populations, 
however, have also been shown to confer some disadvantage to HIV-exposed 
individuals. CXCL12, which encodes SDF-l, (the ligand for CXCR4) has also been 
implicated in modulating host susceptibility to infection, but data are less clear in this 
case. As shown in Table l.4, it is not only chemokine gene polymorphism that can 
modulate susceptibility to infection. The recent description of the effects of segmental 
duplication of the CCL3LI gene, which also encodes a CCR5 ligand, has further
51
expanded our understanding o f the host’s involvement in directing the process of HIV 
infection (Gonzalez et al., 2005).
The central importance o f the MHC class I antigen processing and presentation system, 
in terms o f HIV-1 pathogenesis, however, is not in doubt. Because HLA class I alleles 
differentially bind viral peptides, restrict generation of CD8+ CTLs and thus govern 
response to viral antigens, variation in these alleles within humans greatly varies the 
ability of different individuals to either promote or impede the initial establishment of 
infection and indeed its progression. The specific details o f MHC variation and its 
significance in disease are thoroughly reviewed in Kaslow, Dorak and Tang, 2005. It 
would be inappropriate, however, to mention MHC class I variation and not refer to 
recent research which has outlined a dominant role of HLA-B in mediating the potential 
co-evolution of HIV and HLA. As mentioned, the importance of HLA-B in governing 
disease outcome is well known. In this study, however, preliminary evidence suggests 
that because of its importance, the rate o f diversification o f the HLA-B allele is much 
more rapid than HLA-A and-C loci, in the face o f pressure exerted by the presence of 
HIV. The HIV genome accordingly bears the evolutionary scars o f repeated CTL 
escape from HLA-B induced immune pressure. Whilst not proving definitively that a 
process of HLA and HIV co-evolution is at work, in the light of this study a picture is 
emerging which is highly indicative of such a process, especially in populations where 
HIV morbidity and mortality rates are high (Kiepiela et a l, 2004).
Virus
Unlike genetic variation in the host population, the importance of HIV genetic variation 
in relation to disease is much less well understood. The literature on this subject will, 
however, be thoroughly reviewed in the introduction to Chapter 3 of this thesis. Rather, 
at this juncture it should be noted that our ability to currently classify HIV-1 sequence 
variation into subtypes facilitates epidemiological studies of HIV-1. Whilst the 
significance of viral genetic variation (manifest as subtypes) if any, is not clear, their 
existence enables detailed studies of HIV transmission dynamics, on a global scale, to 
be performed. In recent years, subtyping of HIV sequence data produced for clinical 
resistance testing, for example, has indicated an increase in subtype diversity in the UK 
(Parry et al., 2001, Tatt et al., 2004). This suggests that the ‘import’ of new genetic 
variants into the UK population from distinct geographical locations is taking place, and
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gives both researchers and clinicians an important perspective on the transmission 
dynamics within this population: where incident infections are arising and which 
sections o f the population are most at risk, for example (Tatt et al., 2004). Furthermore, 
whilst classification o f HIV-1 variation into subtypes in no way describes the totality of 
HIV-1 sequence variation within populations, it does provide a system that allows the 
effects o f HIV-1 sequence variation to be studied in sufficient numbers to be 
meaningful.
1.6 Project introduction
The aim of this thesis is to characterise the genotypic and phenotypic features of the 
different types and subtypes of HIV. The question is asked: are the differences between 
genotypic variants o f HIV manifested phenotypically and if so, do they have biological 
relevance?
It is true that in considering HIV subtype as a ‘risk’ factor, many epidemiological 
studies are flawed in that even if subtype is a true causal factor in disease phenotype, it 
may be indistinguishable from other potentially multiple factors that contribute to a 
particular outcome such as faster or slower disease progression. Comprehending these 
data can be difficult at the best of times, so for this study a conceptually more simplistic 
approach will be taken. Firstly, a computational method for accurately classifying large 
amounts of HIV sequence data, by subtype, will be created. In order for large-scale 
studies to be performed in which viral subtype is related to clinical outcome, this 
method must be both rapid and accurate and make use o f the must abundant source of 
sequence data, preferably linked to clinical information. Secondly, the phenotypic 
characteristics of several different HIV-1 subtype isolates and HIV-2 will be 
established, in vitro. The aim of this is to determine if, in a homogenous environment, 
some viral variants are reproducibly more or less ‘fit’ than others. Finally, if different 
viral subtypes grow differently in cell culture the hypothesis may be put that genetically 
variable strains of HIV will induce different transcriptional profiles within infected 
cells. If this is true, and these agree in any way with previously published observations 
regarding differences between HIV subtypes, this could lend weight to the argument 
that subtype is an important causal factor in the phenotype of HIV disease.
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Furthermore, by studying the transcriptome of cells infected with divergent strains of 
HIV using DNA microarrays, it should be possible to define a core response to the 
presence o f this virus, regardless o f variant type. These may indicate the pathways with 
which HIV must interact in order to complete its life cycle and thus provide novel 
targets for antiviral intervention.
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Chapter 2.0 Development of a HIV subtyping tool
2.1 In tro d u c tio n
Prior to the mid-1980s and introduction of polymerase chain reaction (PCR) to the 
laboratory, viruses were mainly identified by growth in cell culture and observation for 
cytopathic effects (CPE). This method was routinely used as the first means of 
detection and presumptive identification of the virus in question. Before the 
introduction of molecular methods, typing and subtyping of viruses was mainly 
achieved by serotyping: a method that employs antibodies that define antigenic 
differences. Serologic methods have been used to define major viral groups, or types, 
such as influenza virus types A to C, parainfluenza virus types 1 to 4, poliovirus types 1 
to 3, and herpes simplex virus types 1 and 2 (HSV-1 and -2, respectively) (Arens,
1999). Some virus species, however, such as human cytomegalovirus (HCMV) and 
measles virus, cannot be divided into different types or subtypes based on serology 
because significant antigenic differences do not exist (Arens, 1999). Thus, whilst 
serotyping has been useful for making relatively large distinctions between viruses it 
does not have the ability to distinguish certain viral types, or between individual isolates 
within a serotype. Such fine classification has become possible with the development 
o f molecular methods o f virus classification.
PCR and the ability to amplify single copies of DNA or RNA molecules to detectable 
levels, together with DNA sequencing, has revolutionised the process o f detection and 
characterisation of viral genomes. As a result, laboratories whose interest is the 
diagnosis and epidemiology of viral diseases have largely converted from conventional 
techniques of virus detection and identification, to more rapid, novel, and sensitive 
molecular methods. It is possible, however, that in doing so useful phenotypic 
characteristics o f viruses are not being determined and this may impair studies of virus 
biology. This concern could be applied to many viruses, but is perhaps an inevitable 
outcome of the paradigm shift of virus classification: from a discipline solely dependent 
on the observation of viral phenotypic traits (in vivo or in vitro), to one in which 
phenotypic information has become secondary to the detail contained in the viral 
genome sequence.
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A summary of molecular methods for characterisation of viruses is presented in Table 
2.0, and a selection o f the viruses to which these methods have been applied is 
summarised in Table 2.1. Multiple methods exist to facilitate the subtyping of viruses, 
ranging in their complexity, efficiency, spectrum of detection and suitability for 
different viruses. O f all the methods, however, it is DNA sequencing and methods that 
employ sequence-based hybridisation, especially microarray and chip-based techniques, 
which currently dominate the field o f viral subtyping or more specifically, genotyping.
Table 2.0 Molecular methods for characterisation of viruses.
Method Restriction Probe 
enzyme
Basis for Level of 
distinction resolution
Advantage(s) Disadvantage(s)
Nucleotide
sequencing
No No Nucleotide Single 
sequence genome (if 
cloned)
Wide applicability; Technically complex; produces 
can identify single large amounts o f data; 
nucleotide mutations automated sequencing requires 
expensive equipment
Solid phase plate No 
assay (SPPA)
Yes Nucleotide Subtypes 
sequence
Simple; Developed for HIV. Does not 
commercially detect circulating recombinant 
available forms
Microarray and 
BioChip
No Yes Nucleotide Single 
sequence genome (if 
cloned)
Wide applicability; Technically complex; produces 
can identify single large amounts o f data; requires 
nucleotide mutations expensive equipment
RFLP analysis Yes No Restriction Subtypes 
sites
Simple; wide Samples only the restriction 
applicability sites; difficult to use with RNA 
viruses
Southern
blotting
Yes Yes Restriction Subtypes
sites, probe
sites
Wide applicability; Samples only the restriction 
ability to analyse sites and probe sites; technically 
complex genomes complex; may require 
radioisotopes
Oligonucleotide No
fingerprint
analysis
No RNase T| Subtypes, 
cleavage quasi­
sites species
Directly applicable Involves complex 
to RNA viruses; can electrophoresis procedure 
detect point 
mutations
RH No Yes Probe sites Subtypes Simple; May not correctly identify all 
commercially subtypes o f  HCV 
available
DE1A No Yes Probe sites Subtypes Simple; May not correctly identify all 
commercially subtypes o f HCV 
available
RNase
protection assay
No Yes Probe sites Subtypes Readily applicable to Requires a radioactive probe; 
RNA viruses technically difficult
SSCP analysis No No Mobility Subtypes 
differences
Detects a few Identifies the presence but not 
mutations in a large the location of mutations 
number o f bases; 
simple procedure
IIMA No No Mobility o f Quasi- 
hetero- vs species 
homo­
duplexes
Can visualize a large Cannot distinguish quasispecies 
number o f with <2-3% nucleotide 
quasispecies differences; technically difficult 
and complex
Cienome 
segment length 
polymorphism 
analysis
No No Segment Subtypes 
length
Easy technique for Cannot detect mutations (detects 
use with segmented only variations in segment 
genomes length); applicable only to 
viruses with segmented 
genomes
M odified from Arens, 1999.
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Table 2.1 Application of molecular subtyping methods to specific viruses.
Virus Method(s) Referenced)
Adenovirus RFLP analysis Hierholzer, 1992, Hierholzer et al., 1988, Li et al., 1996
CMV
Huang et al., I980a,b, Kilpatrick at al.. 
RFLP analysis. PCR-RFLP analysis. Southern 1976, Spector et al.. 1982, Tolpin et al.. 
blotting, glycoprotein B genotyping 1985, Winston et al., 1985, Chem et
al., 1998
Dengue virus Nucleotide sequencing D eubele /a ., 1993
Epstein-Barr virus RFLP analysis, analysis o f termini
Falk et al., 1995, Katz et al., 1988, Rabb- 
Traub and Flynn, 1986, Sidagis et al., 
1997
Enterovirus
RFLP analysis, RT-PCR-RFLP analysis, Fujioka et al., 1995, Kuan, 1997, Minor et 
oligonucleotide fingerprint analysis, SSCP al., 1982, Mulders et al., 1995, Nottay et 
analysis, nucleotide sequencing al., 198 1
HBV Southern blotting, SSCP analysis, PCR-SSCP analysis, nucleotide sequencing, PCR/RFLP Hardie et al., 1996, Hasegawa et al., 2004
HCV SSCP analysis, PCR-SSCP analysis, RH, DEIA, nucleotide sequencing
Biasin et al., 1997, Castelain et al., 1997, 
Lareu et al., 1997, Lee et al., 1997, Le 
Pogam et al., 1998
HIV HMA, HTA, nucleotide sequencing, SSPA
Delwart et al., 1993, McNeamey et al., 
1992, Nelson et al., 1997, Tatt et al., 2000, 
Ou et al., 1992, Gonzalez-Villasenor et al., 
2000
HSV RFLP analysis. PCR-RFLP analysis. Southern blotting Buchman et al., 1978, 1979
Influenza virus RNase protection assay, HMA, nucleotide sequencing, DNA chip, microarrays
Lopez-Gallindez et al., 1988, Subbarao et 
al., 1998, Zou, 1997, Kessler et al., 2004, 
Li et al., 2001
JC virus Nucleotide sequencing Agostini et al., 1997
Measles virus RT-PCR-RFLP analysis Katayama et al., 1997
Parainfluenza virus Serotyping, sequencing Beraud et al., 1984, Komada et a!.. 19 9 1
Parvovirus B I9 SSCP analysis. PCR-SSCP analysis Ken- et al.. 1995
RSV RNase protection assay, PCR-RFLP analysis, sequencing Cristina et al., 1991, Storch et al., 1991
Rhinovirus Serotyping, nucleotide sequencing Cooney et al., I982, Duechler et al., 1987, Hughes et al., 1988, Rivera et al., 1988
Rotavirus Genome segment length polymorphism analysis Arens and Swierkosz, 1989, Dolan et a!., 1985, Gaggero et al., 1992
Small round-structured
viruses (Norwalk-like Southern blotting, nucleotide sequencing 
viruses)
Ando et al., 1995, Levett et al., 1996, 
Yamazaki el al., 1996
Varicella-zoster virus RFLP analysis, long PCR-RFLP analysis Adams et al., 1989, Takayama et at., 1996
M odified from Arens, 1999.
Today, after approximately 30 years of sequencing and databasing of sequence data, the 
NCBI database Entrez Genomes contains 1864 reference sequences for 1344 viral 
genomes and 36 reference sequences for viroids. Not only are these data central to our 
ability to investigate and understand the molecular biology of viruses, but also provide 
an invaluable resource in the study of the molecular phylogeny of viruses and their 
evolution. The availability of well-characterised reference sequences for many viruses, 
together with thousands of sequences of viral isolates deposited daily around the world,
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has enabled the construction o f virus phylogenies using phylogenetic techniques, and 
the categorisation o f virus families, type and subtypes, based on sequence data.
2.1 1 Phylogenetics and subtype classification
After sequencing, the cornerstone to any genotypic classification - be it o f an entire viral 
genome or a short fragment o f a particular gene, are the phylogenetic methods used to 
determine the relationships between the sequences being studied.
Phylogenetics is a mathematical analysis o f sequence similarity that determines the 
evolutionary relationships between sequences based on derived similarity or difference. 
The task of molecular phylogenetics is to convert information in sequences into a 
phylogram, or phylogenetic tree. Three o f the many phylogenetic analysis methods 
currently in widespread use were used in the course of this work; hierarchical clustering 
o f sequence identity matrices, neighbour joining (NJ - implemented from within 
CLUSTALW) and maximum parsimony (MP). The three methods fall into two 
phylogenetic categories, distance methods (hierarchical clustering, NJ) and discrete 
methods (MP). Common to all, however, is the fact that the basis o f determining the 
relationship between sequences relies on determining their similarity. To determine 
overall maximal similarity between two or more sequences, they must first be correctly 
aligned.
2.1.1.1 Sequence alignment
The most fundamental aspect o f sequence analysis is pair-wise sequence alignment, 
during which two sequences are compared to determine if there is a relationship 
between them that is unlikely to have occurred by chance. This therefore requires the 
sequences to be accurately aligned, a way o f scoring the similarity between the aligned 
sequences, and a method to determine the significance of the alignment relative to a 
measure o f a chance alignment of the same score (Holmes and Durbin, 1998). Most 
common scoring methods are additive, where each position within an alignment is 
assumed to be independent o f other positions. A score is derived from each position in 
the alignment, which is then summed along the length o f the sequence. Matches score 
more highly than mismatches, producing an overall higher score where the sequences 
aligned are more similar. In addition, one or both sequences may contain regions that 
are absent from the other. Such insertions or deletions do not score. In many sequence
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alignment tools, however, the most simplistic match/mismatch score of 1/0 
(respectively) is replaced by a scoring system that attempts to quantify the degree of 
mismatch between two positions in the sequence, giving greater insight into the 
similarity, or difference, between aligned sequences (described in section 2.1.1.4).
Pair-wise alignment is often used as the basis for a more useful form of sequence 
analysis, the multiple alignment. A common implementation of the multiple sequence 
alignment is CLUSTALW (Thompson, 1994). CLUSTALW generates a distance 
matrix of alignment scores from all sequence pairs, then uses a clustering algorithm (NJ 
- Saitou and Nei, 1987) based on those distances to construct a guide tree to relate those 
sequences. Nodes within the tree are then aligned in order of decreasing similarity, 
starting with the two most similar sequences. The result of this process is a set of 
sequences aligned to each other.
2.1.1.2 Phylogenetic trees
A phylogenetic tree is a mathematical structure that is used to model the proposed 
evolutionary history of a group of sequences or organisms. The pattern of historical 
relationships is the phylogeny or phylogenetic tree, which can be estimated using a 
variety of methods. Regardless of the methods by which the tree itself is generated, 
however, it always consists of nodes, connected by branches. Terminal nodes represent 
sequences for which data are held, whereas internal nodes represent hypothetical 
ancestors that can be inferred by examination of the data in hand. The ancestor of all 
the sequences in the tree is the root (Figure 2.0).
Figure 2.0 A sim ple rooted tree and a sso c ia ted  term s (from Page and Holmes, 2001)
Terminal node
Internal node 
(hypothetical ancestor)
Branch
Root
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Various kinds o f information may be associated with the nodes and branches o f a tree, 
depending on the method used to construct it. Most trees attempt to estimate the 
amount o f evolution that takes place between each node on the tree, translated in the 
tree topology as branch length.
Phylogenetic trees may be either rooted, or unrooted. A rooted tree has a node 
identified as the root from which all other nodes descend, and hence has direction. The 
closer a node is to the root o f the tree, the older it is in evolutionary time. Rooting a 
tree, therefore, gives a clear picture o f the ancestor-descendant relationships within the 
sequences studied. Typically, a sequence that represents an ancestor, or distant relative, 
o f the sequences being studied is chosen as the root. If studying HIV-1 group M 
sequences, for example, a HIV-1 group O sequence could be used as the root. Un­
rooted trees lack a root and as such do not infer the same relationships between 
sequences as when displayed in a rooted tree. In un-rooted trees the proximity o f nodes 
can only be interpreted as indicating the similarity or distance of the sequences at those 
nodes, to each other. There is therefore no directionality to un-rooted trees.
2.1.1.3 Distance methods
Distance based phylogenetic methods rely on matrices o f pairwise sequence distances, 
the most simple sequence distance being the fraction of identical residues (nucleotide or 
amino acid) between two aligned sequences. Given an alignment of sequences, distance 
methods first convert these aligned sequences into a matrix of pair-wise genetic 
distances. A measure o f dissimilarity between sequences is calculated for every pair of 
sequences in the alignment as the fraction o f positions in which the two sequences 
differ. The distance method process therefore takes place in two stages; first, the 
evolutionary distance is calculated for every possible sequence pair in the given 
alignment, and second, the tree is inferred on the basis o f the relationship between the 
distance values. In the case of the simplest method used in this study, straight sequence 
identity is calculated from the sequence alignment and then tree building achieved using 
hierarchical clustering (Page and Holmes, 1998). Models more complex than merely 
considering straight sequence identity or similarity exist, however, for both protein and 
nucleotide sequences. For nucleotide sequence, the first alternative model proposed that 
all nucleotide substitutions were equally likely (Jukes-Cantor); this was then modified 
to include transition/transversion frequencies and organismal base composition (Kimura
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et al., 1980). The General Reversible model (Yang et al., 1994) allows for unequal 
frequency between each o f the 6 pairs o f nucleotide substitutions. In this study, 
however, we did not attempt to use a more complex model than simply measuring 
sequence identity -  rather two separate tree building methods were employed to 
represent the same distance matrix (hierarchical clustering and NJ).
Distance methods o f determining molecular phylogeny are the most simple as they 
assume that the genetic distance between sequences being compared can be applied to a 
tree to directly reconstruct the evolutionary history of those sequences. It is rare, 
however, that these distances match exactly tree metrics. As such, ‘goodness o f fit’ 
methods seek the tree that best accounts for the ‘observed’ distances. Alternatively, the 
tree whose sum of branch lengths is minimal (i.e. constrained to find the tree with the 
shortest evolutionary pathway) may be sought (‘minimum evolution’). In this study, 
hierarchical clustering and NJ algorithms were used to build trees based on sequence 
identity. The former is the simplest method, and is not commonly used to represent 
phylogenetic relationships between sequences. NJ - the second distance based 
phylogenetic method used (Studier and Keppler, 1988), however, is one o f the most 
popular methods for tree building and is implemented within the CLUSTALW 
algorithm. It combines computational speed with ease o f implementation and employs 
a minimum evolution strategy on the basis of which a single tree is built by gradually 
finding neighbours exhibiting the minimum genetic distance. NJ, however, is a 
heuristic method for estimating the minimum evolution tree and does not guarantee to 
find the most likely tree. The main criticism of distance methods such as these, 
therefore, is that by summarising a set of sequences by a pair-wise matrix, information 
that could be used to better understand the relationship between those sequences, is lost.
2 .1.1.4 Discrete methods
Discreet methods for construction of phylogenetic trees attempt to avoid the loss o f 
information inherent in distance-based methods, when sequences are converted to 
distances. The two main discrete methods are Maximum parsimony and Maximum 
likelihood.
Maximum parsimony, the third and most complex phylogenetic method used in this 
study, is a discrete tree building method that takes a multiple alignment of sequences as
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input and chooses the tree (or trees) that requires the fewest evolutionary changes, or 
mutations. That is, starting from an initial topology, the maximum parsimony algorithm 
infers the minimum number of mutations required to justify all nodes o f the tree at 
every sequence position. The process is repeated for all theoretically possible tree 
topologies and the tree requiring the minimum number o f evolutionary changes, called 
the minimum tree, is selected as the best tree. It is the case, however, that by 
constraining the optimal tree to one that invokes the fewest possible evolutionary 
changes, the result may not necessarily reflect the minimal evolution between two 
terminal nodes. Given that all evolutionary changes between two sequences may not be 
visible, such as multiple substitutions at the same nucleotide position, the dissimilarity 
between two distantly related sequences might be underestimated in a parsimony tree. 
Despite this, we used an MP method in this study: PHYL1P protpars (Felsenstein, 
1989). This program counts amino acid substitutions in terms of the mutations at the 
nucleotide level that would be required to go from one amino acid to another.
As an alternative, the discrete method maximum likelihood chooses the tree (or trees) 
that, o f all trees, is the most likely to produce the observed data. It is computationally 
significantly more expensive than any methods described above and, whilst perhaps 
constituting the best method available to reconstruct a molecular phylogeny, it has not 
been used in this study.
2.1.2 Viral subtyping
In essence, molecular characterisation and subtype classification o f viruses relies upon 
the basis that viral genes may vary (mutate), within the functional constraints of the 
proteins they encode. PCR amplification and sequencing allows small sections o f the 
viral genome, including small variable regions that define viral subtypes within more 
conserved genome regions, to be compared. In addition, with the development of ‘long 
PCR’ methods entire viral genomes may be amplified and used to determine subtype 
specific classification, which in this case may include traits held in un-translated 
regions, unique as they may include random mutations that persist in the absence of 
immunological pressure. Furthermore, with whole-genome analysis recombinant 
genomes, composed of two or more different subtype-derived fragments, may be 
detected.
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In certain cases, however, small regions o f a viral genome sequence may be the only 
genetic information available. For example, clinical isolates of HIV routinely have only 
protease (PR) and part of reverse transcriptase (RT) amplified and then sequenced (PR- 
RT). The products o f these genes are drug targets, which are sequenced to determine 
antiretroviral resistance. Such regions were not traditionally considered suited to 
subtyping due to low levels of sequence variation. However, several studies have 
suggested that it is possible to distinguish between subtypes based on the sequence 
variation within pol (Pasquier et al., 2001, Njouom et al., 2003, Gale et al., 2004). In 
this situation, therefore, a readily available resource may be exploited for HIV 
subtyping.
2.1.2.1 HIV subtyping
The molecular classification o f HIV was previously described (Chapter 1.0). In short, 
maximum likelihood phylogenetic analysis o f env gene sequences revealed three 
lineages; M (major), O (outlier) and N (non-M/O) (Simon et al., 1998). Within group 
M, 9 major subtypes were identified, termed A-D, F-H, J and K, and within the subtype 
A and F groupings the sub-subtypes Al and A2, and FI and F2 were characterised 
(Robertson et al., 2000). Several circulating recombinant forms have also been 
described. HIV subtyping methods predominantly rely on phylogenetic analysis o f 
HIV-1 nucleotide sequences, often o f the envelope gene. For more high throughput 
analysis, however, three web-based genotypic subtyping tools are available, at NCBI 
(Subtyping Tool), Stanford (HIV-SEQ) and Los Alamos (SUDI) websites.
The NCBI Subtyping tool uses the BLAST algorithm to score local sequence similarity 
along a sliding window of nucleotide sequence to match the most similar subtype to a 
query sequence (Rozanov, 2004), and any part of the HIV genome may be analysed. 
Alternatively, the Stanford tool calculates genetic distance between the query sequence 
and a set of reference sequences, but will classify only PR-RT sequence. Both of these 
web based subtyping tools use a limited set of subtype reference sequences that 
represent only a small fraction of the true sequence variability within each HIV subtype. 
Both methods also compare the query sequence against each reference sequence 
independently, and as a consequence they lack the ability to assign subtype based on 
group properties, or subsets of properties. The use of a BLAST based tool to analyse 
very highly related sequences (NCBI) is also problematic as the sequence modelling
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and statistics associated with BLAST were designed to evaluate the probability o f a 
match compared with random sequence (http://www.ncbi.nlm.nih.gov/BLAST/). This 
form o f random model is therefore inappropriate when comparing clinical HIV-1 
sequences with HIV-1 reference sequences, as whilst the lowest BLAST score may 
indicate the most probable subtype, the scores from other subtypes are equally likely to 
be significantly similar. Essentially the use of BLAST, in this context, renders the 
computed statistics invalid. The Stanford subtyping tool, however, provides a better 
alternative and it is this method which is used to subtype the majority of sequence data 
produced during resistance testing as the same website provides a facility to 
simultaneously detect resistance and resistance-associated mutations 
(http://hivdb.stanford.edu/). Neither the NCBI nor Stanford methods attempt to assign 
any confidence to the subtype predictions made, however, making assessment o f the 
reliability, sensitivity and specificity of their subtype predictions very difficult. Both 
methods require nucleic acid as input.
It is clear, therefore, that the subtyping methods available vary in the level of 
computational and statistical robustness for assigning subtype, the two methods 
mentioned providing only a basic means o f assigning subtype. An alternative method, 
SUDI, is designed to help determine if a newly defined set o f related sequences should 
most appropriately be considered a new subtype, a new sub-subtype, or part of a 
previously defined subtype. Ideally, it should be used in conjunction with other tools 
that will identify recombination and phylogenetic relationships, and as such requires a 
certain level or pre-processing of HIV sequence (requiring phylogenetic analysis 
packages and some considerable computing power).
To date, most studies involving the determination of HIV subtypes have used the gag 
and env genes for subtyping as their genetic variability is greater than that seen in pol. 
As mentioned previously, however, the more conserved pol gene is sequenced routinely 
in many laboratories to identify antiretroviral therapy (ART) resistance-associated 
mutations and as such has made nucleotide and amino acid sequences from these 
regions widely available as material for subtyping HIV-1. As a consequence of recent 
guidelines (Hirsch et al., 2000; Miller et al., 2000), the practice o f sequencing this 
region o f the HIV genome in patients exposed to ART will become increasingly 
commonplace. The volume of Pol sequences available, or more specifically PR amino
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acids 1 -  99 and RT amino acids 1 -  340 (PR-RT), should thus prove valuable in 
molecular epidemiological studies. It is for these reasons that the aim of the work 
described in the first section of this thesis was to develop a HIV subtyping tool that 
could use sequences, produced for resistance testing, as its input.
2.1.2.2 Relevance o f  HIV genotyping 
Epidemiology
The accurate and rapid determination o f HIV-1 subtypes is important from an 
epidemiological standpoint. By monitoring the distribution of subtypes in a population 
much information can be gleaned about the transmission dynamics o f the epidemic in 
question, its age and the rate of introduction o f new sequences. Since the onset of the 
HIV pandemic in the early 1980s there has been a renewed interest in the emergence 
and evolution o f infectious disease. In the case o f HIV, the use of molecular 
phylogenetics in the reconstruction o f the HIV-1, -2 and SIV phylogeny was described 
in the introduction to this thesis. The use of phylogenetic trees has been central to this 
process, but their use is not limited merely to understanding the relationships between 
sequence data in a historical sense. On the contrary, molecular phylogenetic methods -  
be they reconstruction o f a full maximum likelihood tree, or the classification of viral 
subtypes and analysis of their distribution in a host population -  are the cornerstone of 
contemporary studies of infectious disease, and the development o f predictive 
algorithms o f how new and emerging diseases may affect populations in the future.
One o f the earliest well documented uses of phylogenetic analyses of HIV sequence 
data, prior to the inception of the subtype classification, was the study of the ‘Florida 
Dentist’. In 1990 the Centres for Disease Control (CDC) received reports o f AIDS in a 
young woman in Florida whose only risk of HIV infection was that she had previously 
been treated by a dentist suffering from AIDS. The investigation that followed 
uncovered a number o f the dentist’s former patients who were also HIV positive, the 
inference being that the dentist had also infected these people. Env sequences were 
amplified from the dentist, the individuals involved and from several individuals living 
in the local community (not linked to the dentist), and a phylogenetic tree reconstructed 
(Figure 2.1). This revealed that 5 of a cohort of 7 patients, with no other risk factors for 
HIV infection, had sequences closely related to those of the dentist. This strongly 
suggested that the dentist infected them as a result of dental treatment (Ou et al., 1992).
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Dentist 
Pt. C 
Pt. A 
Pt. G 
Pt. B 
Pt. E 
Pt. A 
Dentist 
LC. 2 
LC. 3 
Pt. F 
LC. 9 
LC. 35 
LC. 3 
Pt. D
Figure 2.1 Phylogenetic tree relating HIV-1 envelope coding sequences to a HIV-1 
infected Florida dentist.
Pt. A-G indicates HIV-1 seq u en ces  taken from sev en  patients (Pt) of the infected dentist. LC 
(local control) sam ples w ere taken from HIV-1 infected individuals living within a 90-mile radius 
of the dental practice. Two sam ples of w ere used from both the dentist and patient A. 
Reproduced from Ou e t  al., 1992.
This example shows how sequence information in the form of mutations that had 
accumulated within patients, between transmission events, could recount the very recent 
history o f its spread. When performed at population or global levels this sort o f detailed 
study o f individuals, although complex, allows patterns of transmission and spread of 
HIV to be monitored: such an approach has been used to model transmission dynamics 
within the MSM population in the UK (Hue et al., 2005). Such a study however, whilst 
significant, is immensely computationally expensive and requires highly sophisticated 
analysis and interpretation. At the population level therefore, whilst less sophisticated, 
the classification o f distinct genetic variants of HIV (subtypes) that are co-circulating 
and the monitoring of their prevalence and dynamic spread in a population may be 
valuable for epidemiological studies.
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Genotype, phenotype and antiretroviral resistance
With sequence variation, differences in viral infectivity, transmissibility and 
immunogenicity may exist (Robertson et al., 2000). Whether the various groups, 
subtypes and recombinant forms o f HIV-1 have biological differences, however, is 
largely unclear and cannot effectively be determined without accurate genotyping of 
viruses from large numbers o f HIV-infected patients and relating this to clinical 
information.
More clear, however, is the relationship between HIV genetic subtype and natural 
resistance to antiretroviral drugs (Apetrei et al., 1998, Descamps et al., 1997, Descamps 
et al., 1998), as well as between subtypes and the efficiency o f serological and 
molecular tests for HIV diagnosis (Apetrei et al., 1996, Simon et al., 1994, Parekh et 
al., 1999). Major mutations linked to resistance to non-nucleoside RT inhibitors 
(NNRTIs) can be detected in all HIV-1 group O isolates (A98G and Y181C) and in one 
group M (subtype J) virus (V I081) (Vergne et al., 2000). In terms of accessory 
resistance mutations, a study of 142 subtype B or D virus isolates derived from 
treatment-naive patients, showed that only 5.6% had no drug resistance associated 
mutations in the protease gene (Vergne et al., 2000). A phylogenetic study of a group 
of seroconverters from France that combined pol gene sequencing with envelope 
serology also revealed a diverse range of viruses (Fleury et al., 2003): the protease 
polymorphisms K20I and M36I were highly prevalent in subtypes CRF02(AG), G, J, 
F2, and CRF06(cpx). Only three isolates, however, were found to have NRTI- or 
NNRTI-associated resistance mutations: one subtype D isolate (M l841), one subtype J 
isolate (T69N, K70R), and one subtype A isolate (K103N). It can therefore be seen that 
knowledge regarding the subtype of virus with which a patient is infected may have a 
bearing on treatment choice. The need for such information was clearly illustrated in a 
report that described, among 30 patients failing nclfinavir-containing therapy as their 
first protease inhibitor (PI) regimen (19 were infected with HIV-1 subtype B and 11 
with subtype G), nelfinavir-associated resistance mutations differed significantly 
depending on viral subtype (Gomes et al., 2002). The results suggest that the two 
distinct pathways (D30N and L90M) which lead to nelfinavir resistance may be guided 
by subtype-specific polymorphisms within the backbone of the protease gene, and that 
subtype G infected patients could be at much higher risk of developing broad PI cross­
resistance when nelfinavir is used as the initial PI. This apparent differential response
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Table 2.2 Published studies on drug resistance in persons infected with HIV-1 non-B 
isolates.
Region C ountry Reference M ain subtypes Patients
Africa Cote d ’Ivoire Adje et al., 2001 A, AG, D, G, H 68
Uganda Weidle et al., 2002 A, C, D 94
Gabon Vergne et al., 2002 A, AG, AE, D, G, H, J 22
Zimbabwe Kantor et al., 2002 C 21
Europe United Kingdom Barlow et al., 2001 A, C, D, F, G, H 25
Cane et a t ,  2001 C 43
Pillay e ta l . ,  2002 A, AG, AE, C, D, F, G, II 67
Frater et a t ,  2001 A, C, D 18
Spain Perez-Alvarez et  a t ,  2001a,b G, BG 31
Latin Brazil Caride et a t ,  2000, 2001 F, A 5
America Brindeiro et  a t ,  2002 A, C, F 17
Cuba Ruibal-Brunet et  a t ,  2001 A, C 16
M.East Israel Grossman et a t ,  2001 B, C 73
Modified from Kantor and Katzenstein, 2004.
to Pis among HIV subtypes is also suspected to be an issue with subtype A and G 
viruses, due to the presence of multiple polymorphisms many of which are located near 
classically described PI mutations. For example, it has been shown that Nigerian HIV 
subtype A and G isolates frequently contain between nine and 17 amino acid 
substitutions within the protease gene, all o f which would be classified as secondary 
mutations or polymorphisms (Agwale et al., 2002). A comprehensive review of studies 
of drug resistance in non-subtype B HIV-1 is presented by Kantor and Katzenstein, 
2004, summarised in Table 2.2.
It remains to be seen whether multi-drug resistant (MDR) viruses will emerge more 
rapidly during ART when such minor resistance conferring mutations are present before 
treatment initiation. As recent estimates state that in the United Kingdom over 50% of 
current infections are caused by non-subtype B viruses (Tatt et al., 2004) it is likely to 
become increasingly important that we can accurately assign subtype to HIV-1 
sequences.
2.1.3 Aims
Amino acid sequences contain less variation than nucleotide sequences due to the 
redundancy within the genetic code, and are not preferred for performing phylogenetic 
analyses. Handling amino acid sequence, however, significantly reduces the volume of 
sequence to be analysed and clinical management of sequences generated by drug
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resistance testing often results in the storage o f translated protein sequences rather than 
nucleotide sequence because the predictions o f drug resistance are based on amino acids 
changes rather than nucleotide changes. Furthermore, in certain cases data is stored 
only as amino acid changes relative to a consensus sequence (subtype B). To subtype 
such a sequence the non-mutated sites must be derived from the consensus. 
Accordingly, to maximise the amount o f data that we could analyse, the feasibility of 
subtyping protein sequences, namely a 430 amino acid region of the Pol polyprotein, 
generated as part of routine HIV-1 drug resistance monitoring (PR-RT), was 
investigated.
Specifically, different clustering methods were investigated, to see if established HIV-1 
subtype phylogenies could be recreated using amino acid sequences. Then from initial 
subtype alignments for Gag, PR-RT and Env the relative levels of amino acid sequence 
variation between these proteins was determined, and for the PR-RT alignments 
position specific scoring matrices (PSSMs) that define the sequence variability of each 
subtype were created. These PSSMs are the basis o f the subtyping tool, with which 
clinically derived PR-RT sequences may then be compared and subtype assigned. This 
method alleviates the need for extensive phylogenetic analysis and clustering o f clinical 
sequences to accurately define a subtype, whilst utilising a method that uses rigorously 
characterised subtype profiles. Test clinical PR-RT sequence datasets were acquired 
from resistance testing facilities in London, Birmingham and the Caribbean.
The collection of subtype data at the population level and linking this to clinical data 
such as development of resistance, resistance mutations, time to AIDS and transmission 
may help reveal if any differences in these factors exist, between genetic variants of 
HIV. The development of the subtyping tool here described and its implementation in 
the National Resistance Database may go some way to initiating this kind of study.
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2.2 Methods
2.2.1 Sequence Data
Full-length HIV-1 genomes and individual Gag, Pol and Env GenBank accession 
numbers were obtained from GenBank using scripts that were written to create and 
maintain the viral database VIDA (Alba et a l, 2001). Scripts that returned GenBank 
accession numbers of the viral genomes and proteins o f the virus families within VIDA 
(modified by R. Myers) were used to search GenBank for HIV-1 genomes and proteins. 
Protein sequences corresponding to the accession numbers obtained from VIDA were 
downloaded from the National Centre for Biotechnology Information (NCBI 
http://www.ncbi.nlm.nih.eovA. 72 sequences used as HIV-1 reference subtypes were 
obtained from the Los Alamos HIV-1 Database (http://hiv-wcb.lanl.gov/content/index) 
(Table 1, Appendix).
2.2.2 Sequence Processing
In order to analyse the sequence variation within HIV-1 genomes, Gag, Pol and Env 
sequences from full-length HIV-1 genomes and Los Alamos reference sequences were 
combined to generate multiple alignments. This dataset was created by assembling a 
list of all complete HIV-1 genomes, together with their accession numbers for Gag, Pol 
and Env proteins. The three lists of accession numbers (Gag, Pol and Env) were 
compared with the NCBI non-redundant protein database (nr), downloaded as a FASTA 
formatted flatfile, and the HIV-1 sequences returned using a custom written Perl script. 
Each genome was then checked for the presence of Gag, Pol and Env proteins using a 
MS Access database, and in cases where there was a protein missing from a genome the 
relevant stretch of nucleotide sequence was translated using an in-house translation tool 
and added to the overall dataset. The accession numbers of HIV-1 subtype reference 
nucleotide sequences (Los Alamos Database) were incorporated into this database.
The Final GENBANK and Los Alamos combined dataset included 170 Env proteins, 
187 Gag proteins and 174 Pol proteins, the number o f proteins is not equivalent as not 
all o f the HIV-1 genomes were full length (~9 Kb), with proteins of partial size being 
excluded. The Pol dataset was further processed into a PR-RT dataset, the sequence 
length analogous to that produced for HIV resistance testing.
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2.2.3 Phylogenetic Analysis
Three phylogenetic analyses were performed to group sequences by HIV-1 subtype, 
using the Los Alamos reference dataset to facilitate the partitioning o f HIV sequences 
for the generation o f sequence alignments that represent each HIV-1 subtype. These 
were maximum parsimony (Phylip, protpars), neighbour joining (ClustalW) and 
agglomerative hierachical clustering using complete linkage based on sequence identity 
matrices. The neighbour joining algorithm was implemented in ClustalW, after 
sequence alignment. To perform maximum parsimony, protein distances were 
calculated using Protdist and the distances applied to the maximum parsimony tree 
using Fitch, the tree generated using Protpars and Consense. All programs were part of 
the Phylip package. To perform the former analysis a programme for calculating 
sequence identity scores was used, taking it’s input as a multiple sequence alignment 
and then returning a matrix o f pairwise sequence identities based on the number of 
absolute amino acid matches along the length o f two sequences from the original 
multiple alignment. The output was used to build linkage trees, using the software 
package STATISTICA (Version 6.1, StatSoft, Inc. USA). These methods were used to 
both curate subtype specific alignments for development of a subtyping algorithm, and 
to see if simple measures o f genetic distance are sufficient to distinguish between 
different subtypes, using amino acid sequence, specifically in the PR-RT region. A 
table of all full-length sequences and their classification by each o f the three methods is 
shown in Appendix, Table 2.
2.2.4 Sequence Variability
Subtype specific HIV-1 sequence alignments for Gag, Pol and Env were analysed to 
assess the levels of sequence variation that they contained. This was achieved using the 
in-house program conPSSM which, in addition to creating a consensus amino acid 
sequence for each subtype alignment, records the number of amino acid variants within 
a given alignment at each position in that sequence, compared to a consensus. These 
data enabled the construction of contour plots (using STATISTICA) which represent the 
deviation of individual sequences, away from a subtype B reference, and which is 
grouped by subtype so variation both within and between subtypes, across Gag, Pol and 
Env, may be analysed.
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2.2.5 Mutation analysis
The frequency of resistance mutations present in subtype specific profiles and London- 
derived clinical data was assessed, using the custom written program Mutant. This 
compares each sequence to a consensus, and detects changes that have been 
characterised as either primary or secondary resistance mutations (Parikh et al., 2001). 
The frequency of these in each subtype specific profile was calculated using MS Excel, 
expressed as the percentage of sequences in which each mutation was detected, in each 
profile.
2.2.6 PSSM generation and method validation
The subtype specific alignments generated for the PR-RT section of Pol were used for 
calculating subtype-specific PSSMs, which form the basis o f the subtype analyser 
(STAR) subtyping tool. There were 11 subtype-specific multiple alignments for this 
genomic region, representing subtypes; A, AG, B, C, D, FK, G, H, J, N and O. As these 
multiple alignments were derived from one global multiple alignment they were in 
effect aligned with each other.
The process o f PSSM building is implemented within the first stage o f the STAR 
program. Specifically, the fraction of each amino acid at each position within each of 
the 11 subtype alignments was calculated and stored, giving a matrix (per subtype) 
where the first dimension was alignment position and the second dimension contained 
the fraction of each amino acid present at that position. By using the fraction of amino 
acids present at each position the matrices became normalised thereby removing the 
effect of variation in the number of sequence members present within each subtype 
alignment. Two extra elements were also added to the 20 amino acid elements in the 
second dimension, representing gaps and unassigned amino acids.
A method of resampling data in order to assess confidence in the ability to assign 
subtype (leave one out validation) was performed. This assessed the ability of STAR to 
accurately assign subtype, and also allowed the calculation of the mean and standard 
deviation of scores produced for the sequences that define a subtype PSSM, thereby 
representing the confidence thresholds for assigning sequences to subtype groups. The 
lower boundaries o f the confidence threshold were calculated based on the average 
identity score for each subtype, minus 1 and 1.5 standard deviation measures.
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2.2.7 Dataset updates
As GENBANK. is continuously updated with new HIV sequence additions that are 
useful to expand under populated PSSMs, a rule base for updating subtype profile 
alignments was established to enable inclusion o f the most recent PR-RT sequence data 
available from the most recent GenBank release (137 - August 2003). Using the 
BLAST algorithm GenBank NR was searched with HIV-1 PR-RT, returning 
approximately 28,000 sequences. These were sorted using a Perl script to retain only 
those sequences that contain both the protease and reverse transcriptase active site 
motifs DTG and YXDD, separated by 254 amino acids. 10,065 such sequences were 
aligned and all sequences containing greater than 2% ambiguous amino acid calls were 
removed, leaving 865 sequences. These 865 sequences were further filtered to remove 
sequences containing defined primary drug resistance mutations, with the exception of 
subtype O sequences known to have the natural polymorphism Y181C, otherwise 
associated with nevirapine exposure. NJ was used to subtype the resulting 654 
sequences by clustering them with the sequences from original subtype profiles and by 
STAR. From these, only unambiguously subtyped sequences (372) were used to 
expand profiles to an arbitrary maximum of 100 sequences per PSSM.
2.2.8 Analysis of clinical datasets
Clinical sequences were obtained from the Health Protection Agency (HPA) 
laboratories in London (n=843) and Birmingham (n=885), where they were generated as 
part of standard resistance monitoring, and from the Caribbean Epidemiology Centre 
(CAREC, n=71) for subtyping using STAR.
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2.3 Results
Currently the most extensive HIV sequence resources are those generated from clinical 
laboratories in developed countries, where routine genotypic drug sensitivity analysis is 
performed. It would be useful for subtype to be determined from such sequence, 
especially at source. As such data will continue to grow the aim of this chapter was to 
develop a subtyping tool for use in the clinical setting that will assign HIV-1 subtype 
based solely on the PR-RT amino acid sequence (named subtype analyser; STAR).
23.1 Creating sequence datasets
GenBank was searched extensively, in order to retrieve as many HIV-1 sequences as 
possible for the curation of subtype-specific sequence profiles, for the Gag, Pol and Env 
regions o f the genome. The resulting dataset, including Los Alamos reference 
sequences, comprised 170 Env proteins, 187 Gag proteins and 174 Pol proteins - the 
number o f proteins is not equivalent as not all o f the HIV-1 genomes were full length 
(~9 Kb), with proteins o f partial size being excluded. The 174 Pol sequences, (protease, 
reverse transcriptase, RNAse H and integrase) were processed further to give a set of 
proteins containing all o f HIV-1 protease (99 amino acids) and the N-terminal 340 
amino acids from reverse transcriptase (PR-RT). The combined 439 amino acid 
sequence is analogous to the maximum that is routinely sequenced as part of 
antiretroviral drug therapy monitoring. Four amino acid multiple sequence alignments 
(Gag, Pol, PR-RT, and Env) were generated using ClustalW, manually edited and used 
in subsequent phylogenetic analysis.
23.2 Phylogenetic analysis of HIV-1 Gag, Pol, PR-RT, and Env
Complex models of evolution are necessary for the most accurate phylogenetic methods 
of sequence analysis and, as such, these methods can be computationally very intense 
and time-consuming, especially when large numbers of sequences are processed. We 
therefore wished to determine whether a simple method of measuring distance between 
amino acid sequences would be sensitive enough to distinguish between HIV subtypes, 
along the length of the genome, compared to analysis using more complex phylogenetic 
methods. If so, then large numbers of non-subtyped sequences could be initially 
grouped by HIV-1 subtype using Los Alamos reference sequences within the dataset
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(according to their placement within phylogenetic trees), and sequence alignments 
generated that represent expanded collections o f sequences o f defined HIV-1 subtype, 
for Gag, PR-RT and Env. Provided that there was sufficient divergence between 
subtypes in the PR-RT region, subtype-specific profiles could then be created which 
would contain as extensive a representation o f the true diversity within each subtype in 
this genomic region as possible. This could then be used as the basis for a HIV-1 
subtyping tool, which would take sequence data produced during resistance testing as its 
input.
Initially three phylogenetic analyses were performed on protein multiple sequence 
alignments, namely; maximum parsimony (MP, Phylip, protpars), neighbour joining 
(NJ, ClustalW) and agglomerative hierachical clustering using complete linkage based 
on sequence identity matrices (section 1.2.3). It was decided that where two o f the three 
tree building methods agreed on the assignment of subtype to an unknown sequence, 
relative to a reference sequence, that sequence would be assigned as being of that 
subtype. The assignment o f subtype was refined by generating additional trees 
(neighbour joining) from subsets of the Gag, Pol and Env alignments and checking the 
placement of sequences within those trees. In most cases a conservative strategy of 
removing sequences that did not position within trees consistently, was adopted. This 
resulted in the exclusion of sequences in an attempt to preserve the integrity of subtype 
alignments rather than trying to incorporate every possible sequence. The final dataset 
comprised 153 Gag sequences, 144 Pol (and therefore PR-RT) sequences and 140 Env 
sequences, classified into 11 subtype groups; A, AG, B, C, D, FK, G, H, J, N and O.
The final set of HIV-1 genomes containing Gag, PR-RT and Env proteins was given an 
in-house accession number of the form 00A A BBCC11 (Table 1/2, Appendix):
00 -  corresponds to the number of the genome (numbers 1-72 Los Alamos sequences, 
numbers >500 -  sequences derived from GenBank).
A A -  Two-letter code used to represent the subtype of the Gag sequence, eg AA = 
subtype A, AB = subtype A / B recombinant, XX = unassigned.
BB -  Two-letter code used to represent the subtype of the Pol sequence.
CC -  Two-letter code used to represent the subtype of the Env sequence.
1 1 -  Refers to a key for country of origin.
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Overall, the NJ and MP trees produced were remarkably similar. The trees generated by 
hierarchical clustering based on sequence identity matrices, however, were less similar 
and between all methods the placement of recombinant reference sequences was 
inconsistent.
2.3.2.1 Neighbour joining
Initially, NJ trees of Gag, PR-RT and Env amino acid sequence were created (Figure
2.2). The reference sequences within the trees are marked with coloured circles and in 
the case o f all proteins studied these reference sequences cluster together in distinct 
branches, associated with non-reference sequences, presumably of the same subtype. 
The Gag and Env trees produce clusters with clear separation from each other, 
indicating that the increased variability in these regions of the genome enables easier 
separation o f the different subtypes based on amino acid sequence. Despite the less 
‘neat’ topology of the PR-RT tree, however, there data revealed that in the majority o f 
cases each virus was classified as the same subtype in Gag, PR-RT and Env. To 
support the accuracy o f this neighbour joining analysis, it was observed that 
recombinant reference sequences, for example CRF12-BF - a BF recombinant that is 
mainly subtype B within PR-RT, but F in Gag and Env - was classified as such (Figure
2.3). The same effect was observed for CRF01-AE, an AE recombinant that is subtype 
A within Gag and PR-RT, but E (a putative subtype) in Env. In this case, CRF01-AE 
Gag and PR-RT amino acid sequence clustered with A, but its Env sequence formed a 
distinct cluster (Figure 2.4). In some cases, recombinant non-reference sequences were 
detected: two sequences published as subtype C were classified as BC recombinants, 
across Gag, Pol and Env. These may be true recombinant genomes, or may represent 
discrepancies between the clusters generated for each gene.
Additional observations made from these trees are firstly, that the subtype F and K 
sequences cluster together in all cases, and are indistinguishable from each other in their 
branching pattern (Figure 2.2). If this observation holds true for trees built using other 
phylogenetic methods, these two subtypes should be merged to form a single profile. 
Secondly, CRF02-AG appears to cluster distinctly from subtypes A and G in all trees. 
This suggests that it may be possible to create a recombinant-specific profile for this 
genotype.
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Figure 2.2 N eighbour joining trees of Gag (A), PRRT (B) and Env (C) seq u en ces .
NJ w as implemented in ClustalW to generate the trees shown.
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Figure 2.3 Example of identification of CRF012-BF, a BF recom binant, using NJ
an alysis o f Gag, PR-RT and Env am ino acid seq u en ce .
The shaded bar (A) represents the genom e structure, and (B), (C) and (D) show the subclusters 
within the Gag, PR-RT and Env NJ trees that reflect the recombinant structure of the BF
recombinant genom e. This analysis shows the utility of using amino acid sequence for
phylogenetic analysis and affirms its use, together with MP and sequence identity, in creation of 
subtype-specific datasets for development of a subtyping tool.
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Figure 2.4 Example of identification of CRF01-AE, an AE recom binant, using NJ 
an alysis o f Gag, PR-RT and Env am ino acid seq u en ce .
The A and AE sequences cluster together within Gag and PR-RT (A and B), but separately 
within Env (C), indicating that the Env sequence is a subtype distinct from A, but not particularly 
closely associated with any other subtype.
Gag PR-RT
Env
79
From this initial analysis, use of amino acid sequence to subtype HIV-1 PR-RT appears 
sufficiently accurate. In order to test further the classifications made using NJ trees, 
therefore, MP and sequence identity trees were generated for Gag, PR-RT and Env.
2.3.2.2 Maximum parsimony and Hierarchical clustering based on sequence identity 
matrices
Two further methods of phylogenetic analysis were performed, namely MP and 
clustering by sequence identity, in order to assess the likelihood that subtype predicted 
by NJ is reliable and furthermore, just how well a simple measure of distance can 
discriminate between subtypes using amino acid sequence. A repeat of the manual 
analysis of clustering patterns within NJ trees was performed for MP and sequence 
identity/hierarchical clustering trees, and the subtype assigned to Gag, PR-RT and Env. 
The analysis o f PR-RT sequences is described in detail, as this dataset was most 
rigorously analysed prior to the creation o f subtype-specific profiles for this region of 
the genome (Figure 2.5).
Comparison of the NJ and MP trees for PR-RT revealed a general similarity in their 
topology. In both cases, groups N and O were the most distant sequences, forming 
branches distinct from the main tree with no additional sequences clustering with them. 
This reflects the relative paucity of sequence data for these HIV-1 groups, compared to 
group M. For the group M subtypes, however, distinct clusters of sequences were found 
around subtype B and C reference sequences. In addition, both methods showed 
subtypes F and K clustering together. Subtype G sequences cluster in close proximity 
to the F/K sequences, but appear to form a distinct branching pattern where G reference 
sequences co-cluster with additional non-reference sequences. The two subtype J 
sequences, however, were placed discordantly in NJ and MP trees; NJ placing the two 
reference sequences in proximity to the group N cluster, and MP placing them within 
the subtype H cluster. With respect to subtype H, these reference sequences clustered 
close to subtype D, according to NJ. Both NJ and MP methods clustered subtype D 
reference sequences in close proximity to the subtype B reference sequences, which is 
in agreement with the suggestion that subtypes B and D might be more accurately 
classified as sub-subtypes of the same subtype (Robertson et al., 2000). The clustering
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Figure 2.5 Maximum Parsim ony and hierarchical clustering based  on seq u en ce  identity 
trees o f HIV-1 PR-RT seq u e n c e s .
(A) The tree shown w as generated using Protpars and C onsense. Protein distances were 
calculated using Protdist and the distances applied to the maximum parsimony tree using Fitch. 
All programs were part of the Phylip package. (B) The tree distance matrix w as generated 
using the in-house program SeqID and the tree constructed using Statistica (over page).
*
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Figure 2.5 continued
B
O
o
o
•
o
♦
*
©
*
B
D
H
C
0
H
J
A
F
K
O
82
of sequences around subtype A reference sequences within PR-RT showed that 
sequences o f sub-subtypes A1 and A2 clustered separately, with sequences from the 
recombinant subtype CRF01 (AE) lying between them. Two other recombinant 
reference sequences also clustered within the general subtype A cluster o f PR-RT 
sequences; subtype CRF02 (AG) and subtype CRJF03 (AB). As mentioned, 
classification of sequences clustering with the subtype F and K reference sequences is 
somewhat complicated as the sub-subtypes FI and F2 as well as subtype K clustered 
independently, yet within the same overall cluster. Given that subtype K is very closely 
related to subtype F and it has been suggested that it should perhaps be redesignated as 
sub-subtype F3 (Triques et al., 1999, Triques et al., 2000), these sequences were 
merged to form an FK cluster and thus FK subtype specific profile alignment, for 
subsequent analysis.
Compared with more formal phylogenetic analysis, hierarchical clustering using 
complete linkage of sequence identity derived distances provided some anomalies in 
terms of classification o f non-reference sequences, compared with either NJ or MP. For 
example, in the PR-RT trees generated using NJ and MP subtype D reference sequences 
clustered in close proximity to the subtype B reference sequences. Hierarchical 
clustering, however, placed reference subtype D sequences within the cluster containing 
reference subtype B sequences, indicating that hierarchical clustering of sequence 
identities fails to discriminate between subtypes B and D. Using this tree, it was 
difficult to infer whether any other non-reference sequences were subtype D, making 
the manual classification o f these sequences, from this tree, very difficult. Furthermore, 
CRF05 (DF) recombinant sequences that clustered closely to subtype D reference 
sequences in PR-RT NJ and MP trees, grouped with the subtype H reference sequences 
by hierarchical clustering, and an F/K cluster o f sequences was evident within the 
subtype A radiation. The hierarchical clustering o f the subtype A reference PR-RT 
sequence, however, was in good agreement with the classifications made using NJ and 
MP. CRF01 (AE) reference sequences clustered between sub-subtype Al and A2 
sequences and CRF02 (AG) clustered independently but close to the subtype A 
reference sequence cluster.
Thus, whilst some were in agreement, certain sequence classifications made using 
hierarchical clustering based on sequence identity were contrary to those made using
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more complex phylogenetic methods. It is perhaps the tree building stage of 
classification using sequence identity (using hierarchical clustering in STATISTICA) 
that limits this method in its use as a phylogenetic tool, rather than the measure of 
sequence identity itself. A summary of the level o f agreement between subtyping 
methods is presented in Table 2.3. Although NJ and MP are more consistent, 
hierarchical clustering performs well enough to suggest that simple measures of 
distance are sufficient to allow subtype assignation in PR-RT. Given its agreement with 
MP, the use of NJ to classify any further sequence data into subtype-specific datasets 
was deemed appropriate.
Table 2.3 Agreement between phylogenetic methods in the subtype classification of 
PR-RT amino acid sequences from non-classified HIV-1 sequences from complete 
genomes, in GENBANK.
No. Seq 169
% Total Agreement 94.08 
% NJ/D 94.67
% NJ/MP 96.45
% D/MP 95.27
NJ -  neighbour joining
MP -  maximum parsimony
D -  Sequence identity / hierarchical clustering
2.3.2.3 Compilation o f  subtype alignments
Following manual assignation o f subtype to each sequence in the PR-RT dataset by 
three methods and derivation of a consensus, alignments were generated for 11 HIV-1 
subtypes: 9 single subtypes; A, B, C, D, G, H, J, N and O, one composite; FK, as 
subtypes F and K were difficult to separate on phylogenetic trees, and one recombinant; 
AG (Table 2.4). CRF02 (AG) is a circulating recombinant form of subtypes A and G, 
which was well populated in terms of sequence numbers and formed clusters 
independent o f subtype A across Gag, PR-RT and Env sequences. CRF01 (AE), 
however, was not separated into a discreet alignment for this analysis, as it is subtype A 
in PR-RT. Thus, the AE sequences were added to the A PR-RT alignment, explaining 
the increased number of subtype A Gag and PR-RT sequences, compared to Env. This 
variation in the number of sequences attributed to each region of the genome, for each 
subtype, is largely a product of recombinant sequences being identified. Furthermore, 
certain sequences were removed from the analysis where it was not immediately clear to
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Table 2.4 Distribution of Gag, Pol/PR-RT and Env sequences assigned to subtypes.
Subtype Gag Pol/PR-RT Env
A 28 26 20
AG 10 16 13
B 36 33 33
C 44 39 41
D 8 8 7
FK 10 9 11
G 4 4 5
H 4 3 3
J 3 2 2
N 2 2 2
O 4 2 3
Total 153 144 140
which subtype cluster they belonged. Whilst this rationalisation o f data reduces the 
number o f sequences within each subtype-specific alignment, it removes the detrimental 
effect o f using sequences that are difficult to classify and thus may compromise the 
efficiency o f a subtyping tool, based on such data.
2.33 Variation in HIV across genome -  suitability for subtyping?
Several reports have described that Pol sequence variation is sufficient to distinguish 
between subtypes (section 2.1.2), and phylogenetic classification of sequences based on 
PR-RT sequence seems robust. To better characterise the sequence variation across the 
HIV genome in the data collected and classified for STAR, subtype specific sequence 
variation was therefore analysed along the length of the Gag, Pol (including PR-RT) 
and Env proteins. A consensus sequence generated for the subtype B alignment was 
compared to each of the subtype specific alignments established previously and the 
percentage o f disagreement at each position was used to generate a trace for each 
subtype that shows sequence differences relative to subtype B, displayed as a contour 
map (Figure 2.6). Different subtypes were ordered relative to their similarity to the 
subtype B consensus sequence; subtype B is at the bottom of each graph and subtype O 
at the top, with a general trend of increasing variation between the two. Traces derived 
from both Gag (Figure 2.6-A) and Env (Figure 2.6-C) proteins show constant variation 
along the length of the proteins, with many regions showing intense variation, such as 
amino acids 530 to 570 in Env. This corresponds to stem IIIB, IIB’, IIC, IIC’, IIA, III- 
IV and III-IV’ of the rev response element (HIV Sequence Compendium, 2001). Such
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Figure 2.6 Protein seq u en ce  variation in (A) Gag (n = 153), (B) Pol (n = 144) and (C) Env 
(n = 140) relative to a c o n se n su s  reference B subtype seq u en ce .
Regions of sequence variability are shown using contours with the degree of sequence identity 
illustrated by the colour change; green (high) through yellow to red (low).
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highly variable regions were generally not subtype specific, but represented regions of 
higher variability in all subtypes. Although less variable, however, subtype specific 
‘hotspots’ o f variation exist in the PR-RT region o f Pol (Figure 2.6-B), and it is 
probably these subtype discriminating regions that enabled the NJ and MP phylogenetic 
methods to clearly classify HIV-1 PR-RT sequence into subtype groups (section 2.3.2). 
The identification o f these regions o f variation between subtypes within PR-RT is 
important as they could be ‘weighted’ during the subtyping process. This would in 
effect emphasise the differences between subtypes and increase the ease with which 
they are discriminated between, when using a simple measure of sequence identity.
2.3.4 PSSMs and method validation
PSSMs are a way of representing the sequence variation within a multiple sequence 
alignment, with which a sequence can be compared. As such, PSSMs were created for 
each o f the subtype specific alignments described. The basic algorithm of this 
subtyping tool is shown in Figure 2.7.
In more detail, the STAR algorithm assigns subtype by virtue of matching amino acids 
in a query sequence, to those at the same position within subtype specific profiles. 
Specifically, the query sequence is aligned with a subtype multiple sequence alignment 
using the profile alignment algorithm within ClustalX. The subtyping tool was 
designed to predict the subtype of a user inputted amino acid query sequence, 
containing the whole o f HIV-1 protease (amino acids 1-99) and a portion of the HIV-1 
reverse transcriptase (amino acids 1-340). To check that the inputted sequence was of 
the appropriate region of HIV-1 Pol and to trim or extend the ends o f the amino acid 
string, it is aligned with a consensus sequence of all 11 subtype specific multiple 
alignments. Whilst the consensus sequence used is biased towards subtype M, this does 
not alter the ability of subtype N and O sequences to align with it. Alignment o f the 
query sequence determines the start and stop points of the query sequence and inserts 
gaps in the regions where insertions have been observed within reference sequences. 
Insertions within the query sequence relative to the reference sequences are excised, 
because no subtype information is present for those regions. At this point the query 
sequence is effectively aligned with the total diversity (in-terms of insertions and 
deletions) within the 11 subtype alignments. This strategy allows the PSSMs to be
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calculated once only at the start o f the process (before any sequences are inputted), 
rather than having to recalculate the subtype PSSMs with each new query sequence.
The aligned query sequence is then compared with each subtype-specific matrix. Each 
position o f the aligned query sequence is compared with the equivalent position in the 
first dimension of the matrix. A normalised frequency analysis o f each position in the 
subtype alignment is performed. This describes the amino acid variation at each position 
within the subtype in question. The query sequence is then compared to this frequency 
analysis, resulting in the generation of a score for each amino acid in the query, 
indicating its frequency within the subtype with which it is being compared. A score is 
generated corresponding to the matrix-derived fraction o f the amino acid in the test 
sequence (the second dimension of the matrix). This score is summed along the length 
o f the query sequence, the total score representing the quality o f match between the 
query sequence and the subtype matrix. A score is generated for each of the subtype 
alignments that the query sequence was compared with, the highest score suggesting the 
likely subtype o f the test sequence. The result may be depicted as a graphical 
representation of subtype, along the length of the query sequence analysed, or returned 
as consensus subtype assigned for the length of the sequence. Certain subtype- 
discriminating regions of the sequence may be weighted to score more significantly 
than those that are more conserved. This option, however, was not explored as in the 
absence o f weighting good subtype classification, in terms of the numerical distance 
between the correct classification score and the next highest incorrect score, was 
observed.
If the subtype score falls below a defined threshold, however (1.5 standard deviations 
from the mean leave one out validation subtype scores, see below), the sequence is 
flagged as low confidence and the subtype profile can be explored further through 
graphical representation. In this case, sequences are re-analysed using a sliding window 
method. Each position in the query sequence is considered together with 14 flanking 
amino acids, giving a default window size of 15. These 15 positions in the query 
sequence are compared to all aligned subtype profiles. The average frequency score 
across the window, per subtype, is then assigned to the amino acid at the centre. The 
window is then moved forwards in increments o f one amino acid, until each position in 
the sequence has been scored. This option enables the detection of recombinants in the
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PR-RT region, provided that there is sufficient genetic distinction between recombining 
HIV-1 subtypes.
Prior to its use with clinically derived input sequences, however, an assessment of the 
ability o f this method to accurately classify a set of test sequences o f known subtype 
was performed. The sequence dataset as a whole did not contain sufficient numbers of 
sequences to allow partitioning into a training and test dataset, so a leave one out 
analysis strategy was adopted in order to evaluate the performance of STAR. This 
involved removing each sequence from its subtype alignment, recompiling the subtype 
PSSM in its absence, and testing the ability o f the method to correctly classify the 
sequence when removed from the subtype-specific PSSM. From an initial dataset of 
174 sequences, 144 were used in this analysis as the remaining 30 sequences were 
classified as recombinant forms and hence were not included in the subtype alignments.
STAR correctly predicted all but one of the sequences during the leave one out analysis, 
predicting one subtype H sequence as subtype D (Table 2.5). This was an improvement 
over the initial implementation of STAR (Gale et a l, 2004), where 5 misclassifications 
were made. This improvement was achieved by the amalgamation of subtype F and K 
datasets, as suggested by NJ and MP trees (section 2.3.2).
Table 2.5 Leave One Out Analysis of STAR subtyping tool.
Subtype n. Pos FP Fn
A 26 26 0 0
AG 16 16 0 0
B 33 33 0 0
C 39 39 0 0
D 8 8 1 0
FK 9 9 0 0
G 4 4 0 0
H 3 2 0 1
J 2 2 0 0
N 2 2 0 0
O 2 2 0 0
Total 144 143 1 1
Accuracy
Coverage
Precession
0.99
0.99
0.99
n. -  number of  sequences in 
subtype
Pos -  number of  sequences 
correctly identified 
Fp -  number of  sequences 
incorrectly assigned to a 
subtype
Fn -  number of  sequences that 
were not assigned to a 
subgroup 
Accuracy = pos/n.
Coverage = pos/(pos+fn) 
Precision = pos/(pos+fp)
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2.3.4.1 Updating PSSMs
Each Genbank release provides more sequences with which to populate PSSMs. Not all 
sequences are o f appropriate quality to be used (i.e. abundant ambiguity codes), so a 
rule base for updating PSSMs was devised (Gale et al., 2004). This identified 372 
candidate sequences, which were analysed relative to the core 144 sequences, by 
building a neighbour joining tree (Figure 2.8). These subtyped sequences were used to 
further populate each subtype profile to an arbitrary maximum of 100 sequences. 
Specifically, A, AG, B and C profiles each contain 100 sequences, D, 50; F/K, 30; G, 
18; H, 4; J, 3; N, 5; 0, 6. Following the update of subtype profiles, leave one out 
validation confirmed that inclusion of new sequences in profile alignments did not 
significantly affect performance of the algorithm. Three of 516 sequences were 
misclassified, giving an accuracy rate of 98.8%. These 3 sequences were incorrectly 
assigned as subtype AG instead of subtype A (2) and subtype C (1).
2.3.5 Recombinants and confidence thresholds
Whilst leave one out analysis was used to assess the ability o f the subtype analysis tool 
to accurately assign subtype, as described it also allowed the calculation of the mean 
and standard deviation of scores produced for the sequences that define a subtype 
PSSM, thereby representing the confidence thresholds for assigning sequences to 
subtype groups.
Specifically, based on the classification of the 516 defined subtype sequences (this time 
including known recombinant sequences, previously removed -  section 2.3.4), a lower 
threshold score for confidence in subtype prediction could be assigned. Two lower 
thresholds were assessed, namely 1 and 1.5 standard deviations (SD) below the mean 
subtype score for the resampled leave one out validation data. At the more stringent 1 
SD an average of 14% of subtype assigned sequences fell below the threshold and were 
therefore flagged as being of putative subtype. This number decreased to 7.7% at 1.5 
SD from the mean, the distribution being equivalent among all subtypes. A typical 
example of score distribution is shown for the resampled subtype B alignment (Figure 
2.9) where 5 sequences from 100 are flagged at 1.5 SD below the mean (5%). Analysis 
o f 11 sequences identified as recombinants containing subtype B sequence within the 
Pol region (Los Alamos Database) showed only 3 sequences (BF recombinants) scored
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Figure 2.8 N eighbour joining tree of HIV-1 PR-RT am ino acid seq u en ce  for dataset  
updating purposes.
Tree generated from 516 sequences, 144 used within the initial STAR program and 372  
additional sequences derived from GenBank. The positions of the initial 144 sequences  
classified into 11 subtype groups are indicated with coloured dots.
D o
FK •
G •
H o
J •
N •
O •
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within 1.5 SD of the subtype B alignment. The remaining recombinant sequences (8) 
were all flagged as being o f putative subtype.
For such ‘flagged’ sequences, by virtue o f the sliding window scoring function, a 
graphical representation o f the subtype along the length of the query sequence can be 
extracted to aid subtype prediction (Figure 2.10). As an example, four sequences from 
subtype B were visualized. Subtypes classified as within 1.5 SD of the mean subtype 
score are well demarcated from the next most similar high scoring subtype (Figure 2.10- 
A). When a sequence that corresponded to an authentic subtype B sequence but which 
fell bellow the 1.5 SD cut-off (Figure 2.10-B) was examined, it was still possible to 
assign the subtype as B and to visualize the region of the profile that lead to the low 
classification score, namely amino acids 190 -  300. More importantly this analysis 
enables the visualization of recombinant subtypes. These sequences will always be 
more difficult to classify but will usually fall below the 1.5 SD cut-off were they can be 
readily identified by sliding window plots. For example, Figure 2.10-C shows an AB 
recombinant (Liitsola et al., 1998) which scores as subtype A for amino acids 1-151 and 
subtype B for amino acids 230-499. One unclassified sequence fell within 1 SD of the 
subtype mean. Visualization of this sequence (Figure 2.10-D) showed that it was indeed 
subtype B for over 50% of the sequence and unclassified for the rest, thus explaining its 
low scoring subtype B assignment.
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Figure 2.9 D istribution o f  STAR s c o r e s  w ithin  th e  su b ty p e  B leave  o n e  out a n a ly sis .
Dots (•) are used to indicate non-recombinant subtype B seq u en ces. Squares (□ )  indicate 
recombinant seq u en ces  containing som e subtype B seq u en ce. The 4  seq u en ces  indicated by 
broken lines are plotted in figure 2.10. (A) (Fig 2.10-A) illustrates a high scoring subtype B 
seq u en ce . (D) (Fig 2.10-D ) show s a high scoring recombinant BF seq u en ce. The three 
recombinant seq u en ces  (□ )  scoring above the lower 1.5 standard deviation threshold are all BF 
recombinants. (C) (Fig 2.10-C ) represents an AB recombinant scoring below the lower 
threshold. (B) (Fig 2.10-B) highlights one of the 2 non-recombinant subtype B seq u en ces that 
score below the lower threshold.
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Figure 2.10 Graphical visualisation  of the 4 se q u e n c e s  highlighted in Figure 2.9.
Each graph plots amino acid position against the percentage match to a sliding window of 
amino acids along the sequence length. The solid line traces the score against the subtype B 
PSSM and the dashed line traces the score against the second highest scoring PSSM. (A) and 
(B) show non-recombinant subtype B sequences, with (A) showing a sequence that generates 
a high subtype B STAR score (GenBank accession  AF256209) and (B) show s a low confidence 
“flagged" subtype B sequence with low scoring regions against the subtype B PSSM making it 
poorly separated in som e regions from the next highest scoring PSSM (GenBank accession  
U26546). (C) and (D) show recombinant sequences. (C) show s an AB recombinant sequence  
that would be detected as recombinant with a high score against subtype A, before switching to 
a high score against subtype B. This sequence (GenBank accession  AF193277) has been  
identified previously as an AB recombinant. (D) show s a plot of one of the 3 high scoring BF 
recombinants. The BF recombinant (GenBank accession  AF385935) scores similarly to 
subtypes B and F initially and then scores more highly compared with subtype B along the last 
200 amino acids.
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2.3.6 Testing the method -  clinical dataset
Given the accuracy o f the new subtyping algorithm, as defined by leave one out 
validation, PR-RT sequences were obtained from the resistance screening facility, 
Department of Virology, UCL (n=843), the resistance screening facility, Health 
Protection Agency (Birmingham, n=885) and from the Caribbean Epidemiology Centre 
(CAREC, n=71). Nucleotide sequences were translated into amino acid sequence where 
necessary and the sequences were subtyped as a batch, by submitting a FASTA 
formatted multiple sequence file to STAR. Subtyping was achieved at a rate of 36 
sequences per minute (Intel Pentium IV processor with 2.5 Ghz RAM). Results indicate 
that, o f 843 PR-RT sequences from the London clinic, STAR classified 84% with high 
confidence: 72.1% as B, 10.5% as A, 4.4% as AG, 5.7% as C, 6.1% as D, 0.7% as F/K 
and 0.6% as G (Figure 2.11-A). In the Birmingham dataset 78.9% were classified as B, 
5.9% as A, 0.8% as AG, 10.3% as C, 3.1% as D, 0.1% as F/K, 0.6% as J, and 0.3% as G 
(Figure 2.11 -B). Finally, analysis o f the Caribbean sequences revealed that 87.3% were 
classified as B, 8.5% as D, 1.4% as C and 2.8% as FK (Figure 2.11-C). In this case, 
however, the scores representing genetic distance (used to assign subtype) were 
significantly lower than those seen when subtyping the London and Birmingham 
clinical sequences (Figure 2.12). This finding may reflect the lack of closely related 
sequences in the PSSMs. It is more likely, however, that these low scores are a result 
o f the fact that these Caribbean sequences were considerably shorter in length than the 
sequences provided by the London clinic. This will lead to an overall lower score as the 
scoring algorithm does not normalise according to sequence length.
2.3.7 Impact of drug resistance mutations on subtype assignment
All existing subtyping tools face the same problem when assigning subtype to PR-RT 
sequence, namely if resistance mutations are present in the clinical isolates they will 
increase the level of dissimilarity to the reference subtypes, even though the greater 
genetic distances in these cases is not necessarily linked to subtype variation. By 
utilising a PSSM based method, however, the impact of these mutations is reduced as 
any amino acid residue will only score proportionally to its frequency within reference 
datasets. Provided resistance mutations are not present in subtype profiles, they will be 
excluded from the subtyping process. Accordingly, the frequency of such mutations in 
both reference sequences and clinical isolates of defined subtype (London dataset) were
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Figure 2.11 Pie charts show ing the p ercen tages of each  subtype identified within the 
London (A), Birmingham (B) and Caribbean (C), d atasets, a s c lassified  by Star.
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Figure 2.12 Distribution of Star sco res  for the Caribbean and London test datasets.
This figure show s the considerably lower STAR scores for Caribbean PR-RT sequences, 
compared to London sequences. The scores are below the confidence threshold assigned as a 
result of leave one out analysis, used to identify poor sequences and potential recombinants in 
the test and London datasets.
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determined. Specifically, the in-house program Mutant was used to report all mutations 
within a query sequence that are not due to natural variation and select those sequences 
containing key mutations that can be considered to indicate a history of exposure to 
antiretroviral therapy (Parikh et al., 2001, Table 2.6). The frequency of such mutations 
in subtype clusters o f clinical and reference sequences are shown in Figure 2.13. 
Sequences from the London clinic showed a consistently high frequency of resistance 
mutations in subtype B sequences with approximately twice the average number of 
resistance mutations (per genome) than the non-B clinical isolates. The sequences that 
made up the subtype profiles also appeared to contain very low levels of amino acid 
substitutions associated with drug resistance (Table 2.7). This is either suggestive of 
exposure to ART or more likely reflects natural amino acid variation in certain 
subtypes. Interestingly, the subtype A dataset appears to contain a proportionally higher 
level of drug resistance associated amino acid variation, than the other subtypes (Table 
2.7).
2.3.8 Impact of subtype on sequencing efficiency
An additional dataset was provided by the Birmingham PHLS, which included 
information gathered for 1534 separate clinic attendances by HIV positive patients. 
Data included; reason for testing, viral load, drug adherence, sequencing efficiency and 
viral subtype. A preliminary examination o f the relationship between subtype and both 
viral load at time of testing and sequencing efficiency was performed. In terms of viral 
load, the distributions shown in Figure 2.14-A are equivalent for subtypes A, B, C, D 
and G, suggesting that within this dataset there is no clear relationship between the 
subtype o f virus with which patients are infected, and their viral load at time of testing. 
Interestingly, however, the data presented in Figure 2.14-B shows a clear relationship 
between sequence failure and HIV-subtype. For patients where sequencing and subtype 
classification has been achieved on at least one previous occasion, subsequent 
sequencing failure for subtype B viruses occurs in only 5% of cases, whereas for all 
other non-B subtypes sequencing failure rates are substantially higher. Whilst for 
subtypes AE (n=l 1), AG (n=2), G (n=9) and K (n=2) these results could be a product of 
the very small sample sizes studied, for subtypes A (n=97), C (n=166) and D (n=54) the 
sequencing failure rates of 20, 26 and 14% respectively seem to be a clearly significant 
observation in relation to resistance sequencing methodologies, if not statistically.
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Table 2.6 R esistan ce  m utations (primary and assoc ia ted ) used  to c la ssify  se q u e n c e s  
a s drug ex p o sed  and/or potentially drug resistant (number represents am ino acid  
position).
P ro tea se____________________________________________________________________________
Primary 3 0 . 3 2 , 4 8 , 5 0 , 8 2 , 8 4 , 8 8 , 9 0
Associated______ 46, 47. 54, 71__________________________________
R e v e r se  Transcrip tase_____________________________________________________________
Primary 41, 65. 69, 70, 74, 75, 100, 101, 103, 115, 181, 184, 190, 215,  219
Associated______ 118, 210_______________________________________
Figure 2.13 R esistan ce m utations within different su b typ es.
Mean number of resistance mutations within PR and RT, from HIV-1 clinical isolates (classified 
by STAR, from the London dataset) and present in original reference sequences comprising the 
subtype-specific PSSM s (obtained from GENBANK and Los Alamos).
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Table 2.7 Percent prevalence of resistan ce  m utations in subtype reference d a tasets  
(pre-update).
_________________________________________________ S u b t y pe ______________________________
RT mutations A AG B C D F G H J
K219Q 7 .7  1 2 .5  0 0 0 0 0 3 3 .3  0
K65E/R 3 .9  6 .3  0 0 0 0 0 0 0
K70R 1 9 .2  1 2 .5  3  0 0 0 25 3 3 .3  0
L100S 0 0 0 2.6 0 0 0  0 0
M41L 0 0 0 0 1 2 .5  0 0 0 5 0
T215I/Y/S 15 .4  0 6 0  0 0 0  0 5 0
T69N/D/I/S________ 7 .7  6 .3  0 2 .6  0 1 4 .3  0 0 0
PR mutations_______ A AG B C D F G H_____J _
A71T 3 .9  0 0 0 0 0 0 0  0
D30N 0 0 0 5.1 0 0 0  0 0
M46I______________ 100 0 0 0 0 0 0  0 0
No. sequences_____ 26_____ 16 33 39_____8_____7_____ 4_____ 3_____ 2
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Figure 2.14 R elationship betw een viral load, seq u en ce  failure and subtype.
(A) Viral load distribution in subtype A, B, C, D and G infections, based on data from 1519 
individual testing occasions. (B) Percentage of sequence failures of all reported resistance 
sequencing of PR-RT, for HIV-1 subtypes A, AE, AG, B, C, D, G and K. The number of reports 
in each category (N) is noted, of which the bar represents percentage failure.
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In terms of sequencing efficiency at least, this data reveals that patients infected with 
non-subtype B HIV-1 are not being managed optimally with respect to monitoring drug 
resistance. This therefore highlights the importance, in a population where 21.1% of 
patients harbour non-subtype B viruses (Figure 2.11-B), o f determining viral subtype as 
soon as infection is diagnosed. Only if this is known can patient genotypic monitoring 
strategies be optimised.
102
2.4 Discussion
As one of the most extensive sources of HIV sequence data, clinical resistance testing 
provides a highly valuable data resource. If such sequence data were to be accurately 
classified at source, in terms of subtype, the resulting information would prove 
invaluable in the study of the distribution and clinical significance o f the various HIV-1 
subtypes, and aid in the optimisation of patient management strategies.
The most accurate method of grouping amino acid sequences is by extensive 
phylogenetic analysis. Methods such as maximum likelihood, however, are user 
dependent, computationally expensive and unsuitable for clustering large datasets such 
as those produced in clinics carrying out HIV genotyping. Accordingly, a subtyping 
tool named Subtype Analyser (STAR) has been developed here, which allows 
comparison of a query sequence against the full genetic diversity o f a characterised 
group o f subtype-specific sequences, which are defined as tables o f amino acid 
frequencies, based on multiple sequence alignments. STAR intentionally uses amino 
acid sequences as clinical HIV-1 resistance sequences are often reported and databased 
as amino acid changes relative to a reference sequence. STAR can subtype such data 
following reconstruction of the full-length amino acid sequence. In addition, because of 
the high nucleotide variation rate of HIV-1, synonymously variable positions within 
nucleotide sequences may rapidly saturate and as such confound nucleotide based 
subtype classification schemes. The use o f shorter amino acid sequences also 
considerably increases the computational speed with which subtype classification can be 
achieved.
2.4.1 There is sufficient sequence divergence in Pol to distinguish between 
subtypes
As Gag and Env have been traditionally used for HIV subtype classification, following 
curation of amino acid sequence datasets representing subtypes A, B, C, D, FK, G, H, J, 
group N and group O for Gag, Pol, PR-RT and Env proteins, using three separate 
phylogenetic methods, an investigation of the sequence variability between all the 
subtypes for which profiles were created, across Gag, Pol and Env, was performed. 
This revealed that the least sequence variability was seen in the Pol region (Figure 2.6), 
as expected. Subtypes B and D showed the greatest similarity, suggesting that it may be
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difficult to distinguish between these two subtypes using a subtyping tool based on 
amino acid sequence. It is clearly very important, however, to be able to distinguish 
between these two genetic variants o f HIV. Subtype D viruses are typically sub- 
Saharan African in origin, whereas subtype B predominates in Western Europe and the 
USA. In terms of monitoring the spread o f non-B subtypes into these regions therefore, 
subtypes B and D must be readily identifiable based on PR-RT if this subtyping 
algorithm is to be a useful epidemiological tool. Phylogenetic analysis, coupled with 
leave one out validation studies showing a mean 99% accuracy, however, suggest 
STAR is both robust and applicable to subtyping HIV-1 based on the PR-RT regions 
sequenced for routine drug sensitivity testing. This agrees with previously published 
data (Pasquier et a l, 2001, Njouom et a l, 2003). The variation within amino acids 
sequences from HIV-1 PR-RT, when assessed in the context of STAR, are sufficient to 
allow discrimination between the genetically most similar, as well as more distantly 
related subtypes.
The creation of tables of amino acid frequencies based on multiple sequence alignments 
(subtype-specific profiles) required the careful curation o f subtype-specific PR-RT 
sequence datasets. The subtype specific alignments generated by the initial 
phylogenetic analyses and sequence analysis were accordingly refined, including the 
merging of CRF01 (AE) sequences with the subtype A profile, as this CRF is subtype A 
within PR-RT. A distinct CRF02 (AG) profile, however, was created as representatives 
o f this CRF clustered separately from subtypes A and G. Subtypes F and K were 
merged because they were difficult to distinguish between, perhaps unsurprising as it 
has been proposed that subtype K should be reclassified as sub-subtype F3 (Triques et 
a l, 1999, Triques et a l, 2000, Van der Auwera et a l, 2001).
2.4.2 Different patterns of resistance mutations were detected in subtype profiles
Drug resistance mutation analysis of sequences within subtype-specific profiles was 
performed, as the absence of resistance mutations from profiles was a prerequisite for 
them not influencing the accuracy of subtyping, especially of drug-exposed viruses. 
Analysis of the original reference sequences showed a very low level of resistance 
mutations, as required. Certain sequences, however, were found to possess certain 
resistance-associated mutations presumably present as natural polymorphisms. Subtype 
A sequences in particular appear to have a proportionally higher level of drug resistance
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associated amino acid polymorphisms, compared to the other subtypes (Table 2.7). If 
this variation is reflected in all subtype A viruses it is possible that they may progress to 
ART resistance quicker or via different pathways than other genotypes, a suggestion 
which warrants further investigation. Such observations have been made for subtypes O 
and J previously (Descamps et al., 1997) highlighting the potential importance of 
subtype classification in assessing and perhaps predicting treatment outcomes. At 
present, however, HIV subtype is an uncertain factor when making clinical decisions 
about antiretroviral therapy. Whilst current research may soon help to elucidate the 
important subtype-dependent differences that affect virologic response to therapy, it is 
hoped that by providing a reliable method o f HIV subtyping this may be made easier 
and may help drive the expansion of drug treatment efforts, while simultaneously 
contributing to their effectiveness across different geographical regions and HIV 
subtypes. It is also interesting that a difference in the efficiency of resistance 
sequencing was detected, for different HIV-1 subtypes (Figure 2.14-B): sequence 
failures were proportionally much higher for non-B subtypes. It may therefore not only 
be treatment strategies, but also monitoring and diagnostics, which require adjusting 
when a particular patient’s subtype status is known.
2.43 Testing of a clinical dataset and inclusion of a measure of confidence
As part of the STAR algorithm, a basic means o f assessing the reliability of each 
subtype classification was created: if  the classification score falls below a defined score 
threshold, it is marked as low confidence (‘putative subtype’) and may be further 
examined by virtue of a sliding window option (section 2.3.4). This option enables the 
detection of recombinants in the PR-RT region, provided that there is sufficient genetic 
distinction between recombining HIV-1 subtypes (Figure 2.10). The inclusion of a 
method of assessing the reliability of a subtype assignation is novel, and was included 
as other subtyping tools currently available do not provide this level of rigour.
To demonstrate the utility of STAR, 843 HIV-1 PR-RT sequences derived from clinical 
samples, from London; 885 HIV-1 PR-RT sequences derived from clinical samples, 
from Birmingham; and 71 HIV-1 PR-RT sequences derived from clinical samples, from 
the Caribbean, were subtyped using this new tool. The distribution of HIV-1 subtypes 
within this dataset reflects the previously reported prevalence of non-B strains in the 
UK (Parry et al., 2001), and in the Caribbean (Vaughn et al., 2004). Furthermore, 84%
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of the subtype assignations made for UK-based patients are made with high confidence, 
a measure not available with any other web-based batch subtyping tool. This level of 
confidence is a virtue o f the fact that the STAR algorithm has been designed to take into 
account the inherent variability within sequences produced for resistance evaluation. 
That is, sequence features such as resistance mutations (identified in the clinical test 
dataset) are corrected for within the scoring system due to their extremely low 
frequency o f occurrence in subtype profiles. Such heterogeneity in clinical isolates 
increases the level of dissimilarity to the reference subtypes, resulting in greater genetic 
distances not necessarily linked to subtype variation. With STAR these factors do not 
affect the subtyping process.
Interestingly, however, whilst the Caribbean sequences were classified with high 
accuracy, the actual scores resulting in classification of each sequence were lower than 
that seen for the sequences classified from UK clinics (Figure 2.12). As a result, all 
sequences fell below the 1.5 SD confidence level, indicating that sequences which are 
from locations geographically distinct from those of sequences within the subtype 
profiles (used to set the confidence threshold), and which are produced by an alternative 
resistance testing protocol resulting in generation of a shorter PR-RT sequence, are less 
likely to score with high confidence. Because o f this observation alternative scoring 
methodologies for STAR are in development which will overcome the sensitivity o f this 
current measure of confidence in classification, both to more rare sequences not 
represented within subtype profiles and to shorter Pol sequences.
2.4.4 Recombinants within PR-RT may be identified
The occurrence of novel circulating recombinant forms (CRFs) of HIV-1 are being 
increasingly reported. CRFs, however, can only be detected by sub-gcnomic subtyping 
tools if the signature recombination sitc(s) are within the region used for classification. 
For example, STAR cannot identify CRF01 which is subtype A in the 5’ region of the 
genome and subtype E in the 3’ region. Accordingly, the PR-RT sequence of this AE 
CRF clusters with subtype A sequence. In the case of CRF02 (AG), however, this 
recombinant strain possesses sufficient genetic divergence in PR-RT to distinguish it 
from other subtypes. This enabled the creation of a recombinant subtype profile for the 
PR-RT region; hence STAR can identify CRF02 without the need for extra analysis.
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Furthermore, by creating a confidence threshold and assigning ‘putative subtype’ flags 
to sequences that score below 1.5 SD of the subtype mean score it is possible to identify 
further recombinants in PR-RT (Figures 2.9 and 2.10). Thus, STAR may detect AG 
recombinants outright, or other types of recombination in the PR-RT region provided 
there is sufficient genetic divergence between the recombining subtypes. It should also 
be noted that the methodology behind STAR is not confined to analysis of the PR-RT 
region of HIV-1. If other regions o f the HIV-1 genome become routinely sequenced for 
drug resistance, STAR could be expanded to encompass their classification.
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Chapter 3.0 Phenotypic characterisation of HIV-1 
subtypes and HIV-2 in vitro
3.1 In tro d u c tio n
As described in the introduction to this thesis, several distinct subtypes and an 
increasing number of recombinant forms are responsible for the current HIV-1 
pandemic. Despite the involvement of multiple genetic variants of HIV in the causation 
o f disease worldwide, however, there has been a large skew in research focus on 
subtype B, which is the most prevalent subtype in the western world. As a 
consequence, it is currently not clear whether genetically distinct HIV-1 subtypes have 
different biological properties that cause differences in disease progression, or 
transmissibility. The accurate subtype classification of HIV isolates, for example using 
STAR, and the linking of this information to clinical observations, at a population level, 
may go some way helping answer these questions.
On the whole, however, it remains to be seen whether the properties and consequences 
of HIV infection can be generalised across the non-B subtypes that affect the majority 
of infected persons in the developing world. A limited number of preliminary studies 
have attempted to address the question as to whether HIV-1 subtypes differ; at the 
population level in their transmission and disease progression, or in vitro in terms of 
their fitness, replication capacity and sensitivity to antiretroviral drugs.
3.1.1 Epidemiological studies
The rate of HIV-1 disease progression varies widely between infected individuals and it 
was demonstrated as early as 1989 that variability in the biological properties of HIV 
isolates is one of the factors influencing the course of HIV infection (Tersmette et al., 
1989). A significant correlation was found between the mean replication rate of isolates 
obtained from an individual and the rate of CD4+ T-ccll decline observed: in 
individuals with low-replicating HIV isolates no significant CD4+ T-cell loss was 
observed, but recovery of high-replicating isolates, in particular syncitium inducing (SI) 
isolates, was associated with rapid decline o f CD4+ T-cell numbers and development of
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AIDS. With the subsequent association o f the SI/NSI characteristics of HIV with 
sequence variation in the env gene (Cheng-Mayer et al., 1990) and the discovery o f the 
main HIV-1 co-receptors CCR5 (Deng et al., 1996, Dragic et a l, 1996, Alkhatib et a l, 
1996) and CXCR4 (Feng et al., 1996) the link between coreceptor usage and disease 
progression was established (Connor et al., 1997). Several reports have also linked 
sequence variation among divergent HIV-1 subtypes with differing coreceptor usage, in 
vitro cytopathogenicity and therefore potentially disease progression (de Wolf et a l, 
1994, Rubsamen-Waigmann et al., 1994, Zhong et al., 1995, Tscheming et al., 1998). 
In terms o f host effects, as described in Chapter 1.0, a deletion allele of the CCR5 co- 
receptor gene has been reported to slow disease progression in heterozygotes compared 
with individuals homozygous for the normal CCR5 gene (Dean et al., 1996). Age at 
seroconversion has also been shown to influence disease progression (Pezzotti et al., 
1996). Other human allelic variants shown to influence the susceptibility to HIV-1 
infection and/or the subsequent rates of disease progression include: genes that control 
viral entry into susceptible cells (chemokines and chemokine receptors); genes involved 
in immune regulation, such as interleukin-10 (IL-10), interleukin-4 (IL-4), tumour 
necrosis factor-alpha (TNF-alpha), and mannose-binding lectin (MBL); and genes 
involved in the adaptive immune recognition by T cells, (human leukocyte antigen 
(HLA) type; reviewed by Anastassopoulou and Kostrikis, 2003, Kaslow et al., 2005). 
Both host and virus therefore play important roles in directing the progression of disease 
over time. It could be argued, however, that host effects are more likely to induce 
differences in disease progression between infected individuals, as the host has a great 
capacity for behavioural and external changes (such as nutrition or coinfection) that can 
be shown to directly influence the progression o f disease. This is compounded in that, 
besides replication rate and coreceptor usage, few other virus-specific characteristics 
have been directly attributed to particular differences in disease phenotype. 
Epidemiological studies relating virus type to disease progression, however, have 
provided some evidence that suggests HIV genotype may play an important role in HIV 
disease.
3.1.1.1 Disease progression
Early studies of different subtypes of HIV-1 and their association with disease 
progression provided somewhat conflicting data. It was initially shown that the rates of
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disease progression, evaluated by the decline in CD4 lymphocyte count, were similar 
between groups of Ethiopian immigrants infected with HIV-1 subtype C and non- 
Ethiopian Israelis infected with subtype B (Galai et al., 1997). This study, however, 
compared two groups receiving antiretroviral therapy with different demographic 
composition, mode of transmission and host genetics. In contrast, a study from Senegal 
reported that individuals infected with HIV subtype A were found to progress clinically 
more slowly than those infected with non-A subtypes (Kanki et al., 1999). In this study 
women infected with a non-A subtype were eight times more likely to develop AIDS 
than those infected with subtype A. However, another study investigating the influence 
of genetic subtype of HIV-1 and the ethnic origin o f the infected individual on the rate 
of disease progression found no significant differences in the rate of disease progression 
or CD4 lymphocyte decline between individuals infected with subtypes A, B, C or D 
(Alaeus et al., 1999). Furthermore, a study in Thailand reported that HIV-1 subtypes B 
and E (AE) were associated with similar degrees of immunosuppression and 
opportunistic infection patterns among a group of HIV-1 infected individuals 
(Amomkul et al., 1999), but in this case all individuals were AIDS patients. Finally, in 
London it was reported that differences in CD4 lymphocyte count decline and 
progression to AIDS in HIV-1 infected Africans and non-Africans could not be 
attributed to ethnicity or viral subtypes (Del Amo et al., 1998). In this study, however, 
it was presumed that the Africans were infected with subtypes A and C, and non- 
Africans with subtype B, making such data very hard to interpret.
The studies described, therefore, used cohorts composed of individuals who may or may 
not have been receiving antiretroviral therapy, were not homogenous in terms of host 
genetic composition, mode of transmission, demographic composition, or time of 
infection (Galai et al., 1996, Del Amo et al., 1998, Alaeus et al., 1999) and largely 
generated conflicting results. Accordingly, subsequent epidemiological studies looking 
at the relationship between HIV-1 subtype and disease progression have typically aimed 
to investigate populations where these problems are controlled. One such study looked 
at 164 individuals infected with envelope subtype A or D viruses in a Ugandan 
population, one hundred and seventeen of whom had estimated dates of seroconversion, 
HIV-1 infection being almost exclusively acquired by heterosexual transmission and 
where antiretroviral drugs were not available (Kaleebu et al., 2001). It was reported 
that, whilst disease progression in participants infected with subtypes A and D was not
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significantly different for most end-points, there was a tendency for those infected with 
subtype D to progress faster than those infected with subtype A: there were over three 
times more deaths with subtype D compared to subtype A. This disparity between 
subtypes A and D, however, did not reach statistical significance for most indicators of 
progression. This work was followed by a second, larger study, in which the effect of 
HIV-1 envelope subtypes A and D on disease progression was investigated in 1045 
Ugandan adults. In this case, subtype D was found to be associated with faster 
progression to death (P = 0.009) and with a lower CD4 cell count during follow-up (P = 
0.001) compared with subtype A, after adjusting for CD4 cell count at enrolment. The 
conclusion was that, in Africa, envelope subtype D is associated with faster disease 
progression, compared with subtype A (Kaleebu et a l, 2002). Interestingly, this trend 
was observed previously (Alaeus et al., 1999) in a study in which the authors did not 
show a significant difference between individuals infected with subtypes A-D, but there 
was a tendency for subtype D to progress faster than A: the mean CD4 lymphocyte 
count decline in D being twice that in A.
3.1.1.2 Vertical transmission
In addition to differences in disease progression, differences in transmission efficiency 
between subtypes have also been reported. An early study in Tanzania established the 
HIV-1 gag and env subtype and maternal risk factors o f 51 matched transmitting and 
non-transmitting mothers. Transmission differences among genotypes revealed that 
mothers infected with HIV-1 subtypes A, C, or HIV-1 intersubtype recombinant viruses 
were more likely to transmit HIV-1 to their infants than mothers infected with HIV-1 
subtype D. Lower CD4 cell counts at enrolment were associated with transmission, but 
CD4 cell counts within each genotype did not explain differences in transmission 
among HIV-1 genotypes. This study provided the first evidence that HIV-1 genetic 
subtypes may play a role in rates of vertical transmission in an African setting (Renjifo 
et al., 2001). This was followed by a second study in Tanzania, in which transmission 
of viruses with different long terminal repeat (LTR) subtypes was investigated. 
Specifically, the LTR subtype was determined for 45 matched cases and controls; HIV- 
1 subtypes A, C, D and intersubtype recombinant sequences were identified. Statistical 
analysis showed that viruses containing subtype A or intersubtype recombinant LTRs 
were 3.2 and 4.8 times more likely to be transmitted from mother to infant than viruses 
with subtype D LTRs. Viruses containing subtype C LTRs were 6.1 times more likely
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to be transmitted than those with subtype D LTRs. Differences in transmission were 
again shown to be independent of maternal CD4 at enrolment (Blackard et a l, 2001). 
More recently a study in Dar es Salaam, Tanzania, confirmed these observations by 
showing differences in timing for transmission from mothers to their infants. This 
much larger study of 253 HIV-1-infected infants was designed to examine the efficacy 
of vitamins in decreasing mother-to-child transmission. It was found, however, that 
there were significant differences in the distribution of transmission time according to 
subtype: a higher proportion o f HIV-1 subtype C {env) was transmitted in utero than 
subtypes A or D {env) (Renjufi et a l, 2004).
In contrast to these data, however, a study performed in Kenya among 414 women for 
whom HIV-1 subtype and HIV transmission status were available, found that mother to 
child transmission rates were higher among women with subtype D (e«v/p24) compared 
with subtype A (Yang et a l, 2003). Furthermore, women with env/p24 subtype 
combinations D/D, D/A, and A/D had an increased risk of transmission than A/A 
women after adjusting for confounding factors. Not all studies, however, have reported 
subtype specific differences in vertical HIV-1 transmission. A study of 130 HIV 
positive mothers in Nairobi, Kenya, found no difference in transmission frequency 
between HIV-1 subtypes A and D (Murray et a l, 2000). In addition, a study of 31 HIV- 
1-seropositive pregnant Tanzanian women showed that, among eight transmitter 
mothers, four were infected with HIV-1 subtype A, one with HIV-1 subtype C, none 
with HIV-1 subtype D and three with HIV-1 subtype recombinant A/C. The authors 
concluded that these findings show no significant differences in the mother-to-child 
transmissibility of HIV-1 subtypes A, C and D and detected recombinants forms, 
although the study size in this case is particularly small (Tapia et a l, 2003). Perhaps the 
failure to detect subtype D transmission may in fact support the findings o f the research 
by Renjufi et a l, in Tanzania.
Thus, several interesting hypotheses can be proposed regarding the relationship between 
viral subtypes and the perinatal transmission of HIV, in particular subtype A and D 
viruses. Inter-subtype genetic variation may bring about changes in receptor affinity, 
mediated by the env gene, and increased transcriptional activation, mediated by changes 
in the LTR and tat, accounting for these observations. More specifically, the higher rate 
of vertical transmission in mothers infected with subtype D compared to those infected
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with subtype A could perhaps be explained on the basis of viral load, as the mean viral 
load among mothers infected with subtype D virus was often reported as being higher 
than that among mothers infected with subtype A (Yang et al., 2003). The fact that this 
relationship between subtype and vertical transmission appears to be independent of 
viral load, however, suggests that there may be intrinsic properties of subtype D viruses 
that render them more infectious. Women who were either concordant for subtype D 
(D/D) or discordant with subtype A (D/A or A/D) had high transmission rates, 
indicating that it is not recombinant subtypes themselves that result in higher rates of 
transmission in this study population (Yang et al., 2003), but rather the presence o f the 
subtype D sequence in the genome. This suggests that viruses with subtype D are either 
more virulent or have a better fitness capacity or altered cellular tropism for placental 
cells in the Kenyan mothers studied. An alternative explanation could be that subtype A 
viruses are less virulent or less fit and may be transmitted less efficiently from mother to 
child. Most CRF in Africa have at least some subtype A structure (i.e. C R F01A E, 
C R F02A G ) and if such recombination with subtype A occurs due to reduced 
efficiency of replication and transmission in subtype A, then it is likely that the HIV-1 
subtype A epidemic may be replaced by one consisting of non-A subtypes or 
recombinant forms.
The estimated vertical transmission rate in Kenya o f 25% (Datta et al., 1994) is 
comparable with rates in other parts of the world: North American and European 
subtype B transmission rates are in the range of 19-25% (Matheson et al., 1995); in 
South Africa subtype C virus perinatal transmission rate is 24% (Bobat et al., 1997); 
and in Thailand subtype AE virus perinatal transmission rate is 24.2% (Shaffer et al., 
1999). Thus, given that vertical transmission rates from around the world are similar 
despite the prevalence of different subtypes this suggests that subtype may not, globally, 
have an effect on the rate of transmission of HIV-1 from mother to child. Furthermore, 
this may indicate that viral adaptation within the human population has resulted in 
equivalent transmission capacity, irrespective of viral subtype, due to host pressures. 
Differences in host ethnicity, environmental factors and viral genotype may all 
contribute to the subtle differences in transmission frequency recorded. It seems likely 
that HIV-1 subtype, viral load, host ethnicity, environmental factors and the likelihood 
of vertical transmission are intimately linked.
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3.1.1.3 Horizontal (sexual) transmission
Many factors that impact on the sexual transmission of HIV have been described in 
epidemiological studies. These include: the distribution/frequency o f risk behaviours; 
the prevalence of co-factors for HIV transmission (other STDs); immune factors; and 
non-immune factors such as male circumcision (Hu et al., 1999). These factors, in 
combination with the challenge of quantifying incidence, have made attempts to study 
the relationship between likelihood of sexual transmission and HIV-1 sequence 
variation very difficult. Like the role o f HIV sequence variation in vertical transmission 
o f HIV-1, the importance o f subtypes in sexual transmission is far from clear.
One o f the best examples of a well-documented epidemic, however, was the 
independent introduction and subsequent spread o f HIV-1 subtypes AE and B in 
Thailand. Whilst both subtypes were introduced at similar times it is subtype AE which 
has gone on to affect all risk groups within the population (Wasi et al., 1995). Despite 
the many confounding issues in trying to relate genetic subtype to transmission 
characteristics, an observation as clear as this lead to the general hypothesis that certain 
subtypes of HIV-1, such as AE, may be transmitted more successfully through 
heterosexual intercourse. A cross-sectional study o f HIV infected men and their 
partners, in Thailand, showed that there were higher rates of seroconcordance among 
couples infected with subtype AE compared to those infected with subtype B 
(Kunanusont et al., 1995). Subsequent in vitro studies provided support for these 
findings as it was reported that subtype AE viruses from Thai heterosexuals grew more 
efficiently in vaginal epithelial Langerhans cells (LC), than subtype B viruses from U.S. 
homosexuals. This suggests that LC tropism is associated with the efficiency of 
heterosexual transmission of HIV (Soto-Ramirez et al., 1996). The findings of this 
study, however, could not be repeated and further in vitro studies proved non- 
conclusive (Pope et al., 1997, Dittmar et al., 1997). The explanation as to how subtype 
AE predominates in Thailand thus remains highly controversial.
Furthermore, the rates of HIV-1 sexual transmission reported in different studies are 
quite variable. For example, a study in Thailand revealed a high per-act probability of 
heterosexual transmission, which was proposed to help explain the rapid spread of HIV- 
1 during the emergence of the epidemic in Thailand, and perhaps in other countries 
where HIV-1 transmission is predominately heterosexual (Mastro et al., 1994).
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However, as noted other studies have not reported similar transmission frequencies, 
irrespective o f subtype, for either sexual (Mastro et al., 1996) or vertical transmission 
(Shaffer et al., 1999). Whilst some studies may support the notion that different HIV 
subtypes are differentially transmitted sexually, therefore, it is difficult to delineate what 
additional factors might contribute to the differences in the rates o f transmission 
because of the variations in study methodologies and potential confounding factors.
3.1.1.4 Viral set point
The prognostic value o f a single measurement o f plasma virus load among patients 
infected with HIV-1 is widely recognized (Mellors et al., 1997, Anastos et al., 1999, 
Vlahov et al., 1998, O'Brien et al., 1996). Studies involving serial measurements of 
HIV RNA load, however, have provided data that argue both for and against a viral ‘set 
point’ theory, which proposes that virus load for an infected patient stabilises soon after 
HIV seroconversion, with the ‘set point’ achieved being a strong indicator o f future 
disease progression (Katzenstein et al., 1996; Bruisten et al., 1997, Keet et al., 1997; 
O'Brien et al., 1998, Schacker et al., 1998). Researchers have also hypothesised that an 
early dynamic between viral replication and the immune response may influence a 
person's longitudinal pattern of immunologic and virologic markers, as well as their 
clinical prognosis (Henrard et al., 1995). It has also been reported that there may be 
differences in viral load at peak viraemia shortly after infection, before the set point is 
reached, between different HIV subtypes. There is therefore some debate as to whether 
different subtypes may be associated with certain ‘set points’, and thus certain 
phenotypes of clinical disease.
A study carried out by Rinke de Wit et al., (2002) found that CD4 T-cell counts 
remained significantly lower and CD8 T-cell counts significantly higher in Ethiopian 
seroconverters compared with Dutch seroconverters. Viral loads were lower in 
Ethiopians in the first months after seroconversion, subsequently increasing to similar 
levels to the Dutch seroconverters. Furthermore, within the 20 Ethiopian 
seroconverters, 15 were infected with sub-cluster C' and 5 with sub-cluster C (Abebe et 
al., 2000). Interestingly, viral loads were higher in sub-cluster C'-infected Ethiopians, 
suggesting that whilst subtype may have an influence on viral set point and therefore 
subsequent disease, there may be more subtle effects within genotypic variants of HIV 
which could be of biological importance.
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A similar study looked at the difference between subtypes B and AE, again in Thailand 
(Hu et al., 2001). 130 HIV-1-infected seroconverters (103 with HIV-1 subtype E and 
27 with subtype B) were included in the study and serial HIV-1 RNA viral load, natural 
killer cell percentage, CD4 and CD8 lymphocyte counts were monitored over 24 
months, post-seroconversion. Results showed that median viral RNA levels within 3 
months of seroconversion were more than three times higher for persons infected with 
subtype AE than with subtype B, this difference decreasing over time such that viral 
loads were similar at 12, 18, and 24 months following seroconversion. The CD4 and 
CD8 lymphocyte counts were similar in infections with either subtype (Hu et al., 2001).
To what extent these differences are influenced by the interaction between the virus 
genotype and the host environment is not known. Hu et al. hypothesise that higher viral 
loads associated with subtype AE may result from inter-subtype biological differences. 
Characterisation of subtype B and AE viruses from this study cohort showed major 
inter-subtype differences in the proportions of different envelope V3 motifs as well as 
predicted co-receptor usage and phenotype from genetic sequence data (Subbarao et al., 
2000). Furthermore, reported inter-subtype differences in the function of long terminal 
repeat (LTR) transcriptional promoters suggest that subtype AE may replicate more 
efficiently than subtype B in certain circumstances (Jeeninga et al., 2000). The 
epidemiological dynamics of transmission in Bangkok, however, were also proposed to 
have contributed to this phenomenon. That is, subtype AE was introduced into 
Thailand after subtype B, at a time when there was a higher incidence of intravenous 
drug users in the affected population. Accordingly, one might predict a higher 
proportion of persons with subtype AE to have been more recently infected and hence 
have higher mean viraemia (characteristic of acute disease). Thus, if these recently 
infected persons in the study described were serving as source partners, then the subtype 
AE reservoir o f infection would be richer in higher viral loads than the subtype B 
reservoir (Hu et al., 2001). As higher viral load has been associated with higher rates of 
transmission through a variety of modes (Mastro et al., 1998, Shaffer et al., 1999) if a 
person is infected by someone with subtype AE they would be more likely to have 
encountered someone with a higher viral load (thus inoculum), which in turn would 
result in higher initial viral loads in the seroconverter, thus perpetuating the spread of 
HIV-1 subtype AE.
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3.1.1.5 HIV-1 and HIV-2
When considering the importance o f HIV sequence variation in terms of disease 
progression and transmission (both sexual and vertical), the difference between HIV-1 
and HIV-2 provides a very useful comparison. That is, between these two viruses there 
is approximately 50% sequence divergence and whilst HIV-2 shares the same modes of 
transmission as HIV-1 (DeCock et a l, 1993, Poulsen et a l, 1989, Gnaore et a l, 1989), 
the distribution o f HIV-2 infection mainly remains restricted to west Africa where 
prevalence rates have been stable over time, in contrast to the global distribution and 
prevalence of HIV-1 (Clavel et a l, 1986a,b). Further to these observations, numerous 
studies have demonstrated that, unlike between the subtypes of HIV-1, there are clear 
and appreciable differences in transmissibility between the two HIV types, with much 
lower rates of sexual and mother-to-infant transmission for HIV-2 than for HIV-1: 
whereas approximately one-quarter of infants bom to HIV-1-infected women around the 
world become infected in the absence o f preventive interventions (Oxtoby, 1990, 
European Collaborative Study, 1991, Halsey et a l, 1990) approximately 1% of HIV-2- 
infected mothers transmit the infection to their newborns (Andreasson et a l, 1993, The 
HIV Infection in Newborns French Collaborative Study Group, 1994, Adjorlolo- 
Johnson et a l, 1994). It may be that, if the relative differences in transmissibility were 
smaller, these studies might not have been able to demonstrate significant differences. 
Natural history studies have also demonstrated that HIV-2 has a reduced virulence 
compared to HIV-1 (Marlink et a l, 1994), and HIV-2 viral load reflects the difference 
in pathogenicity of HIV-1 and HIV-2 (Popper et a l, 1999).
Accordingly, it may be that using epidemiological studies to identify the differences 
between HIV subtypes (which show approximately 25-30% sequence divergence) may 
be too insensitive to distinguish sequence variation effects from the myriad of other 
factors that modulate HIV-1 transmission and disease progression, at the population 
level, unless extremely large and well-controlled studies are undertaken. If using 
sequence generated for resistance testing, such studies would be compounded by the 
methods for subtype assignment of pol sequence currently available which, if not 
incorporating more complex phylogenetic approaches, must be questioned as to their 
accuracy (Chapter 2).
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3.1.2 In vitro studies
Given the inconclusive link between HIV-1 genetic variation and disease phenotype, the 
simplest hypothesis may be investigated: that genetically variable strains of HIV will 
grow differently in cell culture. If this is true, and the findings agree with previously 
published observations regarding in vivo differences between HIV subtypes, this could 
lend weight to the argument that subtype is an important causal factor in the phenotype 
of HIV disease. Accordingly, several in vitro studies have attempted to characterise the 
phenotypic manifestations o f genotypic variation. Studies looking at the relationship 
between HIV-1 subtype, coreceptor usage and in vitro viral pathogenicity, and HIV 
subtypes B and AE in vitro transmissibility have been described. Study of the HIV-1 
LTRs, PR, env and accessory genes of different subtypes, however, have also generated 
interesting data.
3.1.2.1 The HIV-1 LTR
The LTR is a major determinant for virulence in several animal retroviruses and minor 
changes or rearrangements within the transcription factor binding sites (TFBS) have 
been shown to have a significant impact on cell tropism and pathogenicity (Carvalho et 
al., 1993, Maury et al., 1998). In general the effect o f HIV-1 LTR subtype on viral 
infectivity, virulence and fitness, however, is not known. Small differences in LTR 
transcriptional activity between subtypes have been demonstrated (Jeeninga et al., 2000, 
Montano et al., 1998, Naghavi et al., 2001, Quivy et al., 2002). Whether these 
differences in LTR activity result in subtype-specific differences in replication rate, 
however, was only addressed recently in a study that aimed to determine to what extent 
LTR subtype and the cellular environment contributes to viral replication (van Opijnen 
et al., 2004). Specifically, the importance of the LTR on interactions between six 
cellular environments and nine viral genotypes (A-G and AG) with an isogenic set of 
HIV-1 molecular clones containing a subtype-specific LTR was determined. By 
conducting pair-wise competition experiments between all virus variants in all cellular 
environments it was shown that there are significant differences in replication rate 
between the subtypes and that the LTR-determined viral fitness depends on both the 
host cell type and the activation state. Subtype AE for example, had the strongest 
competitive ability and out-competed all other viruses, which ranked as sub-subtype C2 
being the second best, followed by subtypes A, C l, G, D, AG, B, and F. Conversely,
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when competition experiments were performed in a SupTl -tumour necrosis factor 
(TNF)-environment, subtype AE changed from being the strongest competitor with the 
highest replication rate in SupTl cells to being the worst competitor with the lowest 
replication rate. Thus, these data suggest that a given mutation can have a positive 
fitness effect in one cellular environment and a negative fitness effect in another (van 
Opijnen et a l, 2004). One of the consequences of this study, therefore, is that it may not 
be possible to assign a single fitness value to a particular subtype. The results clearly 
demonstrate a single replication or competition experiment may not provide an accurate 
estimate of fitness, because fitness (as determined by the LTR promoter) depends on the 
interplay between the genetic structure of the virus and the cellular environment. It is 
therefore not possible to tell which subtype is better, but only which subtype is better in 
a particular environment.
3.1.2.2 Protease and Gag
A study of HIV-1 subtype A and C protease enzymes in the presence of several protease 
inhibitors revealed that the biochemical fitness of subtype A and C proteases is higher 
than that of the B subtype protease (Velazquez-Campoy et al., 2001). Considering the 
fact that currently available inhibitors were designed against the B subtype protease, this 
finding is perhaps not surprising. It is difficult, however, to translate the difference in 
biochemical fitness observed into a meaningful biological significance.
Investigations regarding differences between HIV-1 subtypes have also focussed on the 
protease cleavage sites (CS). Specifically, the prevalence and patterns of 
polymorphisms in the Gag, Gag-Pol, and Nef CS of subtype C compared to those in 
non-C HIV subtypes, was assessed. Significant inter- and intrasubtype differences in 
CS, especially in the p2/NC, transframe protein/p6pol, and p6pol/PR sites, were 
identified (de Oliveira et a l, 2003): 58.3% of the 12 CS were significantly more diverse 
in C than in B viruses. The authors propose that natural variation at subtype C CS may 
play an important role, not only in regulation of the viral cycle but also in disease 
progression and response to therapy.
3.1.2.3 Env
The reason that many in vitro studies have focussed on subtype C is that the outgrowth 
of subtype C in southern Africa, India, and China has suggested that subtype C isolates
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may be more fit in vivo. In a recent study by Ball et al., nine subtype B and six subtype 
C HIV-1 isolates were added to peripheral blood mononuclear cell cultures for a 
complete pair-wise competition experiment. It was found that all subtype C HIV-1 
isolates were less fit than subtype B isolates (P < 0.0001), and that intrasubtype 
variations in HIV-1 fitness were not significant. Increased fitness of subtype B over 
subtype C was also observed in primary CD4+ T cells and macrophages, but not in 
skin-derived human LC, and analysis of the retroviral life cycle during several B and C 
virus competitions indicated that the efficiency o f host cell entry may have the greatest 
impact on relative fitness. Furthermore, for a recombined subtype B/C HIV-1 isolate, 
higher fitness mapped to the subtype B env gene rather than the subtype C gag and pol 
genes. This suggests that subtype B and C HIV-1 may be transmitted with equal 
efficiency (via LC) but that subtype C isolates may be less fit following initial infection 
(as shown in T-cell and macrophage experiments) and thus may lead to slower disease 
progression (Ball et al., 2003).
For HIV-1 and HIV-2, however, clear differences in the effect of gpl20 and gpl05 
(HIV-2 envelope glycoprotein) have been proposed to contribute to the distinct 
pathogenicity of the two viruses. Specifically, studies have shown that gpl05 is more 
effective in inducing p-chemokines than gpl20 (Neoh et al., 1997), and it has been 
suggested that HIV-2 gpl05 is able to use a wider range of co-receptors than HIV-1 gp 
120 (Bron et al., 1997). Perhaps more importantly, however, is the observation that 
gpl05 is more inhibitory to T cell proliferation and the up regulation of CD40 ligand 
and 0X40, than gpl20, in the absence o f significant induction of apoptosis. This 
marked immunosuppressive property of the HIV-2 envelope could be beneficial to the 
host by interfering with the heightened state of cellular activation that characterises 
HIV-1 infection and by limiting the bursts of viral replication (Cavaleiro et al., 2000).
3.1.2.4 Accessory genes 
Rev and Vpu
In addition to viral studies which have shown that subtype C has distinct genetic and 
phenotypic properties that differentiate it from other HIV-1 subtypes, the presence of a 
prematurely truncated Rev protein and a 5-amino-acid insertion in Vpu have been 
identified (Gao et al., 1998). Specifically, all subtype C viruses contain a stop codon in 
the second exon of Rev, which would be predicted to shorten this protein by 16 amino
120
acids, and a 15-bp insertion at the 5' end of the vpu gene extends the putative 
membrane-spanning domain of the Vpu protein by 5 amino acids. Although these 
changes are unlikely to alter the function o f the respective gene products in a major way 
it is possible that they could influence their mechanism of action in a subtle, but 
biologically important way. Furthermore, a study of Vpu sequences from 101 strains of 
HIV-1 of various subtypes revealed that all subtype C sequences had a conserved LRLL 
motif at the C terminus that was also found in A/C intersubtype recombinants 
(Mccormick-Davis et al., 2000). In addition to serving as a useful epidemiological 
marker to identify subtype C isolates, this motif may be o f interest as dileucine motifs 
have been demonstrated to mediate lysosomal targeting and endocytosis of CD3 chains, 
IgG Fc receptors, and mannose 6-phosphate receptors, and to be involved in Nef 
mediated CD4 down regulation (Hunziker et al., 1996, Craig et al., 1998). Subtype C 
viruses, therefore, may be distinct in their capacity to modulate T-cell receptor activity 
(Palacios and Weiss, 2004), impair cell-mediated immunity (Kedzierska et al., 2002) 
and traffic acid hydrolases to endosomal compartments (Ghosh, Dahms and Komfeld, 
2003), respectively, which may in turn influence the capacity of this viral subtype to 
persist and replicate within a host.
Tat
A study has also revealed that subtype C Tat exhibits higher transcriptional activity 
from the HIV-1 long-terminal repeat (LTR) in a human T-cell line, compared to 
subtypes B and AE (Kurosu et al., 2002). This higher activity of subtype C Tat was 
associated with two amino acid changes compared to subtypes B and AE, within and 
close to the basic domain. As Tat nuclear localization activity was not affected, these 
data suggests that there may be a significant advantage for the high Tat activity on 
subtype C replication.
3.1.3 Study of HIV-1 primary isolates in vitro
As outlined in the introduction to this thesis, when HIV subtype is thought of as a ‘risk’ 
factor, many epidemiological studies are flawed in that even if subtype is a true causal 
factor in disease phenotype, it may be indistinguishable from other factors that 
contribute to a particular outcome. As a result, the work covered in this chapter 
represents a conceptually more simplistic approach to the study of different HIV-1
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subtypes, in vitro, with the goal of characterising basic differences between different 
viral genetic variants. The cornerstone to this work, therefore, was the production of a 
panel o f HIV-1 group M, O and HIV-2 primary isolates. Following creation of an 
extensive viral resource for in vitro studies, experiments were performed to characterise 
the effect o f viral genetic variation, on in vitro infection phenotype.
3.1.3.1 Primary isolate viruses
The viruses chosen for study are summarised in Table 3.0. All were low passage 
primary isolates, as the aim was to investigate the differences between the growth of 
different subtype viruses in vitro, using material as biologically relevant as possible. 
This was important in order to avoid the confounding issues o f studying heavily tissue 
culture or cell-line adapted viral strains. To date few studies have directly compared a 
large number o f un-modified primary isolates, in the same experimental system. Virus 
stocks were generated in PBMCs and the viruses used for experiments were only two 
passages away from the original sample. Whilst ideally viruses of different subtype 
would have been directly isolated from patients prior to this study, given the 
impracticality o f this and the fact that for several of the viruses chosen sequence and 
phenotypic information was already available, this approach was considered to be 
optimal.
HIV-1 group M subtypes A, AE, B, C, D, and F were selected as they represent the 
diversity o f viral genetic variants which play a significant role in the HIV-1 pandemic. 
A group O virus was also chosen, as there was little information available regarding the 
phenotypic difference between Group M and O viruses, either in vitro or in vivo, despite 
considerable genotypic divergence. Conversely, HIV-2 ETP was included in this study 
as the differences between HIV-1 and HIV-2, both in vitro and in vivo have been well 
documented.
3.1.3.2 Methods o f  study
Environment-specific effects on growth phenotype have been clearly demonstrated for 
the different HIV-1 group M subtypes (van Opijnen et al., 2004). As the aim of this 
chapter was to better characterise the influence of HIV genotypic variation on growth 
phenotype in vitro, a system in which the growth of diverse viruses could be 
experimentally compared was required. Ideally, the cells used must be infectable with
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both X4- and R5-tropic viruses, and contain a form of reporter system that will be 
representative of infection, over time, but would not be subject to bias due to infection 
with genetically divergent HIV-1 subtypes, and HIV-2. It was therefore the aim of this 
chapter to firstly produce and sequence verify a panel of low passage HIV primary 
isolates (Table 3.0). Secondly, their growth characteristics in vitro were assessed in 
PBMCs and on a T-cell line, and finally a reporter cell line was developed to further 
characterise these isolates. Its utility in characterising the ART sensitivity of HIV 
primary isolates was also demonstrated.
3.1.4 Aims
It is a widely held belief that it is unlikely that a single characteristic such as viral 
subtype can account for significant differences in HIV disease progression (Hu et ah, 
1999). The association of subtype with certain viral phenotypic traits, however, may 
bear further exploration, as in some cases subtype may be a surrogate marker for a 
particular viral phenotype of importance in terms of disease phenotype. With this is 
mind it was the aim of this chapter to characterise phenotypic determinants of different 
HIV-1 subtypes and HIV-2 in vitro, in a number of different cellular environments, 
bearing in mind the significance of any such differences in vivo.
Table 3.0 Sum m ary of HIV-1 and -2 primary iso la tes
Subtype Ref. Source CoRe SI/NSI Reference
A 92UG037
Entebbe, Uganda, 1992. 
Asymptomatic seropositive 31-year- 
old female.
ND ND
The WHO Network for HIV 
Isolation and Characterisation, 
1994
AE 92TH001 Thailand, 1992. Seropositive individual.
ND ND
The WHO Network for HIV 
Isolation and Characterisation, 
1994
B SF162 USA, 1989. Isolated from CSF of AIDS patient.
CCR5 NSI Cheng-Mayer eta!., 1989
C 92BR025 Brazil, 1992. Seropositive individual. ND ND
The WHO Network for HIV 
Isolation and Characterisation, 
1994
D 92UG001 Uganda, 1992. Seropositive individual.
ND SI
The WHO Network for HIV 
Isolation and Characterisation, 
1994
F 93BR020 Brazil, 1993. Seropositive individual. ND ND
The WHO Network for HIV 
Isolation and Characterisation, 
1994
0 BCF06 France, 1994. PBMCs of 22yr old AIDS patient.
CXCR4 SI Simon et at., 1998
HIV-2 ETP Portugal, 1999. AIDS patient. dual SI Reeves eta/., 1999
Ref: reference that identifies each isolate, assigned at source
CoRe: coreceptor usage of the isolate in question - ND indicates Not Determined
SI/NSI: refers to the cytopathic characteristics of each virus - SI indicates Syncytium Inducing, NSI 
indicates Non Syncytium Inducing
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3.2 Methods
3.2.1 Cells and viruses
Peripheral blood mononuclear cells (PBMCs) from HIV-seronegative blood donors 
were obtained by Ficoll-Hypaque density gradient centrifugation of buffy coats from 
two separate donors (using Lymphoprep, Nycomed, Norway). Prior to HIV-1 infection, 
cells from both donors were mixed and stimulated with 0.5 pg phytohaemagglutinin/ml 
(PHA, Gibco BRL, UK) for 3 to 4 days and maintained in Roswell Park Memorial 
Institute (RPMI) 1640-2 mM L-glutamine medium, supplemented with 10% foetal 
bovine serum (FBS, BioWest, France), 10 units (U) of interleukin-2/ml (IL-2), 100 
U/ml penicillin and 100 pg/ml streptomycin (P/S, Invitrogen, UK). SupTl.R5 (STI­
RS) and CEM.R5 cell lines were maintained in RPMI 1640-2 mM L-glutamine 
medium, supplemented with 10% FBS, 100 U/ml penicillin, 100 pg/ml streptomycin 
and 1 pg o f puromycin/ml. NP2/CD4/CXCR4, NP2/CD4/CCR5 and HEK 293-T cell 
lines were maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen, 
UK) supplemented with 5 or 10% FBS, 100 U/ml penicillin and 100 pg/ml 
streptomycin, NP2 cells with an additional 1 p g o f puromycin/ml. CVG cells - clone 37 
(CVG-37) were propagated and maintained in RPMI 1640-2 mM L-glutamine medium, 
supplemented with 10% FBS, 100 U/ml penicillin, 100 pg/ml streptomycin, 1 mg 
G418/ml (Invitrogen, UK) and 1 pg puromycin per ml (Invitrogen, UK). Parental 
CEM-G cells were cultured in the presence o f G418 alone. All cells and cell lines were 
incubated at 37°C in 5% CO2 . References are given in Table 3.1.
Table 3.1 Cell lines: Description of cell lines used in this study.
Cell line Description Reference
HEK 293-T 293 cells containing the temperature sensitive gene 
encoding SV40 T-antigen
DuBridge et al., 1987
NP2.CXCR4 CD4 and CXCR4 transduced human glioma cell line Soda et al., 1999
NP2.CCR5 CD4 and CCR5 transduced human glioma cell line Soda et al., 1999
CEM.R5 Human T-lymphoblastoid cell line transduced with CCR5 Trkola et al.. 1999
ST1-R5 Non-Hodgkin's T-cell lymphoma cell line transduced 
with CCR5
Means et al., 2001
CEM-G Human T-lymphoblastoid cell line. Contains plasmid 
encoding LTR-driven humanised S65T GFP
Gervaix et al., 1997
CVG-37 Human T-lymphoblastoid cell line. Contains plasmid 
encoding LTR-driven humanised S65T GFP, and stably 
expresses CCR5
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3.2.2 Production of primary isolate stocks
Six primary HIV-1 isolates (Table 3.0) were obtained from the National Institute for 
Biological Standards and Control (NIBSC, Potters Bar, UK): subtypes A (92UG037); 
AE (92TH001); C (92BR025), D (92UG001), F (93BR030) and O (BCF06). Subtype B 
isolates (SF162) and HIV-2 isolate (ETP) were kind gifts from the Wohl Virion Centre 
(UCL, London). To prepare stocks, 1 ml o f each virus was added to 8xl06 PHA- and 
IL-2-treated PBMCs. After 2 hours (h) of incubation at 37°C, cells were resuspended in 
complete medium (106 cells per ml). Approximately 3-5 days post infection (virus 
dependent), infected cells were co-cultivated with 5x the original number of PBMCs (2 
h, 37°C) prior to resuspension in complete medium (106 cells per ml). Viruses were 
harvested as appropriately by centrifugation at 1200 rpm/5 minutes, removal of virus 
containing supernatant, recentrifugation to clarify and filtration though a 0.45 pM filter 
(Sartorius, UK). Virus was aliquoted into cryovials (Nunc, USA), snap frozen and 
stored in vapour phase liquid nitrogen until use.
3.2.3 DNA purification
DNA was purified from PBMCs infected with all HIV-1 primary isolates using a 
Qiagen QIAamp DNA mini kit (Qiagen, UK). 2x l06 infected PBMCs cells were 
collected after virus harvest resuspended in 200 pi PBS with 20 pi proteinase K 
(Qiagen, UK). Following lysis, samples were incubated at 56°C for 30 minutes, then 
applied to a QIAamp spin column and centrifuged at 14,000g for 1 minute, washed 
twice with appropriate buffers and eluted in a final volume of 100 pi. The concentration 
o f the purified DNA was calculated using a NanoDrop spectrophotometer (NanoDrop 
Technologies, Rockland DE, USA).
3.2.4 Polymerase chain reaction (PCR) amplification
PCR was performed to amplify sections of the group specific antigen (Gag), protease 
(PR) and reverse transcriptase (RT) genes from DNA extracted from HIV-1 infected 
PBMCs (Dyad thermal cycler, MJ Research Inc. Reno NV, USA). A pair of 
degenerate primers were designed to amplify these targets from HIV-1 group M 
subtypes and a separate set to amplify each from HIV-1 group O (Table 3.2). The 
constituents of each reaction (A) and reaction conditions (B) were:
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(A) Reagent Volume (B) Temperature Time
DNA (approx. 50 ng) 2 pi 94°C 120 seconds
Primers ( lOpMol/pl) 2 pi each 94°C 45 seconds
PCR buffer (1 Ox) 5 pi 55°C 45 seconds
MgCl2(25 mM) 4 pi 72°C 60 seconds
dNTPs (10 mM) 1 pi Steps 2-4 an additional 40 times
Taq DNA polymerase (5 U/pl) 0.25 pi 72°C 120 seconds
Distilled water_________________ 35.75 pi
(Promega, UK).
3.2.5 PCR purification
10 pi o f the PCR reaction was separated on a 1% w/v agarose gel in lx Tris-borate- 
ethylenediaminetetraacetic acid (EDTA) (TBE) containing 0.2 pg/ml ethidium bromide 
(Sigma, UK) at 80V. The band of the correct size was excised from the gel and DNA 
purified according to the QIAquick gel extraction protocol (Qiagen, UK). In short, 
following solubilisation of the gel slice at 50°C for 10 minutes, isopropanol was added, 
the solution vortexed and applied to a QIAquick column by centrifugation (14,000g, 1 
minute). After washing with solubilisation and wash buffers the DNA was eluted in 30 
pi o f water.
Table 3.2 PCR primers used in this study.
Primer________Sequence (5’ - 3’)___________________________________________ Target
T7 T AAT ACG ACTC ACT AT AGGG pGEM T-easy
SP6 TATTTAGGTGACACTATAG pGEM T-easy
Env F-I CAACTCAACTRCTGTTRAATGG HIV-1 env
Env R-I GTAATTTCTRGGTCCCCTCCTGA (inner primer)
Env FO-1 GT ACTCAACT AAT ATT AAATGG HIV-1 env gp.O
Env RO-1 GTTACCTCTGGATCTCCACCACT (inner primer)
Env F GYAAGAATGTCAGCACAGTACAATGYACACATGG HIV-1 env
Env R GWATTRCARTAGAAAAATTCYCCTCCACAATT (outer primer)
Env F-O GCAAAAAYATTACAGTAGTTACTTGTACACATGG HIV-1 env gp.O
Env R-O GTGTTACAATARAAGAATTCTCCATGACAGTT (outer primer)
Gag F GGTGCCAGAGCGTCARTATTAAGHGGGGGAGAATTAG HIV-1 gag
Gag R GTAGTTCCTGCTATRTCACTTCCCCTTGGTTCTC
Gag F-O GGTGCCAGTGCGTCTGTGTTGACAGGGAGCAAATTGG HIV-1 gag gp.O
Gag R-O GTTGTYCCAGCAATGTCACTTCCTGTTGGTTCCC
PR F CAGARCAGACCRGAGCCAACAGCCCCRCC HIV-1 PR
PR R GGKCCATCCATTCCTGGCTTYAATKTTACTGG
PR F-O CAGAGACAAGTGTCCCCATCAGCCCCACC HIV-1 PR gp.O
PR R-O GGTCCATCCATTCCTGGTTTTAGTTTTACTGG
RT F CAACATAATTGGAMGAAATMTGTTGACTCAGMTTGG HIV-1 RT
RT R CTRTG YTGCCTT ATTTCT A ARTC AG A YCCT AC AT AC
RT F-O T AAT ATT ATTGG A AG A AAC AT ATT G AC AGG ATT AGG HIV-1 RT gp.O
RT R-O CTATGTTCTGTCAGGGGTAAATCTGATCCTACATAT
SS-fwd GGCTAACTAGGGAACCCACTG HIV-1 strong stop
SS-rev CTGCTAGAGATTTTCCACACTGAC DNA
SSO-fwd GGCCTCTAGCTGAAC'CCGCTG HIV-1 gp.O strong
SSO-rev CTGCTAGAGATTTTCTGCTTCAGT stop DNA
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3.2.6 Preparation of competent bacteria
XL-1 Blue Escherichia coli (Stratagene, UK) were streaked onto Luria-Bertani (LB)- 
agar plates containing tetracycline (10 pg/ml) and incubated at 37°C for 16 h. A colony 
was picked and used to inoculate 3 ml LB-broth (with tetracycline) and shaken at 37°C 
for 16 h. This was added to 500 ml LB-broth and shaken at 37°C until the absorbance at 
600 nm was 0.6 (around 3 h). The culture was then put on ice to cool for 10 minutes. 
The bacteria were pelleted at 3000 xg for 10 minutes at 4°C and resuspended in 15 ml of 
100 mM calcium chloride (4°C). After incubation on ice for 30 minutes, the bacteria 
were centrifuged again and then resuspended in 2.5 ml of 100 mM calcium chloride 
containing 15% glycerol by volume (4°C). The bacterial suspension was frozen at -80°C 
in 200 and 400 pi aliquots.
3.2.7 Cloning
PCR products were cloned into pGEM-T Easy (Promega, UK). 1 pi of DNA was ligated 
into 50 ng of pGEM-T Easy using 3 U of T4 DNA ligase and 5 pi rapid ligation buffer 
(2x) in 10 pi final volume at room temperature (RT) for 2 h or 4°C overnight. The 
ligation reaction was cooled to 4°C and added to 200 pi o f competent XL-1 Blue E.coli. 
After incubation at 4°C for 30 minutes, the bacteria were subjected to heat-shock at 
42°C for 45 seconds and then placed immediately on ice. 400 pi LB-broth was added 
and the bacteria incubated at 37°C for 30 minutes. The bacterial suspension was plated 
onto LB-agar containing 100 pg/ml ampicillin, 0.5 mM isopropylthio-p-D-galactoside 
(IPTG) (Sigma, UK) and 80 ng/ml 5-bromo-4-chloro-3-indolyl-P-D-galactoside (X-Gal) 
(Promega, UK). The plates were incubated at 37°C for 16 h.
3.2.7.1 Screening fo r  positive colonies
Bacterial colonies transformed with vector containing PCR product insert were 
identified by their white colour due to disruption of the LacZ open reading frame. 
Colonies were screened by PCR for the presence of plasmid inserts of the correct size. 
The ingredients of the PCR were as in section 3.2.4 except in half-volumes. The primers 
used were T7 and SP6 (Table 3.2). The conditions used were:
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T emperature Time
94°C
94°C
55°C
72°C
5 minutes 
30 seconds 
30 seconds 
60 seconds
Steps 2-4 an additional 29 times
72°C 5 minutes
Positive colonies were added to 3 ml LB-broth plus amplicillin (50 pg/ml) and grown at 
37°C for 16 h.
3.2.7.2 Purifying plasmid DNA
500 pi of bacterial suspension was frozen at -80°C in sterile 20% glycerol by volume. 
Plasmid DNA was purified from the remaining bacteria using QIAprep miniprep 
protocol (Qiagen, UK), a modified alkaline lysis method (Bimboim and Doly, 1979).
1.5 ml o f culture was pelleted at 14,000xg for 10 minutes and the bacteria resuspended, 
lysed for no more than 5 minutes, the lysis then halted by neutralisation. Cell debris was 
pelleted by centrifugation at 14,000 xg for 10 minutes and the DNA-containing 
supernatant applied to a QIAprep column. The solution was passed through the column 
by centrifugation (14,000 xg, 1 minute), washed as directed and plasmid DNA eluted 
with 50 pi distilled water (average final concentration around 300 ng/pl).
3.2.7.3 DNA sequencing
The identities of clones were also verified by DNA sequencing, using an automated 
application of the chain-termination method (Sanger et al., 1977). 1.5 pi of plasmid 
DNA (or approximately 500 ng) was added to 4 pi of Beckman QuickStart mix 
(containing dATP, dCTP, dTTP, dITP, ddUTP, ddGTP, ddCTP, ddATP and 
thermosequenasc DNA polymerase in Tris buffer, pH 8.9) and 5 pmolcs of T7 or Sp6 
primer. The solution was placed in a thermal cycler and subjected to the following 
conditions:
Temperature Time 
94°C 3 minutes
96°C 20 seconds
50°C 20 seconds
60°C 4 minutes
Steps 2-4 an additional 29 times
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DNA was precipitated from the sequencing reaction by adding 2 pi sodium acetate (1.5 
M), 2 pi EDTA (50 mM, Sigma, UK) and 1 pi glycogen (20 mg/ml, Beckman Coulter, 
UK) in a final volume o f 20 pi, vortexing, and then adding 60 pi 95% (v/v) 
ethanol/water (-20°C) and leaving on ice for 10 minutes. DNA was pelleted by 
centrifugation at 14,000g for 15 minutes at 4°C. The supernatant was removed, the 
pellet washed with 200 pi 70% ethanol/water (-20°C), and dried at RT. DNA was 
resuspended in 40 pi de-ionised formamide (JT Baker, USA) for 15 minutes and 
transferred to a 96-well plate. The sequences were determined using an automated 
capillary DNA sequencer (Beckman Coulter, UK) as per the manufacturer’s 
instructions. Sequence data were analysed using BioEdit software v.5.0.9 (Hall, 1999).
3.2.8 Immunostaining of HIV-2- and HIV-l-infected cells and calculation of titre
The immunostaining method has been described previously (Clapham et al., 1992). 
Briefly, serial dilutions of virus were made and added to confluent NP2/CD4/CXCR4 or 
NP2/CD4/CCR5, depending on viral coreceptor usage. These were incubated at 37°C, 
5% CO2 for 3 h, virus then removed by washing with PBS and replaced with medium. 
After three days methanol-acetone (l:l)-fixed cells infected with HIV-2 or HIV-1 were 
immunostained with HIV-2 human serum diluted 1/4,000 or anti-HIV-1 p24 
monoclonal antibody diluted 1/40 (1:1 mix of EVA 365 and 366 from the Medical 
Research Council AIDS Reagent Program, Potters Bar, United Kingdom). Second-layer 
B-galactosidase conjugates of goat anti-human immunoglobulin G (HIV-2) or goat anti­
mouse immunoglobulin G (HIV-1) were used to detect first-layer antibodies at a 
dilution of 1:400 (Southern Biotechnology Associates, Inc., Birmingham, Ala.). Infected 
cells were stained blue with X-Gal in PBS containing 3 mM potassium ferricyanide, 3 
mM potassium ferrocyanide, and 1 mM magnesium chloride. Foci of infection, which 
stained blue, were counted using light microscopy and virus infectivity was estimated as 
FFU per millilitre.
3.2.9 Production of molecular clone-derived virus, NL4-3 and Yu2
293T cells were passaged 48 h prior to transfection. In a 10-cm2 tissue culture dish, a 
semiconfluent (40 to 60%) monolayer was seeded 24 h later. The transfection reagent 
FuGENE6 was used according to the manufacturer's instructions. Briefly, a total of 4 pg 
of DNA was combined with 200 pi of serum-free Optimem (Gibco, Invitrogen). 15 pi
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of FuGENE6 was added directly and the suspension incubated for 15 minutes at RT. 
The volume was increased to 1 ml with complete DMEM. The transfection mixture was 
added to the cells and incubated at 37°C, 5% CO2 in a humidified incubator. 
Supernatants were harvested after 48 and 72 h.
3.2.10 Preparation and titration of CCR5 lentivirus
CCR5 cDNA was previously subcloned into pBABE-puro. Amphotropic virus stocks 
were prepared by cotransfecting 293T cells with the pBABE-puro.CCR5 construct, a 
VSV-G envelope expression vector (pMDG), and gag-pol expression vector (CMV-1) 
(all kindly donated by Dr. G Towers, UCL). Briefly, 293T cells were passaged 24 h 
prior to transfection in a 10-cm2 tissue culture dish to 25% confluence. Vectors were 
prepared in 15 pi Tris-EDTA and added to 200 pi serum-free Optimen, containing 18 pi 
Fugene6, and incubated for 15 minutes at RT. Volume was increased to 1 ml with 
complete DMEM. The transfection mixture was added to the cells and incubated at 
37°C, 5% CO2 in a humidified incubator. Supernatants were harvested after 48, 72 and 
96 h and titre calculated by TE671 titrations. Briefly, TE671 cells were cultured 
overnight in 6 well plates (Costar) at a density of 1 x 105 cells/well. The following day 
cells were exposed to 1 ml of serial dilutions o f CCR5 lentivirus (10'1 to 10‘6) in 
complete DMEM supplemented with 5 pg polybrene per ml, and incubated at 37°C/5% 
CO2 for 48 h. Virus was then removed and replaced with complete DMEM 
supplemented with lpg puromycin per ml. After an additional 48 h incubation at 
37°C/5% CO2 , media was replaced and 48 h later colonies could be visualised, counted 
and titre calculated.
3.2.11 Establishment and characterisation of CVG cells
CEM-G cells were added to one well of a 24 well plate (Costar) at a density of 1 x 105 
cells/well. CCR5 lentivirus was used to infect these cells, by addition of 1:1 virus to 
complete RPMI (1 ml), incubation at 37°C/5% CO2 for 4-6 h, and removal and 
replacement of 800 pi virus containing supernatant with complete RPMI. This was 
repeated each day for three days, the last day medium being supplemented with lpg 
puromycin per ml. Outgrowth of resistant cells took approximately one week, which 
were then transferred to T75 flask (Nunc) and grown in complete puro-media for 
another week. Staining of the mixed population with a R-phycoerythrin (PE)-
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conjugated mouse anti-human CCR5 antibody (BD Pharmingen) indicated very low 
expression o f CCR5 (FACSCan flow cytometer (Becton Dickinson, Mountain View, 
CA), so limiting dilution plates were made in order to obtain clonal lines. These were 
maintained at 37°C/5% CO2 for four weeks. 20 clones were selected (>2wks), 10 
clones (>3wks) and an additional 10 clones (>4wks). FACS analysis was performed, 
and from these 13 were retained. These were grown up and analysed for CXCR4 (PE- 
conjugated mouse anti-human CXCR4 (Fusin), BD Pharmingen), CCR5 and CD4 (PE- 
conjugated mouse anti-human CD4, BD Pharmingen) expression. Isotype control 
mouse anti-human IgGi-PE (Sigma, UK) was used. Two lines were selected that stably 
express human CCR5 together with CXCR4 and CD4, and have a low level of 
constitutive GFP expression.
As the clonal lines were previously stably transformed with GFP, which is under the 
control of HIV-1 LTR and is transactivated by HIV or SIV Tat upon infection with 
either X4 or R5 tropic HIV-1 or HIV-2, the cells should become green when infected. 
This was assessed by infection with NL4-3 (X4-tropic HIV-1) and Yu2 (R5 tropic HIV- 
1), at an MOI of 0.25. Briefly, molecular clone viruses NL4-3 and Yu2 were added to 
three clones o f interest by incubation of 105 cells with virus at MOI 0.25, for 2 h at 
37°C. Cells were then washed three times with PBS and resuspended in 1 ml complete 
medium. On days 2, 3, 4, 5, 6, 7 and 8 post-infection 200 pi of cells was removed from 
each infection and cell-free supernatants stored at -80°C prior to detection of p24. Cell 
pellets were resuspended in 500 pi 2% formolsaline and stored at 4°C in the dark, prior 
to FACs analysis. Photographs were also taken over this time period (using UV 
microscopy) to record visually detectable changes in GFP expression.
3.2.12 HIV-1 subtype timecourses
3.2.12.1 Replication assay
Six primary HIV-1 isolates (not 92TH001) and ETP were used for infection of PBMCs, 
ST1-R5 and CVG-37 cells. For ST1-R5 and PBMC infections, viruses were added at a 
multiplicity of infection of 0.01 ffu/cell and incubated at 37°C for 4 h in the presence of 
5 pg per ml polybrene. For CVG-37 infections, viruses were added at a multiplicity of 
infection of 0.01 ffu/cell and spinoculated at 13000rpm/25°C for one hour, then
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3000rpm/25°C for lhour, followed by incubation in the presence o f 5 pg per ml 
polybrene at 37°C for 2 h. In all cases cells were then washed three times with PBS and 
resuspended in the appropriate complete medium and six aliquots of 200 pi added to 
separate wells of a 96 well plate (1 x 104 cells/well). Over a period of several days post 
infection (up to two weeks) one well of cells infected with each of the eight viruses was 
removed and cell-free supernatants stored at -80°C prior to detection of p24. Cell 
pellets were resuspended in 500 pi 2% formolsaline and stored at 4°C in the dark, prior 
to FACS analysis. Once optimised, experiments were all performed in triplicate.
3.2.12.2 p24 assay
To prepare plates, the antibody D7320 (Aalto Bio Reagents, Dublin, Ireland), diluted in 
coating buffer (lOOmM NaHC0 3 , pH 8.5) was coated at 0.5 pg/well onto the inner 60 
wells o f Maxi-Sorb high-bind 96 well plates (NUNC, Roskilde, Denmark) by 
incubating them overnight, covered, at RT. The plates were then washed twice with 
200 pi o f TBS (144 mM NaCl, 25 mM Tris, pH 7.5), air dried before use or sealed and 
stored at -20°C. Samples were inactivated by adding Empigen zwitterionic detergent 
(Surfachem Ltd, Leeds, UK) to a final concentration of 1% by volume, followed 
optionally by incubation at 56°C for 30 minutes. The lysates were then stored at -20°C 
as required. The antigen capture works best at a final Empigen concentration of 0.05- 
0.1%, so serial dilutions were made in TBS / 0.05% Empigen and the volume o f the 
wells adjusted to 100 pi with the same buffer. p24 standard is diluted initially into 1% 
Empigen (see below) before construction of a calibration curve in 0.1% Empigen (as for 
samples).
On the day of use, 200 pl/well TBS/2% Marvel fat free skimmed milk powder was 
added to the plates and incubated between 10 minutes -  1 h, washed once with 200 
pl/well TBS and air-dried. Samples and standard (in duplicate) were added and 
incubated, the capture stage completed within 2-3 h at RT. Unbound p24 was washed 
away with 2 x 200 pi of TBS and bound p24 detected with pre-diluted EH12E1 -  AP 
(MRC ADP452) at 0.5 pg/ml. This pre-dilution is at 1:2000 in TBS, containing 4% 
Marvel fat free skimmed milk powder, 20% sheep serum (DAKO code X503) and 0.5% 
Tween 20. Binding was complete after 60 minutes at RT.
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Plates were then washed 5x with 200 pl/well TBS containing 0.5% Tween 20. To each 
well 100 pi Lumi-phos alkaline phosphatase (AP) substrate (Aureon Biosystems, 
Vienna, Austria) was added. This was incubated at RT, in the dark for 1 h. The plate 
was then read using a LUCY luminometer (Anthos Labtech Instruments, Austria), the 
detection range being from 30-1000 pg/ml p24.
3.2.12.3 Flow cytometry
Expression of cell surface CD4, CXCR4 and CCR5, and GFP expression, were 
determined by flow cytometry. Cells were taken from culture and washed twice in PBS 
with 0.01% azide. Cells were then incubated with CD4-PE, CCR5-PE and CXCR4-PE 
(section 3.2.11), in 20pl PBS containing 1% FBS and 0.1% azide per 106 cells for 1 
hour at 4°C. Cells were also incubated with isotype control at the same concentration. 
Cells were washed 3 times in PBS with 0.01% azide. Ten thousand events were 
collected and analysed using a FACScan with Cellquest software (Becton Dickinson, 
UK).
3.2.12.4 Microscopy
CVG-37 cells were observed using an Axiovert 135 (Zeiss, Oberkocken, Germany) 
fluorescent microscope. Pictures were taken using a Contax 167 MT single lens reflex 
camera and E6 Ektachrome slide film (Kodak). Confocal images were generated by 
fluorescence microscopy (Axiovert 100 TV (Zeiss, Oberkocken, Germany) with a MRC 
1024 Confocal (Bio-Rad, Hercules, CA)), captured using Lasersharp software 
(Lasersharp 2000, Bio-Rad) and edited using Confocal Assistant v4.02 software.
3.2.12.5 Drug sensitivity assay
CVG-37 cells were infected as described in section 3.2.12.1. Following spinoculation 
and washing with PBS, cells were resuspcndcd in the appropriate complete medium and 
six aliquots of 100 pi added to separate wells of a 96 well plate (1 x 104 cells/well). To 
each well 100 pi of complete medium, containing the 2x the appropriate final dilution of 
antiretroviral drug, was added, and plates incubated at 37°C, for 5/7 days. The ARVs 
tested were Azidothymidine (AZT), Efavirenz (EFV), and Amprenavir (APV) (all gifts 
from Dr. D. Pillay), at 0.05, 0.01, 0.005, 0.0025 and 0.00lpM. Plates were then sealed 
and centrifuged at 1200 rpm for 5 minutes and cell-free virus containing supernatants
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removed and stored at -80°C. In the case o f drug sensitivity assays for protease 
inhibitors, the virus containing supernatants were added to fresh CVG-37 cells (1 x 104 
cells/well), in a two-step protocol (Pirounaki et al., 2000). Infections were allowed to 
proceed for 7 days and then cells prepared for FACs as described (section 3.2.12.1). 
Once optimised experiments were all performed in triplicate.
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3.3 Results
3.3.1 HIV primary isolate stocks
In order to characterise the effect of HIV genetic variation on growth phenotype, HIV-1 
group M subtypes A, AE, B, C, D, F, group O and HIV-2 primary isolates were 
acquired. Limited basic information was provided (Table 3.0, section 3.1.3.1) so once 
low-passage stocks were produced, coreceptor usage was characterised and proviral 
DNA sequence verified.
3.3.1.1 Titration and coreceptor usage
A sample of each virus was obtained from the Central Facility for AIDS Reagents. This 
was passaged through PBMCs once in order to create a submaster stock (approximately 
20 mis). 1 ml samples of the submaster stock were then expanded on five separate 
occasions to produce approximately 100 mis of virus (per isolate) with which titrations 
and subsequent experiments could be performed. As it was expected that the titre of the 
viruses produced would be particularly low (Moore and Ho, 1995), titrations were 
performed on NP2 CD4/CXCR4-positive and NP2 CD4/CCR5-positive cells. These cell 
lines were selected as they are highly susceptible to HIV infection when exposed to 
virus o f the appropriate tropism (Soda et al., 1999). The tropism for each virus, the titre 
of each virus stock and the mean titres calculated are summarised in Table 3.3. 
Individual stock titres were used to calculate experimental conditions. In the case of 
viruses that were found to be dual tropic, titre was equivalent on both 
NP2/CD4/CXCR4 and NP2/CD4/CCR5 cell lines. Accordingly, the mean of the titre 
on both cell lines is presented.
Table 3.3 Table of coreceptor usage, stock titres and mean titre, for each virus studied.
Subtype
CoRe SM
Titre (ffu/mr1)
W kl Wk2 Wk3 Wk4 Wk5
Mean
titre+
A R5 lxlO2 NR 2.2x103 NR NR NR 2.2x103
AE X4 IxlO2 NR NR NR NR NR NR
B X4/R5 2.1xl05 1.2x106 4.8x105 6.8x10 s ND ND 6.4x105
C R5 2xl04 NR 1.4x103 1.5x103 NR ND 7.6x103
D X4/R5 3xl03 1.2x103 l.SxlO3 3.2x103 9.3x103 ND 3.6x103
F R5 2.2xl02 2.5xl02 2.8x103 *8x103 * 1 x 103 ND *2.5x103
O X4/R5 3.5x102 3x l0 3 5. IxlO3 9.2x103 l . lxlO4 2.4x103 5.7x103
ETP X4/R5 1.2x104 2.3xl04 1.6xl03 ND ND ND 1.2xl04
mean o f titres calculated for all stocks of each isolate *this stock grew on both X4- and R5-NP2 cells. The titre is 
an average.
,\7? no result, no infectious titre was detected in this stock 
ND not done, CoRe - coreceptor usage
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Table 3.4 Table outlining clones of Gag, PR, and RT genes from which sequence was 
successfully generated.
Subtype Gag PR RT
A NC* NC V
AE NC NC V
B V V V
C V V V
D NC V V
F V V V
O V V s
*NC -  not cloned
3.3.1.2 Sequencing and subtyping
To confirm the sequence integrity of viruses being studied genomic DNA was extracted 
from infected PBMCs, from which working stock virus was harvested. Degenerate 
primers were designed (Table 3.2, section 3.2.5) to amplify the gag, PR and RT  genes, 
and PCR products were cloned into vectors for sequencing. The genes successfully 
cloned (as identified by colony screening PCR) are outlined in Table 3.4. Where 
sequencing was achieved a search was performed using BLAST and in all cases, where 
the sequence of the viral genes in question had been published, the corresponding 
reference sequence was matched. As sequencing was successful for the PR and/or RT 
genes of subtypes A, AE, B, C, D, F and group O, these sequences were subtyped in 
order to both confirm their subtype classification, and to test the fidelity of STAR. In 
all cases STAR assigned the correct subtype/type to each cloned PR or RT fragment.
3.3.2 Development of a reporter cell line
Several cell lines have been produced with the specific aims of both being sensitive to 
infection by X4- and R5-tropic strains of HIV, and the ability to ‘report’ infection in a 
readily detectable, rapid and antigen-independent manner. Specifically, studies of both 
neutralisation and drug sensitivity have been performed using HIV-1 susceptible cell 
lines with reporters including secreted alkaline phosphatase (Miyake et al., 2003), 
Iuciferase (Spenlehauer et al., 2001) and p-galactosidase (Pirounaki et al., 2000). Not 
all such cell lines are T-cell in origin and some reporter systems require more 
experimental processing than others. One cell line was available, however, which
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expressed humanised S65T green fluorescent protein (GFP) under control of the HIV-1 
LTR: CEM-G (Gervaix et al., 1997). This cell line exhibits low constitutive 
background fluorescence but a high level o f GFP expression upon infection with HIV-1, 
over 2 to 4 days. Addition of inhibitors o f reverse transcriptase and protease during 
HIV infection of this cell line has been shown to allow the accurate determination of 
drug susceptibility. Furthermore, quantitation of infectivity of viral preparations may be 
determined by assessment of number o f cells infected in the first round o f infection 
(Gervaix et al., 1997). The CEM-G reporter cell line, however, was designed for study 
of syncitium-inducing (X4-tropic) HIV-1 strains only. CEM cells do not endogenously 
express CCR5, so this cell line was chosen for modification such that it could be used to 
directly assess the in vitro growth characteristics o f HIV primary isolates of differing 
subtype and cell tropism (Table 3.3, section 3.3.1.1).
3.3.2.1 Creating a CCR5+ CEM-G cell line
CCR5 was introduced to the CEM-G cell line by infection at high multiplicity with the 
VSV-G pseudotyped MLV-based retroviral vector pBABE-puro.CCR5 (Morgenstem & 
Land, 1990). Because of the reported high efficiency of both infection and expression 
using this system, once selected using puromycin, the bulk cell population was analysed 
for CCR5 expression (Figure 3.0-A). This revealed that, despite a small number of cells 
expressing CCR5 the majority of the population, whilst puro-resistant, did not express 
detectable CCR5. Accordingly, limiting dilutions of the bulk puro-resistant cell 
population were prepared and clonal lines developed. Forty clones were selected and 
expanded further under selection, each then stained with an isotype control antibody and 
anti-CCR5-PE, to determine whether CCR5 was expressed on the cell surface. The 
results for all clones are shown in Figure 1, Appendix. It was expected that, given the 
results from staining and FACs analysis of the bulk population, a few of these clonal 
lines would express high levels of CCR5. The FACS data for the forty clonal lines 
revealed that 14 cell lines appeared to express CCR5. These, therefore, were expanded 
further and the expression level of CD4, CXCR4 and CCR5 determined. The results are 
shown in Figure 3.0-B; six clonal lines expressed a low/medium level of CCR5, Figure 
3.0-C; three clonal lines expressed a medium level of CCR5, and Figure 3.0-D; two 
clonal lines expressed the highest level of CCR5. PBMCs were simultaneously stained 
for CD4, CXCR4 and CCR5 (Figure 3.0-E) and expression profile of these receptors 
was remarkably similar to that seen in CEM-G.R5 clones 33 and 37.
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Figure 3.0 FACs data for developm ent o f CCR5 exp ressin g  CEM-G cell lines.
(A) FACs data showing expression of CD4, CXCR4 and CCR5 on bulk population of puromycin 
selected CEM-G cells infected with pBabe-puro.CCR5 retroviral vector. Whilst results show that 
there is no bulk expression of CCR5, certain puro-resistant CCR5 positive cells are present 
(marked with arrows), (B) FACs data showing expression of CD4, CXCR4 and CCR5 on clonal 
lines, produced by limiting dilution under puromycin selection of CEM-G cells infected with 
pBabe-puro.CCR5. Clones 7, 34, 39, 22, 14 and 28 are low/medium expressors of CCR5.
■ CD4
□ Isotype control
■  No stain
■ CXCR4
■ CCR5
FL2-H eight
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Figure 3.0 (continued) FACs data sh ow in g  exp ressio n  of CD4, CXCR4 and CCR5 on  
clonal lines, produced by limiting dilution under purom ycin se lection  of CEM-G ce lls  
infected with pBabe-puro.CCR5.
(C) Clones 29, 9 and 17 express medium levels of CCR5, and (D) Clones 33 and 37 express 
the highest level of CCR5. The profile of these cells in terms of receptor expression is similar to 
(E) PBMCs
CD#
*10* 'A*10*
D
■ CD4
□  Isotype control
■  No stain
■  CXCR4
■ CCR5
8 33
o
PBMC
CD4
CCR5
CXCR4
10 1 0 : 1 01 0 '
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3.3.2.2 Clones 33 and 37 can be infected with both X4- and R5-tropic viruses 
Given identification of two clonal cell lines that expressed the CCR5 coreceptor to a 
level comparable to that detected on PBMCs, these were infected with the X4- and 115- 
tropic viruses NL4-3 and Yu2. These are infectious molecular clone derived viruses, 
high titre stocks of which were generated to enable infection of the CEM-G.R5 clones 
33 and 37 at a multiplicity of infection (MOI) o f 0.25. Cells were sampled and fixed 
and cell free supernatant collected daily for 7/8 days post-infection (PI). The FACS 
data for infection of these two cell lines with NL4-3 and Yu2 is shown in Figures 3.1 
and 3.2. For both cell lines there was a clear 2- to 3-log shift in GFP expression (FL1 -  
X axis) in infected cells, represented in the lower right quadrant, compared to the 
uninfected cells (lower left quadrant). Photographs of these infections at low 
magnification were captured (Figures 3.1 and 3.2) at 8 days PI. From this FACS data 
the % total cells expressing GFP (representing infection) was calculated for infection of 
both clonal lines with both viruses, and is presented together with the p24 content of 
supernatants collected (Figure 3.3-A and B). Both p24 and GFP results indicate that 
X4- and R5-tropic viruses effectively infected both cell lines: the level of CCR5 
expression on these two cell lines was sufficient to facilitate productive spreading 
infection by an R5-tropic virus, equivalent to the level of infection achieved by an X4- 
tropic virus.
O f the two cell lines studied, however, clone 37 appears to be more equally infectable 
by HIV of both tropisms (Figure 3.3-B) than clone 33 (Figure 3.3-A): at 8 days PI, 13% 
of clone 33 cells were infected with NL4-3 and 23% with Yu2, compared to clone 37, 
where at 8 days PI 27% of cells were infected with NL4-3 and 26% with Yu2. After 8 
days, the infection had generally spread more widely through the culture in CEM-G 
clone 37 cells (8 days PI), indicating this clonal cell line may be marginally more 
permissive to infection than clone 33. It is also apparent from the photographs of clone 
33 and 37 cells infected with NL4-3 and Yu2 8 days PI (Figures 3.1 and 3.2) that the 
two clonal lines adopt different morphologies. Clone 33 formed large aggregates of 
cells, whereas clone 37 typically remained as a single cell suspension, with small 
clumps of aggregated cells. In terms of visual inspection of these two cell lines, it is 
considerably simpler to
140
Figure 3.1 FACS data for an infection time course of HIV-1 NL4-3 (X4-tropic) and Yu2 (R5-tropic), on CEM-G.R5 clone 33 cells.
The increasing number of cells in the lower right quadrant, over time, represents the increasing number of cells in which GFP is expressed and are thus 
infected. The inset pictures were taken at 8 days PI, and demonstrate the appearance of both infected and uninfected clone 33 cells.
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Figure 3.3 S uscep tib ility  o f CEM-G.R5 c lo n e s  33 an d  37 to  X4- an d  R5-tropic HIV 
infection .
Graphs representing the testing of perm issiveness of CEM-G.R5 (A) clone 33 and (B) clone 37, 
to infection by HIV-1 NL4-3 (X4-tropic) and Yu2 (R5-tropic). The bars represent p24 detected in 
cell-free supernatant over 7 days, and the lines % of total cells expressing GFP. This data 
extends to 8 days PI. (C) A longer time course of NL4-3 and Yu2 infection of CEM-G clone 37 
was performed, to a s se s s  the reproducibility of infection and how it spreads through the culture. 
GFP data is in triplicate and p24 duplicate.
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interpret the level of infection when looking at clone 37, rather than clone 33: the 
internal reflection of green fluorescence within the aggregates of infected and un­
infected clone 33 cells creates a deceptively high GFP signal, as interpreted by eye.
As clone 37 seemed preferable, the infection o f this cell line with NL4-3 and Yu2 was 
repeated in triplicate. Cells and supernatant were sampled for 12 days PI to establish if 
the two viruses of different tropism spread equally through the culture over time (Figure 
3.3-C). Results show that this cell line was equally infectable with X4- and R5-tropic 
strains o f HIV-1, over time, and that by day 12 PI up to 80% of cells were infected (as 
defined by GFP expression). Since p24 concentration continued to increase along with 
percent of cells expressing GFP, this suggests that GFP expression was being induced 
as a result o f continuous rounds of viral replication and infection, rather than cellular 
uptake o f exogenous Tat within the culture supernatant, inducing GFP expression in the 
absence of infection as a form of ‘bystander effect’. These data also demonstrate that 
uninfected cells retained a very low level o f green auto-fluorescence after up to 12 days 
in culture, confirming that GFP expression observed was due to HIV infection only. 
Confocal microscope images of CEM-G.R5 clone 37 cells: uninfected; infected with 
NL4-3; and infected with Yu2 are presented in Figure 3.4.
3.3.2.3 Clone 37 can be infected with different HIV-1 subtypes and HIV-2
As a pilot experiment, CEM-G.R5 clone 37 cells were exposed to HIV-1 subtypes A, B, 
C, D, F, group O and ETP primary isolates, at a non-specific MOI. This was done to 
determine if any infection with these viruses could be detected by green fluorescence. 
If so, these cells would be used for characterisation of in vitro growth characteristics of 
each primary isolate, in a more controlled experiment. In all cases, by microscopy, GFP 
expression was observed. Photographs of these infections were captured (Figure 3.5). 
The CEM-G.R5-clone 37 cell line was at this time named CVG-37.
3.3.3 Characterisation
Given previously published data emphasising the importance of the host cell 
environment on growth phenotype in vitro - that genetic variation may have a positive 
fitness effect in one cellular environment but a negative fitness effect in another 
(Quinones-Mateu et al., 2000, van Opijnen et al., 2004), growth characteristics of the
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Figure 3.4 P hase contrast and green flu orescen t p an els sh ow in g  CEM-G.R5 clone 37 
ce lls  4 days PI.
(A) Cells are infected with the X4-tropic HIV-1 strain NL4-3, (B) the R5-tropic strain Yu2, and 
(C) uninfected cells.
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F ig u r e  3 .5  Photographs of CEM-G.R5 c lon e  37 ce lls , infected with HIV-1 subtype A, B, 
C, D, F, Group O and HIV-2 ETP primary iso late  v iru ses, under low pow er m agnification.
Images were captured using a fluorescent microscope and single lens reflex (SLR) camera. 
Cells expressing GFP are evident in all infections, although som e more than others. This 
experiment was not performed at equalised MOI so  d oes not infer any biological comparisons 
between isolates.
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panel o f HIV-1 primary isolates and HIV-2 were assessed in two different cellular 
environments. Specifically, the CVG-37 reporter cell line was used for infection 
studies, with growth assessed by both p24 and green fluorescence (FACS and 
microscopy). In addition, a SupTl T-cell line that has been engineered to express 
CCR5 (ST1-R5) was used for comparative infection studies, but as there is no direct 
reporter o f infection in these cells, images were captured using light microscopy (to 
record cytopathic effects -  CPE) and p24 content o f cell-free supernatant was recorded 
over time, to give a representation o f the progress o f infection. Virus growth on 
PBMCs was also captured using microscopy and photography. Development o f the 
CVG-37 cell line meant that, chronologically, virus growth was characterised first on 
PBMCs and ST1-R5s, and subsequently on CVG-37.
3.3.3.1 Growth curves on PBMC and T-cell lines
Six primary HIV-1 isolates; A, B, C, D, F and O, were used for infection of PBMCs and 
ST1-R5 cells, at an MOI o f 0.01. Subtype AE was not used, as infectious viral titre was 
too low. At this stage titred stocks of HIV-2 ETP had not yet been acquired.
PCR and p24
The MOI of 0.01 was chosen, as this is both realistically achievable using primary 
isolate stocks with infectious titre in the range of 103-4 fiu/ml, and reflects the titres 
previously used for in vitro viral replication studies (Gervaix et a l, 1997). For the STI­
RS infection time courses cells and supernatant were sampled for six days PI and 
photographs of cultures captured on days 2, 4 and 6 PI for ST1-R5 infections, days 1 
and 3 PI for PBMC infections (Figure 3.6-A). As there was no system to immediately 
report infection (as in CVG-37 cells) and it was possible that the p24 assay may not be 
optimal for certain HIV isolates (in particular those which are more distant to HIV-1 
subtype B, for which the assay was optimised), PCR for the early reverse transcription 
product strong stop (SS) DNA (Li et al., 1993) was employed to confirm that active 
HIV-1 replication was responsible for any changes in CPE detected. Specifically, DNA 
was extracted from ST1-R5 cells infected with each virus, at each time point, and the 
success o f DNA extraction determined by performing PCR to amplify a highly 
conserved region of the human endogenous retrovirus (ERV3) DNA, found within the 
genome of every cell (O’Connell et al., 1984). It was expected that DNA extraction 
would be difficult as only 104 cells were infected for each time point, so screening for
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ERV3 enabled the selection of a time point from which DNA was extracted for all 
samples to screen for SS-DNA, thus avoiding false negative results (Figure 3.6-C1). 96 
hours post-infection (HP1) was chosen as all samples were ERV3 positive and screening 
of these revealed that in all cases except the group O virus infection, SS-DNA could be 
detected (Figure 3.6-C2), confirming ongoing HIV-1 replication.
p24 data for the infection of ST1-R5 cells is shown in Figure 3.6-B. Results show that 
o f all viruses, subtype D appeared to replicate the most efficiently in ST1-R5 cells -  p24 
being detectable 1 day PI and accumulating in cell free supernatants up to day 6 PI 
when the concentration of p24 detected is over twice that seen in the next most efficient 
viruses, HIV-1 subtype A and group O. In the case of subtype A, however, infection (as 
represented by p24 concentration) appeared to peak 4 days PI, whereas p24 in the group 
O infection did not appear until 4 days PI, and was still increasing at 6 days PI. Subtype 
C infection followed a similar pattern to subtype A, and subtype F was similar to group 
O in that p24 appeared late, although to a much lower level. p24, however, was not 
detected in subtype B infection, implying that the virus used was non-infectious, or that 
subtype B was restricted in ST1-R5 cells. The latter possibility is, however, unlikely as 
SS-DNA was detected in this time course at 96 HPI. It is also unlikely that the p24 
assay failed, as it was designed with subtype B capsid in mind. These experiments were 
repeated in triplicate, however, and the patterns of differential viral replication were 
consistent.
Microscopy
Photographic images of these time courses (for which PCR and p24 data have been 
described) taken using a single lens reflex camera and light microscope are also 
presented, showing the CPE evident at days 2, 4 and 6 PI for ST1-R5 infections, and 
days 1 and 3 PI for PBMC infections. Figure 3.7 shows uninfected ST1-R5 and 
PBMCs, cultured in the same conditions as the infected cells, over 6 days. By 
comparing these to images those of both infected ST1-R5 cells (Figure 3.8-A and B) 
and PBMCs (Figure 3.9-A and B) it is clear that, by microscopy, infection can be 
confirmed in both cell types as a result o f exposure to all viruses. The X4- or dual­
tropic viruses HIV subtype B, D and O cause a heavy burden of CPE in infected STI­
RS cultures by 96 HPI, largely in the form of
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Figure 3.6 HIV-1 subtype growth com parison  experim ents on ST1-R5 ce lls
(A) Schematic of comparative growth experiment protocol, (B) p24 concentration in cell-free 
culture supernatant, measured over 6 days, for cells infected with HIV-1 subtypes A, B, C, D, F 
and O, (C-1) Erv3 PCR from DNA extracted from cells at each time point. At 96 hours Erv3 
PCR indicates successful DNA extraction. Accordingly, this DNA w as used for HIV strong-stop 
PCR, shown in (C-2). Strong-stop DNA w as detected in all infections, except for with group O 
virus.
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Figure 3.7 Im ages depicting the ch an ges in the appearance of non-infected ST1-R5 and PBMCs, over 144 hours in culture.
The 96 h image for PBMCs is missing.
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Figure 3.8 - a. Im ages depicting the ch an ges in the appearance of ST1-R5 cells, over 144 hours in culture, infected with HIV-1 primary iso la tes  
of subtype A, B and C.
Coreceptor usage of each isolate is noted on the right of each panel of images. Arrows mark large multinucleate cells/syncitia characteristic of infection with 
SI or X4-using viruses.
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Figure 3.8 -  b. Im ages depicting the ch an ges in the appearance of ST1-R5 cells, over 144 hours in culture, infected with HIV-1 primary iso lates  
of subtype D, F and O.
Coreceptor usage of each isolate is noted on the right of each panel of images. Arrows mark large multinucleate cells/syncitia characteristic of infection with 
SI or X4-using viruses.
 ►
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Figure 3.9 -  a. Im ages depicting the ch an ges in the appearance of PBMCs, over 144 hours in culture, infected with HIV-1 primary iso la tes of 
subtype A, B and C.
Coreceptor usage of each isolate is noted on the right of each panel of images. Arrows mark large multinucleate cells/syncitia characteristic of infection with 
SI or X4-using viruses.
 ►
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Figure 3.9 -  b. Im ages depicting the ch an ges in the appearance of PBMCs, over 144 hours in culture, infected with HIV-1 primary iso la tes of 
subtype D, F and O.
Coreceptor usage of each isolate is noted on the right of each panel of images. Arrows mark large multinucleate cells/syncitia characteristic of infection with 
SI or X4-using viruses.
 ►
24h 72h
syncitia and multinucleate cell formation (marked by arrows). This is typical o f X4- 
tropic, or SI/‘fast’ viruses, as first characterised on MT2 cells (Connor et a l, 1997), and 
in all cases by 96 HPI cell aggregates had broken down and the majority of cells in each 
field of view appeared to have lost biofringence and be either dead or undergoing 
apoptosis. The R5-tropic viruses HIV subtype A and C also held to this dogma, in that 
they failed to induce syncitia yet still caused pyknosis and apparent degradation of 
individual cells, leading to a similar end point in terms of observable CPE, by 144 HPI. 
HIV subtype F, however, appeared to cause quite significant syncitial formation on NP2 
cells. The images of infected PBMCs largely confirm the observations made with the 
ST1-R5 cells. CPE, however, was less clear as PBMCs tend to not form aggregates in 
culture so the blister-like syncitia clear in ST1-R5 infection were not so evident. 
Trypan blue exclusion analysis of these cells, however, did confirm cell killing at 144 
HPI, compared to uninfected controls (data not shown).
When comparing the p24 data and the images captured during the infections yielding 
these results, it seems that the p24 data in some cases do not necessarily reflect the 
extent of infection in vitro. For example, subtype B, C, and F infections were clearly 
productive in terms of cell killing, yet the p24 analysis did not reveal as high a level of 
this viral protein in the cell-free supernatant as one might expect.
When considering together the p24 data and microscopic analysis of the infection time 
courses o f HIV-1 subtypes A, B, C, D, F and group O, on the ST1-R5 cell line, it seems 
that the different subtypes o f virus do grow quite differently in vitro. The p24 data 
showed reproducible differences in the rate of p24 accumulation in the supernatant. 
This seems in some cases to agree with the observed CPE (i.e. in the case of subtype D) 
but not in others (i.e. in the case of subtype F). It may be that these differences were 
purely a result o f difference in cytopathic potential of the viruses studied. Whether 
cytopathic potential, perhaps related to coreceptor usage, could be considered a subtype- 
specific trait, however, is a controversial point. It was hoped that by performing the 
infection time courses with viruses of different subtype using CVG-37 cells, this would 
provide a clearer representation of the apparent differences in replication capacity, 
between HIV-1 genetic variants.
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S 3 .S.2 Growth curves on CVG-37
With the CVG-37 reporter cell line, infections were also performed at a multiplicity of 
infection of 0.01 ftu/cell. In this case, however, cells were infected by spinoculation 
followed by incubation in the presence o f polybrene, in an attempt to increase the 
infection efficiency for all viruses. p24 was again measured for each time point and 
each virus, and the extent of infection expressed as percentage of total cells expressing 
GFP (measured using FACS).
Results from analysis of GFP expression show that the HIV-1 subtypes A, D, F, group 
O and HIV-2 ETP spread through the culture equally, all achieving approximately 10- 
15 % infection 5 days PI (Figure 3.10-B). From day 5 onwards, however, the pattern of 
spread of these viruses diverged, with HIV-1 subtype D and group O continuing to 
spread resulting in 60% infection by 12 days PI. HIV-2 ETP also spread but to a lesser 
extent, achieving 30-35% infection, but HIV-1 subtypes A and F appeared to decline 
and fail to infect more that 10-15% of the CVG-37 cells. Similar to the growth 
experiments on ST1-R5 cells, HIV-1 subtypes B and C failed to establish significant 
levels of infection, only 5% of cells expressing GFP as a result o f infection, over the 12 
day time course. The FACS plots for the 12 days PI time point are shown in Fig 3.11: 
GFP expressing infected cells can be clearly delineated from non-infected GFP negative 
cells. Furthermore, the level of shift along the X-axis is comparable to that achieved by 
high titre infection with tissue culture adapted virus. This therefore shows that the use 
o f low titre primary isolate viruses does not adversely affect the capacity of viral 
infection to induce GFP expression.
p24 assays performed using the cell-free supernatants from the infected CVG-37 cells 
assessed for GFP expression largely confirm the observations from GFP data (Fig 3.10- 
A). Specifically, HIV-1 group O and subtype D p24 levels are highest at day 12, 
corresponding to the level of infection detected by GFP expression. p24 was also 
detected in subtype F, A and B infections, but only to a low level and not necessarily 
corresponding to when virus replication was detectable by GFP expression. This again 
highlights a limitation of the p24 assay in that it was insufficiently sensitive to detect the 
progress o f infection within a culture, over time. The levels of p24 detected in this 
series of experiments, however, is much greater than that detected in the ST1-R5
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F ig u r e  3 .1 0  HIV-1 subtype growth com parison  experim ents in the CVG-37 reporter cell 
line.
(A) p24 concentration in cell-free culture supernatant, and (B) percentage of cells expressing 
GFP, both measured over 12 days, as a result of HIV infection of CVG-37 cells with HIV-1 
subtypes A, B, C, D, F, group O and HIV-2 ETP.
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Figure 3.11 FACS plots of CVG-37 cells infected with HIV-1 subtypes A, B, C, D, F, 
group O, HIV-2 ETP and no infection control.
The cells in the lower right quadrant are expressing GFP and therefore infected. Uninfected 
cells are found in the lower felt quadrant. This data dem onstrates the magnitude of GFP 
expression, a s  a s se s se d  by FACS, and that infected and uninfected cells can be clearly 
delineated.
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infections. No HIV-2 ETP p24 data are presented, as the relevant antibody was not 
available.
3.3.3.3 Drug sensitivity
Given the development of the reporter cell line CVG-37 and its proven utility in 
studying the replication of diverse HIV-1 and HIV-2 isolates, the possibility of using 
this cell line as a drug sensitivity assay was investigated. This would both expand the 
repertoire of information gathered on the genetic variants of HIV studied, and provide a 
useful and more rapid method than traditional drug sensitivity assays (Gervaix et a l, 
1997).
The antiretroviral drugs (ARVs) chosen were zidovudine (AZT), efavirenz (EFV) and 
ritonavir (RTV) - a nucleotide reverse transcriptase inhibitor (NRTI), a non-nucleotide 
reverse transcriptase inhibitor (NNRTI) and a protease inhibitor (PI), respectively. The 
assay was first attempted by infecting CVG-37 cells at an MOI of 0.01 with the virus 
NL4-3 (by spinoculation in the presence o f the relevant ARV) as the infection 
efficiency with this virus was previously shown to be high. Titration of each drug onto 
CVG-37 cells, post-infection, in concentrations ranging from 0 to 0.5 pM, however, 
produced unusual dose response curves (Figure 3.12). Specifically, AZT and EFV 
inhibited replication of NL4-3 at concentrations far lower than might be expected. It 
was concluded that this may be a result of spinoculation in media containing drug, in 
effect concentrating the ARVs onto cells and enhancing any inhibitory effects expected. 
In addition RTV appeared to have no effect on replication of NL4-3. Experiments with 
RTV (and other protease inhibitors) were therefore not continued, although a two-step 
protocol is in development (Pirounaki et al.f 2000).
The protocol was modified accordingly, with an increased number of titration points in 
the lower concentration range (between 0 and 0.01 pM). The length of time the infected 
cells were left to incubate in the presence o f drug was also increased (from 4 to 7 days), 
as it had been observed that the primary isolate viruses would replicate more slowly 
than NL4-3. Furthermore, the assay was only performed using HIV-1 subtypes B, D, 
group O and HIV-2 ETP. This is because the subtype A, C and F isolates did not 
achieve an appreciable level of infection (in terms of GFP expression) by 7 days PI.
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Figure 3.12 Graphs show ing titration o f AZT, EFV and RTV on CVG-37 ce lls  infected  
with NL4-3.
(A) Chart shows raw data, in terms of % cells GFP positive 4 days PI, culture in the presence of 
a concentration range of AZT, EFV and RTV. (B) Chart show s the normalised data, required for 
IC50 calculation. For clarity, the X axis is not extended to 0.5 pM.
A
35
25
20
15
10
0 0
0 0.005 0.01 0.02 0.1 0.5
B
co
•4—»□
C
«4-
o
>u
0 0.05 0.1 0.15
Drug concentration (nM)
■ RTV
■ AZT
■ EFV
161
Figure 3.13 - a. Graphs show ing titration o f AZT and EFV on CVG-37 ce lls , infected  
with HIV-1 su b typ es B, D, O and ETP (raw data).
(A-B) Charts show raw data, in terms of % cells GFP positive 7 days PI with HIV-1 subtypes B, 
D, group O and HIV-2 ETP, cultured in the presence of a concentration range of AZT (A) and 
EFV (B).
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Figure 3.13 - b. Graphs show ing titration o f AZT and EFV on CVG-37 ce lls, infected  
with HIV-1 su b typ es B, D, O and ETP (norm alised data).
(C-D) T hese charts show the normalised data, required for calculation of the sensitivity of HIV-1 
subtypes B, D, group O and HIV-2 ETP, to the ARVs AZT and EFV. For clarity, the X axis is not 
extended to 0.5 pM.
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A new stock of HIV-1 subtype B was generated and included in these experiments.
Titration of EFV onto CVG-37 cells infected with HIV-1 primary isolates of subtypes 
B, D, group O and HIV-2 ETP enabled calculation of the concentration of drug at which 
the level of infection was reduced to 50% of that recorded in the absence of drug 
(IC50), for each isolate (Figure 3.13-B (D)): 0.0017, 0.0019 and 0.002 pM for D, B and 
O respectively. The sensitivity for subtype B to EFV was similar to that previously 
calculated using traditional drug sensitivity assays, in the range of 0.001 -  0.003 pM 
(Petropoulos et al., 2000) and as expected the HIV-2 isolate ETP was not sensitive to 
this compound (Wainberg, 2004). The sensitivity o f the subtype D isolate, however, 
was approximately 10-fold less than that previously described (Gao et al., 2004). 
Furthermore, results for the Group O isolate (BCF06) are unusual as group O viruses 
are generally considered not to be sensitive to EFV (and indeed the NNRTI class), due 
to the presence of several natural polymorphisms in the RT gene normally associated 
with resistance, including Y181C (Tuaillon et al., 2004, Wainberg, 2004). These data 
reveal that BCF06 is sensitive to EFV, with an IC50 comparable to subtype B and D. 
Sequence analysis of the cloned group O RT gene, however, showed that this particular 
group O isolate lacks the Y181C mutation. As certain other group O isolates have 
previously been shown to be sensitive to drugs o f the NNRTI class, in vitro, these 
results may be considered to be reliable (Tuaillon et al., 2004).
Titration of AZT onto CVG-37 cells infected with HIV-1 primary isolates of subtypes 
B, D, group O and HIV-2 ETP, however, revealed a slightly less clear picture (Figure 
3.13-B (C)). Other than for subtype B, addition of this drug to infected cells did not 
result in complete suppression of viral replication, even at the highest dose. It is both a 
possibly that this drug was at an incorrect concentration or inadequately formulated, or 
that for some reason the methodology used in this instance, with CVG-37 cells, was 
inappropriate for assaying sensitivity to AZT. These experiments therefore require 
repeating, in direct comparison with a standard MT2 drug sensitivity assay, with the 
same viruses. This should overcome any potential problems of incorrectly formulated 
drug and allow optimisation of the CVG-37 assay, which is in progress.
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3.4 Discussion
Differences between HIV-1 and HIV-2 in terms of disease progression and 
transmissibility have been clearly documented: HIV-2 exhibits a lower rate of 
heterosexual transmission, vertical transmission is rare and progression to AIDS is 
generally prolonged (De Cock et al., 1993). The question remains as to whether similar 
differences exist among the various genetic subtypes of HIV-1. Certain studies, both in 
vitro and epidemiological, have provided indications that there may be biological 
differences among HIV-1 groups and subtypes, but also some apparently contradictory 
results (Hu et al., 1999). Independent of viral subtype, rate o f disease progression 
varies from person to person and is influenced by multiple virological and host factors. 
The evaluation of associations between HIV subtypes and disease phenotypes is 
therefore very difficult, the challenge being in determining whether any associations 
identified are causal, or due to bias or chance. Nonetheless, it would be premature to 
conclude that the genetic variability o f HIV, defined as subtype, does not play any role 
in differences in virus biology, transmission or the development of disease (Peeters, 
2001).
Whilst several different approaches have been adopted to evaluate and thus better 
understand the differences between the subtypes and groups of HIV-1, this study has 
involved the investigation of the differences between a panel of primary virus isolates, 
in vitro. By taking a simple approach and characterising the basic phenotypic 
differences between HIV-1 primary isolates of different subtype, in different cellular 
environments, the aim was to determine if there are any defining and reproducible 
phenotypic discriminants between examples o f the HIV subtypes and whether this could 
be considered to agree with any of the previously published in vitro data. Whilst the 
analysis of growth phenotype cannot be directly extrapolated to the in vivo situation, it 
is reasonable to draw broad parallels between the biological phenotype of HIV isolates 
and potential disease phenotype, as certain characteristics are well documented 
independent markers of clinical outcome (Koot et al., 1993, Karlsson et al., 1994, 
Connor et al., 1997). Furthermore, the comparison of HIV-1 subtypes A, B, C, D, F, 
group O and HIV-2 viruses in a new reporter T-cell line, CVG-37, provides a prototype 
system for the continuation of such studies. Given the apparent lack of consensus with
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regards to the importance of HIV genetic variation on viral phenotype, this study is 
timely in its consideration o f such matters.
3.4.1 Comparison o f  HIV primary isolates in vitro using p24 and microscopy 
Initial growth of viruses through PMBCs in order to generate stocks, revealed that each 
of the viruses: HIV-1 subtypes A, B, C, D, F, group O and HIV-2, grew with particular 
efficiency, some considerably more rapidly than others and with distinctive CPE. As 
these viral stocks were obtained externally and titre was unknown, it was possible that 
the viral inoculum used for these preliminary infection experiments may have been 
sufficiently different to generate the observed differences. Calculation o f virus titre for 
each stock prepared, however, revealed that the titres o f all viruses were consistently 
low -  in the range of 103- 104 infectious units (calculated on NP2 cells) per ml. 
Phenotypic differences between subtypes were maintained on NP2 cells: the X4 or dual 
tropic genotypes (HIV-1 B, D, O and HIV-2 ETP) were fusogenic and resulted in large 
syncitia formation as infection progressed; the R5-tropic viruses (HIV-1 A and C) did 
not produce such distinct CPE. This correlates with the ‘X4=SI, R5=NSI’ rule, but this 
is only truly applicable to MT2 cells. HIV-1 subtype F, however, was different in that 
infection using stocks which showed a preference for R5 coreceptor usage, resulted in a 
heavy burden of syncitia formation during PBMC infection. Furthermore, in two of the 
four working stocks of HIV-1 subtype F, dual coreceptor usage was detected during 
titration on NP2 cells (these stocks also induced the same extensive syncitia on PBMCs 
and NP2 cells). This indicates that coreceptor usage within the viral population in these 
stocks is not particularly restricted, and that growth through PBMCs from different 
donors may have resulted in outgrowth of minority species that use the CXCR4 
coreceptor. Cloning and sequencing of several genomic fragments from provirus within 
infected PBMC DNA enabled confirmation of the subtype identity of the viruses being 
studied.
Growth phenotypes of the different HIV-1 primary isolates were therefore further 
characterised in PBMCs and the T-cell line SupTl.R5 (ST1-R5), and results revealed 
that the differences observed during viral stock preparation and titrations were largely 
perpetuated. Infection was performed at a set multiplicity; infectious titre calculated as 
focus forming units per volume of supernatant on NP2 cells. Previous studies have used 
a standardised amount of p24 for equalized infections, but due to the genetic
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heterogeneity of the viruses studied it was felt that this was inappropriate. Whilst RT 
activity o f supernatant provides an alternative means to equalise viral input, it has 
recently been shown that the relationship between RT activity and infectivity of a viral 
stock, whilst well correlated for R5 tropic viruses, are not well correlated for X4-tropic 
viruses (Marozsan et al., 2004). As viruses of both tropisms are being compared in this 
study, absolute infectious titre on NP2 cells expressing either the X4 or R5 coreceptors 
was deemed the most appropriate way of equalising infection in growth comparison 
experiments.
By monitoring infection of PBMCs and ST1-R5s by microscopy, it was shown that the 
X4- or dual-tropic viruses HIV subtype B, D and O cause a heavy burden of CPE, 
largely in the form of syncitia formation. HIV-1 subtypes A and C failed to induce 
syncitia, yet still caused pyknosis and apparent degradation of individual cells. The SI 
phenotype of HIV-1 subtype F was also evident in both PBMCs and the ST1-R5 cell 
line. Corresponding p24 data for the infections yielding these results, however, did not 
seem to necessarily reflect the extent of infection observed in vitro. For example, 
subtypes B, C, and F infections were clearly productive in terms of cell killing, yet the 
p24 analysis did not reveal as high a level of this antigen in the cell-free supernatant as 
one might expect. This could be due to reduced assay efficiency, the anti-p24 antibody 
having been generated by immunisation of mice with a subtype B epitope. 
Alternatively it is possible that, for different viral subtypes, the ratio of infectious to 
non-infectious virus particles varies. In the case of subtypes A and C, as isolates of this 
subtype are R5-using and have been reported to be typically ‘slow’ in terms of their 
growth in vitro, however, it may be that looking for p24 up to 6 days post-infection was 
too early when infecting with this virus at an MOI of 0.01. It was therefore concluded 
that, in trying to perform such comparative studies, a system was required that did not 
require p24 detection as its output, and preferably would allow infected cell 
visualisation and direct counting. This would surpass the measurement of p24 as a 
marker of progression of infection as, in addition to the flaws previously outlined, the 
p24 assay measures aggregate production and accumulation of viral proteins from 
cultured cells and does not permit an accurate quantitation of the actual number of 
infected cells.
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3.4.2 Development o f  a reporter cell line fo r  in vitro study o f  HIV primary isolates 
The establishment of a CEM-GFP stable cell line has previously enabled the monitoring 
o f X4-tropic HIV infection and antiretroviral drug sensitivity, in vitro (Gervaix et al., 
1997). This cell line and most immortalised T-lymphoblastoid cell lines, however, do 
not endogenously express CCR5, a member of the seven-transmembrane G-protein 
receptor family which is present at the surface of primary CD4+ T cells and monocytes 
permitting entry of primary macrophage and R5-tropic strains of HIV (Deng et al., 
1996, Doranz et al., 1996). Accordingly, the CVG-37 cell line was developed from this 
reporter cell line by addition of the CCR5 coreceptor. Two clonal lines with levels of 
CCR5 expression equivalent to that typically detected on PBMCs were identified and 
their sensitivity to infection determined. This enabled selection of a clonal line with 
low constitutive background fluorescence, but a high level of GFP expression upon 
infection with HIV-1 and HIV-2 (either molecular clone or primary isolate) of either X4 
or R5 tropism (Section 3.3.2.2). This cell line therefore provided a tool with which to 
compare the growth of the diverse range of HIV isolates under investigation in a fast, 
easy, inexpensive, and accurate manner. The efficiency of transactivation of the LTR- 
GFP construct should be comparable between different viral isolates as, despite the high 
level o f sequence variation between HIV-1 and HIV-2, the function o f Tat 
transactivation has been shown to be highly conserved between lentiviruses (Hooker et 
al., 2002) and GFP expression is efficiently and strongly induced upon infection with 
viruses of both types. The use of these cells in drug sensitivity assays was also 
demonstrated, and the development of this system for more extensive studies of drug 
sensitivity of HIV-1 genotypic variants is underway.
Infection of CVG-37 with all isolates at a multiplicity of infection of 0.01 ffu/cell 
revealed that HIV-1 subtypes A, D, F, group O and HIV-2 ETP spread through the 
culture equally until 5 days PI, but from day 5 onwards the pattern of spread of these 
viruses diverged, with HIV-1 subtype D and group O continuing to spread, reflecting 
previous observations in the ST1-R5 cell line. HIV-2 ETP also spread but to a lesser 
extent, but HIV-1 subtypes A and F appeared to decline and failed to infect more than 
10-15% of the CVG-37 cells. Similarly to the growth experiments on ST1-R5 cells, 
HIV-1 subtypes B and C failed to establish significant levels of infection - only 5% of 
cells expressed GFP as a result of infection, over the 12-day time course. These 
observations were highly reproducible. Regardless of the overall level of infection,
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however, in response to all subtypes mean green fluorescence values in GFP+ infected 
cells were equivalent, indicating that all viral subtypes and types were capable of 
efficiently transactivating the LTR-GFP construct. Measurement of p24 in the 
supernatant at each time point was largely in agreement with the pattern of GFP data, 
and supports the notion that increasing GFP expression is a product of ongoing viral 
replication. The levels of p24 detected in this series of experiments, however, was 
much greater than that detected in the ST1-R5 infections, most probably attributable to 
the increased efficiency of initial infection using spinoculation.
3.4.3 HIV-1 primary isolates o f  different subtypes grow differently in vitro 
When taken together the GFP and p24 data describing the growth of HIV-1 subtype A, 
B, C, D, F, group O and HIV-2 ETP reveal that, in the CVG-37 cell line, there are 
substantial and reproducible differences in the patterns of viral replication and spread 
between distinct viral types and subtypes. Furthermore comparison to growth 
experiments performed in a different T-cell line, ST1-R5, reveals a significant 
correlation between the replication efficiencies of the viruses studied, particularly HIV- 
1 subtype D, and group O. This implies that, in the T-cell environment, the primary 
isolates of subtype D and group O had a greater replicative capacity than the isolates of 
HIV-1 subtypes A, B, C and F. The reasons for these differences, however, are by no 
means clear. As described in section 3.1.2, studies o f the HIV LTR, protease, gag and 
accessory genes; rev, vpu and tat, have produced evidence that implies sequence 
variation within these genes may be manifested phenotypically, detected as changes in 
the way in which different viral subtypes grow in vitro, and thus perhaps in the way 
they behave in vivo. These effects, however, are typically subtle and whilst 
cumulatively they may help account for the observations made in this study, the 
individual contributions of subtype-specific variation within each gene cannot be 
determined. A considerable amount of research, however, has addressed what is a clear 
relationship between viral coreceptor usage, growth phenotype in vitro and disease 
progression in vivo, but few efforts have been made in terms of evaluating the 
association between subtype and coreceptor usage. The data presented here show that 
there is a clear delineation in growth phenotype on T-cells, between the X4 and R5X4 
using isolates (subtype D, O and ETP), and R5 using isolates of subtypes A and C, 
subtype F being an exception (Figure 3.14). As the different viral subtypes have 
previously been suggested to favour use of certain coreceptors (Tscheming et al., 1998)
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w ith this experim ental observation, certain  exp lanations m ay be proposed as to why 
these v iruses o f  different subtype grow  w ith such  reproducible differences, in vitro.
3.4.4 Subtype dictates coreceptor usage and therefore growth phenotype in vitro 
T he reasons w hy X 4-tropic viruses grow  m ore rap id ly  in vitro are not well understood. 
As g p l2 0  sequence seem s to drive this pheno type it m ay be hypothesised that the 
sequence characteristics o f  an env w hich confer X 4-usage, m ay also be those w hich are 
responsible for enabling  cells infected w ith an  X 4-tropic virus to have an increased 
capacity  for HIV replication; perhaps by enhanced  fusogenicity  im proving virus entry 
o r re lease from  cells. A lternatively, by in teracting  w ith the C X C R4 coreceptor the cell 
signalling  resulting from  viral engagem ent m ay be m ore advantageous for subsequent 
viral entry, replication  and egress. A lso, by  targeting  this receptor the virus m ay avoid 
certain  cellu lar pathw ays that are refractory  to infection. R egardless o f  the m echanism , 
how ever, the differences betw een envelope-associated  viral phenotype in vitro would 
seem  to be an experim ental phenom enon that reflects the difference betw een the 
envelope sequences and glycosylation  state. A s these sequence features are highly 
pred ictive o f  clinical progression in a large p roportion  o f  people, it seem s likely that this 
will hold true in the various non-B  subtypes (M oore et al., 2004).
F ig u r e  3 .1 4  A generalised  representation of the pattern of viral growth (adapted from  
p24 and GFP data) and extent of CPE ca u sed  by primary iso la tes o f different HIV-1 
su b typ es and HIV-2 (ETP) overtim e, in CD4+ T -cells lines.
The coloured sections em phasise the relationship between viral growth rate, capacity to induce 
syncitia formation, coreceptor usage and subtype.
LU 
CL
o
"Oc  
03 
c 
o
o  Q)
J B a E f*  etp
S
® ^ '  R5X4 p
R5 B, A  C
 ►
t i m e
170
Given that the genetic differences between subtypes appear to have resulted in different 
env tropism, one may postulate that this explains their differing behaviour in vitro, and 
thus potentially may result in differences between them, in vivo.
Whilst the mechanistic relationship between coreceptor usage and phenotype in vitro is 
not well understood, however, many o f the features of the gpl20 envelope viral protein 
involved in coreceptor usage have been revealed. The sequence of the V3 region is 
highly associated with the coreceptor phenotype, together with the V1V2 region 
(Pollakis et al., 2001): the overall amino acid charge appears to dictate coreceptor usage 
with higher positive charges being associated with the SI phenotype and utilisation of 
the CXCR4 coreceptor (de Jong et al., 1992a, de Jong et al., 1992b), in particular at 
positions 11 and 25 of the V3 loop. A low frequency of V3 glycosylation has also been 
associated with CXCR4 usage, and the N-linked glycosylation site downstream of the 
first V3 cysteine has been shown to be a major determinant influencing viral replication 
phenotype (Pollakis et al., 2000). These features thus have enabled the creation of 
several computational methods of predicting coreceptor usage, based on Env sequence. 
An alignment of V3 sequences of the viruses studied is shown in Figure 3.15-A. Using 
a number of methods for predicting coreceptor usage (Jensen et a l, 2003, Pillai et al., 
2003), it seems the in vitro observations made here reflect the in silico predictions, in 
that the subtype D and group O viruses are predicted to and do use the CXCR4 
coreceptor, and are those which grew most efficiently through culture. Subtypes A and 
C are predicted to use CCR5 and their growth in vitro reflected this. Subtype F, 
however, is predicted as using CXCR4, whereas in vitro it showed a preference for 
CCR5 usage. Neighbour joining trees representing these V3 sequences (Figure 3.15- 
B/C) reveal the genetic segregation between CXCR4 and CCR5 using viruses (B) and 
that, when amino acid positions 11 and 25 are removed from the alignment, that this 
segregation remains (C). This implies that it is not only positions 11 and 25 that are 
important in determining tropism, but also the underlying variation between the 
different subtype isolates studied. Subtype D and group O V3 sequences are the most 
distant to the others, which correlates with their behaviour in vitro. The subtype F 
sequence however, whilst predicted as CXCR4 using, clusters with the CCR5 using 
viruses. The tree topology thus reflects more closely the behaviour of this virus in vitro 
and perhaps indicates that viruses such as the subtype F isolate, with a tendency to
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F ig u r e  3 .1 5  The relationship betw een subtype, V3 loop genotype and phenotype.
(A) Alignment of V3 loop sequences of each of the viral isolates studies, except HIV-2 ETP, and 
their predicted coreceptor usage*. Position 11 and 25 are highlighted (blocks) to indicate the 
residues most important in the ‘charge rule’ of predicting coreceptor usage. Positions 24, 27 
and 32 implicated in contributing to the X4 phenotype (Jensen e t al., 2003) are marked (red 
arrows). ‘Prediction of coreceptor usage was performed using a PSSM based method 
(WebPSSM, M Jensen, University of Washington), the Charge Rule, and three machine 
learning techniques: Support Vector Machine (SVM); C4.5; and PART, all provided via WetCat 
(S Pillai and B Good, University of California, San Diego). (B) Neighbour joining tree of V3 
sequences shown in (A). (C) Neighbour joining tree of V3 sequences shown in (A), with 
positions 11 and 25 removed.
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exhibit dual tropism, use a different ‘sequence key’ to gain access to T-cells via 
CXCR4, as they have retained that ability to use CCR5. Accordingly, in these cases the 
standard ‘rules’ may not apply in coreceptor usage prediction (Pillai et a l, 2003).
Alternatively, these data could indicate that the subtype F virus, rather than using a 
different sequence ‘key’, is merely further along the pathway of accumulated mutations 
that result in CXCR4 usage (Jensen and van ‘t Wout, 2003). PSSM analysis (Jensen et 
a l, 2003) allows the calculation of a V3 ‘score’ which, rather than being a binary 
definition, places viruses on a continuous scale from R5- to X4-using and accordingly 
takes into consideration the background variation in V3 sequence outlined in this small 
study as being important. Analysis of the subtype F sequence gives a score of -5.75, 
which compared to the scores for R5-using subtype A and C (-7.49 and -10.67 
respectively) and X4-using subtype D (8.33) perhaps places this virus marginally closer 
to X4-usage, in terms of score. It should be noted, however, that this tool is designed 
for analysis of subtype B sequences.
It therefore seems that, at least in vitro, coreceptor usage, viral replication phenotype 
and subtype are intrinsically linked. The env characteristics of the viral isolates studied 
can therefore go some way to explaining the differences between them, in terms of 
replication phenotype. It seems likely that there are viral factors, other than V3 
sequence, dictating the differences between the isolates of different subtype observed in 
vitro, which may therefore play an important role, in vivo.
3.4.5 Preferential coreceptor usage in certain subtypes may affect disease phenotype 
It has previously been reported that CXCR4 usage determines the biological phenotype 
o f all subtypes, but that there is evidence for subtype-dependent differences in 
coreceptor usage: dual usage is significantly more rare among subtype D isolates, and 
the CXCR4-using phenotype is rare among subtype C isolates (Tscheming et a l, 1998). 
The in vitro experiments and V3 loop analysis described here support this notion, and if 
these apparent subtype-specific differences in coreceptor usage and thus viral 
replication capacity are reflected in vivo, this creates the possibility that genetic 
subtypes may differ in clinically important properties such as virulence, tissue tropism 
and transmissibility.
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The most striking conclusions that may be drawn from the review of literature in 
sections 3.1.1 -  3.1.2 are that: subtype D viruses have been associated with higher viral 
loads, rate of disease progression, in some cases transmission frequency, and typically 
grow well in culture (in primary and T-cell lines) with a preference for CXCR4 usage; 
and that subtype C viruses have been identified as particularly slow growing in culture, 
with a preference for R5 usage, yet have received particular attention in terms of 
research as they currently dominate the HIV-1 pandemic. Taking these observations 
into consideration, it would seem that the in vitro data presented here agree with these 
data and it is tempting to hypothesise that in the case of subtype D, growth phenotype in 
vitro does in fact reflect that manifested in vivo. For subtype C, however, it seems that 
there is a dichotomy between epidemiological observations and in vitro findings, which 
is most likely to be due to the growth disadvantage that R5-tropic viruses seem to suffer 
in T-cells, in vitro. It is therefore important to note that no presumption is made in this 
study that the attenuated replication capacity of R5-tropic viruses compared to X4 
viruses, in vitro, reflects a real life attenuation of these isolates. In addition to the 
potential explanations made in section 3.4.4, it may be genetic variants of HIV which 
are characterised as CCR5 using require additional factors for productive infection in 
culture not provided in experimental systems used here, such as additional coreceptors 
or a particular form of cell-cell contact in a certain cellular environment. X4-tropic 
viruses may not require this. It may also be that the T-cell lines used in this study 
express high levels of p-chemokines (the natural ligands for CCR5) either endogenously 
or in response to infection, which impede the progression of R5-using viruses by 
reducing coreceptor availability. Thus, data generated in the experimental system used 
in this study must not be over interpreted. It is tempting to suggest, however, that the 
subtype D data are intriguing and it will be interesting to see if, in the future when 
group O viruses have been further studied, whether they too show enhanced disease 
progression in vivo, or like HIV-2, which in CVG-37 cells grew better than several of 
the HIV-1 subtypes but in vivo has a much attenuated clinical course, the results 
obtained in this study are merely a reflection o f this genotype’s ability to gain access to 
T-cell by an as yet undetermined mechanism.
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In vivo, the presence of X4-tropic virus in HIV+ patients has long been observed as 
indicative of a poor prognosis (Cheng-Mayer et al., 1988, Fenyo et a l, 1988, Tersmette 
et al., 1988), as whilst approximately 50% of isolates from patients with AIDS have an 
X4-tropic phenotype, identification o f X4-tropic viruses at seroconversion is relatively 
rare. Whether this is a feature of a selective bottle neck at transmission resulting in 
positive selection of R5-tropic viruses, and an indication that X4 tropic viruses herald a 
decline in CD4+ count associated with the onset o f AIDS because they are inherently 
more pathogenic is unclear. At present, it seems that the common perception is more 
along the lines that chronic immune activation is the proximal cause of T-cell loss, 
which facilitates the outgrowth o f X4 tropic viruses in the later stages of disease when 
sites of the body (for example gut associated lymphoid tissue - GALT) where R5-tropic 
viruses had more successfully colonised earlier in infection, become exhausted 
(Grossman and Paul, 2000, Moore et al., 2004). The question remains, however, if the 
viral subtype which you harbour is closer in terms of both evolutionary distance and 
time to switching to CXCR4 usage, is your prognosis worse? The potential prognostic 
value of ‘V3 scoring’ has been described previously (Jensen and van ‘t Wout, 2003). It 
may be, therefore, that if further studies were performed which confirm previous 
observations and bear out those made in this study with regards to the relationship 
between viral subtype, growth in vitro and coreceptor usage, then viral subtype may 
also be of prognostic value.
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Chapter 4.0 Transcriptional profiling of HIV infection 
and the significance of genotypic variation
4.1 In troduction
Genomics represents the study of whole sets o f genes or gene products, rather than 
individual genes. With the completion o f the draft human genome sequence (Venter et 
a l, 2001, International Human Genome Sequencing Consortium, 2004) and the 
availability o f whole genomes o f over 1000 viruses and 100 microbes (Entrez Genome, 
August 2004), many of which are known human pathogens, this field has rapidly 
become integral to the understanding o f the process of infection at the molecular level. 
To achieve this several novel experimental approaches and technologies have been 
developed, collectively termed functional genomics. DNA microarray hybridisation 
analysis has become one such established methodology for measuring the expression 
levels of whole-genome encoded mRNAs due to its simplicity, comprehensiveness, data 
consistency, and high throughput.
4.1.1 Microarray technology
The underlying principle of all array experiments is that labelled nucleic acid molecules 
in solution hybridise, with high sensitivity and specificity, to complementary sequences 
immobilised on a solid substrate. This enables parallel quantitative measurement of 
many different sequences in a mixed population (Southern et al., 1999, Brown and 
Botstein, 1999). This hybridisation property of DNA was first exploited in 1975 when 
Ed Southern pioneered the technique of detecting specific DNA fragments in a mixture 
separated by gel electrophoresis (Southern, 1975). Widespread use of this methodology 
revolutionised the field of molecular biology and soon variations on the Southern 
theme, including Northern and Western blotting (RNA and proteins respectively) 
together with scaling up of the number of DNA fragments studied at one time (Lennon 
and Lehrach, 1991), laid the foundations for microarrays. With increasing availability 
of the necessary hardware, namely robots and desktop computers, microarray 
technology has become a widely exploited tool in the post-genomic era.
Several methods for constructing microarrays have been developed (Ramsay, 1998, 
Watson et a l, 1998), two of which predominate. In one, DNA microarrays are
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constructed by physically attaching DNA fragments such as library clones, polymerase 
chain reaction (PCR) products or oligonucleotides to a solid substrate (Schena et a l, 
1995). For the second, arrays are constructed by synthesising single-stranded 
oligonucleotides in situ by use o f photolithographic techniques (Lockhart et a l, 1996). 
Gene expression array experiments can also be performed by hybridising a single 
labelled mRNA sample to "macroarrays" of DNA elements on positively charged nylon 
or nitrocellulose filters (Tau et a l, 1999, Richmond et a l, 1999, Cohen et a l, 2000a, 
Eckmann et a l, 2000, Rosenberger et a l, 2000). Because this format does not require 
any special arraying or scanning equipment, arrays can be made and analysed relatively 
cheaply. The major disadvantages o f this format, however, are reduced sensitivity 
(Cohen et a l, 2000a), limited elements, and the need for higher concentrations of 
labelled cDNA. For a description of different array methodologies, see Table 4.0.
4.1.2 Microarray methodology
For DNA microarrays, relative transcript abundance can be measured in two ways, 
either by labelling two samples with different fluorescent dyes, hybridising them 
simultaneously and determining the fluorescence ratio for each spot on the array, or by 
hybridising a single labelled sample. In the latter case, as for oligonucleotide arrays, 
multiple probes from the same gene, each with a corresponding mismatch probe that 
serves as internal control, as well as labelled transcript of known amounts for standard 
genes makes quantitative measurement of transcript abundance possible after 
hybridising a single labelled sample (Lockhart et a l, 1996). For both techniques use o f 
fluorescent labelling enhances sensitivity and the dynamic range of measurement, 
although radiolabelling provides the best dynamic range.
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Table 4.0 Summary of various array technologies
Filter Array Microarray Affymetrix Rosett;
Solid Support Nylon membrane Glass slide Glass Glass
Probe PCR product or PCR product or Oligonucleotide Oligon
oligonucleotide oligonucleotide
Synthesis Robotic deposition Robotic deposition In situ by photolithography In situ
deposit
Label 33P Cy3 and Cy5 Fluorescein Cy3 an
Labelling Reverse transcription or Reverse transcription or Reverse transcription or Revers
method end-labelling amino-allyl ligation biotinylation allyl lij
Scanning Phosphor imager Fluorescent scanner Affymetrix scanner Fluores
Messenger RNA from eukaryotic cells is usually extracted by affinity purification of 
mRNA with an oligo-dT resin, followed by incorporation of dye-labelled nucleotides 
into cDNA molecules during reverse transcription. Typically either poly(dT), which 
primes from the poly(A)-tail o f mature mRNA, random primers, or sequence specific 
oligonucleotides, either those used to construct the microarray or a minimally complex 
mixture of octamers sufficient to hybridise to the 3’ end of every ORF (Talaat et al.,
2000) are used in this step. The fluorophores most commonly used are Cy3 and Cy5, 
but this does differ between array types. Membrane arrays employ the use of 
radiolabels such as 33P, for example. In the case o f cDNA or oligonucleotide arrays, 
fluorescent labels are detected either using charge coupled device (CCD) camera or 
photomultiplier tube (PMT) scanner. A schematic o f spotted cDNA microarray 
methodology is shown in Figure 4.0-A.
A significant limitation of current microarray technologies, however, is the large 
amount of input mRNA required to generate labelled cDNA for array analysis. With 
very small tissue samples one can either increase cDNA labelling and hybridisation 
efficiency, or include an amplification step to generate sufficient RNA/cDNA for use 
with a standard labelling method. The Affymetrix system uses a single round of 
amplification as a routine part of the labelling protocol. RNA amplification techniques, 
however, must preserve the relative abundances of the different RNAs within the 
starting population and be highly reproducible.
4.1.3 cDNA Microarray data analysis
The most basic cDNA microarray experiment involves the comparison of two samples, 
for example infected and uninfected cells. In this situation the two samples are labelled 
with different fluorophores, hybridised on the same microarray and the image scanned 
to generate an image of the array from which numerical data for each element, or spot, 
can be extracted. Typically these data equate to the intensity of each spot compared to 
the background intensity of the slide, resulting in an expression ratio for each gene, 
subsequently converted to log base 2 (log(2)). This transformation provides an intuitive 
view of the data as up- and down-regulation are of the same magnitude, and creates a 
normal distribution of the expression ratios (Figure 4.0-B). By depicting these data 
graphically as a scatterpot, with the log(2) ratio of each spot (M) against log(2) overall 
intensity (A), the resulting M vs. A plot enables identification of differentially
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Figure 4.0 DNA microarray tech n ology .
(A) Schematic of microarray methodology, a s  applied to the study of gene expression in the 
context of viral infection. The cDNA probe is prepared by labelling the sample (virally infected 
cells) and reference (normal cells) RNA with different fluorescent dyes: red for sample (Cy5) 
and green for reference (Cy3). T hese are combined in equal amounts and hybridised to a glass 
slide that has spotted onto it multiple cDNAs, each representing a different gene. After 
hybridisation the array is scanned -  the com posite image represents the relative abundance of 
mRNA for each gene on the array, in the sam ples. That is, if a spot is yellow, the mRNA in 
question is equally abundant in both conditions. If it is red, it is more abundant in infected cells 
and if it is green, the mRNA is more highly expressed in uninfected cells. In the case  of this 
example, such an experiment would help determine which gen es are differentially expressed in 
cells during viral infection. Reproduced from Darryl Leja, htto://www.accessexcellence.orq/ 
AB/GG/microArray.html. (B) Representation of log2 transformed gene expression 
measurements and their derivation from raw data. Reproduced from Kellam and Liu, 2002.
A
Prepare cDNA Probe Prepare Microarray
SampleReference
Reverse 
transcription 
Label with 
fluorescent dye
C om bine
Equal
Amounts
Hybridize 
probe to 
microarray SCAN
Microarray T ech n ology
Expression
values
• O O o o o •
Cy5 5000 10000 6000 20000 15000 10000 16000
Cy3 40000 40000 12000 20000 7500 2500 2000
Ratio 1/8 1/4 */2 1 2/1 4/1 8/1
Log(2) ratio -3 -2 -1 0 1 2 3
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expressed genes as outliers. Multiple repetitions of this experimental format increase 
confidence in the data, reducing the variance (Yang and Speed, 2002) and allowing the 
statistical significance of observations to be established. This can be achieved by 
several means, including t-Tests (Wolfinger et al., 2001) Z-scores (Thomas et al.,
2001), analysis of variance (Kerr et al., 2000) and Wilcoxon rank sum (Mann-Whitney 
U) statistics (Chambers et al., 1999). Three replicates of each data point are widely 
considered as sufficient (and practical) for statistical analysis, although larger numbers 
are always desirable (Lee et al., 2000). Dye-swap experiments are also useful to control 
for differential incorporation of the two dyes (Tseng et al., 2001), these only being 
relevant in the context of the specific experiment being performed.
The design of a microarray time course experiment requires the consideration of a 
number of factors. An important consideration is what kind of reference RNA to use: 
all samples subsequent to time zero may be compared (hybridised) with the time zero 
sample (Iyer et al., 1999) or, alternatively, all samples from the time course can be 
compared to an independent common reference (Perou et al., 1999). In the latter case, 
the expression ratios generated for each gene (sample/reference or Cy5/Cy3) are a 
measurement of gene expression level in the sample relative to the reference. This 
therefore enables comparison of experiments performed at different times, in different 
laboratories, provided that the same reference RNA is used. In the former case the 
expression ratios derived are more intuitive as they relate the gene expression level in 
the sample relative to a biologically informative reference, for example uninfected cells 
(where the sample is infected cells). These data, however, can never be cross-compared 
to data derived from other experiments performed with a separately prepared reference. 
Both reference options have advantages and disadvantages, but the latter method seems 
to be gaining favour with increasing attempts to integrate microarray data from 
disparate sources (Brazma, 2001).
4.1.3.1 Data normalisation
Before array data can be analysed, however, it must be normalised (median centring). 
This adjusts for systematic differences in the labelling and detection efficiencies (for the 
different labels) and differences in the quantity of RNA, and allows the comparison of 
gene expression levels across multiple slides. The effect of the reference on log(2) ratio 
values is that it shifts all values by a constant. This therefore allows for removal of the
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reference effect, making gene expression ratios independent of the reference sample. 
This can be achieved for genes, by subtracting the median gene expression value for 
each row from all the values in the row, thereby making the median value for the row 0. 
This can be performed iteratively for every row in the gene expression matrix.
For normalisation of arrays, the most common method is to apply a scaling factor that 
sets the average or median expression ratio to 1 (corresponding to a log(2) ratio of 0), 
given a normal distribution. This ‘global normalisation’ assumes that the Cy3 and Cy5 
intensities on a slide are related by a constant factor, and that the number of genes up- 
regulated balances the genes down-regulated so, on average, there is no change in 
median or mean gene expression levels.
Following this pre-processing of experimental data, further analysis may be performed 
in order to extract biological information. Many other normalisation procedures exist, 
for a concise review on this subject and other fundamentals of cDNA microarray data 
analysis see Leung and Cavalieri, 2003.
4.1.3.2 Clustering
A microarray experiment produces an enormous amount of data about genes that are up 
and down regulated at a given time and/or in a given condition, which is of very little 
use in the absence of some way to present the data in an interpretable and biologically 
meaningful manner. Sophisticated data exploration techniques have been developed 
which rely upon the assumption that shared gene expression often implies shared 
function (Bassett et al., 1999, Eisen et al., 1998, Yeung et al., 2004). That is, within a 
dataset clustering genes into groups based on a measure of similarity in their gene 
expression over all samples provides a means for data exploration and visualisation.
The aim of clustering is to organise a collection of patterns into clusters, based on 
similarity, so that the patterns within the same cluster are more similar to each other 
than they are to a pattern belonging to a different cluster. This is not dissimilar to the 
way in which HIV PR-RT sequences were partitioned into subtype groups (Chapter 2) 
for example using the NJ method. The Euclidean distance is one of the more commonly 
used measures of dissimilarity, others including Pearson’s correlation or Spearman’s 
Rank correlation, Mahalanobis distance, Chebyshev distance and Canberra metric.
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Once the pattern proximity has been calculated (based on distance), the clustering (or 
pattern-grouping) methods are used to construct tree structures of the data. These may 
be hierarchical or non-hierarchical, and unsupervised or supervised (Alon et al., 1999, 
Tamayo et al., 1999, Eisen et al., 1998, Ben-Dor et al., 1999). Unsupervised clustering 
is often followed by a form of supervised clustering where, if a co-regulated class of 
genes is known, supervised clustering algorithms (trained to recognise known members 
o f the class) can assign uncharacterised genes to that class.
The clustering method used for analysis o f microarray data presented here is average- 
linkage hierarchical clustering (Hartigan, 1975, Eisen et al., 1998). This groups genes 
by their expression pattern across the samples (gene vector), and groups samples by the 
expression pattern of the genes within each sample (sample vector). Data are assembled 
into a matrix o f log(2) expression ratios, each row representing a single gene and each 
column a single array. Gene and array expression vectors are compared in pair-wise 
fashion by their Pearson correlation coefficient. The two most similar vectors are joined 
by a node and the average vector calculated. This average vector replaces the two joined 
vectors and the process is repeated. This agglomeratively builds up a dendrogram 
relating all the genes or samples by their expression pattern. The shorter the branch 
connecting two genes or samples, the more similar the expression patterns. The tree 
structures force the genes and arrays in the expression matrix to be reordered so that 
genes or samples with similar expression patterns become clustered together. 
Expression levels are represented as a colour scale from green, representing negative, 
through black to red, red representing positive log(2) expression values which are 
derived directly from the initial data matrix. This provides a simple visual means for 
identifying groups of co-expressed genes. A means of ordering the data termed 1- 
dimensional self-organising maps (SOM) may then be used to order the clusters along 
the axis of the dendogram according to their similarity (Eisen et al., 1998, Tamayo et 
al., 1999).
4.1.4 Gene expression profiling of the host and pathogen interaction
Global profiling of gene expression is an ideal approach for assessing gene function as 
it is generally accepted that a gene is usually transcribed only when and where the 
function of its product is required. In the context of infection, by examining the 
locations and conditions under which a gene is expressed inferences may be made about
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its role in the interaction between host and pathogen. Since high-density DNA 
microarrays were first described in 1995, the use of this technology has made a marked 
impact on a number of fields o f research, including cellular physiology, cancer biology 
and pharmacology. Given the number o f microbial genomes for which all sequence is 
known it is practically reasonable to also produce arrays for pathogens. Arrays for 
Mycobacterium tuberculosis (Wilson et al., 1999), Plasmodium falciparum  (Hayward et 
al., 2000, Rathod et a l, 2002), Streptococcus pneumoniae (de Saizieu et a l, 2000), 
Salmonella typhimurium (Eckmann et a l, 2000, Rosenberger et a l, 2000) and Listeria 
monocytogenes (Cohen et a l, 2000c) have indeed been generated and used to analyse 
pathogen interactions with the host and response to antimicrobials. Such arrays have 
also proved key in annotating the genomes o f these organisms and close relatives 
(Koonin et a l , 1997, Tatusov et a l,  2000), for the identification of candidate virulence 
factors (Cotter and Miller, 1998), and in microbial genotyping (Kato-Maeda et a l, 
2001).
Microarrays have also been used for the study of viral and host gene expression, during 
infection (see Table 4.1 for full list o f virus array studies). Some viruses, such as 
HCMV, HSV-1, KSHV, HPV-31, rhesus rotavirus, RSV and influenza virus, have 
pleiotropic effects on host gene expression, modulating the transcription of many genes 
across numerous functional groups. Some of the differences between expression 
patterns generated by different viruses could be due to cell-type specific expression 
patterns or differences in the array methodologies used. Despite these limitations, 
however, comparisons can be made between array results from cellular infection by 
different viruses and common expression changes can be found in host genes of certain 
functional groups, including: the interferon response; cytokines; stress responses; 
protein synthesis and the cell cycle.
Many microarray studies have revealed that infection of human cells with a diverse 
range of viruses leads to an increase in the expression of interferon-stimulated genes, 
induction of which is indicative of the activation of the cellular anti-viral response 
(reviewed in Goodboum et a l, 2000). The function of interferon responsive genes in the 
anti-viral response is supported by array analysis showing that the induction of 
interferon-responsive genes in vivo in the liver of a chimpanzee during infection with 
HCV correlates with the clearance of viraemia (Bigger et a l, 2001). Some viruses,
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however, are able to suppress the transcriptional induction of host anti-viral genes, for 
example whilst UV-inactivated HSV-1 leads to up regulation of interferon-stimulated 
genes, transcriptionally active HSV-1 is able to counteract this and keep the level of 
these genes constant (Mossman et al., 2001). Coincident with the up regulation of 
interferon responsive genes during viral infection, increased expression of various 
cytokine genes is observed, the expression o f certain cytokines probably being a 
common feature o f infection by all viruses. For example IL-6 is up regulated upon 
infection by HSV-1, HCMV, HHV-6, HPV, influenza and coxsackievirus B3, and 
expression of RANTES is induced by HCMV, rhesus rotavirus, HPV-16 E6 and E7, 
RSV, PVM and HTLV-1 (for all references see Table 4.1). Adenoviruses, however, 
down regulate certain cytokines including CLL2, CXCL1, and IL-6.
Protein synthesis and the cell cycle are both affected, in different ways, by different 
viruses. Array analyses have shown that infection by HSV-1, reovirus serotype 3, 
echovirus 1 and HIV-1 lead to cell cycle arrest at the G2 to M transition by up 
regulation of GADD45, a cdc2 kinase inhibitor, suggesting this may be a common 
mechanism for virus induction of cell cycle arrest. HPV-31 infection, however, 
stimulates entry into the cell cycle and HSV-1 US11 inhibition o f cell growth arrest and 
the HIPK2/p53 pathway has recently been described (Giraud et a l, 2004). The 
alternative effects of different viruses on cell cycle gene expression are therefore likely 
to reflect variation in viral replication strategies. The induction of stress-response genes 
is also common in response to infection by many viruses. Typically these genes are 
associated with heat shock and oxidative stress (Palmiter, 1998), often involving 
modulation of GADD45.
For HIV infection, DNA microarrays have been used to investigate both whole virus 
and virus protein-specific effects on cellular gene expression. Despite the apparent 
simplicity of this virus, however, many facets of its interaction with the host remain to 
be understood.
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Table 4.1 Viruses whose effects on host gene expression have been measured using 
DNA arrays.
The array type used and approximate number of g e n e s  analysed is indicated (in brackets). A
Order Family Species Array type Reference(s)
dsDNA virus Adenovirus Adenovirus types 5 and 12 Membrane (18376) Vertegaal et al., 2000
Adenovirus type 2
Microarray (12309) Zhao et al., 2003
Herpesvirus HSV-1 Membrane (588) Khodarev et al., 1999
Microarray (57) Stingley et al., 2000
Membrane (588) Hobbs and DeLuca, 1999
Microarray (19000) Mossman et al., 2001
Membrane (149) Hill et al., 2001
Membrane (18378) Tsavachidou et al., 2001
Affymetrix (4626) Ray and Enquist, 2004
Human cytomegalovirus (HCMV) Affymetrix (4x 1650) Zhu et al., 1998
Affymetrix (12626) Browne et al., 2001
Microarray* (8942) Simmen et al., 2001
HHV-6 Membrane (1152) Mayne et al., 2001
EBV Membrane (4146) Carter et al., 2002
KSHV Membrane (10000) Mikovits et al., 2001
Microarray* (4165) Moses et al., 2002
Membrane (2350) Poole et al., 2002
Microarray (9180)
Affymetrix (
Pseudorabies virus (PRV) Affymetrix (4626) Ray and Enquist, 2004
Marek’s disease virus (MDV) Membrane (1126) Morgan et al., 2001
Papillomavirus HPV-31 Microarray (7075) Chang and Laimins, 2000
Poxviruses Modified vaccinia Ankara (MVA) Microarray (15000) Guerra et al., 2004
Varicella-zoster virus (VZV), Membrane (147) Cohrs et al., 2003
dsRNA virus Reovirus Reovirus serotypes 1 and 3 Affymetrix (12626) Poggioli et al., 2002
Rhesus rotavirus Microarray (38432) Cuadras et al., 2002
ssRNA- virus Paramyoxvirus Measles virus Membrane (3x1176) Bolt et al., 2002
Respiratory syncytial virus (RSV) Membrane (268) Zhang et al., 2001b
Affymetrix (12626) Tian et al., 2002
Pneumonia virus o f  mice (PVM) Affymetrix (12626) Domachowske et al., 2002
Orthomyoxovirus Influenza virus Microarray (4608) Geiss et al., 2001
ssRNA+ virus Picomavirus Poliovirus Microarray (10000) Johannes et al., 1999
Echovirus 1 Membrane (588) Pietiainen et al., 2000
Coxsackievirus B3 Microarray (7000) Taylor et al., 2000
Theiler's murine encephalomyelitis Membrane (15?) Palma and Kim, 2004
virus (TMEV)
Flavivirus Hepatitis C virus (HCV) Affymetrix (7000) Bigger et al., 2001
Microarray (1080) Honda et al., 2001
Microarray (23040) Okabe et al., 2001
Affymetrix (6000) lizuka et al., 2002
Dengue virus Affymetrix (22,283) Warke et al., 2003
Bunyavirus Sin Nombre virus (SNV) and non- Affymetrix (12000) Khaiboullina et al., 2004
pathogenic Prospect Hill virus
(PHV)
dsDNA-RT Hcpadnavirus Hepatitis B virus (HBV) Microarray (1080) Honda et al., 2001
virus Microarray (23040) Okabe etal.,2001
Microarray (2208) Wu et al., 2001a
Membrane (12393) Xu et al., 2001
Affymetrix (6000) lizuka et al., 2002
ssRNA-RT Retrovirus HIV-1 Microarray (1506) Geiss et al., 2000
virus Affymetrix (6800) Corbeil et al., 2001
Membrance (1176) Gibellini et al., 2002
Human T-cell 
(HTLV-l) 
Human foamy 
SFVcpz(hu))
leukaemia virus-1
virus (HFV or
Membrane ( 10000) 
Membrane (588) 
Membrane (588)
* denotes the use of a microarray with only one fluorophore.
Mikovits et al., 2001 
de La Fuente et al.. 2000 
Wagner et al., 2000
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4.1.4.1 HIV and Microarrays
Several different approaches have been used in the past to study the effects of HIV on 
host cells, during infection. As HIV possesses few protein encoding genes, it must 
interact with multiple host proteins and pathways in order to facilitate it’s life cycle and 
whilst reliance on the host for processes such as transcription and translation of the 
provirus are particularly obvious, other virus-host interactions taking place during 
infection are not so intuitive. By studying host proteins incorporated into virions initial 
conclusions were made (Ott, 1997), for example the presence of HLA-antigens, 
adhesion molecules and other cell surface proteins integrated into the virion surface 
enabled a link to be forged between viral acquisition of host factors and immune 
modulation and evasion. Studying factors within HIV particles also provided clues to 
the involvement of host factors including cyclophilin (Franke, 1994, Thali et al., 1994, 
Ott et al., 1995) and ubiquitin (Ott et al., 1996) in the HIV life cycle, observations 
which prefaced some of the most recent advances in our understanding of the biology of 
retroviruses and their evolution (Kino et al., 2004, Towers et al., 2003, Sheehy et al., 
2003, Kobayashi et a l, 2004).
Numerous approaches have been used for the functional genomics analysis of the 
effects of HIV on host cells, using microarrays. These include infection with HIV 
produced from infectious molecular clones or primary isolates (van ‘t Wout et a l, 2003, 
Vahey et a l, 2002, Geiss et a l, 2000) as well as the study of HIV-1 accessory 
genes/proteins in isolation (Izmailova et a l, 2003). In the latter example it was found 
that HIV-1 infection or Tat expression induces interferon-responsive gene expression in 
immature human dendritic cells without inducing maturation. Among the induced gene 
products are chemokines that recruit activated T cells and macrophages, the ultimate 
target cells for the virus, suggesting that HIV-1 Tat reprograms host dendritic cell gene 
expression to facilitate expansion of HIV-1 infection. To address the function of the 
HIV-1 accessory protein, Vpr, cDNA microarray techniques were used to analyse the 
regulation of a panel of host cellular genes during infection with isogenic HIV-1; either 
with or without Vpr expression. Results indicate that Vpr can down regulate the 
expression of genes involved in cell cycle/proliferation regulation, DNA repair, tumour 
antigens and immune activation factors, and up regulate many ribosomal and structural 
proteins. Such information regarding the involvement of several cellular genes in HIV 
infection is thus very important, both for understanding Vpr functions and for the
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development of therapeutics targeting the Vpr molecule (Janket et a l, 2004). Cell lines 
engineered to constitutively express HIV accessory proteins including Tat and Nef have 
also revealed much about their functional interactions with the intracellular milieu 
(Shaheduzzaman et al., 2002, de la Fuente et al., 2002). In Nef expressing cell lines 
genes expressed at higher levels include proteases, transcription factors, protein kinases, 
nuclear import/export proteins, adaptor molecules and cyclins, some of which have 
previously been implicated as being important for HIV replication and pathogenesis. 
These data indicate that Nef expression can alter the expression of cellular genes and 
suggest that this alteration in cellular gene expression may serve to optimise the cell to 
support subsequent stages o f viral replication (Shaheduzzaman et al., 2002). 
Conversely most of the cellular genes in Tat expressing cells were down regulated. This 
was most apparent for cellular receptors that have intrinsic receptor tyrosine kinase 
(RTK) activity and signal transduction factors that mediate RTK function, including the 
Ras-Raf-MEK pathway (de la Fuente et al., 2002). The authors postulate that this down 
regulation of receptors may allow latent HIV-1 infected cells to either hide from the 
immune system or avoid extracellular differentiation signals. A small number o f genes 
were found to be up regulated, however, including co-receptors for HIV-1 entry, 
translation machinery, and cell cycle regulatory proteins (de la Fuente et al., 2002).
By comparing gene expression in cells both permissive and resistant to HIV infection 
(Kartvelishvili et a l, 2004), patterns have also been characterised that correlate with 
resistance. Specifically, analysis of a cell clone resistant to HIV-1 infection revealed 
that it expressed a soluble resistance factor and displayed changes in several cellular 
genes affecting HIV-1 susceptibility and expression. Among up regulated genes, three 
were linked directly to the cellular resistance to HIV-1, one being the transcription 
repressor CTCF. The remaining two are yet to be characterised.
Moving closer to the in vivo situation, a unique study published in 2004 used functional 
genomics to evaluate the effects of antiretroviral therapy on HIV-1 infection of 
lymphatic tissue (Li et al, 2004a). By studying patients both before and after treatment 
in cross section, approximately 200 treatment-responsive genes - many of them known 
mediators and moderators of immune activation and defences, particularly innate 
defence genes - were found to be expressed at all stages of HIV-1 infection. Most of the 
treatment-responsive genes were categorised as mediators of trafficking, reformation of
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active follicles and tissue repair. The authors propose a model in which nearly 
counterbalanced functions of mediators and moderators of immune activation and 
defences account for the slow dynamics of HIV-1 infection before treatment, suggesting 
that there could be a role for anti-inflammatory agents, alone or in combination with 
HAART, in treating HIV-1 infection by altering this balance to mitigate pathology. A 
similar, but much smaller study, looked at the restoration of gut associated lymphoid 
tissue (GALT) after onset o f HAART (Guadalupe et al., 2003). An increase in 
expression of genes associated with cell trafficking was observed (supported by other 
experimental data) demonstrating that lymphocyte homing plays an important role in the 
restoration of intestinal CD4+ T cells in GALT following HAART. An additional in 
vivo study looked at latently infected, resting CD4+ T-cells of HIV positive individuals 
(Chun et a l, 2003) during phases of viraemia and aviraemia. It was found that these 
cells, from viraemic patients, are capable of producing cell-free virus spontaneously ex 
vivo, whereas those from aviraemic patients (despite evidence for transcription of RNA) 
did not. Expression profiling of these resting T-cells from viraemic patients revealed 
specific and significant up regulation o f genes involved in transcription regulation, 
RNA processing and modification, protein trafficking and vesicle transport, suggesting 
that active viral replication has a profound effect on the physiologic state o f resting 
CD4+ T-cells, ultimately resulting in the release of HIV without exogenous stimuli. 
Finally, animal models have also been used to further understand the pathogenesis of 
neuro-AIDS (Roberts et al., 2003) and thymic disruption (Miller et al., 2003).
To date, however, no microarray studies have addressed the effects of different genetic 
variants of HIV on host cell gene expression. As described in earlier chapters, the full 
range of HIV genetic variants are of clinical significance in that they play a role in the 
HIV-1 epidemic. Furthermore, HIV isolates representing the considerable genetic 
variation within HIV-1 have quite different growth characteristics on the same T-cell 
substrate. The hypothesis may therefore be put that these differences might be further 
explained by identifying differences in the host cell transcriptome during infection with 
different strains of HIV-1. Differential modulation of host gene expression may provide 
evidence in support of the published differences in pathogenicity, disease progression or 
transmissibility of different viral subtypes, groups or at the furthest ends of the 
spectrum, between HIV-1 and HIV-2. Microarray profiling of cells infected with 
different HIV-1 subtypes and HIV-2 may also identify a ‘core’ HIV response program.
189
molecular mechanism of pathogenesis of the related yet quite distinct hantaviruses Sin 
Nombre and Prospect Hill (Khaiboullina et a l, 2004). Finally, array based comparisons 
of hepatitis B and C viruses have revealed the mechanisms by which these very 
different viruses cause the same clinical endpoint, hepatocellular carcinoma (HCC). 
Characterisation of these distinct mechanisms potentially provides a novel tool for 
diagnosis and treatment of HBV- and HCV-associated HCCs (Okabe et a l, 2001, lizuka 
etal., 2002).
In the case of HIV, however, such array-based studies comparing genetic variants of the 
same viral species in an attempt to explain their phenotypic differences have not been 
undertaken. This is perhaps not surprising, as it is widely believed that the 
heterogenous distribution of different HIV-1 subtypes may not be due to any inherent 
properties of the viral strains themselves but rather the chance results of founder effect 
where one or more subtypes are introduced and consequently established in a 
population before other subtypes. These subtypes have subsequently been classified by 
modem phylogenetic techniques (Robertson et al., 2000). No large scale, accurate 
subtyping, however, has been carried out on infected populations in order to facilitate 
ongoing epidemiological studies of the relationship between HIV subtype and disease 
(Chapter 2). Because the subtype classification of HIV isolates has not come about as a 
result o f detectable, specific biological or phenotypic characteristics, it follows that 
functional genomics has not been immediately exploited to further understand the 
importance of HIV subtypes. Epidemiological evidence, in vitro studies and the 
observations described in this thesis, however, have suggested that there may be 
differences between biological properties of different HIV genotypes. Microarray 
studies might therefore be of use in trying to understand the impact of HIV sequence 
variation on viral and therefore perhaps disease phenotype.
4.1.5 Using functional genomics in the study of HIV subtypes
The following experiments describe the effect of HIV-1 subtype B, HIV-1 group O and 
HIV-2 on the transcriptional profiles of the CD4+ T-cell line ST1-R5. In chapter 2 the 
growth characteristics of these viruses was established on different T-cell lines and 
these isolates provide what are perhaps the ends of the spectrum of terms of growth 
phenotype. The inclusion of HIV-2 is also pertinent, as clear differences between HIV-
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2 and HIV-1 have been shown, both in terms of disease characteristics and their direct 
effect on cells in vitro.
4.1.5.1 HIV infection o f  T-cells
The first high-density microarray studies o f HIV infection of T-cells described the 
transcriptional effects o f low multiplicity HIV-1 LAI infection on the CD4+ T-cell line 
CEM-CCRF (Geiss et al., 2000) and human PBMCs (Vahey et al., 2002), in time 
course assays. These studies revealed that multiple genes could be identified that were 
specifically and consistently up and down regulated during HIV infection. The results 
of both studies, however, are difficult to interpret. Both infection at low multiplicity 
(leading to an asynchronous infection) (Geiss et al., 2000) and studying a heterogenous 
PBMC target cell population (Vahey et al., 200) whilst examining cellular gene 
expression 2-3 days post-infection can lead to confounding changes in gene expression 
over time.
More recently these concerns were addressed by the use of high titre virus to infect 
various CD4+ T-cell lines, monitoring the level of >4600 cellular RNA transcripts 
within 24 hours of infection (van ‘t Wout et al., 2003). A total o f 409 of 4608 genes 
were significantly regulated at one or more time points post-infection: 165 had 
increased and 244 had decreased levels of stable RNA expression. Overall levels of 
signalling and activation were found to be increased, including several genes involved 
in cell activation, signalling and communication that were up regulated within 1-8 hours 
post infection, prior to detection of significant virus replication. This observation was 
also made in cells infected at a lower MOI (Geiss et al., 2000, Vahey et al., 2002) or 
when exposed to HIV-1 Nef (Simmons et al., 2001). In addition infected cells had 
decreased levels of proliferation, reflected in a decrease in the expression of cell cycle 
inducers and an increase in expression of repressors. This was proposed to reflect the 
cell-cycle G2 arrest generated by HIV-1 in response to viral Vpr (Planelles et a l, 1996). 
Genes involved in cell division and transcription, a family of DEAD box protein RNA 
helicases, and genes involved with translation and RNA splicing were mainly down 
regulated. A small group of transcription factors including EGR-1 and JUN, however, 
were up regulated, alluding to a specific role o f these in increasing HIV-1 production. 
Finally, a series of enzymes involved in cholesterol biosynthesis, regulated by the sterol
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responsive element binding protein 2 (SREPB2), were up regulated in all cell lines 
studied (van ‘t Wout et al., 2003).
In this seminal study, it was found that transcriptional changes induced by HIV-1 were 
most pronounced at 24 hours post-infection. At this stage regulation differences were 
also evident between different cell types studied, prompting the suggestion that studying 
host-cell responses in different target cells (i.e. both permissive and non-permissive) 
might provide an opportunity to identify host proteins essential for HIV-1 replication 
(van ‘t Wout et a l ,  2003).
Given the findings of previous microarray experiments looking at HIV infection of T- 
cells, it was decided that a similar approach should be taken in that infection o f T-cells 
with HIV-1 subtype B, group O and HIV-2 should be carried out at a high multiplicity 
and gene expression should be analysed within 24 hours of infection. As described in 
Chapter 2, the infectious titre of the primary isolate stocks (as determined by NP2 cell 
titration) is low compared to that which can be achieved with cell line adapted viruses 
or molecular clones. To achieve the desired high multiplicity of infection a small 
number of cells must therefore be infected. When RNA is limiting in microarray 
experiments, an amplification step to generate sufficient RNA/cDNA for use with a 
standard labelling method may be used. Furthermore, with very small cell numbers, 
extracting mRNA prior to amplification also becomes problematic and requires careful 
optimisation.
4.1.5.2 RNA amp I ijication
Amplification of RNA was developed and used in gene expression analysis long before 
the advent of microarray technology (Van Gelder et a l, 1990). This involved reverse 
transcription of mRNA with an oligo dT/T7 promoter primer, followed by synthesis of 
double stranded cDNA, antisense RNA then transcribed in vitro using T7 polymerase 
generally resulting in a 1000-fold amplification of the original amount. Unlike PCR 
amplification this method was found to be linear and not biased by the size of the 
template (under optimal conditions). It is the case that the majority of amplification 
methods used today in microarray experiments are based on this methodology, and 
many publications have addressed the question of reproducibility of different 
amplification methods and attempted to quantify the bias introduced to the data by the
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RNA amplification process. The main conclusions from such work are that, although 
amplification methods introduce slight changes in the transcript ratios compared to 
standard labelling, they are highly reproducible and, for small sample size, in vitro 
transcription is the preferred method. Different labelling strategies, however, should 
not be used within a single study, and all samples should be equally treated (Gomes et 
al., 2003, Jenson et al., 2003, Schneider et al., 2004, Wilson et al., 2004). This 
includes the length of time the RNA is amplified for, as time-dependent degradation of 
aRNA has been observed with amplifications exceeding 4 hours (Spiess et al., 2003). 
Thus, there are certain “quality vs. yield” issues inherent in T7-based RNA 
amplification. It has also been proposed that there should be a general standardisation 
of the RT reaction for small-sample profiling with regard to the Minimal Information 
about a Microarray Experiment (MIAME) requirements (Kenzelmann et al., 2004). A 
recent report that total RNA, mRNA and aRNA can all be used in expression profiling 
analysis as long as the test and reference samples are generated by identical method 
within single study is also important to note. That is, if using amplified RNA the 
reference must also be amplified (Li et al., 2004b).
4.1.6 Aims
The aim of this chapter is to use cDNA microarrays to determine whether genetically 
distinct strains of HIV result in differing modulation of host transcription, during the 
first 24 hours of infection. The consequences of this in terms of viral phenotype, 
disease phenotype, biomarkers of disease and identification of potential novel 
therapeutic targets will be discussed.
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4.2 Methods
4.2.1 Cell and viruses
The viruses used were those previously characterised (see Chapter 3): HIV-1 subtype B 
(SF162), HIV-1 group O (BCF06) and HIV-2 (ETP). The cell line used for these 
experiments was ST1-R5 (mycoplasma free), which had been previously used to study 
these isolates. The ST1-R5 cells were maintained in RPMI 1640-2 mM L-glutamine 
medium, supplemented with 10% FBS, 100 U/ml penicillin, 100 pg/ml streptomycin 
and 1 pg of puromycin/ml.
4.2.2 Reference RNA
For optimising and assessing RNA amplification methods, RNA was extracted from 
large numbers of ST1-R5 cells.
4.2.2.1 RNA extraction
106 ST1-R5 cells were centrifuged in individual 15 ml centrifuge tubes, resuspended in 
1.0 ml TRIZOL (Gibco) and stored at -80°C. For extraction, frozen lysates were 
thawed at 37°C and centrifuged at 12,000 xg for 10 minutes at 4°C. Following 
incubation at room temperature (RT) for 5 minutes, 250 pi chloroform was added and 
the tube shaken for 15 seconds, incubated for a further 3 minutes at RT then centrifuged 
at 12,000 xg for 15 minutes (4°C). The aqueous phase was transferred to a new tube 
containing 625 pi chloroform and shaken for 15 seconds, incubated at RT for 3 minutes, 
then centrifuged at 12,000 xg for 15 minutes (4°C) and the aqueous phase transferred to 
a new tube. 625 pi isopropanol was added, the tube vortexed and incubated at RT for 
10 minutes, followed by centrifugation at 12,000 xg for 15 minutes (4°C). The pellet 
was washed in 1ml 75% ethanol and air-dried at RT for 5 minutes before re-suspending 
in 50pl RNase-free water.
4.2.2.2 DNasel treatment and purification o f  RNA
After RNA extraction, the samples were treated with DNasel (Promega) in a final 
volume of 200 pi, at 37°C for 1 hour (h), after which terminator solution was added 
(1/10th total volume) (0.1 M EDTA, 1 pg/pl glycogen) to stop the reaction. An equal 
volume of phenol:chloroform:isoamyl alcohol (Sigma) was added to the DNase treated 
RNA, vortexed for 10 seconds then centrifuged at 13,000 rpm for 10 minutes at RT.
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The top aqueous layer was transferred to a new tube and phenolrchloroform extraction 
was repeated. The RNA was precipitated using 1/5th volume 8 M ammonium acetate and
2.5 volumes 95% ethanol at -20°C for 2 h, then centrifuged at 14,000 rpm for 30 
minutes (4°C) to pellet. The RNA was washed with 200 pi of ice-cold 80% ethanol and 
air dried for 5 minutes, prior to re-suspension in 30 pi DEPC-water and immediate 
storage at -80°C.
4.2.2.3 mRNA extraction
Two methods of mRNA extraction were used from total RNA extracts or cell lysates: 
Oligotex mRNA mini kit (Qiagen) and Dynal Dynabeads (Dynal Biotech, Sweden). 
The reaction mixtures were adjusted according to the total amount of RNA that had 
been extracted and manufacturer’s protocol followed. In short the oligotex protocol 
relies upon the selective binding of poly-A mRNA to beads coated with oligo-dT 
oligomers. The method involves several wash steps using a column and filter system, 
the mRNA eventually eluted from beads requiring subsequent concentration, achieved 
using a Microcon-30 filter in a Microcon 1.5ml tube (Millipore). Similarly, the Dynal 
beads system relies upon the oligo-dT binding capacity of mRNA, in this case however 
the coated beads are magnetic and can be drawn out of solution using a magnet. After 
washing steps, the mRNA may be eluted from the beads into as small a volume as 
desired. Consequently, mRNA concentration is not necessary. For both methods RNA 
was eluted into RNase free DEPC-water and immediately stored at -80°C.
4.2.2.4 RNA quantitation
Both total RNA (TRNA) and mRNA were quantified using an Agilent Bioanalyser, 
which detects RNA by laser-induced fluorescence. Specifically, each Nano-LabChip® 
contains an interconnected set of microchannels that separates nucleic acid fragments 
based on their size as they are driven through it electrophoretically. Each chip is 
prepared by addition of a gel-dye mix followed by individual RNA samples (up to 12 
per chip) to each well. RNA ladder and marker (RNA 6000 ladder, Ambion, USA) are 
added to separate wells. During the chip run, the dye intercalates directly with the RNA 
and all bands pass the detector at different speeds. The software automatically 
compares the unknown samples to the ladder fragments to determine the concentration 
of the unknown samples
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Figure 4.1 R epresentative b ioanalyser traces.
(A) good quality TRNA; (B) degraded  TRNA and (C) good quality mRNA (source: 
http://www.agilent.com).
hravih degraded 2XS peakstrong IX S  & 2 8 S  rihosomal p e a k s broad distribution, little IXS or 2XS
and to identify the ribosomal RNA peaks. The ladder also serves as a built-in quality 
control measurement of system performance under standard conditions. Resulting, 
therefore, is an assessment of both quality and quantity of RNA (see Figure 4.1 for 
example bioanalyser output) (Naderi et a l, 2004). The RNA 6000 Nano LabChip Kit 
was used, as samples analysed were all expected to be in the range of this assay (5-500 
ng/pl for TRNA and 25-250 ng/pl for mRNA/aRNA). All reagents were allowed to 
warm to RT for 30 minutes and RNA ladder was denatured at 65°C for 4 minutes then 
held at 4°C, prior to use.
4.2.3 RNA amplification
Ways to both extract and amplify RNA were investigated, in order to determine the 
optimal conditions for preparing mRNA for microarray analysis.
4.2.3.1 In vitro amplification o f RNA - In house
A  T7-based method of RNA amplification was previously developed in our laboratory. 
It is a modified Eberwine method (Van Gelder et al., 1990) and was used to amplify 
from ST1-R5 TRNA (extracted using Trizol). The following were mixed in a 0.5 ml 
PCR reaction tube:
Reagent Volume (pi)
Total R N A (lpg) kT ”
QligodT-T7 primer (0.5 pg/pl) 1_____________
OHgodT(21)-T7 primer: 5' TCT AGT CGA CGG CCA GTG AAT TGT AAT ACG ACT CAC TAT 
AGG GCG T(21) 3' [56-mer]
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These were placed at 70°C for 10 minutes, chilled on ice followed by incubation at 
42°C for 5 minutes. The first strand master mixed was prepared according to the
following table:
Reagent Volume (pi)
5x first strand buffer (Gibco BRL) 4
0.1 DTT (Gibco BRL) 2
10 mM dNTP mix 1
RNasin (Promega) 1
Superscript RT 11 (Gibco BRL) 1
The mastermix was added to the samples and incubated at 42°C for 1 h. lp l was 
removed for PCR (see table below) to check whether intact RNA was successfully 
obtained.
Reagent___________________________________ Volume (pi)
ss cDNA 1
lOx PCR buffer (Qiagen) 5
10 mM dNTPs (Promega ) 1
Forward primer (100 ng/pl) 2
Reverse primer (100 ng/pl) 2
Taq DNA polymerase (5 U) (Qiagen) 0.5
Sterile water 38.5 ___
The second strand master mix was subsequently prepared:
Reagent___________________________________ Volume (pi)
Second strand synthesis buffer (Gibco BRL) 30 
10 mM dNTPs 3
DNA poll (Gibco BRL) 4
E. Coli RnaseH (Gibco BRL) 1
E. Coli DNA ligase (Gibco BRL) 1
DEPC water 92
The master mix was added to the remainder (19 pi) of the first strand reaction and 
incubated at 16°C for 2 h. 2 pi of T4 DNA polymerase (Gibco) were added and 
samples incubated for a further 10 minutes at 16°C. The samples were extracted once 
with phenol/chloroform/isoamyl alcohol (25:24:1) (Sigma) and the aqueous layer was 
collected and purified using a pre-rinsed Microcon-100 column (Millipore) according to 
manufacturer’s instructions. If necessary, the sample volume was reduced to 8 pi by 
vacuum centrifugation.
The Ampliscribe T7 transcription kit (Cambio) was used for in vitro transcription. 
Specifically, the transcription mix was prepared adding the reagents in the following 
order:
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Reagent Volume (pi)
1 Ox Amp T7 buffer 2
ATP 1.5
CTP 1.5
GTP 1.5
UTP 1.5
0.1 M DTT 2
These were added to the 8 pi o f ds cDNA along with 2 pi of T7 RNA polymerase and 
incubated at 42°C for 3 h. 1 pi of RNase-free DNase was added and reaction placed at 
37°C for 15 minutes. The aRNA was purified as before and stored at -80°C. Quality 
was assessed using an RNA 6000 Nano LabChip Kit.
4.2.3.2 In vitro amplification o f  RNA — RiboAmp RNA Amplication kit 
The second RNA amplification protocol used was also a T7-based method, but with 
inclusion of an internal primer for amplification from both ends of synthesised cDNAs 
(RiboAmp RNA amplification kit, Arcturus, UK). Unlike the in-house method for 
amplification, this protocol is optimised for amplification of very small amounts of 
RNA and is designed to be used with the Picopure RNA Isolation Kit (Arcturus, UK), 
which isolates TRNA, prior to amplification. Both methods were followed as per 
manufacturer’s instructions. The effect of using Dynal Dynabeads to extract mRNA 
from cells prior to RiboAmp amplification was also assessed, as was using different 
starting cell numbers (from which RNA was extracted). RNA quality was assessed 
using an RNA 6000 Nano LabChip Kit.
4.2.3.3 PCR screening o f  cDNA fo r GapDH
To assess the efficiency of cDNA synthesis following RNA extraction by different
methods (prior to amplification), cDNA was screened for presence of glyceraldehyde-3-
phosphate dehydrogenase (GapDH). This is a cellular gene whose expression is
generally maintained at a detectable level throughout the life of a cell, therefore
providing a good positive control. The constituents of each reaction were:
Reagent______________________Volume (pi)
DNA (approx. 50 ng) 2
Primers (10 pMol/pl) 1 each
PCR buffer (1 Ox) 5
MgCl2(25mM ) 4
dNTPs (10 mM) 1
Taq DNA polymerase (5 U/pl) 0.25 
Distilled water 35.75
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Cycling conditions were as in section 3.2.7.1. PCR products were separated on a 1% 
w/v agarose gel in lx TBE containing 0.2 pg/ml ethidium bromide (Sigma, UK) at 80V.
4.2.4 Time courses
Cells were infected at an MOI o f 1.0, the multiplicity calculated as the ratio of 
infectious units (as defined using NP2 cell titration) to cell number. Specifically, for 
each infection 104 cells per time point were incubated with the appropriate volume of 
virus at 37°C for 3 h. The volume was equalised for each infection. Cells were then 
centrifuged to pellet and washed once in medium prior to addition to a 96 well plate 
(104 cells per well), and incubation at 37°C. Two time courses were carried out, one 
during which samples were harvested at 0 and 24 hours post-infection (HPI) and a 
second where 0, 2, 6, 12 and 24 HPI were sampled. Each time point was performed in 
triplicate. Given prior investigation, the Picopure total RNA isolation kit was used to 
extract RNA from samples and mRNA was subsequently amplified using the RiboAmp 
RNA amplification kit. Success o f amplification was determined using an RNA 6000 
Nano LabChip Kit.
4.2.5 Labelling
A direct incorporation method (CyScribe First-Strand cDNA Labelling Kit) was used 
(Amersham Biosciences, GE Healthcare). Specifically, the following reagents were 
added to 1 pg of amplified RNA, 500 ng of mRNA or 10 pg TRNA in a 0.5 ml PCR 
tube on ice: 1 pi random nonamers (for aRNA), 1 pi anchored oligo(dT) (for mRNA or 
TRNA) and water to a final volume of 11 pi. The reaction mixture was incubated at 
70°C for 5 minutes followed by incubation at RT for 10 minutes. Subsequently, 4 pi 5x 
CyScript buffer, 2 pi 0.1 M DTT, 1 pi dCTP nucleotide mix, 1 pi dCTP CyDye-labelled 
nucleotide and 1 pi CyScript reverse transcriptase were added to the reaction mixtures. 
These were centrifuged at 13,000 rpm at RT for 30 seconds and then incubated at 42°C 
for 1.5 h. On all occasions reference RNA was labelled with Cy3 labelled nucleotide 
and sample with Cy5. The RNA was then denatured by addition of 2.5 pi 0.5 M EDTA 
(pH 8.0) and 10 pi 0.1 M NaOH and incubated at 70°C for 10 minutes, the reaction 
neutralised by addition of 10 pi 0.1 M HC1, 3 pi CoT-1 DNA (Gibco), and 450 pi TE
200
(pH 8.0). Labelled RNA was purified using a Microcon-100 filter and reduced to 12 pi. 
The labelled RNA was immediately prepared for hybridisation.
4.2.6 Hybridisation
The Cy3 and Cy5 labelled probes were made up to 14 pi with TE (pH 8.0) and the 
hybridisation mixtures prepared follows: 12 pi 20x SSPE (Sigma), 1.1 pi 0.5 M EDTA, 
2 pi poly (IA40-60 (Pharmacia), 2 pi yeast tRNA (Sigma), 14 pi Cy3 probe, 14 pi Cy5 
probe, and finally 1 pi 10% SDS. The mixture was vortexed and incubated at 98°C for 2 
minutes followed by 37°C for 20 minutes. Subsequently lp l lOOx Denhardt’s solution 
(Sigma) was added to the probe mixture and the mix centrifuged at 13,000 rpm for 15 
minutes at RT. The human cDNA Gen2 arrays (Hs_clone_Av2, MRC-HGMP, UK) 
were transferred to hybridisation chambers, pre-heated to 65 °C, and allowed to warm 
for 30 minutes. Glass cover slips were cleaned by immersion in 95% ethanol for 2 
minutes and centrifugation at 1000 rpm for 2 minutes to dry. The probe (46 pi) was 
applied to the array by adding it to the glass coverslip, this was then applied to the pre­
warmed array by gently lowering the array over the coverslip until capillary action 
adhered the two together and distributed the probe, with no need for application of 
pressure. The array was placed back into the hybridisation chamber and 150 pi 4x 
SSPE (65°C) added, the chamber lid was firmly secured and the assembly transferred to 
a 65°C water bath and incubated for 16 h.
After incubation the hybridisation chamber was dismantled at 65°C and the array 
carefully removed and immersed in 2x SSPE heated to 50°C. Once the coverslip had 
dissociated the array was immersed in fresh 2x SSPE for 2 minutes at RT (rolling), 
followed by lx SSPE for 2 minutes and O.lx SSPE for 3 minutes. Subsequently, the 
array was transferring it to a clean 50 ml Falcon tube and centrifuged at 1,000 rpm for 2 
minutes to dry.
4.2.7 A rray scanning
Arrays were scanned at 10 pm resolution using the GenePix 4000B array scanner (Axon 
instruments, Molecular Dynamics) and the images analysed using GenePix Pro 3.0 
software. Cy3 and Cy5 fluorophores were simultaneously excited at 532 nm and 635 
nm respectively and the resultant light detected with two PMTs. The voltages across the
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PMTs were adjusted so that the signals from the two array channels were balanced. The 
GenePix software combines the data from the two channels to create a single composite 
image. A template was fitted over the array image using a spot-finding software 
algorithm. All the elements on each array were checked by eye and manually corrected 
where necessary. Data were extracted from the image by the software using the adjusted 
template and the normalisation factor (average ratio between signals in the Cy3 and Cy5 
channels) calculated automatically by the GenePix software. Expression ratios were 
calculated as the median of the ratios between the local background-subtracted Cy3 and 
Cy5 signals on a pixel-by-pixel basis by the software. The data were exported to a 
spreadsheet created in Excel, ArrayAnalyser. The median of ratios were filtered to 
remove flagged array elements and elements for which the signal to background ratio 
was below that calculated as the average for negative control elements included on the 
array, in both Cy5 and Cy3 channels.
4.2.8 Array analysis
4.2.8.1 Cluster and treeview
The final array data were analysed using Cluster software (Eisen et al., 1998). The 
program Cluster assembles a set of elements (genes or arrays) into a tree, where 
elements are joined by tree branches whose length is proportional to the distance 
(correlation coefficient) between the elements. Array elements for which expression 
measurements failed the signal to noise ratio filter were removed and the data converted 
to log(2). The arrays and genes were then median centred (the median expression ratio 
within each array or of each array element across all arrays was set to 0). Genes and/or 
arrays were clustered by average-linkage hierarchical clustering and a self-organising 
map algorithm applied, in order to direct the orientation of nodes generated by 
hierarchical clustering. The results were visualised using the software Treeview.
4.2.8.2 Significance analysis o f microarrays
SAM (Significance Analysis of Microarrays) is a statistical technique for finding 
significantly differently expressed genes in a set of microarray experiments (Tusher et 
al., 2001) and functions as a software package (written by B. Narasimhan) for Excel. 
The input to SAM is a gene expression matrix from a set of microarray experiments, as 
well as a response variable from each experiment. In the case of these experiments, the
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response variable is infected at time X vs. infected at time Y, or infected with virus X 
vs. infected with virus Y. By inputting normalised log2 ratios (>4 replicates for each 
array/response variable) SAM identifies genes with statistically significant changes in 
expression by assimilating a set of gene-specific T-tests. Each gene is assigned a score 
on the basis of its change in gene expression relative to the standard deviation of 
repeated measurements for that gene. Genes with scores greater than a threshold are 
deemed differentially expressed. The percentage of such genes identified by chance is 
calculated by a false discovery rate (FDR). To estimate the FDR, genes are randomly 
permuted in a form of bootstrapping. The FDR threshold can be adjusted to identify 
smaller or larger sets of genes. The FDR for these experiments was selected as 5%.
4.2.8.3 Gene A nnotation
Genes were annotated using DAVID (Database for Annotation, Visualization and 
Integrated Discovery, http://appsl .niaid.nih.gov/david/). By inputting a list of accession 
numbers Gene Ontology (GO) pathways were produced, which provide a unique 
identifier for each gene annotated for a cellular process or function within GO. Genes 
were then matched to the KEGG (Kyoto Encyclopedia of Genes and Genomes) 
description of known cellular pathways.
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4.3 Results
In order to perform microarray studies on HIV infection of T-cells, a small number of 
cells were infected at an MOI of 1.0, with HIV-1 subtype B, group O and HIV-2 ETP. 
Accordingly a number of protocols had to be performed and optimised, including 
extraction of RNA, synthesis o f reference RNA, analysis of amplification 
methodologies and optimisation o f time course strategies, prior to the microarray 
experiments themselves.
4.3.1 RNA extraction and quality
43.1.1 RNA extraction and amplification
Although a variety of methods have been developed for the extraction and purification 
of RNA, prior to amplification or labeling for microarray analysis, there have been few 
systematic evaluations to optimise these methods. A recent publication went some way 
to address this problem by experimentally determining the best method for each step of 
RNA extraction with respect to yield, purity and size distribution of the transcripts. In 
short, DNase treatment of diluted total RNA samples followed by phenol extraction is 
the optimal way to remove genomic DNA contamination. Purification of double 
stranded cDNA is best achieved by phenol extraction followed by isopropanol 
precipitation at room temperature. Extraction with guanidinium-phenol and lithium 
chloride precipitation are the optimal methods for purification of amplified RNA 
(aRNA) and labelled aRNA respectively (Naderi et al., 2004). Whilst demonstrating 
the importance of an optimised RNA extraction protocol, this study did not address how 
best to extract RNA from small sample sizes. This problem has to a large extent been 
overcome by the commercial development of several RNA extraction methods designed 
for samples as small as a single cell. These methods usually take two forms in that they 
either enable extraction of total RNA (TRNA) (usually using membrane/filter 
technologies) or mRNA (relying on poly-dT coated resin and filtration, or magnetic 
beads). How three of these different methods affect RNA quality, the most critical 
factor for microarray success, was assessed here. The methods are Trizol extraction, 
Dynal Dynabeads (mRNA, Dynal) and Oligotex (mRNA, Qiagen).
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Specifically, the three RNA extraction methodologies were tested on 103 and 104 
SupTl-R5 (ST1-R5) cells in order to assess their efficiency for processing small sample 
sizes. Extractions were performed as described and the efficiency of extraction assessed 
by performing cDNA synthesis on extracted RNA followed by PCR screening for 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Results showed that RNA 
could not be effectively isolated from 103 cells by any method, as GAPDH could not be 
detected in cDNA synthesised from extracted TRNA (using Trizol) or mRNA 
(Dynabeads and Oligotex). Using 104 cells, however, GAPDH was clearly detectable in 
cDNA synthesised from Oligotex- and Dynabeads-extracted mRNA, but not from 
Trizol extracted TRNA, implying 104 cells is a reasonable number to use if the former 
two methods are to be employed (Figure 4.2-A). To extend this analysis, 2 rounds of 
amplification were performed from the extracted mRNA using an in-house modified 
Eberwine protocol previously validated. These data indicate that, after extracting RNA 
from 104 cells using both Oligotex and Dynabeads, efficient amplification can be 
achieved (Figure 4.2-B), and that the aRNA yield is higher when amplifying from 
mRNA extracted with Dynabeads. After extraction of TRNA from 104 cells using 
Trizol, however, no amplification was possible. Taken together, these data indicate that 
o f the three methods, Trizol should not be used for extracting RNA from small samples 
prior to amplification and, whilst Dynabeads and Oligotex give reasonable results from 
104 cells, they cannot be used to successfully extract mRNA (in order to synthesise 
cDNA) from 103 ST1-R5 cells.
An additional observation, with respect to the quality of amplified RNA (Figure 4.2-B 
(i) and (ii)) is that, irrespective of the RNA extraction method, the majority of aRNA 
produced is very short in length; ranging from 80 -  90 nucleotides. It has previously 
been reported that the size distribution of aRNA is strongly dependent on quantity of 
input RNA. For example, when the RNA input is below 50 ng of mRNA or 100 ng of 
TRNA, the average size of the aRNA after one round of Eberwine amplification is less 
than 200 nucleotides (Li et a l, 2003), in accordance with the results produced here. 
Current advances in amplification technology, however, mean that several techniques 
now exist that do not reduce aRNA length to this extent.
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Figure 4.2 Evaluation of extraction and amplification methods.
Analysis of the efficiency of:
(A) reverse transcription and GapDH amplification 
from 103 or 104 ST1-R5 cells, and (B) result of two 
rounds of amplification of RNA, extracted by three 
different methods (i) Oligotex; (ii) Dynabeads; (iii) 
Trizol, from 104ST1-R5 cells.
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It was therefore decided that an alternative amplification method should be optimised, 
working from 104 cells with the aim of improving the quality of aRNA produced. As 
both Oligotex and Dynabeads gave similar results in terms of efficiency of extraction 
and subsequent amplification, it was decided that both methods would be used to 
produce mRNA reference, and a substrate on which amplification methods could be 
tested, the aim being to select the best combination of RNA extraction method and 
amplification procedure.
4.3.1.2 Synthesis o f reference RNA
TRNA was extracted from 106 ST1-R5 T-cells to both provide a control for validation 
of amplification techniques using microarrays, and from which to extract mRNA (for 
amplification). This was achieved using a Trizol extraction method followed by mRNA 
extraction using either Oligotex or Dynabeads, in the latter two cases 90 pg of TRNA 
used for extraction of mRNA. The quality and quantity of isolated RNA was assessed 
using an Agilent bioanalyser (Figure 4.3).
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Figure 4.3 B ioanalyser traces of ST1-R5 TRNA and mRNA.
Representative bioanalyser traces for: (A) TRNA, extracted using Trizol from 106 cells, in a final 
volume of 100 pi; (B) mRNA, extracted from 90 pg TRNA using dynabeads in a final volume of 
40 pi; (C) mRNA, extracted from 90 pg TRNA using oligotex in a final volume of 40 pi.
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Extraction of TRNA using the Trizol method was effective and yielded RNA, with no 
observable DNA contamination and no degradation (Figure 4.3-A). mRNA extraction 
was achieved using two separate methods, both of which yielded mRNA of 
approximately the same quality and concentration (Figure 4.3-B and C). Assuming that 
approximately 2% of the TRNA used for these extractions should be mRNA 
(http://www.ambion.com/techlib/tn/93/9313.html) the yield achieved was acceptable.
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That is, in total 1640 to 1960 ng o f mRNA was extracted from 90 pg TRNA, 
approximately 1.8 -  2.2 %.
4.3.J.3 Validation o f  RNA amplification
Whilst amplification was successfully achieved from mRNA extracted from 104 cells, 
as described, the sizes of the amplified RNA molecules were poor compared to other 
published amplification methods (Figure 4.2). An alternative amplification method was 
therefore used, namely RiboAmp RNA amplification (Arcturus) that has been designed 
for molecular analysis on RNA samples which previously were too small for microarray 
analysis. Specifically, this method enables linear amplification from 1 ng of TRNA and 
has a “patent-pending” T7 based linear amplification method, which is distinct in its use 
of exogenous primers during the second strand synthesis step, which are optimised to 
provide a representative aRNA population with consistent length. Prior to commencing 
a large-scale gene expression study we assessed the length and quality of RNA 
amplified using this method, by comparing the resulting aRNA to the TRNA and 
mRNA generated previously (section 4.3.1.2), using microarrays. Specifically, six 
microarrays were hybridised with samples derived from ST1-R5 TRNA in the 
combinations shown in Table 4.2. All amplifications were performed using RNA 
extracted from 104 cells. The aim was to determine firstly, whether the labelling and 
hybridisation protocol was effective; secondly, that the profile of mRNAs within TRNA 
were faithfully reproduced when the RNA was amplified; and thirdly whether it is best 
to amplify from mRNA, extracted from TRNA prior to amplification (using 
Dynabeads), or from TRNA, produced directly from a small number o f cells. In the 
latter case a method designed for extraction of TRNA from small sample sizes was used 
(Picopure RNA isolation kit, Arcturus). Results are shown in Figure 4.4.
Table 4.2 Table of microarrays performed to assess RNA extraction and amplification 
methodologies.
Cy3
vs
Cy5
ST1-R5 TRNA 
ST 1-R5 mRNA (dynabeads) 
ST1-R5 mRNA (oligotex) 
ST1-R5 mRNA (dynabeads) 
ST1-R5 mRNA (oligotex) 
ST1-R5 aRNA (RiboAmp from TRNA)
ST1-R5 TRNA 
ST 1-R5 aRNA (RiboAmp from TRNA) 
ST1-R5 aRNA (RiboAmp from TRNA) 
ST1-R5 aRNA (RiboAmp from mRNA) 
ST1-R5 aRNA (RiboAmp from mRNA) 
ST1-R5 aRNA (RiboAmp from mRNA)
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Figure 4.4 Evaluation of the p r o c e ss  of RNA amplification and determination of  
optimal hybridisation cond itions.
(A) Schem atic of series of m icroarray hybridisations performed to determ ine optimal 
amplification protocol. (B) G raphs displaying SNR correlations for Cy5 and Cy3 channels, 
representing ST1-R5 TRNA vs. ST1-R5 TRNA; ST1-R5.R5 mRNA (dynabeads) vs. ST1-R5.R5 
aRNA (RiboAmp from TRNA); ST1-R5.R5 mRNA (oligotex) vs. ST1-R5.R5 aRNA (RiboAmp 
from TRNA); ST1-R5.R5 mRNA (dynabeads) vs. ST1-R5.R5 aRNA (RiboAmp from mRNA); 
ST1-R5.R5 mRNA (oligotex) vs. ST1-R5.R5 aRNA (RiboAmp from mRNA); and ST1-R5 aRNA 
(RiboAmp from TRNA) vs. ST1-R5 aRNA (RiboAmp from mRNA).
aRNA (from TRNA)
I
aRNA (from mRNA)
mRNA (beads)
mRNA (oligotex)
B
1. TRNA vs. TRNA 2. aRNA vs. aRNA
R=0.92R (193
3. aRNA (from TRNA) vs. mRNA (oligotex) 4. aRNA (from mRNA) vs. mRNA (oligotex)
R 0.80 R - 0.825
5. aRNA (from TRNA) vs. mRNA (beads) 6. aRNA (from mRNA) vs. mRNA (beads)
R=0.81 R=0.74
SN R  Cy5
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For each array, the data was filtered by signal to noise ratio (SNR) in each channel. 
Ideally, there would be 100% correlation between TRNA and aRNA hybridisations and 
the overall correlation coefficient would be equal to 1. The scattering of values around 
the identity line reflects the influence o f gene specific RNA amplification factors and 
experimental noise. Hybridisation of TRNA against itself gives a correlation coefficient 
of 0.93, with a tight distribution o f values around the identity line (Figure 4.4 B-l). 
This indicates that the labelling and hybridisation of these samples was effective and 
does not introduce a significant bias into the data. Hybridisation of aRNA amplified 
from mRNA (Dynabeads) with aRNA amplified from TRNA (Picopure) also gives a 
high correlation coefficient (0.92). This implies that amplification from either mRNA 
extracted from TRNA, or straight from TRNA, does not adversely influence the 
resulting hybridisation profile (Figure 4.4 B-2). In all cases, for both channels, the 
scattering of values is equally distributed on both sides of the identity line, which 
indicates an overall linear amplification (Figure 4.4 B-3-6). Correlation coefficients are 
roughly equivalent, ranging from 0.74 to 0.83, regardless of reference RNA source and 
amplification substrate. Thus, there is a good correlation between signal intensities 
resulting from non-amplified mRNA as compared to aRNA, suggesting that aRNA 
hybridisations will correspond well, although not identically, to those obtained with 
unmodified samples. This is in agreement with the literature.
Bioanalyser analysis of amplified RNA indicate that the RiboAmp method also greatly 
improves the size profile of aRNA synthesised (compared to results with the Eberwine 
method, section 4.3.1.1, Figure 4.2-B). With RiboAmp, the majority of amplified 
transcripts were 300 - 400nt in length. Furthermore, RNA amplified directly from 
TRNA, as opposed to mRNA first isolated from TRNA (using Dynabeads), showed an 
improved size range, with an increased proportion of amplified transcripts being 
between 1000 and 5000 nt. This adverse effect of the Dynabead purification step is 
perhaps due to the preferential selection o f high abundance short mRNAs by the 
Dynabeads prior to amplification. This would lead to an overall shortening of the RNA 
species represented in the amplified population. By amplifying from TRNA, however, 
all mRNA present is an amplification target and should therefore contribute to the 
amplified population (Figure 4.5).
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Figure 4.5 Com parison of the s ize  profiles of amplified RNA, generated from either 
TRNA or mRNA.
Overlayed bioanalyser traces of aRNA produced using the RiboAmp method, from TRNA 
(extracted using Picopure RNA isolated kit - g reen) and mRNA (extracted from Trizol-extracted 
TRNA using Dynal dynabeads - red). The shoulder on the green trace (to the right) indicates an 
increased abundance  of longer length aRNA transcripts in the RNA amplified from TRNA. This 
is reduced in the RNA amplified from mRNA.
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4.3.1.4 Validation o f reference RNA
Whilst mRNA was used as a control in the previous microarrays in order to assess the 
fidelity of amplification, for the arrays looking at the effect of HIV infection on host cell 
transcription an alternative reference was sought. This is because separate experiments 
become difficult to compare over time unless a common control, or reference RNA, of 
which the quality is highly controlled is used. A Universal Human Reference RNA 
(Stratagene, UHR-RNA) was selected, which is comprised of a collection of TRNA 
pooled from ten cell lines for optimal broad gene coverage. A recent report that 
described the use of aRNA in expression profiling analysis, however, outlined the 
importance of the test and reference samples being generated by an identical method: if 
using amplified RNA the reference must also be amplified (Li et al., 2004b). Hence, a 
similar set of experiments were performed for the UHR-RNA as were previously used 
to establish fidelity of amplification. UHR-RNA was amplified using the RiboAmp 
system and hybridised to arrays with un-amplified UHR-RNA. Furthermore, in order to 
establish the optimal amount of reference to label and hybridise, a range of labelled 
UHR-aRNA concentrations were hybridised (5, 2, 1 and 0.5 pg). Ideally, if the UHR- 
RNA is optimal and amplification has not biased the mRNAs represented,
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Figure 4.6 A nalysis of the fidelity of RNA am plification of UHR-RNA.
(A) Composite array im age of hybridisation of 1 pg UHR-RNA vs. amplified UHR-RNA. Uniform 
yellow colour indicates that amplification of the reference RNA is linear and that the broad 
hybridisation property of the TRNA reference h as  not been adversely affected by amplification.
(B) Correlation coefficients for hybridisation of 0.5, 1, 2, and 5 pg UHR-RNA vs. amplified UHR- 
RNA. T hese data  confirm the observation (in A) that the correlation betw een amplified and un­
amplified reference is good.
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the majority of the spots on the array should be yellow and give a strong and uniform 
signal (Figure 4.6). An example of such an array image is shown in Figure 4.6-A, 
where the majority of array elements are strongly co-hybridised. This indicates a broad 
and strong hybridisation pattern, which is preserved in aRNA. This is confirmed by 
analysis of the correlation coefficients between the signal to noise ratios for each 
channel (Figure 4.6-B). These correlations are consistently high, ranging from 0.93 to 
0.98. A hybridisation amount o f 1 pg aRNA was selected for later array experiments, as 
this condition gave a uniformly hybridised array with low background (Figure 4.6-A).
4.3.2 HIV gene expression analysis using spotted cDNA arrays
cDNA microarrays were performed in order to analyse, in triplicate, the gene expression 
profile of cultured ST1-R5 cells both at and between 0 and 24 HPI with high 
multiplicities of HIV-1 subtype B, Group O and HIV-2 ETP infection (1 ffii/cell). What 
is termed 0 HPI in this case is in fact 3 HPI, as cells were pre-incubated with virus for 3 
h prior to washing and plating in fresh medium. The final array data were filtered 
according to signal to noise ratio and clustered using Cluster software (Eisen et al, 
1998). Array elements for which expression measurements had been filtered from any 
of the arrays were removed and the data converted to log(2) prior to normalisation 
(median centring). A self-organising map algorithm was then applied, in order to 
control the orientation of nodes generated by average-linkage hierarchical clustering, 
and the results were visualised with the software Treeview (Eisen et al., 1998).
4.3.2.1 HIV induces clear changes in gene expression by 24 HPI 
The complete dataset of filtered, normalised, clustered microarray data for ST1-R5 cells 
infected with HIV-1 subtype B, group O and HIV-1 ETP and 0 and 24 HPI is shown in 
Figure 4.7. The arrays cluster appropriately; duplicate datasets (per array) representing 
three replicates of each time point i.e. B01, B02 and B03, cluster together. Group O and 
HIV-2 (ETP) cluster together at 0 HPI and 24 HPI, but subtype B forms a separate 
branch within which 0 HPI and 24 HPI branches diverge. The strongest up and down 
regulated genes, represented by red and green colouration respectively, appear to be in 
response to subtype B infection. This may reflect the different conditions in which the 
initial 3 h virus pre-incubation was performed: the differences in viral titre meant that
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Figure 4.7 Com plete im age of filtered, norm alised, clustered microarray data for S T I­
RS ce lls  infected with HIV-1 subtype B (B), group O (O) and HIV-1 ETP (E).
The dendogram  on the left of the im age rep resen ts  g en es clustered due to their similarity in 
expression level. The dendogram  along the top of the image represen ts arrays clustered 
according to their similarity to o ther arrays. It can be seen  that the arrays cluster appropriately 
in that the duplicate arrays representing th ree replicates of each  time point i.e. B01, B02 and 
B03, cluster together. Group O and HIV-2 (ETP) cluster together at 0 HPI and 24 HPI, but 
subtype B forms a sep ara te  branch within which 0 HPI and 24 HPI branches diverge. The 
strongest up and down regulated g en es , rep resen ted  by red and green colouration, 
respectively, ap p ear to be in response  to subtype B infection.
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the Group O and HIV-2 ETP infections were performed in almost neat infected cell 
supernatant, whereas in order to equalise volume the subtype B infection was performed 
in a higher concentration of fresh medium. Previous studies have shown that re- 
exposure to serum after starvation results in almost immediate changes in gene 
expression (Iyer et al, 1999). It should also be noted that, although the tree structure 
shows the correct order in terms o f grouping of viruses and time points, branch lengths 
occasionally show variation and complexity i.e. E243 (ETP 24 HPI, replicate 3), Figure 
4.7. Whilst the reasons for this are unclear, it may be that in this case infection with 
HIV-2 ETP did not take place as efficiently as in the other two replicate experiments, an 
explanation which is likely given the clustering patterns observed when all arrays were 
further analysed by re-clustering the log(2) expression data individually, for each virus 
(Figure 4.8-i, ii, iii-A). In this representation o f data, E243 clusters with E01 and E03 
(ETP 0 HPI, replicates 1 and 3) (Figure 4.8-iii-A).
Differential regulation of genes at 24 HPI, compared to 0 HPI, is also presented 
graphically by plotting paired 0 and 24 HPI log(2) transformed expression data for each 
gene in response to each virus (Figure 4.8-i, ii, iii-B). This was ordered based on the 0 
HPI data and the results confirm the observations in Figure 4.7: the response to subtype 
B infection at 24 HPI, in terms of magnitude of gene expression change, appears to be 
greater than that seen in response to HIV-1 Group O or HIV-2 infection, indicated by an 
increased range in both positive and negative log(2) expression changes (-1 to +1). The 
data for HIV-1 group O and HIV-2 ETP infection are similar in that log(2) expression 
values are within an equivalent range (-0.5 to +0.5). From this representation of 
expression data two other observations were made. Firstly, there is a trend in all 
infections in that genes that were most strongly up- or down regulated at 0 HPI seem to 
be those which become most strongly down- or up regulated at 24 HPI, indicating a 
commonality in the way in which the cells are responding to these viruses. Secondly, it 
is important to note that in the subtype B infected cells at 0 HPI there appears to be a 
much greater range in up and down regulated genes (Figure 4.8-i-B). This indicates that 
in the three infection conditions at 0 HPI the cells do not have equivalent gene 
expression profiles and in the case of subtype B gene expression levels show much 
greater variation. Whilst efforts were made to standardize the infection procedure, 
perhaps the inclusion of a 3 h incubation period prior to initiation of the time course, as
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Figure 4.8 — i. Com plete im age of filtered, norm alised, clustered microarray data for 
ST1-R5 ce lls  infected with HIV-1 subtype B.
(A) Arrays cluster appropriately, with replicates of 0 HPI and 24 HPI forming distinct clusters.
the left dendogram ). This data is illustrated in (B), a graph representing differentially regulated 
gen es at 24 HPI with subtype B HIV-1. Paired 0 and 24 HPI log2 transform ed expression data 
for each gene w as ordered based  on the 0 HPI data. The grey histogram represen ts the range 
of gene expression values of infected cells at 0 HPI, and the blue bars represen t how this is 
altered by 24 HPI.
Clear clusters of up- and down-regulation of g en es  are  apparen t (marked by coloured blocks in
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Figure 4.8 — ii. C om plete im age of filtered, norm alised, clustered microarray data for 
ST1-R5 cells  infected with HIV-1 Group O (O).
(A) Arrays cluster appropriately, with rep licates of 0 HPI and 24 HPI forming distinct clusters. 
C lear clusters of up- and down-regulation of g en es  are  apparen t (marked by coloured blocks in 
the left dendogram ). This data  is illustrated in (B), a graph representing differentially regulated 
g en es at 24 HPI with Group O HIV-1. Paired 0 and 24 HPI log2 transform ed expression data 
for each  gene w as ordered based  on the 0 HPI data. The grey histogram represents the range 
of gene expression values of infected cells at 0 HPI, and the blue bars represen t how this is 
altered by 24 HPI.
A
Figure 4.8 — iii. C om plete im age of filtered, norm alised, clustered  microarray data for 
ST1-R5 ce lls  infected  with HIV-2 ETP.
(A) Arrays cluster appropriately, with replicates of 0 HPI and 24 HPI forming distinct clusters. 
C lear clusters of up- and down-regulation of g e n e s  a re  apparen t (marked by coloured blocks in 
the left dendogram ). This data is illustrates in (B), a graph representing differentially regulated 
g en es a t 24 HPI with HIV-2 ETP. Paired 0 and 24 HPI log2 transform ed expression data for 
each  gene w as ordered based  on the 0 HPI data. The grey histogram represents the range of 
gene expression values of infected cells a t 0 HPI, and the blue bars represent how this is 
altered by 24 HPI.
described, is responsible for this. This is important to bear in mind as later statistical 
analysis may be affected by such factors.
4.3.2.2 Gene expression at 0 HPI is also variable
To further describe this variability in gene expression in response to the three different 
infecting viruses at both 0 HPI and 24 HPI, the distribution in mean log(2) expression 
values for each group of arrays was determined and descriptive statistics calculated 
(Figure 4.9-A and B). From the graph it is clear that in the case of subtype B infection, 
at 0 HPI, the variation in gene expression is much greater than in Group O or HIV-2 
infections (Figure 4.9-A). This is reflected in the statistics calculated for each 
distribution, B having approximately twice the standard deviation of O and HIV-2 
(Figure 4.9-B). At 24 HPI, however, whilst the range in gene expression values in 
response to subtype B infection is still large, the standard deviation and sample variance 
has decreased. This is indicative of an overall convergence of gene expression by 24 
HPI, creating a distribution that is more similar to the variation seen in response to 
Group O and HIV-2 infection. In the case of these two viruses little change in standard 
deviation, sample variance or range o f gene expression is observed between 0 and 24 
HPI. This implies that the response to infection is characterised by a general up 
regulation of genes expressed at a low level prior to infection, balanced by a decrease in 
genes normally more highly expressed. Hence these data reflects previous observations.
4.3.2.3 Genes are significantly regulated at 24 HPI in response to all viruses 
Differentially expressed genes were identified using SAM with the two-class paired 
response setting, 100 permutations, and a false discovery rate of less than 5%. Due to 
the differences between the 0 HPI samples from HIV-1 subtype B infection, compared 
to group O and HIV-2 ETP, the 0 HPI samples were not amalgamated - rather the 
significantly up and down regulated genes at 24 HPI were determined for each virus, 
relative to the corresponding 0 HPI sample. The pairwise, per virus, 0 vs. 24 HPI SAM 
results are shown in Figure 4.10, where the SAM plots are derived from analysis of 
filtered log(2) ratios for each array element. Specifically, SAM calculates an observed 
d-value, or "relative difference" (d(i)) for each gene, which is a statistic based on the 
ratio of change in gene expression to the standard deviation in the data for that gene. 
This is plotted relative to the ratio of change in randomly permuted gene expression to 
the standard deviation in the data for that gene, d^i). For the majority of genes, d{i)
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Figure 4.9 E valuation  of varia tion  in g e n e  e x p re s s io n  d a ta  a t 0 an d  24 HPI.
(A) Graph representing the distribution of log(2) ratios for each array element (after filtering) for 
ST1-R5 cells infected with HIV-1 subtype B, Group O and HIV-2 ETP, at both 0 and 24 HPI. 
HIV-1 subtype B results in a larger distribution in gen es both up and down regulated, in 
comparison to reference at 0 and 24 HPI. The distribution is smaller at 24 HPI. Cells infected 
with HIV-1 group O and HIV-2 ETP display a similar distribution of both up and down regulated 
genes, at 0 and 24 HPI. The plot indicates that there is no appreciable difference in distribution 
of gene expression values in cells infected with th ese two viruses at the two time points studied.
(B) Table of general statistics derived from the log(2) expression data for each array element 
(after filtering) for ST1-R5 cells infected with HIV-1 subtype B, Group O and HIV-2 ETP, at both 
0 and 24 HPI. The mean, standard deviation and sample variance and range of values are all 
greater for subtype B infection, than for O and ETP and both 0 and 24 HPI.
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B0 B24 0 0 024 ETP0 E7P24
Mean -0.009 -0.011 -0.004 -0.006 -0.008 -0.004
Standard Delation 0.293 0.223 0.108 0.123 0.113 0.106
Sample Variance 0.086 0.050 0.012 0.015 0.013 0.011
Ranqe 2.150 2.358 1.619 1.776 1.869 1.437
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~ ds(i) i.e. there is no change in expression level between the two samples, but some 
genes are represented by points displaced from the d(i) = d ^ i)  line by a distance greater 
than a threshold, A, depicted by broken lines. This value was computed individually for 
each analysis and corresponds to a defined false discovery rate in this case of 5%, in the 
significantly regulated genes. These outliers therefore represent the significantly up and 
down regulated genes (Tusher et a l, 2001) (Figure 4.10).
This analysis shows that significantly regulated genes were found in response to all 
viruses at 24 HPI, and that infection with HIV-1 group O and HIV-2 ETP resulted in 
more significant up- and down regulation at 24 HPI than infection with HIV-1 subtype 
B, as d(J) values calculated for significantly regulated genes 24 HPI with HIV-1 Group 
O and HIV-2 ETP are much higher compared to subtype B. Figure 4.11 shows the 
distribution in d(i) values for all significantly up- and down regulated genes and 
emphasises this observation: whilst the graphs for each virus show roughly comparable 
numbers of up- (red data points) and down regulated genes (green data points), the d(i) 
values reveal the difference in significance: despite the apparent strong up- and down 
regulation o f genes in response to subtype B infection (Figure 4.7), the significance 
values for these genes is less.
The explanation for this lies if the observation made previously that variation in gene 
expression values at 0 and 24 HPI in subtype B infection is greater than that in Group O 
or HIV-2 infection (Figure 4.8/4.9). As mentioned, the d(i) value for each gene is 
calculated based on the ratio of change in gene expression to standard deviation in the 
data. For subtype B the standard deviation of the gene expression distribution is greater 
due to the increased variation in expression values, so the calculated ratio of change in 
gene expression to standard deviation in the data is greater. Hence the d(i) value for 
each gene is smaller; in effect (for subtype B) the significance of changes in gene 
expression are masked by the variation in the 0 HPI HIV-1 subtype B data. In 
interpreting the d{i) value for each gene care must be taken, therefore, as if the same 
gene were similarly up regulated in response to subtype B and group O viruses by virtue 
of the fact that the standard deviation in the group O data is smaller than that in the 
subtype B data, the regulation of that gene would appear more significant in the case of 
infection with Group O. Consequently, in further analysis the d(i) value for each gene 
will be taken as a reflection of both significance and variation within the data, but not an
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F ig u r e  4 .1 0  S ign ificance an a lysis  o f microarray (SAM) plots derived from analysis of 
filtered log(2) ratios for each  array elem ent, for ST1-R5 ce lls  infected with HIV-1 subtype  
B, Group O and HIV-2 ETP.
The graphs show observed d(i) and expected d^i)  values: the blue line indicates where 
d{i) = d^/) and the dotted lines represent the cut-off A. Where gen es are represented by points 
displaced from the d{i) = cfe(i) line by a distance greater than a threshold, A, these are called 
significantly up regulated (in red) or down regulated (in green) at 24 HPI, as compared to 0 HPI. 
A was computed individually for each analysis so  each allows for a false discovery rate of 5%, 
in the significantly regulated genes. T hese data show significantly regulated genes are found in 
all cases, and that infection with HIV-1 group O and HIV-2 ETP results in more significant up 
and down gene regulation at 24 HPI than infection with HIV-1 subtype B.
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Figure 4.11 Distribution o f d(i) va lu es for differentially regulated g e n e s  in resp o n se  to  
HIV-1 subtype B, group O and HIV-2.
Chart indicates the distribution of d(i) values for each  gene  generated  by SAM for significantly 
up regulated (A) and down regulated (B) g en es  at 24 HPI, a s  com pared to 0 HPI, in ST1-R5 
cells infected with HIV-1 subtype B (B), group O (O) and HIV-2 (ETP).
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absolute measure of significance. The numerical order of significant genes in terms of 
d(i) value will be interpreted as the order o f significance.
4.3.2.4 Evidence fo r  core and diverging responses
The lists of genes significantly up- and down regulated at 24 HPI were compared to 
determine the relationship between the transcriptional responses of ST1-R5 cells to 
infection with the three viruses. In response to HIV-1 subtype B infection, 677 genes 
were found to be significantly up regulated and 646 significantly down regulated. In 
response to HIV-1 group O infection, 554 genes were found to be significantly up 
regulated and 616 significantly down regulated, and as a result o f HIV-2 ETP infection 
317 genes were found to be significantly up regulated and 245 significantly down 
regulated. The results of comparing these lists of genes are shown in Figure 4.12. 
Specifically, a core response to infection was identified, in which cells infected with all 
viruses showed up regulation of 45 and down regulation of 50 genes. In response to the 
viruses studied, genes were also identified that were significantly up and down 
regulated during infection by two of the three viruses, perhaps representing more 
diverging responses to infection. The majority of the significantly regulated genes, 
however, were not shared between the different infection conditions. This suggests that, 
in addition to the core response, divergent and specific cellular responses may occur as 
a result of infection with different genetic variants of HIV. Full gene lists are in 
Appendix, Table 3.
4.3.2.5 The core response to HIV infection
In order to determine the nature of the core transcriptional response of ST1-R5 cells to 
HIV infection, the genes found to be significantly regulated that were functionally 
annotated by the Gene Ontology were placed into both biological process and molecular 
function categories (http://appsl.niaid.nih.gov/david/). The GO classifications for 
genes significantly up (Figure 4.13-A) and down regulated (Figure 4.13-B) 24 HPI with 
HIV-1 subtype B, Group O and HIV-2 ETP, compared to 0 HPI, showed a range of 
effects of infection on cellular function. For up regulated core response genes these 
include biological processes: cell cycle, nucleic acid metabolism, signal transduction, 
biosynthesis, lipid metabolism, response to stress, protein metabolism, cell-cell 
signalling, immune response and response to external stimulus. Of these the molecular 
functions are categorised as: binding, signal transducer activity, catalytic activity,
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Figure 4 .1 2  Core and diverging r e sp o n se s  to  HIV-1 subtype B, group O and HIV-2 
infection at 24 HPI.
(A) Venn diagram  showing num bers of significantly up regulated g en es at 24 HPI, a s  com pared 
to 0 HPI, in ST1-R5 cells infected with HIV-1 subtype B (B), group O (O) and HIV-2 (ETP). (B) 
Venn diagram  showing num bers of significantly down regulated g en es  at 24 HPI, a s  com pared 
to 0 HPI, in ST1-R5 cells infected with HIV-1 subtype B (B), group O (O) and HIV-2 (ETP).
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Figure 4.13 C lassification  o f core re sp o n se  g e n e s  up- and dow n regulated in resp o n se  
to  HIV-1 subtype B, Group O and HIV-2 ETP infection, 24 HPI.
Pie charts representing the G ene Ontology biological p rocess and molecular function 
classifications for g en es  significantly up regulated (A) and down regulated (B) 24 HPI infection 
with HIV-1 subtype B, Group O and HIV-2 ETP, com pared to 0 HPI. Only g en es that have been 
annotated are  included. T hese  rep resen t the  ‘core re sp o n se ’.
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transcription regulator activity and transporter activity. Down regulated biological 
processes in this core response include: cell growth and/or maintenance, protein 
metabolism, response to external stimulus, catabolism, cell death, immune response, 
response to stress and signal transduction, and of these genes the molecular functions 
include: catalytic activity, binding, transporter activity, signal transducer activity and 
structural molecule activity. In order to further dissect this core response, the biological 
processes identified and the genes both up and down regulated in this class, were 
studied in more detail.
Cell growth and maintenance
At 24 HPI several genes in this core response are those associated with cell growth and 
maintenance. In particular negative cell cycle regulators including Radi, a cell cycle 
checkpoint gene required for cell cycle arrest and DNA damage repair in response to 
DNA damage (Marathi et ah, 1998); the anti apoptotic factor epidermal growth factor 
receptor (EGFR) (Kari et ah, 2003); BIRC3, which inhibits p53 dependent apoptosis by 
activation of NF-kB (Stoffel et al., 2004); and Cyclin G2, which has been shown to be a 
negative regulator of cell cycle progression (Bennin et al., 2002) were all found to be up 
regulated. These changes may reflect the impact of viral Vpr, which has been shown to 
induce G2 arrest (He et al., 1995, Jowett et a l, 1995, Rogel et al., 1995). NIMA kinase 
(NEK3), a kinase that has a putative role in regulation of mitosis, was up regulated, but 
its ion channel substrate, FXYD domain containing ion transport regulator 1 
(ATP1G1/HOMG2), was down regulated. Positive cell cycle regulators and apoptotic 
factors were correspondingly down regulated, including: DNAJA2, a positive cell cycle 
regulator (Edwards et al., 1997); CD27-binding (Siva) protein, which induces apoptosis 
in T lymphocytes via a caspase-dependent mitochondrial pathway (Py et al., 2004); 
BC12-antagonist (BAD) which positively regulates cell apoptosis by forming 
heterodimers with BCL-xL and BCL-2, reversing their death repressor activity (Won et 
al., 2003); and FAST kinase, which phosphorylates TIA1, an apoptosis-promoting 
nuclear RNA-binding protein which is a strong inducer of lymphocyte apoptosis (Tian 
et al, 1995, Li et a l, 2004c). Tat-interacting protein 30 (TIP30), which is a novel 
serine/threonine kinase that phosphorylates the C-terminal domain of the largest RNA 
polymerase II subunit and induces the expression of apoptosis related genes Bad and 
Siva, was down regulated, a finding which corresponds with the observed down
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regulation of BAD and Siva described. As TIP30 also interacts with amino acids 1-48 
of HIV-1 Tat, including the Tat activation domain, and enhances Tat activation o f the 
HIV-1 LTR promoter (Xiao et al., 1998), its down regulation as part of this core 
response suggests an anti-apoptotic, or anti-viral mechanism not previously observed.
H-ferritin function is essential for the control of cell proliferation and transformation by 
c-MYC, a proto-oncogene transcription factor that can both activate and repress the 
expression of target genes. Specifically, c-MYC represses the expression of the heavy 
subunit of the protein ferritin (H-ferritin) which sequesters intracellular iron, and 
stimulates the expression of the iron regulatory protein-2 (IRP2) which increases the 
intracellular iron pool. Down regulation o f H-ferritin during infection suggests that this 
effect of cell cycle regulation may also be important in HIV infection (Ameglio et al., 
1993, Wu et al., 1999). In addition, annexin A2 is down regulated. In complex with 
S100A10, annexin A2 controls the distribution of transferrin receptor-containing 
recycling endosomes. Together these data allude to a relationship between HIV 
infection and iron metabolism (Zobiack et al., 2003), but this is as yet poorly 
understood. It has been suggested that high iron status, both in blood and intracellularly 
(i.e. within macrophage) may adversely influence the outcome of HIV-1 infection and 
thus these data might suggest a direct role of HIV infection in this pathology (Gordeuk 
et al., 2001).
Transcription, transcriptional regulation and translation
Genes involved in transcription, transcriptional regulation and translation were also 
inhibited during infection with all viruses, including the transcription factors p38 
interacting protein and MondoA; DEAD box polypeptide 49 (an ATP-dependent RNA 
helicase); Pirin, an iron-binding nuclear protein and transcription cofactor (Wendler et 
al, 1997); Peroxiredoxin 2, which regulates the signal transduction pathways that utilise 
AP-1 to influence cell growth and apoptosis (Butterfield et al., 1999); and exportin, a 
protein belonging to the RAN-GTPase exportin family that mediates export of tRNA 
from the nucleus to the cytoplasm (Arts et al., 1998). This general repression, in 
combination with the induction of cell cycle repressors and inhibition of cell cycle 
activators in response to HIV infection, agrees with previous observations (van t ’Wout 
et al., 2003). Interestingly, peroxiredoxin activity may also be capable of inhibiting 
HIV infection (Butterfield et al., 1999).
228
Certain transcription and splicing factors, however, were up regulated implicating them 
in facilitating HIV production. These include: the transcription factor AP-2 gamma 
(activating enhancer binding protein 2 gamma), a sequence-specific DNA-binding 
transcription factor involved in the activation o f several developmental genes, and c-fos, 
which encodes a leucine zipper protein that can dimerise with proteins of the JUN 
family, thereby forming the transcription factor complex AP-1; SERTA domain 
containing 2 (SERTAD2); and zinc finger protein 131. Interestingly, exposure to 
extracellular Tat has been shown to induce the expression of both c-fos mRNA and 
protein in serum-starved, non-infected Jurkat CD4+ lymphoblastoid T cells. This Tat- 
mediated induction of c-fos may therefore contribute to the immune hyper-activation 
that characterises the progression to AIDS, which constitutes the optimal environment 
for HIV-1 replication (Gibellini et al., 2001). RNA binding motif protein 25 (SI 64) and 
splicing factor arginine/serine-rich 5 (SFRS5), which play roles in constitutive splicing 
and can modulate the selection of alternative splice sites, were also induced. In relation 
to nucleic acid biosynthesis, IMP (inosine monophosphate) dehydrogenase 1, the rate- 
limiting enzyme of de novo GTP biosynthesis (Natsumeda et al., 1990) was also up 
regulated.
An increase in expression of Importin p, implicated by some studies in nuclear 
translocation of the pre-integration complex (PIC) allowing HIV to infect non-dividing 
cells, was detected (Gallay et al., 1997, Depienne et al., 2001). In addition several o f 
the thyroid hormone receptor interacting protein (TRIP) family were up regulated. This 
is interesting, as Trip-1 has been shown to simultaneously modulate responses involving 
both cytokine and nuclear receptors in cells of erythroid lineage (Ingley et al., 2001). 
Thyroid hormone receptor (TR), for example, binds to the integrated HIV-LTR in 
chromatin in vivo and represses the LTR in the absence of thyroid hormone (TH) by 
recruiting co-repressor complexes containing histone deacetylases. Upon TH binding, 
TR causes chromatin remodelling and LTR activation, probably in cooperation with 
other cofactors such as Tripl (Ishizuka et al., 2001). This up regulation of TH- 
responsive factors may therefore represent a mechanism during HIV lytic replication to 
ensure HIV-LTR activity (Hsia and Shi, 2002).
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Response to external stimulus and cell signalling
In response to infection the general level o f gene expression related to cell signalling 
and activation, in response to stress, was increased. The growth factors vascular 
endothelial growth factor (VEGF) and VEGF-C were up regulated, most likely induced 
by the action of HIV Tat, which has been demonstrated in vitro (Benelli et al., 2000). 
Growth factor receptor-bound protein 10 (GrblO), which acts as a positive regulator in 
VEGF-R2 signalling and protects VEGF-R2 from degradation by interacting with 
Nedd4, a component of the endocytic machinery, was also up regulated (Murdaca et al., 
2004). Coincident with this up regulation, possibly through Tat, an up regulation in 
tissue inhibitor of matrix metalloproteinase 2 (TIMP2), a peptidase involved in 
degradation o f the extracellular matrix, was observed. On one hand, this factor has been 
shown to partially inhibit the monocyte invasion induced as a result o f VEGF 
expression, perhaps suggesting some form of host cell response to Tat induced gene 
expression changes (Lafrenie et al., 1996). However, TIMP-2 also forms a receptor in 
complex with the membrane-type- 1-matrix-metalloproteinase (MT1-MMP). This 
regulates the generation of functionally active matrix metalloproteinase 2 (MMP-2) 
(Murphy et al., 1999). It is known that combined Tat and fibroblast growth factor 2 
(FGF2) augment active MMP-2 release by increasing the levels of both activated MMP 
and cell membrane-associated TIMP-2, whilst decreasing the amount of secreted TIMP- 
1 and -2. These in vitro effects are associated with the induction of vascular 
permeability and oedema in vivo by combined Tat and FGF2, and are thought to be key 
factors in the vasculopathy of HIV-1-infected individuals (Toschi et al., 2001).
Immune response
Receptors and signalling molecules involved in immune responses are modulated 
during HIV infection. As part of this core HIV transcriptional response, down 
regulation o f major histocompatibility complex (MHC), class I-C was detected, which 
has been directly attributed to the affect of HIV Vpu (Kerkau et a l,  1997) and Nef (at 
the protein level - Andrieu et al., 2001). The activity of Nef in down regulating MHC, 
however, requires peroxisomal acyl-CoA thioesterase (hTE), which binds to a region of 
the Nef core in close proximity to the putative CD4 binding site. Nef mutants disrupted 
in this binding domain were found to be defective in MHC class I down modulation and 
enhancement of viral infectivity (Liu et a l, 2000, Cohen et a l, 2000b). Down 
regulation of h(TE) in response to all viruses was detected, therefore suggesting that Nef
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exploits a cellular pathway for MHC-1 surface expression that can be regulated 
transcriptionally by the removal o f a necessary cofactor. Not all Nef alleles bind to hTE 
with high affinity, however, so the role of hTE during HIV infection in far from clear 
(Cohen et al., 2000b). Nef has also been shown to induce CD4 down regulation 
(Greenberg et a l, 1997), and whilst CD4 transcript down regulation was not detected in 
this core response, the adaptor-related protein complex 2 (AP2) which belongs to the 
adaptor complexes medium subunits family, was up regulated. It has previously been 
shown that Subunit H of the V-ATPase binds to the medium chain of AP2 and connects 
Nef to the endocytic machinery, allowing it to carry CD4 from clathrin coated pits at the 
cell surface to lysosomes, for its degradation (Geyer, 2002). Up regulation of AP2 may 
therefore be part of the viral modulation o f endocytic processes that, amongst other 
things, results in down regulation o f CD4. Together these data suggest that HIV 
protein-mediated down regulation o f MHC-1 and CD4 at the cell surface are augmented 
by transcriptional modulation o f cellular pathways that are part of the same process.
In addition, AP2 is important in the process of gpl20 internalisation from the cell 
membrane, shortly after its delivery there from the endoplasmic reticulum. It is thought 
that this rapid internalisation of envelope proteins may be disadvantageous to the virus 
in that it prevents viral assembly at the cell membrane. It may be a function o f Gag 
binding to the cytoplasmic domain of gp41, therefore, which prevents its recognition by 
the intracellular transport machinery and hence its internalisation, allowing viral 
assembly and budding at the cell membrane. An up regulation of AP2 may therefore be 
a mechanism by which the host can overcome this ‘masking’ effect and enable 
internalisation of gpl20, disrupting viral budding. Conversely, this up regulation of 
AP2 may be advantageous to the virus, as internalisation of envelope by AP2 may result 
in its re-direction to a sub-cellular compartment where HIV budding also takes place 
(Morita and Sundquist, 2004).
Lipid and protein metabolism and intracellular trafficking
One of the most striking patterns of gene modulation directly resulting from infection of 
ST1-R5 cells by all viruses studied, was the up regulation of genes encoding enzymes 
involved in the cholesterol biosynthesis pathway. These genes are among the most 
strongly regulated elements detected on the arrays, this cluster shown in Figure 4.14 
including; lysophosphatidic acid acyltransferase-delta; 24-dehydrocholesterol reductase;
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acetyl-Coenzyme A acetyltransferase 2 (acetoacetyl Coenzyme A thiolase); 3-hydroxy- 
3-methylglutaryl-Coenzyme A reductase (3-HMG-CoA reductase); and mevalonate 
kinase. It is well established that the HIV envelope has a higher 
cholesterol/phospholipid ratio than the host cell plasma membrane and that removing 
cholesterol from virions (Liao et al., 2001, Ono & Freed, 2001) or inhibition of 
cholesterol biosynthesis with Lovastatin inhibits HIV-1 production both in vitro 
(Maziere et al., 1994) and in vivo (del Real et al., 2004). This statin inhibition is 
thought to be mediated via several mechanisms, including: disruption of cholesterol-rich 
domains on the cell surface (lipid rafts) which are proposed to provide platforms for 
specific regulated protein-protein interactions required for the process o f viral assembly 
and through which HIV-1 buds during viral maturation (van ‘t Wout et al., 2003); 
inhibition of actin cytoskeletal rearrangement by down regulation of Rho activity (del 
Real et al., 2004); and by diminishing HIV-1 attachment to target cells by suppression 
of ICAM-l-LFA-1 interactions (Giguere and Tremblay, 2004). Since all cholesterol is 
provided by the host, it is reasonable to hypothesise that HIV may facilitate up 
regulation of intracellular cholesterol. Other microarray studies have demonstrated that 
HIV infection up regulates both the LDL receptor and many genes in the cholesterol 
biosynthesis pathway (van t ’Wout et al., 2003) and more specifically, the viral protein 
Nef has been shown to be a driving force in this up regulation of cholesterol 
biosynthesis (Zheng et al., 2003). It is well known, however, that cytokines induce 
marked changes in lipid metabolism that lead to hyperlipidemia, which represents part 
of the innate immune response and may be beneficial to the host (Feingold et al., 1998). 
Changes in lipid and lipoprotein metabolism may be beneficial in a number o f ways 
including: lipoproteins competing with viruses for cellular receptors; apolipoproteins 
neutralizing viruses; lipoproteins binding and targeting viruses for destruction; 
redistribution of nutrients to cells involved in the immune response and/or tissue repair; 
and lipoproteins binding toxic agents and neutralizing their harmful effects. In the 
context o f autoimmunity, it has been shown that inhibition of cholesterol biosynthesis 
using statins reduces the inducible expression of MHC class II molecules and blocks the 
expression of costimulatory molecules necessary for the induction of autoaggressive T 
cells (Youssef et al., 2002). They also shift the balance of cytokines produced by 
autoaggressive T cells from T helper-1 (TH1) proinflammatory cytokines, such as IFNy 
and TNF, to Tn2-type cytokines, including IL-4, IL-5, IL-10, and IL-13 (Steinman et 
al., 2004).
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Figure 4.14 Cluster diagram sh o w in g  su b se t  o f core resp o n se  g en es .
Cluster of g en es found using SAM to be significantly up regulated (A) and down regulated (B) at 
24 HPI with HIV-1 subtype B, Group O and HIV-2 ETP, com pared to 0 HPI. T hese represent 
the ‘core resp o n se’ g en es  which include exam ples of the top 20 m ost significantly up and down 
regulated genes, by rank order of d(i) value.
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Accordingly, up regulation o f cholesterol biosynthesis early during viral infection may 
be important in the expansion o f ThI proinflammatory responses -  crucial in initial 
attempts to control viral replication. Recent collaborative efforts to understand this 
process have involved microarray studies o f several different viral infections, in vitro. 
These data suggest that sterol biosynthesis is up regulated in lytic (HIV, HCMV, RSV), 
but not latent (KSHV) enveloped virus infections, and that this regulation can occur 
both early (HCMV) and late (HIV, RSV) in the virus life cycle. Regulation may also 
involve the entire biosynthetic pathway (HCMV, HIV) or specific genes (RSV) (van 't 
Wout et al., 2004). It seems therefore, that up regulation of cholesterol biosynthesis 
during viral infection may be advantageous for both host and pathogen. Perhaps the co­
evolution of both has resulted in this intimate relationship, the cause and effect o f which 
will be very difficult to distinguish.
The proteasome subunit p6 precursor and proteasome subunit P6 itself, which cleaves 
peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway, were both 
down regulated. As well as normal cellular protein degradation the proteasome is 
responsible for degradation of HIV integrase (Mulder and Muesing, 2000), and HIV Tat 
has been shown to interact with this subunit and interfere with its processivity (Seeger 
et al., 1997, Huang et al., 2002, Apcher et a l, 2003). Furthermore, Vif binds to the 
cellular cytidine deaminase APOBEC3G and targets it for degradation through an 
interaction with the proteasome (Sheehy et al., 2003). Down regulation of this subunit 
therefore may be a result of Tat, and may promote viral infectivity by reducing the 
degradation rate of its viral proteins, such as integrase. Conversely, down regulation of 
the proteasome may reduce viral infectivity by circumventing the activity o f V if in 
targeting of the host anti-viral protein APOBEC3G for degradation, allowing it to be 
incorporated into virions and disable viral progeny.
Finally, modulation of intracellular trafficking occurs during this core response to HIV 
infection. In addition to AP2 being up regulated, potentially contributing to down 
regulation of surface CD4 expression by interaction with HIV Nef; SEC6-like 1, 
syntaxin 5a and Vam6 were down regulated. SEC6-like 1 is a component of the 
exocyst complex; a multiple protein complex essential for targeting exocytic vesicles to 
specific docking sites on the plasma membrane (Matem et al., 2001). Vesicle docking 
is thought to be regulated, in part, by the specific interactions of syntaxin with a vesicle-
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associated membrane protein, synaptobrevin/VAMP. Vam6 promotes lysosome 
clustering and fusion in vivo (Caplan et al., 2001). Whilst these proteins have not 
previously been identified as being regulated in infection, there may be some functional 
relevance of this apparent down modulation o f factors involved in vesicle docking and 
fusion. A further gene, Surfeit 4, was up regulated. In eukaryotic cells protein transport 
between the endoplasmic reticulum and Golgi compartments is mediated in part by non- 
clathrin-coated vesicular coat proteins (COPs) and whilst the specific function of Surfeit 
4 has not been determined, its yeast homolog is directly required for packaging the 
soluble secretory protein glycosylated pro-alpha-factor into COPII vesicles (Belden and 
Barlowe, 2001).
Several genes were regulated as part o f this core response to HIV infection, whose 
functions are unknown. These are genes with accession numbers: R11659 (up 
regulated), and; BE548179, R24842, BE547709 (down regulated). It will be interesting 
to see if, as these genes are characterised, they fall into place with any o f the 
observations described or whether they will indicate other processes o f host cell 
modulation either by HIV itself, or as part of this core response to HIV infection.
4.3.2.6 The ‘significance ’ o f the core response
The core response described, comprised of 95 both up and down regulated genes, may 
be considered to encompass both the fundamental responses of a host cell to HIV 
infection, and the more conserved ways in which HIV can modulate the gene expression 
of its host cell. It could be presumed therefore, that these most conserved host -  
pathogen interactions occurring during HIV infection may be associated with more 
consistent and strong examples of gene modulation, in experimental repeats. These 
examples would therefore be the most statistically significant, with high d{i) values 
(section 4.3.2.3). In order to determine whether this is the case, the top twenty most 
significantly up and down regulated genes, as classified by SAM in response to HIV-1 
subtype B, group O and HIV-2 ETP infection at 24 HPI, were identified. The number 
of these genes that are part of the core response was calculated and the results are shown 
in Figure 4.15.
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Figure 4.15 The ‘sig n ifica n ce’ of core  re sp o n se  g en es .
Graph show s the relative proportions of core re sp o n se  and unique g en es (only regulated in 
response to one virus) in the top 20 m ost significantly regulated genes, a s  a result of infection.
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Clearly, whilst core response genes are among the top 20 up and down regulated genes 
in response to B, O and ETP infection, they do not account for them all. In subtype B 
infection, core response genes comprise only 30% of the most significantly up- and 
20% of the most significantly down regulated genes. In response to Group O and HIV- 
2 ETP infection, approximately 50% of the top 20 up and down regulated genes are 
those found to be part of the core response. It would seem that in addition to conserved 
and strong interactions between the host cell and HIV, there are significant processes of 
gene modulation occurring that are unique to each genetic variant of HIV. By 
examining these genes, potential differences between the ways in which HIV-1 subtype 
B, group O and ETP interact with the host cell may begin to characterised.
Prior to this analysis, however, these core response genes that comprise approximately 
50% of the top 20 significantly up and down regulated genes in response to infection 
were analysed. The highly significant core response genes shown in Table 4.3 mainly 
include up regulated genes that are associated with lipid metabolism, cell cycle and 
intracellular trafficking, and down regulated genes that are associated with apoptosis, 
iron handling and immune response. There is, however, a dichotomy as, whilst HIV-1 
group O and HIV-2 ETP share in common the majority of core elements in the top 20 
ranking genes, the highest ranking core response genes regulated in response to HIV-1 
subtype B are generally not shared. It could be that this indicates that the core response,
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Table 4.3 Table sh ow in g  core r e sp o n se  g e n e s  that are in the top 20 up and down  
regulated g en es , in ST1-R5 ce lls  infected  with HIV-1 subtype B, group O and HIV-2 ETP.
UP REGULATED -  CORE RESPONSE DOWN REGULATED CORE RESPONSE
Gene B O ETP Gene B O ETP
Vascular endothelial GF N* Y* Y MHC class 1 N Y Y
HMG CoA reductase Y Y Y B cell RAG assoc protein N Y Y
7-DHCR N Y Y Ferritin Y Y Y
acetyl CoA thiolase N Y Y annexin A2 N Y Y
mevalonate kinase N Y Y Pirin N Y Y
AP2 N Y Y CD27 Siva BP Y Y Y
AP2 assoc, protein N Y Y KIAA0368 protein N Y Y
cyclin G2 Y N N HIV Tat interactive protein N N Y
splicing factor arg/ser rich Y N N FXYD domain containing ion transport regulator 2 
myosin light pp 
Hypothetical protein F U 10432 
Gluathione-s-transferase pi
N
N
N
Y
N
N
N
N
Y
Y
Y 
N
*Y/Y indicates that the core response gene in question is in the top 20 up/down regulated genes 
*N indicates that the core response gene in question is NOT in the top 20 up/down regulated genes
in subtype B infection, is modulated in a different way compared to HIV-2 and group O 
infections. This observation, however, may also be a product of the way in which data 
was analysed. As described in section 4.3.2.1-2, greater variation in the data for 
subtype B arrays at 0 HPI affected the way in which values of ‘significance’ were 
calculated in SAM. It may therefore be that the top 20 ranking genes for subtype B do 
not represent only the most strongly up and down regulated genes 24 HPI, as they do for 
group O and HIV-2 ETP, due to the described experimental ‘noise’.
In order to determine, therefore, whether the top 20 significantly regulated genes in 
response to subtype B infection are dissimilar to those regulated by O and ETP by virtue 
of gene expression or if it is an artefact of data processing, the log (2) gene expression 
ratios for each of the 9 up- and 12 down regulated genes (Table 4.3) at 0 and 24 HPI 
were analysed (Figure 4.16). In 8 of the 9 up regulated genes, levels of gene expression 
account for the results seen. For example, HMG Co-reducatase is highly up regulated 
in response to all viruses and this gene is found in the top 20 for each. Similarly, for 9 
of the 12 down regulated genes the levels of gene expression account for the results 
seen; for example for CD27 binding protein (SIVA) and ferritin there is a clear and 
consistent down regulation of gene expression, which is reflected in the ranking 
analysis. In the case of VEGF, 7-dehydrocholesterol reductase, acetyl-Coenzyme A 
acetyltransferase, mevalonate kinase, adaptor-related protein complex 2 and 
transcription factor AP2 gamma, where these core response genes are in the top 20 for
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O and ETP but not B, however, the graphs indicate that the changes in gene expression 
in response to subtype B are comparable to those seen in response to O and ETP, if not 
stronger. In these cases the higher level o f variation in the subtype B data at 0 HPI has 
lead to the underestimation o f the significance of variation, in comparison to the other 
virus conditions. With regards to the cyclin G2 data, this gene is found to be highly 
significantly regulated by SAM in response to subtype B, but less so in response to O or 
ETP infection. However, by looking at the raw data it might be presumed that this gene 
is not significantly regulated in response to O and ETP. In this case, therefore, the 
opposite to the situation with subtype B could be true in that there is so little variation at 
0 HPI in O and ETP data that the small variation between 0 and 24 HPI is found to be 
significant. Alternatively, these results may be false, within the 5% FDR of the SAM 
method.
For the down regulated genes, a similar picture emerges. The data for FXYD domain 
containing ion transport regulator 2 (FXYD2) and KIAA0368 protein, however, are 
unusual in that in response to B infection these genes appear to be up regulated, but to O 
and ETP they are down regulated. Calculation of p-values from the log(2) data for 
KIAA0368 expression at 24 HPI compared to 0 HPI revealed that the apparent up 
regulation in response to subtype B is not significant (p = 0.079), whereas the down 
regulation in response to O and ETP is (p = 0.00123 and 0.0169 respectively). The 
error bars for B at 0 HPI indicates that this data should be treated with caution due to 
excessive variability. In the case of FXYD2, calculation of p-values reveals that there is 
no significant difference in expression of this gene as a result of B, O or ETP infection 
(p = 0.199, 0.0617 and 0.458 respectively). Again, this gene may be one of the 5% 
incorrectly called as being significantly regulated, within the 5% FDR. This analysis 
provides a useful quality control for SAM: all genes of interest should be analysed in 
this way to ensure exclusion of false positives/inclusion of false negatives.
4.3.2.7 Genes regulated by 2/3 viruses
The core response of ST1-R5 cells to HIV infection has been defined as the genes 
significantly up and down regulated, in response to all viruses studied, at 24 HPI. As 
shown in Figure 4.12, however, there are many genes significantly regulated at 24 HPI 
that were found in response to only two viruses. To investigate these responses further
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Figure 4.16 A nalysis o f core re sp o n se  g e n e s  that are in the top 20 up (A) and dow n (B) 
regulated g en es , in ST1-R5 ce lls  in fected with HIV-1 subtype B, group O and HIV-2 ETP.
The data plotted is the m ean Log(2) (Cy5/Cy3), and standard  error, of 6 replicate spots for each  
gene 0 and 24 HPI.
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lists of genes positively and negatively regulated in two out of the three infections 
studied were compiled and placed into biological process categories, as defined by the 
Gene Ontology Consortium (http://appsl.niaid.nih.gov/david/). This showed that these 
genes essentially fall into the same categories identified previously for the core 
response, including up regulation of genes associated with cell cycle arrest, nucleic acid 
metabolism, signal transduction, lipid metabolism, response to stress/stimulus, protein 
metabolism, cell signalling and immune response. Down regulated biological processes 
include cell growth and/or maintenance, protein metabolism, response to external 
stimulus, catabolism, cell death, immune response, response to stress and signal 
transduction. Data for regulation o f the cell cycle (Figure 4.17-A and -B) by the three 
viruses is presented. KEGG charts for all genes up and down regulated by the three 
viruses studied at 24 HPI were created, the viruses resulting in up/down regulation of 
particular genes super-imposed as different colours (Figure 4.17-A and -B). In terms of 
up regulation of factors involved in the cell cycle B and O dominate in that they alone, 
or in combination, are associated with the majority of genes found to be significantly up 
regulated. These genes regulated by B and O are mainly cyclins and cyclin-dependent 
kinases. The genes found to be regulated by two of the three viruses (purple, pink and 
grey boxes) constitute approximately one third of the genes found to be significantly 
regulated, the majority being shared between B and O (5 genes, purple), followed by O 
and ETP (3 genes, grey) and B and ETP (1 gene, pink). This order might suggest that B 
and O are closer in terms of the way they affect the cell cycle than B or O compared to 
ETP.
In terms of gene down regulation in this particular pathway, 11 genes were identified. 
Of these approximately half were regulated by two of the three viruses (purple, pink and 
grey boxes), and of those regulated in response to one virus alone, three were down 
regulated in response to HIV-1 subtype B (red), 3 in response to HIV-1 group O (light 
blue) and 1 in response to HIV-2 ETP infection (dark blue). No clear patterns emerge 
in these down regulation data, but it is interesting to note that ETP alone down regulates 
p53, which plays an important role in the regulation of cell cycle and activation of 
apoptosis in response to DNA damage. Whilst genes both up and down regulated are 
not identified in response to all viruses, it is likely that the genes identified here serve to 
augment the core responses identified and described. It is possible that some examples
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Figure 4.17 - A. KEGG chart of g en es  associa ted  with the cell cycle, significantly up regulated in ST1-R5 ce lls  at 24 HPI with HIV-1 subtype B, 
group O and HIV-2 ETP.
The colours represent which infection leads to up regulation of the gene in question ie. TGFIJ is up regulated during infection with B and ETP (pink) and 
Kip1,2 is up regulated during infection with subtype B alone (red).
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Figure 4.17 - B. KEGG chart of g en es  a ssoc ia ted  with the cell cycle, significantly down regulated in ST1-R5 ce lls  at 24 HPI with HIV-1 subtype  
B, group O and HIV-2 ETP.
The colours represent which infection leads to down regulation of the gene in question ie. GADD45G is down regulated during infection with B and ETP 
(pink) and HDAC is down regulated during infection with subtype B alone (red).
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represent subtle d ifferences in the in teraction  betw een the host cell and d ifferent HIV 
types/subtypes, but this cannot be confirm ed.
4.3.2.8 Diverging responses to HIV infection
A core response to  HIV infection  has been  described  (section 4.3.2.5). O f  all the core 
response genes, particular exam ples w ere found to be w ithin the m ost highly up and 
dow n regulated  genes (Figure 4 .16), as defined  by SA M  analysis. As such it m ay be 
concluded that these genes constitu te  an im portan t ro le in the ‘co re ’ interaction betw een  
H IV  and the host cell. W ithin the h ighly  ranking regulated  elem ents, how ever, are 
exam ples o f  genes that are not shared betw een  cells in fected  w ith the different viruses. 
In exam ining these genes, it m ay be possib le  to iden tify  differences betw een the w ays in 
which HIV-1 subtype B, group O and H IV -2 E T P  in teract w ith  the host cell.
HIV-1 subtype B, O and HIV-2 ETP differentially regulate multiple genes 
Lists o f  significantly  up and dow n regu lated  genes w ere com pared in order to determ ine 
w hether any w ere differentially  regu la ted  betw een  the v iruses studied i.e. i f  any genes 
w ere significantly  up regulated during infection w ith one virus, that w ere significantly  
dow n regulated during infection w ith another, and vice versa. This analysis revealed  95 
genes differentially  regulated by tw o o f  the v iruses studied (Figure 4.18-A ). O f  these 
four are up- and 10 are dow n regulated  in 2 o f  the 3 viruses (F igure 4.18-B  and C). O f  
these 10 dow n regulated genes (F igure 4 .18-C) the m ajority  are dow n regulated  in H IV - 
1 B /O  infections, yet up regulated in H IV -2 infection suggesting a difference betw een 
HIV-1 and -2. The num ber o f  genes d ifferen tially  regulated  betw een the individual 
viruses studied, how ever, is fairly com parable.
Figure 4 .1 8  Numbers of differentially regulated g en es .
Table show s the number of genes that are significantly differentially regulated in response to 
infection with HIV-1 subtype B, group O and HIV-2 ETP (A). The numbers of gen es that are 
down regulated in response to one virus, but up regulated in response to the other two are 
shown in (B). Conversely, the numbers of gen es that are up regulated in response to one virus, 
but down regulated in response to the other two are shown in (C). Gene lists are recorded in 
Appendix, Table 3.
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In order to further dissect the nature o f these differences in gene expression during 
infection with HIV-1 subtype B, group O and ETP, of the 95 differentially regulated 
genes that have been identified, only those genes that fall within the top 50 significantly 
regulated (as defined by d-value) will be considered. There are 10 genes, including 
three that indicate a difference between HIV-1 and HIV-2 in terms of cell cycle 
regulation and sensitivity to apoptosis, five indicating differences in transcriptional 
regulation, and two in relation to cell signalling.
Cell cycle regulation and sensitivity to apoptosis
LAG1 was ranked at position 20 in the list o f genes up regulated during HIV-2 ETP 
infection, but was ranked 602 in the list o f genes down regulated during HIV-1 group O 
infection. Over expression of LAG 1 has been shown to selectively induce the synthesis 
of stearoyl-containing sphingolipids and ceramide in mammalian cells, and LAG1 and 
its homologues are likely to play a role in ceramide signalling, which affects growth, 
proliferation, stress resistance, and apoptosis (Jazwinski and Conzelmann, 2002). It 
may be postulated, therefore, that an increase in LAG1 expression during HIV-2 
infection potentiates an increase in ceramide synthesis, leading to one of cell cycle 
arrest, apoptosis, terminal cell differentiation or senescence, all representing forms of 
stress response. Interestingly, elevated intracellular levels o f ceramide have also been 
shown to inhibit HIV-1 infection (Finnegan et al., 2004), which was proposed to occur 
as a result o f perturbation of localised membrane domain structure and organisation. 
Infectivity is reduced due to the low probability of CD4 and coreceptor engagement, and 
trafficking of virions via an endocytic pathway that leads to non-productive infection 
(Schaeffer et al., 2004, Finnegan et al., 2004). It would seem, therefore, if ceramide 
biosynthesis is differentially regulated during HIV-1 and HIV-2 infection, via LAG1, 
that this could contribute significantly to the differences in the way these viruses behave 
both in vitro and in vivo.
Secondly, Pim-2 oncogene, a pro-survival kinase which phosphorylates the pro- 
apoptotic protein BAD thus reversing Bad-induced cell death (Yan et al., 2003) was 
ranked at positions 17 and 3 in the list o f up regulated genes, in response to O and ETP 
infection, respectively, but was at position 174 the list of genes down regulated during 
subtype B infection. A reduced frequency of HIV-2 infection-associated in vitro 
apoptosis in T-cells has been reported (Machuca et al., 2004). No explanations were
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given for this finding, so perhaps the strong up regulation of Pim-2 oncogene during 
HIV-2 infection may bear further inspection. It is worth noting that in studies of 
mammalian reoviruses, which have served as useful models for studies of the viral and 
cellular mechanisms that are operative in host cell damage and death (Clarke and Tyler,
2003), Pim-2 is one of the few apoptosis regulatory genes that is down regulated 
following reovirus infection (DeBiasi et a l, 2003), associated with an enhancement in 
apoptosis. This provides support for the notion that differential regulation o f PIM-2 
between different genetic variants o f HIV might engender these different viral variants 
with distinct apoptotic phenotypes. This consequently may be reflected in the 
cytopathology of the diseases they cause, a suggestion also put by the authors of a 
recent publication describing a decreased level of T-cell apoptosis during HIV-2 
infection in vitro (Machuca et a l, 2004).
Finally, two individual ESTs corresponding to cyclin-dependent kinase 5 (cdk5) were 
found to be down regulated in response to HIV-1 subtype B infection (ranked at 16 and 
17) and HIV-1 group O infection (ranking 48 and 53), but were up regulated in response 
to HIV-2 ETP (ranking 433) infection. Cdk5 has been shown to influence several 
cellular processes in terminally differentiated cells, in particular neurons and in the 
kidney, and HIV-1 Tat has been shown to down-regulate the expression of p35, a 
neuron-specific activator of cdk5. This leads to deregulation of neuronal differentiation 
and survival (Peruzzi et a l , 2002), suggesting a role for factors released from HIV-1 
infected cells that trigger a cascade of events leading to neurodegeneration. 
Furthermore, a role for Cdk5 as a regulator of podocyte differentiation, proliferation, 
and morphology has been demonstrated in vitro and in vivo: specific inhibition o f Cdk5 
in differentiated cultured podocytes induces shape changes, with cellular elongation and 
loss of process formation compared to the characteristic phenotype (Griffin et a l,
2004). HIV-associated nephropathy (HIVAN), characterised by proteinuria and 
progressive renal failure, is a well-known complication of HIV infection, and reversal of 
HIVAN end-stage renal failure after the initiation of HAART has been demonstrated 
(Scheurer, 2004). Thus, HIV-1 associated down regulation of cdk5, via Tat, may 
contribute to the development o f HIVAN in HIV-1 infected patients. Its differential 
regulation during HIV-2 infection indicates that differences between these viral variants 
may influence the frequency of certain HIV-associated pathologies. The significance of 
differential cdk5 regulation via Tat within T-cells, however, is not clear.
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Differential activation of cdk5, together with Pim-2 and LAG1, may therefore indicate 
differential modulation of cellular survival signals in HIV-1 versus HIV-2 infection, 
potentially impacting on the pathology o f these diseases.
Transcriptional regulation
TFIIH, which interacts with HIV-1 Tat as a component of the HIV-1 transcription pre­
initiation complex (Garcia-Martinez et al., 1997) was ranked at position 46 in the list of 
down regulated genes, in response to ETP infection, but was at position 101 in the list 
of genes up regulated during subtype B infection. In addition, cyclin dependent kinase 
7 (Cdk7), a component of CAK (a trimeric complex of cyclin H, MAT1 and Cdk7 
which is an essential component o f the TFIIH transcription factor), was significantly up 
regulated in response to subtype B and group O infection (Nekhai et al., 2000). 
Together, these data suggest a difference between HIV-1 and HIV-2 in the expression of 
host factors essential for viral transcription: in HIV-1 infection there is a greater up 
regulation of host factors required for viral transcription, compared to HIV-2 infection. 
Similarly, general control of amino-acid synthesis 5-like 2 (hGCN5) was ranked at 
position 39 in the list o f up regulated genes in response to ETP infection, but was at 
position 122 the list of genes down regulated during subtype B infection. Research has 
shown that Tat is directly acetylated at lysine 28 within the activation domain, and 
lysine 50 in the TAR RNA binding domain, by Tat-associated histone acetyltransferases 
p300, p300/CBP-associating factor, and hGCN5 (Col et al., 2001, Bres et al., 2002) so 
differential regulation o f hGCN5 between HIV-1 subtype B and HIV-2 ETP might 
suggest a different relationship between HIV-1 and -2  Tat proteins, and the host factors 
that activate them. In addition, hGCN5 has been shown to be involved in histone 
acetylation and factor recruitment at the HIV LTR in response to Tat, so differential 
regulation of hGNC5 may also indicate divergent processes of LTR activation between 
HIV-1 and HIV-2 (Lusic et al., 2003). Furthermore, B-cell CLL/lymphoma 6 (BCL6) 
is a sequence-specific repressor of transcription and was ranked at position 27 in the list 
of down regulated genes in response to ETP infection, but was at position 238 in the list 
of genes up regulated during subtype O infection. BCL6 can repress transcription from 
HIV-1 promoter/enhancer region (Baron et al., 1997), possibly explaining its up 
regulation during HIV-1 O infection. BCL6 may also regulate apoptosis by repression 
of programmed cell death-2 (PDCD2) (Baron et al., 2002).
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Between HIV-1 subtype B and group O infections, retinoid X receptor alpha (RXRA), a 
nuclear receptor, was ranked at position 37 in the list o f down regulated genes in 
response to group O virus, but was at position 653 in the list of genes up regulated in 
response to subtype B. It was recently demonstrated that retinoids, the bioactive 
metabolites of vitamin A, repress HIV-1 replication in monocytic cell lines by blocking 
LTR-directed transcription by transactivation of cellular gene expression (Hanley et al.,
2004). The finding that the synthetic pan-retinoic acid receptor antagonist BMS- 
204493 activates HIV-1 replication in a dose-dependent manner, implies that
modulation of the retinoid receptor during infection may have an important effect on 
regulation of infection.
Cell signalling
Mitogen-activated protein kinase 8 (MAPK8/JNK) is involved in a wide variety of 
cellular processes such as proliferation, differentiation, transcription regulation and
development, and is known to be activated by HIV-1 Tat (Kumar et al., 1998) and Nef
(Varin et al., 2003); this activation having been postulated to contribute to AIDS 
pathogenesis by fuelling the progression of disease via stimulation of HIV-1 provirus 
present in such cellular reservoirs as mononuclear phagocytes. Analysis of
differentially regulated genes revealed that MAPK8 was ranked at position 29 in the list 
of up regulated genes in response to ETP infection, but was at position 538 in the list of 
genes down regulated during subtype B infection, suggesting differences between HIV- 
1 and HIV-2 in the manner in which such intracellular signalling networks are 
modulated during infection.
Finally, chloride channel 4 (C1C4) was ranked at position 34 in the list of up regulated 
genes in response to ETP infection, but was at position 468 in the list of genes down 
regulated during group O infection. This channel is involved in the regulation of 
hepatic copper transport (Wang and Weinman, 2004), and whilst other physiological 
roles remain unclear, defects it this channel have been associated with myotonia and 
certain kidney disorders (Dworakowska and Dolowy, 2000). Recent molecular 
investigation, however, has indicated that C1C4 contributes to endosomal acidification 
and trafficking: specific disruption of endogenous C1C4 expression by transfection of 
C1C4 antisense cDNA acidified endosomal pH and altered transferrin trafficking in 
cultured epithelial cells (Mohammad-Panah et al., 2003). The modulation of this ion
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channel, during infection, m ay th ere fo re  be o f  im portance as HIV-1 Tat has been show n 
to enter T -cells using  c la th rin -m edia ted  endocytosis, before low -pH -induced and 
H sp90-assisted endosom al transloca tion , fo llow ing  w hich cell responses are induced 
from  the cytosol (V endeville et al., 2004). D ow n regulation  o f  this channel during 
HIV-1 group O  infection m ay therefore  re flect a m echanism  o f  altering Tat delivery  and 
the resulting bystander effect (V endev ille  et a l, 2004). Furtherm ore, the entry, 
trafficking and exit o f  HIV  partic les from  cells are heavily  dependent on the endosom al 
com partm ent. As m entioned p reviously , in addition to  assem bly at the p lasm a 
m em brane, retroviruses u tilise  late endosom al m em branes/m ultivesicu lar bod ies as 
assem bly sites, im plying an endosom e-based  pathw ay for viral egress (Sherer et al., 
2003). Thus, d ifferential regulation  o f  C1C4 in response to  HIV-1 and H IV -2 infection 
m ay indicate divergent w ays in w hich  these v iruses in teract w ith or m odulate these 
pathw ays, to ensure their passage th rough  the cell. These differentially  regula ted  genes 
are sum m arised in Figure 4.19 and the raw  L og(2) data for these genes are show n in 
Figure 4.20.
F ig u r e  4 .1 9 .  Summary of g e n e s  found to be differentially regulated in resp o n se  to HIV- 
1 subtype B, group O and ETP infection.
The gene nam es are  shown within the bars and the virus in which the opposite regulation w as 
observed is noted next to the bar i.e. in re sponse  to subtype B infection one gene, cdk5, w as 
down regulated for which the opposite regulation w as observed in response  to ETP infection (up 
regulated). The g en es shown (in the bars) a re  only those  within the top 50 ranking up or down 
regulated genes, detected 24 HPI.
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Figure 4.20 A nalysis of g e n e s  for w hich significant diverging r e sp o n ses  w ere  
identified, one of w hich is within the top 50 o f either up or down regulated g en es , in ST I­
RS ce lls  infected with HIV-1 subtype B, group O and HIV-2 ETP.
The data plotted is the m ean Log(2) (Cy5/Cy3), and standard  error of 6 replicate spots for each  
gene 0 and 24 HPI. The virus in re sp o n se  to which the gene  regulated w as within the top 50 is 
marked in each c a se  with an  asterisk (*).
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From the summarised data it is clear that ETP infection results in strong and significant 
up and down regulation of eight genes, that are significantly regulated in exactly the 
opposite way in response to HIV-1 subtype B (n=3) or group O (n=5) infection. Group 
O infection result in differential regulation o f three genes, two of which the opposite 
was observed for subtype B and one in ETP infection, and one gene was differentially 
regulated in subtype B infection -  the opposite response being identified in response to 
ETP. This shows that, within the top 50 significantly regulated genes upon which this 
analysis is based, HIV-2 ETP displays more examples of significantly divergent gene 
regulation, during infection, compared to HIV-1 subtype B and group O.
4.3.2.9 Analysis o f  early versus late gene expression
Whilst the majority of gene expression changes in response to HIV infection have been 
reported to occur at approximately 24 HPI, at experimental time points prior to this 
significant changes in gene expression have been detected (van ‘t Wout et a l, 2003). 
With an experimental system and data in hand regarding the core and divergent changes 
in gene expression in ST1-R5 cells 24 HPI with HIV-1 subtype B, group O and HIV-2 
ETP (compared to 0 HPI), therefore, an additional study of gene expression within this 
time-frame was performed. Specifically, duplicate arrays of ST1-R5 cells infected with 
HIV-1 subtype B, Group O and HIV-2 ETP at 0, 2, 12 and 24 HPI were performed and 
the gene expression at 12-24 HPI statistically compared (using SAM) to 0-2 HPI. The 
aim was to determine whether there are any differences between the extent and 
functional classifications of genes expressed ‘late’ (12-24 HPI) during the first 24 hours 
of infection, compared to at 24 HPI. By performing this analysis it was also hoped that 
the data regarding the core and diverging transcriptional responses to the three viruses 
studied (sections 4.3.2.5 -  4.3.2.7) could be expanded upon, and the effect of the 
different virus preparations and the possible effects of serum re-exposure after infection 
on subsequent variation in transcriptional responses could be further characterised (Iyer 
et al., 1999).
The late response to infection
Analysis of the genes found to be significantly regulated by all viruses studied, late 
during the first 24 hours of infection, revealed several differences to the 24 HPI data 
(Figure 4.21). For subtype B, whilst at 24 HPI (compared to 0 HPI) 677 genes were
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Figure 4.21 Core and diverging r e sp o n se s  to HIV-1 subtype B, group O and HIV-2 
infection at 12-24 HPI.
(A) V e n n  d i a g r a m  s h o w i n g  n u m b e r s  o f  s i g n i f i c a n t l y  u p  r e g u l a t e d  g e n e s  a t  1 2 - 2 4  H P I ,  a s  
c o m p a r e d  t o  0 - 2  H P I ,  i n  S T 1 - R 5  c e l l s  i n f e c t e d  w i t h  H I V - 1  s u b t y p e  B  ( B ) ,  g r o u p  O  ( O )  a n d  H I V - 2  
( E T P ) .  (B) V e n n  d i a g r a m  s h o w i n g  n u m b e r s  o f  s i g n i f i c a n t l y  d o w n  r e g u l a t e d  g e n e s  a t  1 2 - 2 4  
H P I ,  a s  c o m p a r e d  t o  0 - 2  H P I ,  i n  S T 1 - R 5  c e l l s  i n f e c t e d  w i t h  H I V - 1  s u b t y p e  B  ( B ) ,  g r o u p  O  ( O )  
a n d  H I V - 2  ( E T P ) .
A
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3 7 6
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found to be up regulated and 646 genes were down regulated, analysis of the 12-24 HPI 
data compared to 0-2 HPI, revealed only 16 up- and 47 significantly down regulated 
genes. This observation is consistent with previous observations that the majority of 
gene regulation in response to HIV infections occurs around 24 HPI (van ‘t Wout et al., 
2003). Analysis of gene expression changes in response to HIV-1 group O and HIV-2 
ETP at 12-24 HPI, however, generated very different results. For group O at 12-24 
HPI, 337 genes were significantly up- and 560 genes significantly down regulated, 
compared to 554 and 616 genes, respectively, at 24 HPI. For HIV-2 ETP at 12-24 HPI 
467 genes were significantly up- and 325 genes significantly down regulated, compared 
to 317 and 245 genes, respectively, at 24 HPI. These results therefore indicate that in 
response to the conditions for HIV-1 group O and HIV-2 ETP infection, at 12-24 HPI 
there was significant differential regulation of genes, compared to 0-2 HPI. This 
observation, however, is somewhat contrary to the data presented in section 4.3.2.2, 
which describes gene expression at 0 HPI in group O and ETP infection as being much 
less variable than that in subtype B infection, presumably due to rapid changes in gene 
expression as a result of serum shock in the subtype B infection, during the 3 hour 
incubation period (prior to T=0).
Figure 4.22 Proportions of g e n e s  up and dow n regulated at 12-24 HPI, a s  com pared to  
24 HPI, in HIV-1 group O and HIV-2 ETP infections.
Graph shows that, of the genes found to be significantly up- and down-regulated at 24 HPI, only 
a small proportion were similarly identified in the merged 12/24 HPI data (grey sections of the 
blue bars) during HIV-1 group O and HIV-2 ETP infection.
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In order to determine, therefore, if  these changes in gene expression in HIV-1 group O 
and HIV-2 ETP infection 0-2 HPI were as a result o f infection, an analysis of the 
proportions of genes commonly up- and down regulated between 12-24 HPI, compared 
to 24 HPI was performed. This showed that for group O, only 15-20% of the genes up- 
and down regulated at 12-24 HPI were also identified as being significantly regulated at 
24 HPI, and for HIV-2 ETP a smaller number of genes (2-10%) were found in the 
analysis o f both experiments to be similarly regulated (Figure 4.22). That is, the 
majority of genes identified as being significantly regulated in response to O and ETP 
between 12-24 HPI are not the same as those found to be significantly regulated at 24 
HPI. This implies that these genes are not regulated in response to infection, but rather 
the conditions under which infection was performed. It is likely that the process of 
putting cells into complete medium at T=0, after infection in almost neat infected cell 
supernatant during the 3 h incubation period with HIV-1 group O and HIV-2 ETP, also 
initiated a form o f serum shock response in these infections. In support o f this 
hypothesis, a comparison of the genes up and down regulated at 0 HPI in response to 
subtype B infection to those up and down regulated at 0-2 HPI in group O and ETP 
infection revealed approximately 50% similarity. A model may therefore be proposed 
to explain these observations in which serum shock in the O/ETP infections occurs after 
infection, at the experimental T=0 (three hours after the serum shock in the subtype B 
infection). This delayed shock response in O/ETP infections gives the impression, 
when 0-2 HPI and 12-24 HPI data are compared, that significant changes in gene 
expression are taking place sooner after infection in response to these viruses, compared 
to subtype B. This result is, however, likely to be an artefact of the infection strategy 
(Figure 4.23).
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Figure 4.23 Model of ch an ges in gen e expression  in resp on se  to infection and infection conditions, over time.
This schem atic indicates that cells infected with subtype B are subject to a brief serum  shock at the beginning of the experiment (blue dashed line), w hereas 
group O and ETP infections are exposed to serum  in a sustained m anner after 3 h (black dashed  line). This produces the high variation in subtype B T =0 
data. Virally induced changes in gene expression do not appear until close to T=24 (complete blue and black lines for B and O/ETP respectively). When 
T=12-24 (B) and T=0-2 HPI (A) data are com pared, therefore, the group O and ETP infections shown a greater number of genes differentially regulated at 12- 
24 HPI, due to the delayed serum  exposure (at T=0). The differences in response to serum  re-exposure depicted may be a s  a result of cells in the subtype B 
infection going from old medium to fresh medium, during infection, w hereas the group O/ETP infected cells go from almost neat virus supernatant to complete 
medium (T=0), perhaps resulting in a more profound and lasting change in gene expression.
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Table 4.4 S p ecific  core  r e sp o n se  g e n e s  up and d ow n  regulated at 12-24 HPI.
T hese g en es  were identified in SAM analysis of 12-24 HPI vs. 0-2 HPI arrays, a s  being 
significantly regulated in response to all 3 viruses. ‘Y’ indicates that the gen e in question w as 
also identified in the core response characterised at 24 HPI, and ‘N’ indicates that the g en e  in 
question w as not.
UP REGULATED DOWN REGULATED
Gene 24 HPI Gene 24 HPI
RNA binding motif protein 17 N B cell RAG associated protein Y
G protein-coupled receptor 17 N Dishevelled, dsh homolog 2 Y
Vimentin Y
Neogenin precursor N
Intercellular adhesion molecule 3 N
CD53 antigen N
Pirin Y
Ferritin, heavy polypeptide 2 Y
KIAA0368 protein Y
general transcription factor IIH, Y
polypeptide 4, 52kDa
The late core response
Despite the experimental ‘noise’ apparent in this experimental analysis, a smaller set o f 
core up- and down regulated genes can be identified, at 12-24 HPI (Table 4.4). The 
genes identified reveal a set of strongly and consistently down regulated genes. 
Examples of genes previously classified as being part of the core HIV response (section
4.3.2.5) have again been identified, including ferritin, KJAA0368 protein, B cell RAG 
associated protein and vimentin. This provides support of their role in a general cellular 
response during HIV infection as they are consistently detected as being significantly 
down regulated, regardless of time course or method of analysis. Additional 
significantly down regulated genes were identified. These include neogenin precursor, 
intercellular adhesion molecule 3 (ICAM-3) and CD53 antigen. Recently, it was 
demonstrated that ICAM-3 acts as a costimulatory molecule to increase HIV-1 
transcription and viral production, allowing productive infection of quiescent CD4+ T 
lymphocytes (Barat et al., 2004). Furthermore down regulation of CD53, a member of 
the tetraspanin protein family that plays an important role in regulating T-cell signalling 
when associated with MHC II at the cell surface, implies a role for this protein in 
response to infection. The significantly up regulated genes identified at both 12-24 HPI 
and 24 HPI, however, are less congruent. Two genes were identified as being in the top 
50 significantly regulated genes in both B and ETP infections (serine/threonine kinase 
18 and STAT1 respectively), but there is a distinct absence of any previously 
characterised core response genes. This indicates that the 12-24 HPI data for up
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regulated genes is not as similar to the 24 HPI data, as it is in the data for down 
regulated genes. The general trend that down regulated genes are identified in 24 HPI 
and 12-24 HPI merged data, but up regulated genes are not, does suggest that down 
regulation of genes happens earlier in HIV infection than up regulation, although this 
has not previously been observed and may merely be a by product o f infection 
conditions, rather than infection itself.
Diverging responses late in infection
In order to determine if genes identified to be differentially regulated in cells infected 
with HIV-1 subtype B, group O and HIV-2 ETP at 24 HPI, were also differentially 
regulated in the second set of time courses and arrays performed (for 0-2 vs. 12-24 HPI 
analysis), the 24 HPI data from the repeat experiments was analysed. The same patterns 
o f up and down regulation were found in the repeat arrays for six of the ten genes of 
interest, namely: Pim2 oncogene; LAG1; TFIIH; BC16; NXF1 and hGCN5, verifying 
this data (Figure 4.24). Results for the other four genes were not conclusive. These 
data therefore corroborate the findings from previous analysis of differentially 
expressed genes at 24 HPI (section 4.3.2.8, Figure 4.19): regulation of these genes are 
strongly associated with subtype/type specific infection.
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Figure 4.24 Identification of g e n e s  differentially regulated late during the first 24 hours 
of infection betw een  HIV-1 Subtype B, Group O and HIV-2 ETP.
G enes for which significant diverging re sp o n ses  w ere previously identified, one of which is 
within the top 50 of either up or down regulated g en es, in ST1-R5 cells infected with HIV-1 
subtype B, group O and HIV-2 ETP. The data  plotted is the m ean Log(2) (Cy5/Cy3), and 
standard error of 3 replicate spo ts for each  gene  0 and 24 HPI. The virus in response  to which 
the gene regulated w as within the top 50 is m arked in each  c a se  with an asterisk (*).
Pirn -  2 oncogene
u
♦
¥
¥
•  f
♦
♦
.  t
LAG1/LASS6
l—
♦—
1 H
U  ^ *
1
I¥
.  t
TFIIH
i  
^ *
*  5
£
*
* 1
5  BCL6u -cT00 -0-5
.3 ,
-1.5 - I
-2 
.1 < . z * n « * i
Nuclear RNA export factor 1
hGCN5
I
I
X
♦
I
1
X.
* t
B O ETP
257
4.4 Discussion
HIV infects CD4+ T lymphocytes eventually inducing their severe depletion, which is 
the defining feature of AIDS. It is not clear precisely how the virus exploits the host 
cell to maximise viral particle production, or whether this process differs between 
different genetic variants o f HIV, but evidence is accumulating that HIV plays a central 
role in regulating the host cell in order to achieve this aim (Arendt and Littman, 2001). 
While biochemical approaches have been extensively employed to study the 
intracellular response to HIV infection, the advent of DNA microarrays has provided a 
powerful new tool to help illuminate the extensive effects of HIV on host-cell gene 
expression.
In this study, a method of gene expression profiling of T-cells during the first 24 hours 
of infection with the low titre primary isolates viruses HIV-1 subtype B (SF162), group 
O (BF306) and HIV-2 (ETP) was developed, which reveals both core and diverging 
transcriptional responses to infection. The core response identified represents a general 
HIV-response program, orchestrated by both host and virus. The complex interplay 
between the two is borne out as a situation in which the virus attempts to harness the 
host cell to ensure its own propagation, whilst the host possesses mechanisms to disable 
the virus and drive itself towards death, bringing the infection cycle to an end. Many 
previously well-documented aspects of this process were observed in this study, with 
the addition of novel core response processes described for the first time. Augmenting 
this core response are more divergent, virus-specific transcriptional responses. The 
detection of these indicates that different genetic variants of HIV have acquired specific 
and directed mechanisms of host interaction in order to successfully propagate 
themselves. Several findings may begin to explain the observed differences in 
phenotype between the viruses studied, both in vivo and in vitro. The results presented 
outline the importance of viral genetic variation in the processes of infection and 
disease.
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4.4.1 A method for microarray analysis of low titre, high multiplicity HIV 
infection.
For microarray analysis o f HIV-1 subtype B, group O and HIV-2 ETP a high 
multiplicity of infection was required to ensure synchronous infection. Initial 
investigations of the interaction between HIV and T-cells were particularly hampered 
by the use of a low multiplicity o f infection and long time courses (Geiss et a l, 2000). 
As the infectious titre of the primary isolate stocks used was low compared to that 
which can be achieved with cell line adapted viruses or molecular clones, to achieve the 
desired high multiplicity of infection a small number of cells were infected, meaning 
that RNA available from infected cells became limiting. Accordingly, a number of 
RNA extraction and amplification protocols were studied in order to identify a method 
which would effectively amplify RNA from 104 cells whilst preserving the relative 
abundances of different mRNAs within the starting population in a reproducible 
manner.
The resulting method proved to be efficient in producing linearly amplified RNA (with 
good correlation with un-amplified RNA) in a reproducible and consistent manner. 
Amplification of reference RNA was also performed in keeping with recent reports that 
it is important for sample and reference RNA to be generated in the same way (Li et al., 
2004b). The hybridisation properties of the amplified reference RNA were consistent 
with that of the un-amplified RNA, important as one of the main purposes of using a 
universal reference RNA is to enable different array experiments to be cross compared, 
provided they use the same reference RNA.
The study of low titre viruses such as those used here would previously have not been 
possible without the optimisation of the infection, RNA extraction and amplification 
protocols described. It should be noted, however, that there is a particular limitation 
inherent in the experiments here presented, relating to the comparison of viruses of 
different viral titre. Specifically, in order to equalise the volume in which infection was 
performed, different volumes of virus and medium were combined, for each isolate. As 
a result, during infection the cells were not only exposed to different viruses, but also 
different concentrations of cytokines, growth and signalling factors, which also have the 
potential to significantly affect cellular gene expression. This is clearly outlined in
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sections 4.3.2.2 and 4.3.2.9 where extensive analysis was used to show that the infection 
conditions for HIV-1 subtype B compared to group O and HIV-2 ETP result in different 
patterns of gene expression early during infection, seemingly independent o f the type of 
HIV infecting the cells. As such this study provides both an example of experimental 
variation potentially providing misleading data, and how to extract meaningful data 
from ‘noisy’ data using the appropriate analytical tools with due care and attention. The 
successful use of this method therefore demonstrates its utility in studying low titre viral 
infections of small numbers of cells, and may equally be applied to other viruses or low 
passage HIV isolates derived from patient samples. The use of purified virus may bear 
further investigation for future studies.
4.4.2 The core response to HIV infection
Genes identified as being significantly regulated during infection with all three viruses 
included those involved in modulation of cell growth and maintenance; transcription, 
transcriptional regulation and translation; response to external stimulus; cell signalling; 
immune responses; lipid and protein metabolism; and intracellular trafficking (section
4.3.2.5). It seems that this broad range of responses are elicited around 24 HPI and that 
whilst some may represent more universal cellular responses to infection others are 
more pointed. These may be specific methods of antiviral defence orchestrated by the 
host, for example down regulation of TIP30 which function as a Tat-enhancer, or are 
examples of gene regulation driven by the virus itself, such as down regulation o f MHC 
class I-C by HIV Vpu (Kerkau et al., 1997) and Nef (Andrieu et al., 2001). It is very 
difficult when considering the majority of these core responses, however, to distinguish 
between the two forces - host and virus - when attempting to dissect the nuances of 
cellular transcriptional responses to HIV infection.
4.4.2.1 Virus versus host: driving the core response to HIV infection 
The viral accessory proteins Tat, Nef, Vpr and Vpu have all been shown to affect the 
host in such a way to propagate infection, and the down regulation of MHC class I 
(Vpu/Nef), up regulation of negative cell cycle regulators (Vpr), and up regulation of 
growth factors (Tat) are all examples o f their effects, detected in this study. Their 
functions, however, are most probably far from completely understood and the true 
extent to which they contribute to this core response is by no means clear. It would 
require the systematic knock out o f these accessory genes in the context of infection to
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ascertain their function in a given cell type. It is possible, however, that in the absence 
of one accessory gene another may compensate for it, or conversely loose certain facets 
of its functionality, further increasing the ambiguity regarding their function. Several 
studies have involved the exposure o f cells to either endogenously or exogenously 
expressed accessory proteins such as Tat (Gibellini et al., 2001, Izmailova et a l, 2003, 
reviewed in section 4.1.4.1), revealing important functional consequences of their 
presence in a host cell. Outside o f the context of infection, however, such work can be 
difficult to interpret as the host is relatively inert: conclusions drawn are partly clouded 
by the lack of a host response which may significantly alter that which is elicited by the 
transient presence of a viral protein alone. Perhaps a better approach, therefore, may be 
to systematically knock out the genes being regulated by HIV accessory proteins, rather 
than the accessory proteins themselves, in the context of infection. There are several 
host genes identified as being regulated as part o f this core response, which could be 
targeted in order to assess their significance during HIV infection.
4.4.2.2 VEGF
VEGF up regulation was found to be part o f the core response to HIV infection, which 
has previously been attributed to the action of HIV Tat (Benelli et al., 2000). The 
literature, however, is somewhat in disagreement as to the importance o f this 
observation, in relation to HIV. Several studies have described an increase in VEGF 
expression levels during HIV infection both in vitro (Ascherl et al., 1999) and in vivo 
(Wang et al., 2004) - one study in particular associating elevation of serum VEGF with 
the occurrence of HIV encephalopathy (HIVE), the mechanism for which is not 
understood (Sporer et al., 2004). Another study investigating the utility of VEGF 
concentrations in serum as a predictive marker for AIDS-related Kaposi’s Sarcoma 
(AIDS-KS), however, found that serum concentrations of VEGF were not influenced by 
HIV-1 infection (Renwick et al., 2002). The main importance of elevated serum VEGF 
has thus not been related to HIV infection itself, rather the focus has been on its role in 
the development of AIDS-KS. KS cells produce and respond to angiogenic factors such 
as VEGF, with this factor being crucial in the development of KS tumours (Comali et 
al., 1996). HIV Tat also plays a major role in the pathogenesis of AIDS-related KS by 
augmenting the angiogenic activities of VEGF, and activating the VEGF receptor-2 
(Aoki and Tosato, 2003). Furthermore, KS cells themselves also display elevated 
expression of VEGF (Comali et al., 1996). As strong VEGF up regulation as a result of
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HIV infection alone was observed in this study, however, it would be interesting to 
determine whether inhibition o f VEGF expression will actually affect HIV replication. 
It has been proposed that VEGF up regulation via the activity of extracellular Tat is part 
of a viral-driven process of suboptimal activation of T cells, in which partial activation 
signals enhance latent HIV infection by favouring entry into anergy (Benelli et al., 
2000). Thus, RNA inhibition o f VEGF expression or use of synthetic molecule 
inhibitors such as SU5416, which has been shown to decrease VEGF mRNA expression 
levels in a dose- and time-dependent manner (Zhong et al., 2004), could be used to 
study infection in the absence o f this factor. If VEGF expression is important to the 
process of HIV replication, as well as in the development of AIDS-related 
vasculopathies, this should become more clear.
4.4.2.3FOS
Similarly, the Tat-mediated induction o f fos described previously in uninfected T cells 
(Gibellini et al., 2001) was detected as part o f the core response to primary HIV 
infection. This has been proposed to be involved in the up regulation of genes critical 
for the activation of T lymphocytes, such as interleukin 2 (IL-2), thus contributing to an 
optimal environment for HIV-1 replication in activated CD4+ T cells. In addition to 
this function, however, the role of fos in the enhancement of HIV-1 gene expression in 
primary human CD4 T-cells, via NFAT-1, has been described (Chen et al., 1998, Cron 
et al., 2000, Giffin et al., 2003). NFAT has been considered as a therapeutic target for 
prevention of HIV-1 LTR-directed gene expression in HIV infection (Cron et al., 2000). 
Given the observation that fos is strongly up regulated as part of the core response to 
HIV infection, studies in which fos expression is inhibited and the efficiency of 
transcription and infection monitored, should help show how important this factor is: 
whether it is most important in priming the cellular environment for the process of viral 
replication, or whether its direct involvement in viral transcription is sufficiently 
influential to make it a valid therapeutic target. It has been observed that HIV-1 
seropositive individuals are less likely to progress to clinical immunodeficiency while 
undergoing treatment with NFAT inhibitors such as cyclosporin A (Schwarz et al., 
1993, Levy et al., 1995, Andrieu et a l, 1988), as part of combination therapy. Such 
inhibitors might help limit the risk o f acquisition of resistance to other anti-viral agents. 
If fos were confirmed to play a significant role in the process of viral replication and be
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important in the chronic immune activation characteristic of AIDS progression, it too 
could be a valid drug target.
4.4.2.4TJP30
TIP 30, a serine/threonine kinase which induces the expression of apoptosis related 
genes and interacts with amino acids 1-48 of HIV-1 Tat enhancing Tat activation of the 
HIV-1 LTR promoter (Xiao et a l, 1998), was down regulated as part of the core 
response to HIV. It would seem advantageous that an infected cell would down 
regulate TIP 30 in response to infection, as this may function as a means to both reduce 
Tat activity and cellular pathology as a result o f an increase in apoptosis. Conversely, 
the reduction in expression o f apoptotic factors could be advantageous to the virus. 
Experimentally, if TIP 30 were provided either exogenously in an experimental 
infection system, or effectively inhibited using a small molecule inhibitor or small 
interfering (si) RNA, it would be interesting to determine (as above for fos) if HIV 
transcription or infection efficiency would be altered. It is also interesting to note that 
expression of TIP 30 in an adenovirus vector system has been shown to inhibit the 
proliferation of tumour cell lines through both p53-dependent and p53-independent 
pathways (Zhang et a l, 2004), and that TIP 30 deficiency has conversely been shown to 
increase susceptibility to tumorigenesis (Jiang et al., 2004). Thus, it may be that down 
regulation of TIP 30 during HIV infection may play a role in the complex processes that 
lead to the development of lymphoproliferative disorders (Little, 2003), as well as in the 
modulation of viral replication and the cellular microenvironment.
4.4.3 Identification of core response elements is clinically important
Whilst the core response to HIV infection may be taken as an indicator as to the most 
important and basic interactions between the host and virus, defining its replication 
strategy and pathological consequences, its characterisation may also be considered as 
an important tool in the search for future antivirals and biomarkers of disease. A good 
example o f the latter was the identification of VEGF as being significantly up regulated 
in response to HIV-1 subtype B, group O and HIV-2. The biological significance of 
this was discussed in section 4.4.2.1 and the literature described: there is a lack of 
consensus regarding both the relationship between HIV and VEGF elevation, and its 
potential use as a biomarker in the prediction or therapeutic monitoring of AIDS-KS 
(Renwick et al., 2002). Given the clear results in this study in terms of transcriptional
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up regulation of VEGF, however, further experiments are required to confirm up 
regulation at the secreted protein level. If  this could be shown, studies of patients would 
bear re-visiting. Previous in vivo studies o f VEGF levels in serum have not been 
longitudinal or looked at more than 50 patients. It will only be by monitoring large 
numbers of patients, over time, that the relationship between VEGF levels in serum and 
factors such as CD4 count, viral load, KS or other vasculopathies, will be determined. 
Besides CD4 count and viral load measurements there are very few prognostic markers 
of clinical progression and the development of AIDS-associated diseases. The use of 
microarrays to identify other core response factors, up regulated and secreted during 
infection, could significantly reduce the amount o f time spent searching for new 
biomarkers in the future. This study, for example, also showed up regulation o f TIMP- 
2. As described in section 4.3.2.5, Tat cooperates with certain factors in inducing MMP 
activation and increasing cell membrane-associated TIMP-2, but decreasing the amount 
of secreted TIMP-1 and -2  (Toschi et al., 2001). These in vitro effects are associated 
with the induction of vascular permeability and oedema in vivo, resulting in AIDS- 
related vasculopathy. As increased levels o f MMP-2 are found in plasma from patients 
with AIDS-KS, compared with HIV-1-uninfected individuals with classic-KS (Toschi et 
al., 2001), these results suggest that MMP-2 may also be a useful biomarker for HIV- 
related vasculopathies, or indeed be a therapeutic target to reduce KS aggressiveness or 
vasculopathy in HIV positive individuals. Similarly, changes in plasma TIMP-2 may of 
prognostic or diagnostic use.
In addition to the identification of potential biomarkers of HIV disease, a better 
understanding of the core response to HIV infection also enables the identification of 
potential novel therapeutic targets. There has long been a focus on targeting and 
disabling the gene products of HIV in an attempt to prevent viral replication. Increasing 
attention, however, is now being paid to the host and how host genes may be targeted to 
prevent successful viral replication. A recent study of the role of host factors in HIV 
transcription, for example, offers a strong precedent for exploring knockdown of 
CDK9/CyclinTl (P-TEFb) and other cellular proteins as a potential new strategy for the 
development of AIDS therapeutics (Chiu et al., 2004). As described, this study has 
identified several potential candidates for such targeted inhibition, including VEGF, 
FOS and TIP30 (sections 4.4.2.1-3). These are drawn from the list of core up regulated 
genes, which includes several others.
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Figure 4 .2 5  Genes regulated by SREBPs.
The diagram  show s the major m etabolic interm ediates in the pathw ays for synthesis of 
cholesterol, fatty acids, and triglycerides. In vivo, SREBP-2 preferentially activates g en es of 
cholesterol metabolism, w hereas SR EB P-1c preferentially activates g en es of fatty acid and 
triglyceride metabolism. DHCR, 7-dehydrocholesterol reductase; FPP, farnesyl diphosphate; 
GPP, geranylgeranyl pyrophosphate syn thase; CYP51, lanosterol 14a-dem ethylase; G6PD, 
g lucose-6-phosphate dehydrogenase; PGDH, 6-phosphogluconate dehydrogenase; GPAT, 
glycerol-3-phosphate acyltransferase (R eproduced from Horton et al., 2002).
SREBP-2
Ac*to*c*fyl CoA thiola**
A<*1o<K*tyl CO*
HMG CoA symttMM I
HMG CoA 
HMG CoA roOocUM
Mevalonale 
Mrvsionat* kinase 
Pho*phom*v»lof\at» kinase 
Mavatooata PP <tocarbo*y4aae _ _ _  
GPPaynahaae < 2 2 5 *  
lPP iaotneraae 
FPP synthase 
Squaleo* synuHas* ?
Squaian* 
Squolene expomdase 
Lanosterol synthase 
CVPS1
Lathosterol oxidase
ATP-citral* lyase
Acetyl CoA SREBP-1C
Acetyl CoA certMsylesa
Matonyl CoA
Fatty aod synthase
Long chain tatty acyl elongase
Saturated fatty acids
i Stearoyl CoA desaturase
M onoun& aturated 
tatty ac id s
Glucose-e-P S-P-gluconate v
Fatty acyl CoA 
GPAT
Monoecytglycerol 3-phosphale
r*c#ptOf ______________ ¥______________
Components of the cholesterol biosynthesis pathway illustrated in Figure 4.25, for 
example, were strongly up regulated (section 4.3.2.5): acetoacetyl Coenzyme A 
thiolase; 3-HMG-CoA reductase (HMG-CoA); and mevalonate kinase. It has 
previously been shown that the use of statin compounds can prevent HIV-1 infection in 
cultured primary cells, in animal models and in chronically infected individuals 
(Maziere et al., 1994, Giguere and Tremblay, 2004, del Real et a l, 2004). Specifically, 
statins are HMG-CoA reductase inhibitors normally used to treat hypercholesterolaemia. 
As well as its role in cholesterol biosynthesis (Figure 4.25), however, HMG-CoA 
reductase also generates isoprenoids that modify specific cell proteins post- 
translationally. Rho guanosine triphosphatases (GTPases), for example, must be 
prenylated at their C terminus by HMG-CoA reductase for their function as molecular 
switches that cycle between GTP-bound (active) and GDP-bound (inactive) states to 
control actin cytoskeleton remodelling in response to stimuli (Etienne-Manneville and 
Hall, 2002). By targeting HMG-CoA, therefore, statins block cholesterol biosynthesis,
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but also affect actin cytoskeleton rearrangement by inhibiting Rho GTPases (Koch et 
al., 1997), required for virus entry and exit. In addition, statins may diminish HIV-1 
attachment to target cells by suppressing ICAM-l-LFA-1 interactions (Giguere and 
Tremblay, 2004). It has also been suggested, however, that the RhoA signal 
transduction pathway may inhibit HIV-1 replication via a novel effector activity (Wang 
et al., 2000). This is supported by the recent observation that lovastatin has both pro- 
HIV (increasing viral genome transcription) and anti-HIV effects (inhibiting virus entry 
into and virus production by the target cell), presumably by inhibition of Rho activity 
(del Real et a l, 2004). With this in mind, therefore, perhaps more targeted forms of 
inhibition of factors affected by statins should be explored. If a factor alternative to Rho 
could be targeted in terms of disrupting cytoskeletal rearrangement, for example, then 
the Rho activity of inhibiting viral transcription could be left intact. The observed 
strong up regulation of acetoacetyl Coenzyme A thiolase indicates that this factor is 
important in HIV infection, so perhaps a targeted inhibition o f this gene, rather than one 
further down the cholesterol biosynthetic pathway, could prove advantageous. It would 
be interesting to see whether inhibition of acetoacetyl Coenzyme A thiolase would have 
a similar effect to inhibition of HMG-CoA reductase in vitro. If this were the case it 
would point to an important involvement o f increased intracellular cholesterol in HIV 
replication. Because HMG-CoA reductase inhibition can affect viral replication 
through several pathways, a more targeted approach will also reveal more about the 
relationship between HIV and the host cell.
The up regulation of the factors adaptor-related protein complex 2 (AP2) and surfeit 4, 
involved in intracellular trafficking, was also observed as part of the core response to 
HIV infection. AP2 is involved in the process of Nef-mediated CD4 down regulation 
(section 4.3.2.5), but siRNA induced AP2 knockdown has not been shown to have a 
significant effect on the extent of CD4 down regulation (Rose et al., 2004). These 
experiments, however, were performed outside of the context of infection so the effect 
of AP2 knock-down on viral replication was not determined. That is, as this gene is 
strongly up regulated if may be that AP2 not only functions in mechanisms of protein 
sorting, resulting in aberrant trafficking, intracellular trapping and degradation of 
targeted receptors, but also in the trafficking of viral proteins, such as Env. The strong 
up regulation of surfeit 4 may also bear investigation for the same reasons.
266
Other potential therapeutic targets for which less information is available include the 
factors involved in transcription found to be up regulated as part of the core response: 
AP2 gamma, SERTA domain containing 2, and zinc finger protein 131. The strong up 
regulation of these genes suggests that they may play an important role in the process of 
infection, either in aiding viral transcription or the transcription of host genes in 
response to infection, making them, like P-TEFb, potential targets for the development 
of AIDS therapeutics (Chiu et al., 2004).
4.4.4 The diverging response to HIV infection
As described in Chapter 3, both epidemiological and in vitro studies have provided 
evidence that sequence variation among the genetic variants o f HIV may influence 
disease progression, transmissibility, and viral phenotype. In terms of in vitro studies, 
investigations have largely focussed on the importance o f LTR/accessory gene sequence 
divergence and the functional consequences o f these, but none to date have investigated 
whether such well characterised sequence divergence influences patterns of host gene 
expression, during infection. Several microarray-based studies o f host gene expression 
during HIV-1 infection, however, have greatly increased our understanding o f how 
human cells respond to HIV-1 infection and how HIV-1 is capable o f modulating host 
gene expression. These studies have therefore set the scene for this investigation, in 
which comparison of genetic variants of HIV has not only enabled the characterisation 
o f a core transcriptional response, but has also enabled the identification of examples of 
divergent gene expression, in which two viruses cause directly the opposite effect on 
expression of a particular gene. As with the core response genes, these transcriptional 
responses require confirmation (beyond the scope of this thesis) but the preliminary data 
presented in this study provide a clear insight into how different genetic variants of HIV 
may differentially modulate gene expression, especially in relation to control o f cell 
cycle and apoptosis, and transcriptional regulation. Taken together, these results 
provide some suggestions with regards to how the genetic variation between HIV-1 
subtype B, group O and HIV-2 affects viral phenotype in vitro, and therefore indirectly 
how it may influence the process of infection and disease in vivo.
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4.4.4.1 Transcriptional divergence detected relates to published observed differences 
between HIV-1 and HIV-2
As described previously it has long been known that HIV-2 disease progression seems 
to be much slower than HIV-1, and that HIV-2 is associated with decreased 
transmissibility, protracted stage o f CD4 decline and significantly lower viral load 
(literature reviewed in Chapter 3, section 3.1.1.5). This has, in part, been attributed to 
certain in vitro observations, which are listed here. The data from this study in support 
of these is summarised.
HIV-2 infection appears to result in lower viral replication compared to HIV-1 (Berry 
et al., 1998, Popper et al., 2000).
Whilst HIV-2 specific immune responses are more broad and efficient than those 
detected in HIV-1 infected individuals, potentially explaining this observation 
(reviewed in Andersson, 2001), other factors are likely to contribute. These may 
include the differential expression of host factors involved in viral transcription, such as 
TFIIH, which interacts with HIV-1 Tat as a component o f the HIV-1 transcription pre­
initiation complex (Garcia-Martinez et al., 1997). Expression of this gene was down 
regulated in response to HIV-2, but was up regulated in response to HIV-1 subtype B. 
Together with up regulation of cyclin dependent kinase 7 (Cdk7 - an essential 
component of the TFIIH transcription factor) in response to HIV-1 subtype B, these 
data suggest a difference between HIV-1 and HIV-2 in the expression of host factors 
essential for viral transcription, where transcription from the HIV-1 LTR is favoured. 
Differential regulation of GNC5, BC16 and RXRA. may also contribute to the 
differences between HIV-1 and HIV-2 in terms of transcriptional activity and 
subsequent viral replication rate.
HIV-2 is associated with a lower general level o f  immune activation and apoptosis 
compared with HIV-1 (Machuca et al., 2004)
Up regulation o f Pim-2 oncogene in response to O and ETP infection, but down 
regulated during subtype B infection, provides a direct link between HIV-2 and reduced 
apoptosis (DeBiasi et al., 2003). Confirmation of this observation will prove important 
in understanding this potentially crucial difference between HIV-1 and HIV-2.
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HIV-2 infection is associated with increased CCR5 down regulation (Shea et al., 2004). 
LAG1 was up regulated during HIV-2 ETP infection, but was down regulated during 
HIV-1 group O infection. This may be important as LAG1 expression affects ceramide 
synthesis which, in addition to effecting growth, proliferation, stress resistance, and 
apoptosis (Jazwinski and Conzelmann, 2002) also perturbs localised membrane domain 
structure and organization (Finnegan et al., 2004). Infectivity may be reduced as a 
result of this, due to trafficking o f virions via an endocytic pathway that leads to non­
productive infection (Schaeffer et al., 2004, Finnegan et al., 2004) and disruption of 
coreceptor recycling. Hence both viral infectivity and CCR5 expression may be 
abrogated as a result of LAG-1 up regulation, during HIV-2 infection. It has been 
shown that by enhancing ceramide levels in CD4+ lymphocytes and in monocyte- 
derived macrophages with 4-HPR or Smase, HIV-1 infectivity can be significantly 
reduced without toxicity, making these drugs potentially suitable as anti-HIV 
therapeutics (Finnegan et al., 2004).
4.4.4.2 HIV-1 group O also differentially regulates host cell transcription 
The majority of this discussion has focussed on the transcriptional response of host cells 
to HIV-1 versus HIV-2 infection, as the difference between these two viruses has been 
fairly well studied both in vitro and in vivo. HIV-1 group O infections, perhaps due to 
their rarity, are much less well studied and very few publications have considered the 
importance of their genetic distance from the HIV-1 group M subtypes. Despite the 
lack of corroborating data to support observations, as with the HIV-2 microarray data, 
several interesting findings were made.
As in HIV-2 infection, Pim2 was up regulated in response to group O infection, inviting 
the possibility that group O infection may also be associated with decreased apoptosis in 
vitro and potentially, therefore, an altered pathogenicity in vivo compared to HIV-1 
subtype B. Up regulation of RXRA was also detected in group O infection, whereas 
down regulation of this nuclear receptor was observed in subtype B infection. As 
antagonists of this receptor activate HIV-1 replication it is possible that modulation of 
the retinoid receptor may have an important effect on regulation of HIV-1 group O 
infection. Whether certain subtypes or types of HIV differ in their response to RXRA- 
antagonists, perhaps through variation in their LTR sequence and thus responsiveness to 
repression by host factors, is not known. Finally, cdk5 is actively up regulated in
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response to group O infection, but was down regulated in response to subtype B. Whilst 
the biological importance of this in T-cells is not particularly clear, it is likely that this 
divergent regulation is indicative of the different way in which HIV-1 subtype B and 
group O Tat can act on host cells.
4.4.5 Summary
In considering both the core and diverging responses to HIV infection identified in this 
study, one must conclude that they represent the combination of both cell- and viral- 
driven changes in gene expression that are the most strong and essential, 24 hours post­
infection of ST1-R5 T-cells. Not all processes of transcriptional modulation taking 
place within the infected cell, however, will have been described.
In terms of the core response, given the sequence divergence between HIV-1 B, O and 
HIV-2, it is tempting to consider that the host’s part in this core infection profile is 
perhaps more dominant than in the diverging responses identified: the feature that 
unifies each infection condition is the host, after all. Evidence has been presented, 
however, that points to a strong viral involvement in the modulation of this core 
response (section 4.3.2.5) and of the genes described the regulation of many, at least in 
part, can be attributed to the actions of Tat and Nef.
Evidence has also been presented that shows, in addition to the core response to HIV 
infection, different genetic variants of HIV induce divergent gene expression patterns. 
In certain cases such as Pim2 regulation, these lend support to published observations, 
in particular in relation to the differences between HIV-1 and HIV-2. Other 
observations point to as yet uncharacterised differences between the way HIV-1 B, 
group O and HIV-2 interact with the host, and the significance of these is consequently 
less clear. In understanding the differences between different genetic variants of HIV 
and their interactions with the host, we may begin to better understand the significance 
of viral genetic variation on HIV disease. The comparison of HIV-1 and HIV-2 is very 
important in this respect. Between the different HIV subtypes, however, the effects of 
genetic variation are likely to be subtle, and significantly complicated by the influences 
of host genetic variation and other environmental factors. The importance of subtype 
variation in the development of drug resistance may be more important. The core host 
and viral responses to infection, however, are the unifying factor between HIV infection
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and the fact that infection will ultimately lead to progressive CD4 decline, AIDS, 
opportunistic infections and death. By characterising and better understanding the most 
conserved consequences of HIV infection a clearer view of the interaction between host 
and virus, and how it may be interrupted therapeutically, may be sought.
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Chapter 5.0 Discussion and future work
In the introduction to this thesis the aim was set out as being to characterise the 
genotypic and phenotypic features o f the different HIV-1 types and subtypes, the 
question being asked are the genotypic differences between HIV variants manifested 
phenotypically and if so, does it matter?
In Chapter 2, the development o f a HIV subtyping tool, STAR, was described. This 
was done bearing in mind that, globally, laboratory monitoring of HIV-1 drug resistance 
has the potential to provide an excellent sequence resource for identifying HIV 
subtypes, their movement and by association with clinical data, their clinical 
significance. Any clinical laboratory dealing with drug resistance profiling o f 
potentially thousands of sequences but where subtyping is not the primary concern, 
however, will require an appropriate method for such analysis. The genotypic variation 
between the HIV-1 subtypes in Pol was therefore thoroughly characterised, to form the 
basis of a PSSM-based subtyping algorithm. The resulting program, STAR, will 
automatically and accurately classify 36 sequences per minute and is independent of the 
user. It does not attempt to define subtype boundaries, or replace the phylogenetics and 
phylogenies from which it was derived; rather it is designed as an aid to 
epidemiological investigations and the study of the importance of HIV-1 genetic 
variation. This will only be achieved, however, if STAR is implemented in 
standardized settings and a concerted effort is made in the processes of acquisition, 
compilation and annotation of HIV sequence data produced for resistance testing. 
Current efforts to achieve this are ongoing, in the creation of HIVCentral; a database for 
resistance sequence data and associated clinical information produced across Europe (R. 
Gifford, UCL). A recently updated version of STAR has been implemented in this 
database as the main method for subtyping sequence data (Myers et a l, in press), so it is 
hoped that in this setting questions about the relationship between HIV subtype and: 
disease progression; efficiency of diagnostics; response to therapy; drug resistance 
patterns; and the introduction and spread of genetically distinct HIV variants into 
monitored populations, may be asked. Given the ability of STAR to detect 
recombinants within Pol, such a large-scale analysis may also enable an estimation of 
recombination frequencies within this genomic region. It will only be with such large
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numbers of sequences and accurate subtype classification that, at the population level, 
we may begin to see the importance o f HIV-1 genotype.
The need to develop STAR for such studies therefore naturally alludes to the fact that 
the role viral genotype plays in the phenotype o f HIV disease is, despite several studies 
on the matter, far from clear. Many would argue that the subtle differences so far 
detected are more easily attributable to host or environmental variation, moulding the 
process of disease. A cogent argument for the importance o f founder effects, together 
with a paucity of data with regards to inter-host evolution of HIV in different host 
populations, leaves the notion that biological differences between HIV subtypes might 
exist by virtue of their evolution in genetically distinct host environments, with little 
substance. The importance of intra-host evolution in relation to disease progression, 
however, is well documented; so the question remains in this context do the genetic 
differences between different HIV subtypes modulate intra-host evolution and therefore 
progression of disease? As the virus is intrinsically part of the host, its genetic 
composition moulded by the environment in which it exists, it seems likely that on a 
person to person basis if you start with a different viral genetic variant then this 
interaction may not always have the same end result. The data presented in Chapter 3 
of this thesis display how, when HIV o f different subtypes are placed in the same 
experimental system, they do indeed behave differently. Whilst this may not be a direct 
reflection of the in vivo situation, as a means to outline the potential for phenotypic 
differences between genetic variants of HIV and the extreme difficulty in characterising 
them, these experiments are very clear. In addition, whilst drawing specific conclusions 
from these data is difficult, it does seem that env tropism and coreceptor usage are very 
important in determining viral phenotype in vitro. The mechanisms of this have been 
discussed and are less than clear, but if the genetic variation between HIV-1 subtypes 
does guide their coreceptor preference, as preliminary data presented here suggests it 
might, then it seems inevitable that the HIV-1 subtypes and the subtleties of the process 
of disease they cause, may differ.
In consideration of the experiments required to determine the importance of this 
relationship between subtype, coreceptor usage and disease progression, one must first 
consider that the reasons why 50% of viral isolates from patients with AIDS display 
X4-tropism, but the presence of X4-tropic virus in HIV+ patients at seroconversion is
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rare, are not completely understood. Review of the literature, however, enables a 
general process to be described in which a selective bottleneck at transmission results in 
positive selection o f R5-tropic viruses, which predominate due to their preferential 
access to and replication within body compartments favouring virus of this tropism, 
such as GALT. Over time this becomes exhausted and viruses of X4 tropism, which 
may have been present as minority quasispecies within CXCR4+ cellular compartments, 
gain a competitive advantage (Grossman and Paul, 2000, Moore et al., 2004). The 
chronic activation of CD4+ T-cells has, however, begun the decline in their 
functionality and concomitant with switching and outgrowth of X4-tropic virus, a 
precipitous drop in CD4+CXCR4+ T-cell count occurs, the broad infection capacity of 
X4-tropic viruses (targets including haemopoeitic progenitor cells and thymocytes, 
Bleul et al., 1997, Berkowitz et al., 1998, Rosu-Myles et a l, 2000) enhancing immune 
dysfunction. In combination with destruction of CCR5+ compartments, general 
immune dysfunction due to chronic and aberrant activation, and loss of CD4+ T-cells, 
AIDS is the result. In this setting the important consideration, therefore, is the time at 
which R5 to X4 switch occurs, the suggestion being that the sooner you switch the 
worse your prognosis. It is therefore of interest whether different viral subtypes will 
switch at different times, by virtue of their genetic differences within gpl20 placing 
them at different points on the evolutionary continuum from R5 to X4-usage. In order 
to determine this, longitudinal studies will be required which follow patients of matched 
ethnicity, age, sex, and preferably treatment, but which are infected with different HIV 
subtypes. Whilst in the past such patient cohorts have been few and far between, 
clinical trials of antiretroviral therapies, especially those that are beginning to take place 
in Africa where multiple subtypes of HIV co-circulate, may provide populations 
appropriate for such studies. Envelope sequencing over time would be realistic in this 
setting, and may indicate the prognostic value of V3 scoring (Jensen and van lt Wout, 
2003). If there is an association between changes in V3 score, tropism, viral subtype, 
and the phenotype of HIV disease, it would hopefully be detected. It would also be 
advantageous to repeat experiments performed in this thesis, only with a much larger 
sample of viruses representative of each subtype. It would be interesting to see if 
patterns of coreceptor preference among HIV primary isolates of different subtype are 
borne out, and whether these relate to growth phenotype in vitro, and perhaps therefore 
also the phenotype of disease in the patient from which they were acquired.
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Despite the concentration on the importance of coreceptor usage and its relationship 
with HIV subtype and disease, however, this thesis by no means concludes that this is 
the all-important manifestation of HIV genetic variation that may modulate the 
progression of infection. One only needs to consider HIV-2 as an example o f a virus 
with a typically very broad coreceptor usage and therefore cellular tropism, but which 
has a very attenuated clinical course. Since HIV-2 varies from HIV-1 in approximately 
50% of its genome sequence and between the HIV-1 subtypes this variation may be up 
to 30%, the questions follow; other than coreceptor usage what other features of HIV 
govern its interaction with the cell; how do these interactions differ, between genetic 
variants; and do they effect the phenotype o f disease resulting? Clearly these are the all 
important questions, all of which cannot be addressed at once, if at all. Accordingly, the 
fourth chapter of this thesis describes a series of microarray experiments which aimed to 
answer the question: to what degree is there commonality in the way genetically 
divergent HIV isolates interact with the host cell, in terms of their modulation or 
induction o f host transcriptional processes? In essence, unlike the previous chapter, this 
work was concerned with understanding the most specific and intimate interactions 
between HIV and its host cell. With the resulting information it was hoped that a better 
approach might be sought in dissecting the roles host and virus play in the process of 
infection and, furthermore, whether genetic variation of HIV is manifested in these 
processes.
In terms of achieving a better understanding of the interaction between host and virus 
during infection, the results of chapter four largely confirmed that which has previously 
been described: HIV infection of T-cells generally results in reduced cell cycling and up 
regulation of certain genes required for viral replication and spread (generally accepted 
to be as a result of expression of certain viral accessory genes, in particular Tat) and the 
initiation of a cellular stress-type response. Although not confirmed by additional 
experiments or in other publications, certain more directed mechanisms of host anti­
viral defence and ways in which the virus may modulate cellular transcription processes 
were also described. The strength in this study, however, lies in the fact that three 
genetically distinct HIV isolates were studied in the same system: HIV-1 subtype B, 
HIV-1 group O and HIV-2 ETP. That is, in comparing gene expression in response to 
these viruses, an extra dimension could be added to the results obtained in that patterns 
of gene expression could be segregated, firstly into those that are ‘core responses’,
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which whilst unlikely to be a complete description, may be taken to represent examples 
of the most vital and conserved processes of genetic regulation, orchestrated by both 
host and virus, during HIV infection. An analysis of the core response was performed 
and the fact that certain genes identified may be novel drug targets or biomarkers of 
disease further emphasises the utility of this sort of study. Secondly ‘diverging 
responses’, seen in response to individual viruses, were identified. Careful analysis of 
data and curation of such gene lists further enabled the distinction between genes which 
were uniquely regulated between viruses, and those for which two viruses caused 
directly the opposite effect on expression. In asking what the significance o f this is in 
the absence of complementary phenotypic data, the study of HIV-1 and HIV-2 proved 
advantageous as possible differences in gene expression detected may go some way to 
explaining certain well-defined differences between these viruses in terms of the way 
they behave in vitro. The differential modulation of apoptosis, for example, illustrates 
how changes at the transcriptional level may be manifested in vitro, and consequently 
also in vivo. With these data in hand, therefore, it is possible to answer the question 
posed, in that there is a commonality in the way in which these three genetically distinct 
HIV isolates interact with T-cells, as one might expect. There are also, however, 
diverging responses to the different viruses implying that genetic variation within HIV 
is important in modulating host gene expression. This study therefore sets a precedent 
for further investigation as to whether the genetic variation between the HIV-1 subtypes 
will be manifested, as between HIV-1 and HIV-2, as differences in modulation of host 
gene expression that are reflected in vitro, and which have implications in vivo. It will 
be interesting to see if, as with differences in coreceptor usage brought about by 
sequence variation, whether the different HIV-1 subtypes also lie on a continuum of 
differential transcriptional modulation between HIV-1 subtype B, group O and HIV-2, 
depending on their genetic distance from each.
The fourth chapter of this thesis is incomplete in that it lacks confirmation of gene 
expression data. Ideally, changes in gene expression should not only be confirmed by 
RT-PCR or quantitative PCR at the RNA level, but levels of expressed protein should 
be determined. Together with knock out or inhibition of gene products up regulated as 
part of core or diverging responses, these analysis would lend much greater weight to 
the biological and functional consequences of observations here made. These were 
unfortunately beyond the scope of this thesis. As an indication of the methodological
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optimisation and analytical rigour required for such a study, however, this work is 
complete. And as an initial foray into the study of the interaction of HIV primary 
isolates with the host cell, it perhaps is a positive thing that this work creates more 
questions than answers.
Thus, in returning to the question asked at the beginning of this thesis it can be 
concluded that the genotypic differences between the HIV subtypes are manifested 
phenotypically, when studied in vitro: both in the manner in which they grow, largely 
governed by preferential coreceptor usage; and in the way they modulate host 
transcription, orchestrated by both the virus’ effect on the host and the hosts response to 
the virus. In considering whether the phenotypic manifestations of genotypic variation 
matter, therefore, attention should perhaps be paid to the latter point: both the virus and 
the host determine the outcome of HIV infection. That is, whilst genetic variation 
amongst HIV almost certainly has some effect on the phenotype of disease, it is perhaps 
the host that has the greater influence. Despite HIV’s far greater capacity for genetic 
diversification, the consequences of genetic and behavioural diversity in humans are 
likely to outstrip that which can be achieved by the genetic variation between the HIV-1 
subtypes: in analysing data at a population level relating HIV-1 subtype to features of 
HIV disease, it may be that important features of human host variation will be 
identified. The essential problem, however, is that all such analyses rely on pre-existing 
classifications, such as viral subtype, risk group, sex, ethnicity, and so on. It may be 
that hidden within and across these groupings there are variants of both virus and host in 
which the phenotype of HIV-induced disease, for one reason or another, is different. It 
will only be when such people and viral variants begin to be identified that, together 
with current classifications, we may truly begin to understand the importance of viral 
and host genetic variation. Recent ground breaking research has indeed added insight to 
our consideration of the importance of host genetic variation. For the time being, in 
terms of the importance of viral variation, a greater understanding as to why HIV-2 fails 
to cause a significant disease burden but HIV-1 continues to newly infect and kill 
millions of people worldwide every year, would be a good place to start.
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Chapter 7.0 Appendix
Table 1. HIV-1 subtype reference sequences
Accession New Key* Country of Origin Published Subtype
AF069670 25A A A 1A 136 Somalia A
AF004885 26A A A 1A 125 Kenya A
AJ251057 28A G A G A G 45 W/C.Africa A/AG
M62320 27A 1A 1X X 42 Uganda Al
AF286237 51A A A 2A 212 Cyprus A2
AF286238 52A A A 2A 213 Congo A2
AF193276 23A B A B X X 30 Russia AB
AF193277 24A B A B A B 30 Russia AB
U54771 33A EA EA E41 Thailand AE
U51189 34A EA EX X 41 Thailand AE
U51188 35A E A E A E 9 Central African Republic AE
A F197340 36A E A E A E 9 Central African Republic AE/E?
L39106 29A G X X A G 29 Nigeria AG
AF063223 30A G A G A G 14 Djibouti AG
AF063224 31A G A G A G 14 Djibouti AG
AJ251056 32A G A G A G 45 W/C.Africa AG
AF049337 37Y 1Y 1X X 12 Cyprus AGI
A F119819 38Y 1Y 1Y 121 Greece/Cyprus AGI
A F119820 39Y 1Y 1Y 121 Greece/Cyprus AGI
AJ245481 22Y 1Y 1Y 127 Mali AGIJ
AF064699 19Y 1Y 1Y 18 Burkina Faso AGJ
AJ288981 20Y 1Y 1Y 135 Senegal AGJ
AJ288982 21Y 1Y 1Y 127 Mali AGJ
NC 001802 12B B B B B B 0 None B
U63632 13B B BB B B 44 USA B
U 21135 14BB BB BB44 USA B
M l7451/ M l2508 15BB BB BB22 Haiti B
AY008715 56B C B C B C 33 S.China BC
AY008717 57BCBCBC 33 S.China BC
AY008716 58B C B C B C 33 S.China BC
AF385934 40B FB FB F43 Uruguay BF
AF385935 41BFBFXX 43 Uruguay BF
AF385936 42B F B FX X 2 Argentina BF
U52953 53C C X X C C 7 Brazil C
AF286226 5 4 B C B C B C 1 1 China C
AF286230 55BCBCBC 11 China C
AF 110967 59C C C C C C 6 Botswana C
AF067155 60C C C C C C 23 India C
U46016 61CCCCCC 15 Ethiopia C
AF289548 8CDCDCD 40 Tanzania CD
AF289550 9CDCDCD 40 Tanzania CD
338
AF289549 11CDCDCD 40 Tanzania CD
A F179368 18Y 1X X X X 20 Greece cpx
AJ291719 17Y 1Y 1Y 1J6 France CRF
M 22639(U 16633, Z2) 3D D D D D D 0 none D
KO3454/X04414 4DDXXDD 13 Congo D
M27323 5D D D D D D 13 Congo D
U88824 10D D X X D D 42 Uganda D
AF005494 43F F F 1 F 1 7 Brazil F
AF077336 44F F F 1F113 Congo F
AF076998 6DFDFDF 13 Congo F/FD
AF 193253 7D F D F D F 13 Congo F/FD
AF005495 16B B X X X X 7 Brazil FI
AF075703 45F F F 2F 125 Kenya FI
AJ249238 46FFF1F11 Africa FI
AJ249237 4 7 F 2 F 2F 210 Cameroon F2
AJ249239 49KKKKKK_ 10 Cameroon F3
AJ249235 50K K X X K K 13 Congo F3
AF061640 62G G G G G G 25 Kenya G
AF061642 63GGGGGG_13 Congo G
AF084936 64G G G G G G 13 Congo G
AF005496 65H H H H H H 9 Central African Republic H
AF190128 66H H X X H H 4 Belgium H
LI 1793 67H H X X X X 13 D.R. o f Congo H
AF190127 68H H H H H H 4 Belgium H
AF082394 69JJJJJJ 13 Congo J
AF082395 70JJJJJJ13 Congo J
AJ249236 48F 2X X F 210 Cameroon K
AJ006022 1NNNNNN_10 Cameroon N
AJ271370 2NNNNNN_10 Cameroon N
L20587 7 1O O X X X X J0 Cameroon O
L20571 72O O X X X X 10 Cameroon 0
* Refer to results section 1.3.2 for full explanation o f new key
Table 2. T able show ing m anual sub type c lassification  o f  full length  L os A lam os 
reference sequences and N C B I H IV  genom es.
C lassification  w as perfo rm ed  b y  th ree  separa te  m ethods: m axim um  p ars im o n y  (P hylip , 
p ro tpars), neighbour jo in in g  (C lu sta lW ) and  agg lom erative  h ierach ica l c lu ste rin g  usin g  
com plete  linkage based  on sequence  id en tity  m atrices. F o r each  genom e reg ion , 
c lassification  is g iven as b o th  g roup  an d  subgroup  (w ith in  each  tree). Sequence 
accessions, STAR Identifier, w h e th e r the sequence is a re ference strain , geograph ical 
o rig in  and  published subtype, are all no ted .
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SEE EXCEL FILE Table2.xls ON ENCLOSED CD
Table 3. Gene lists.
Gene lists for: (W orksheet A) Significantly up and down regulated genes in response to HIV-1 
subtype B at 24 HPI; (W orksheet B) in response to HIV-1 group O at 24 HPI; (W orksheet C) 
in response to HIV-2 ETP at 24 HPI. B o th  gen e  ID  (accession  num ber) and  n am e are 
given.
SEE EXCEL FILE Table3.xls ON ENCLOSED CD
Figure 1. FACS analysis of forty CEM-G clones, infected with CCR5-lentivirus and 
grown out under selection, after limiting dilution cloning.
Each line is stained for CCR5 (FL2-red) and background level of green fluorescence 
detected (FL1-green).
SEE SEPARATE EXCEL FILE (Figure l.xls)
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